<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/2F35F66F-18A8-4A4C-8010-343C2CD2AC41"><gtr:id>2F35F66F-18A8-4A4C-8010-343C2CD2AC41</gtr:id><gtr:name>Shanghai University of Traditional Chinese Medicine</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/0E422C9D-CD3C-4FD8-AAEC-F8E200F9490A"><gtr:id>0E422C9D-CD3C-4FD8-AAEC-F8E200F9490A</gtr:id><gtr:name>University of Yamanashi</gtr:name><gtr:address><gtr:line1>1110 Shimokato</gtr:line1><gtr:line2>Chuo-shi</gtr:line2><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/2DB7ED73-8E89-457A-A395-FAC12F929C1A"><gtr:id>2DB7ED73-8E89-457A-A395-FAC12F929C1A</gtr:id><gtr:name>University of Edinburgh</gtr:name><gtr:address><gtr:line1>Old College</gtr:line1><gtr:line2>South Bridge</gtr:line2><gtr:line3>Mayfield Road</gtr:line3><gtr:line4>Edinburgh</gtr:line4><gtr:postCode>EH8 9YL</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3567C904-98E6-4A2F-8FB5-7463E5617DE3"><gtr:id>3567C904-98E6-4A2F-8FB5-7463E5617DE3</gtr:id><gtr:name>First Teaching Hospital of Tianjin University of Traditional Chinese Medicine (TCM)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/6711BFCB-ACD5-4149-9C97-283269DF2778"><gtr:id>6711BFCB-ACD5-4149-9C97-283269DF2778</gtr:id><gtr:name>Mayo Clinic</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/ECCC96A2-526B-4202-B3E2-547EEB8FE057"><gtr:id>ECCC96A2-526B-4202-B3E2-547EEB8FE057</gtr:id><gtr:name>Newcastle General Hospital</gtr:name><gtr:address><gtr:line1>Westgate Road</gtr:line1><gtr:line2>Newcastle Upon Tyne</gtr:line2><gtr:line3>Tyne and Wear</gtr:line3><gtr:postCode>NE4 6BE</gtr:postCode><gtr:region>Unknown</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/6020EDD4-B3F4-4D08-80DE-E387DD4EB8AB"><gtr:id>6020EDD4-B3F4-4D08-80DE-E387DD4EB8AB</gtr:id><gtr:name>University College London Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/9978E639-9888-4344-B787-1B576D46C6C7"><gtr:id>9978E639-9888-4344-B787-1B576D46C6C7</gtr:id><gtr:name>Radiation Therapy Oncology Group RTOG</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/916B2286-CD84-4805-9E62-358639644585"><gtr:id>916B2286-CD84-4805-9E62-358639644585</gtr:id><gtr:name>Intermountain Medical Centre</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/4A179E2C-FB5E-4836-AA80-6301F4DD5AB6"><gtr:id>4A179E2C-FB5E-4836-AA80-6301F4DD5AB6</gtr:id><gtr:name>University of Sydney</gtr:name><gtr:address><gtr:line1>University of Sydney</gtr:line1><gtr:region>Outside UK</gtr:region><gtr:country>Australia</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/190D7A48-DDE9-433F-A7CE-FF7ED52FE177"><gtr:id>190D7A48-DDE9-433F-A7CE-FF7ED52FE177</gtr:id><gtr:name>Acylbadem Oncology and Neurological Science Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/28DF10CD-6250-442A-804C-A8710CF218D1"><gtr:id>28DF10CD-6250-442A-804C-A8710CF218D1</gtr:id><gtr:name>University of Bern</gtr:name><gtr:address><gtr:line1>Universitat Bern</gtr:line1><gtr:line2>Sidlerstrasse 5</gtr:line2><gtr:line4>Bern</gtr:line4><gtr:line5>CH-3012</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Switzerland</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/660C6724-6599-4A53-98E3-F6B84E80A04E"><gtr:id>660C6724-6599-4A53-98E3-F6B84E80A04E</gtr:id><gtr:name>American College of Radiology (ACR)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/F25BC0C5-5284-441F-B79F-A61707946CA0"><gtr:id>F25BC0C5-5284-441F-B79F-A61707946CA0</gtr:id><gtr:name>University of California Los Angeles</gtr:name><gtr:address><gtr:line1>405 Hillgard Avenue</gtr:line1><gtr:line2>Box 951361</gtr:line2><gtr:postCode>90095</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/F7B8A23C-8C70-4939-AD44-01BA9FEEFDDC"><gtr:id>F7B8A23C-8C70-4939-AD44-01BA9FEEFDDC</gtr:id><gtr:name>Osaka Medical Center for Cancer and Cardiovascular Diseases</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/E09F2D7D-023E-4EBF-9408-DA60760176A7"><gtr:id>E09F2D7D-023E-4EBF-9408-DA60760176A7</gtr:id><gtr:name>International Academy of Environmental Sciences (IAES)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/CF449342-AF1A-4D3F-B833-8F6DB8687F7D"><gtr:id>CF449342-AF1A-4D3F-B833-8F6DB8687F7D</gtr:id><gtr:name>Uppsala University Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/C8C5D55B-121D-41A9-9B83-BA5DA0F0BAB8"><gtr:id>C8C5D55B-121D-41A9-9B83-BA5DA0F0BAB8</gtr:id><gtr:name>SG Moscati Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/473F7B5C-70FE-4079-A7A4-9B33054D3495"><gtr:id>473F7B5C-70FE-4079-A7A4-9B33054D3495</gtr:id><gtr:name>University of Rome I (La Sapienza)</gtr:name><gtr:address><gtr:line1>University of Rome</gtr:line1><gtr:line2>Via Pietro Roselli</gtr:line2><gtr:region>Outside UK</gtr:region><gtr:country>Italy</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/430A04B6-0F63-43BA-B78B-8DD4147CAF43"><gtr:id>430A04B6-0F63-43BA-B78B-8DD4147CAF43</gtr:id><gtr:name>University of Paris South 11</gtr:name><gtr:address><gtr:line1>Batiment 300</gtr:line1><gtr:line4>Orsay cedex</gtr:line4><gtr:line5>F-91405</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>France</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/43BEDA5F-E824-412D-A4AC-ED7F1139F5CC"><gtr:id>43BEDA5F-E824-412D-A4AC-ED7F1139F5CC</gtr:id><gtr:name>University of Turin</gtr:name><gtr:address><gtr:line1>Via Giuseppe Verdi 8</gtr:line1><gtr:postCode>I-10124</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/866F91B4-4A6C-4FD3-9023-600DEE062CED"><gtr:id>866F91B4-4A6C-4FD3-9023-600DEE062CED</gtr:id><gtr:name>Tom Baker Cancer Center</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/E20F47CA-8AB4-4F4D-A90D-A290834C65FF"><gtr:id>E20F47CA-8AB4-4F4D-A90D-A290834C65FF</gtr:id><gtr:name>University Hospital Coventry NHS Trust</gtr:name><gtr:address><gtr:line1>Clifford Bridge Road</gtr:line1><gtr:line2>Walsgrave</gtr:line2><gtr:postCode>CV2 2DX</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/E4E1DAA0-8180-41F1-9351-540577DB2B5F"><gtr:id>E4E1DAA0-8180-41F1-9351-540577DB2B5F</gtr:id><gtr:name>Saarland University</gtr:name><gtr:address><gtr:line1>Main Campus</gtr:line1><gtr:line2>Stuhlsatzenhausweg</gtr:line2><gtr:postCode>D-66123</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Germany</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3AB95F1D-E1ED-4D29-8962-0AFCCC8C3B88"><gtr:id>3AB95F1D-E1ED-4D29-8962-0AFCCC8C3B88</gtr:id><gtr:name>TwoCan Associates</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/9CC0A93E-2E80-48EA-8EEB-B34AF125B454"><gtr:id>9CC0A93E-2E80-48EA-8EEB-B34AF125B454</gtr:id><gtr:name>Cancer and Leukaemia Group B</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/B8E667D9-2ADA-46CF-BCD6-6188767B084A"><gtr:id>B8E667D9-2ADA-46CF-BCD6-6188767B084A</gtr:id><gtr:name>Institute for Oncology and Radiology of Serbia</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/EDB80D14-0821-4499-B1A7-5B12CA49F487"><gtr:id>EDB80D14-0821-4499-B1A7-5B12CA49F487</gtr:id><gtr:name>Gynaecologic Oncology Group GOC</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3B6DCB87-479A-4C53-94E2-B62D0DCE8BB7"><gtr:id>3B6DCB87-479A-4C53-94E2-B62D0DCE8BB7</gtr:id><gtr:name>British Columbia Cancer Agency (BCCA)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/8218E276-85FA-4CD5-86AA-232A830B5037"><gtr:id>8218E276-85FA-4CD5-86AA-232A830B5037</gtr:id><gtr:name>University of Texas at San Antonio</gtr:name><gtr:address><gtr:line1>One UTSA Circle</gtr:line1><gtr:line4>San Antonio</gtr:line4><gtr:line5>TX 78249-1644</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/E93A8558-613B-451F-88F8-964379B61001"><gtr:id>E93A8558-613B-451F-88F8-964379B61001</gtr:id><gtr:name>Auckland City Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/150CE820-6372-414E-9F7F-524E27034E23"><gtr:id>150CE820-6372-414E-9F7F-524E27034E23</gtr:id><gtr:name>University of Colorado at Boulder</gtr:name><gtr:address><gtr:line1>Boulder</gtr:line1><gtr:line4>Colorado</gtr:line4><gtr:line5>80309-0425</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/7FB580F4-0B61-43BD-9C4B-FF74C52464BC"><gtr:id>7FB580F4-0B61-43BD-9C4B-FF74C52464BC</gtr:id><gtr:name>Penn State Milton S. Hershey Medical Center</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/4419EA3A-4FB7-4587-B99E-604A19065313"><gtr:id>4419EA3A-4FB7-4587-B99E-604A19065313</gtr:id><gtr:name>Laval Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/4EBF3DC3-B4A4-4E4E-B13D-284698AA70D7"><gtr:id>4EBF3DC3-B4A4-4E4E-B13D-284698AA70D7</gtr:id><gtr:name>Dana-Farber Cancer Institute</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/4D0DCB45-3ED8-494B-8C55-B5E8DF9DB522"><gtr:id>4D0DCB45-3ED8-494B-8C55-B5E8DF9DB522</gtr:id><gtr:name>UNLISTED</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/6F589F40-E565-4758-ABB8-E5998A94450E"><gtr:id>6F589F40-E565-4758-ABB8-E5998A94450E</gtr:id><gtr:name>Guangdong General Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/6FF9A7D0-4C9E-4FE4-9A31-477B6D9031B1"><gtr:id>6FF9A7D0-4C9E-4FE4-9A31-477B6D9031B1</gtr:id><gtr:name>Trondheim University Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/274F2FB0-27BB-4991-A894-796A2AE916E3"><gtr:id>274F2FB0-27BB-4991-A894-796A2AE916E3</gtr:id><gtr:name>The Christie NHS Foundation Trust</gtr:name><gtr:address><gtr:line1>Wilmslow Road</gtr:line1><gtr:city>Manchester</gtr:city><gtr:postCode>M20 4BX</gtr:postCode><gtr:region>North West</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/696A0A2F-736F-4546-B0F4-F347F0F8488E"><gtr:id>696A0A2F-736F-4546-B0F4-F347F0F8488E</gtr:id><gtr:name>Freeman Hospital</gtr:name><gtr:address><gtr:line1>Liver and Renal Transplant Unit
Freeman Hospital
Freeman Road
High Heaton</gtr:line1><gtr:city>Newcastle Upon Tyne</gtr:city><gtr:postCode>NE7 7DN</gtr:postCode><gtr:region>North East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/4E55B119-02E7-43F3-9B39-DD48A6511372"><gtr:id>4E55B119-02E7-43F3-9B39-DD48A6511372</gtr:id><gtr:name>Addenbrooke's Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/05D69417-BE9F-4C72-B26A-053781697575"><gtr:id>05D69417-BE9F-4C72-B26A-053781697575</gtr:id><gtr:name>Sunnybrook Health Sciences Centre</gtr:name><gtr:address><gtr:line1>Sunnybrook Health Sciences Centre</gtr:line1><gtr:line2>5112-2075 Bayview Ave</gtr:line2><gtr:postCode>M4N 3M5</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/624FC0B7-618B-4A6A-B844-5A775EE3819E"><gtr:id>624FC0B7-618B-4A6A-B844-5A775EE3819E</gtr:id><gtr:name>Duke University Health System</gtr:name><gtr:address><gtr:line1>3100 Tower Blvd. Suite 1008</gtr:line1><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/88B8928E-4F94-4628-BBA4-83727B3185C9"><gtr:id>88B8928E-4F94-4628-BBA4-83727B3185C9</gtr:id><gtr:name>Cross Cancer Institute</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/89833E38-8292-47CC-82C3-394FE46D889E"><gtr:id>89833E38-8292-47CC-82C3-394FE46D889E</gtr:id><gtr:name>University of Arizona</gtr:name><gtr:address><gtr:line1>617 N. Santa Rita Ave.</gtr:line1><gtr:line4>Tucson</gtr:line4><gtr:line5>Arizona</gtr:line5><gtr:postCode>AZ 85721</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/2E9AC78C-5AED-4387-A74B-E8561E9FE1C9"><gtr:id>2E9AC78C-5AED-4387-A74B-E8561E9FE1C9</gtr:id><gtr:name>Velindre Cancer Centre</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/297E114F-009E-4736-A80D-4B51D14BD69B"><gtr:id>297E114F-009E-4736-A80D-4B51D14BD69B</gtr:id><gtr:name>Brussels Saint-Luc University Hospital (UCL)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/4A4090D5-D795-4C4B-8A6B-00D25830130F"><gtr:id>4A4090D5-D795-4C4B-8A6B-00D25830130F</gtr:id><gtr:name>University of Duisburg-Essen</gtr:name><gtr:address><gtr:line1>University of Duisburg-Essen</gtr:line1><gtr:line2>Geibelstrase 41</gtr:line2><gtr:line4>Duisburg</gtr:line4><gtr:line5>D-47057</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Germany</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/F666078A-E9B5-4012-916F-07E418EFFB3D"><gtr:id>F666078A-E9B5-4012-916F-07E418EFFB3D</gtr:id><gtr:name>Rene Gauducheau Centre</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/A86004C8-2B5A-4D93-AFC0-4EC170FE24C6"><gtr:id>A86004C8-2B5A-4D93-AFC0-4EC170FE24C6</gtr:id><gtr:name>Germans University Hospital</gtr:name><gtr:address><gtr:line1>Trias i Pujol</gtr:line1><gtr:line2>Carretera del Canyet</gtr:line2><gtr:region>Unknown</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/1B847C1D-9166-4D93-887B-E57CBE4FAC09"><gtr:id>1B847C1D-9166-4D93-887B-E57CBE4FAC09</gtr:id><gtr:name>Ospedale di Circolo e Fondazione Macchi</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/AE36032A-B18A-496F-A445-75C83AA52EDC"><gtr:id>AE36032A-B18A-496F-A445-75C83AA52EDC</gtr:id><gtr:name>Centre for Research and Implementation of Clinical Practice</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/37EF6C9C-5F51-40DD-BED5-B792981BC119"><gtr:id>37EF6C9C-5F51-40DD-BED5-B792981BC119</gtr:id><gtr:name>Imperial Cancer Research Fund</gtr:name><gtr:address><gtr:line1>44 Lincoln's Inn Fields</gtr:line1><gtr:postCode>WC2A 3PX</gtr:postCode><gtr:region>London</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/7B5B059B-D11D-4216-BAC4-CBFF7E5E3C2C"><gtr:id>7B5B059B-D11D-4216-BAC4-CBFF7E5E3C2C</gtr:id><gtr:name>Academic Medical Center</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/4D413F6A-74CA-41ED-915A-69079B55117F"><gtr:id>4D413F6A-74CA-41ED-915A-69079B55117F</gtr:id><gtr:name>University Hospitals Bristol NHS Foundation Trust</gtr:name><gtr:address><gtr:postCode>BS2 8HW</gtr:postCode><gtr:region>South West</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/E42FE499-D972-48A3-ACFC-4873BA7FAD17"><gtr:id>E42FE499-D972-48A3-ACFC-4873BA7FAD17</gtr:id><gtr:name>Sanjay Gandhi Postgrad Inst Med Sciences</gtr:name><gtr:address><gtr:line1>Sanjay Gandhi Postgrad Inst of Med Sci</gtr:line1><gtr:line2>Raebareli Road</gtr:line2><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/69EC6DC4-ACF4-452D-B2AC-0AD52C33A7B9"><gtr:id>69EC6DC4-ACF4-452D-B2AC-0AD52C33A7B9</gtr:id><gtr:name>Crozer-Keystone Health System</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/95130295-6141-4FEB-B5DA-4EC76F5B5DC0"><gtr:id>95130295-6141-4FEB-B5DA-4EC76F5B5DC0</gtr:id><gtr:name>Christiana Care Health System</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/D739677A-6514-46E5-821F-22EEA573D62A"><gtr:id>D739677A-6514-46E5-821F-22EEA573D62A</gtr:id><gtr:name>University of Ghent</gtr:name><gtr:address><gtr:line1>Rectorate Building</gtr:line1><gtr:line2>Sint-Pietersnieuwstraat 25</gtr:line2><gtr:line3>Krijgslaan</gtr:line3><gtr:postCode>B-9000</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Belgium</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/D07BED4C-30ED-4568-9697-9F14A111D7DD"><gtr:id>D07BED4C-30ED-4568-9697-9F14A111D7DD</gtr:id><gtr:name>St Woolos Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/F20FFE5B-3DA6-4629-894F-4CE13B49B4E4"><gtr:id>F20FFE5B-3DA6-4629-894F-4CE13B49B4E4</gtr:id><gtr:name>Vanderbilt University</gtr:name><gtr:address><gtr:line1>Vanderbilt University</gtr:line1><gtr:line2>2201 West End Avenue</gtr:line2><gtr:line4>Nashville</gtr:line4><gtr:line5>Tennessee</gtr:line5><gtr:postCode>TN 37235</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/52D361BC-CE18-46F1-8FFD-655C734C9437"><gtr:id>52D361BC-CE18-46F1-8FFD-655C734C9437</gtr:id><gtr:name>Centro Hospitalario Pereira Rossell CHPR</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/8A31C41F-3CB1-48A0-86D7-014ACCF7D207"><gtr:id>8A31C41F-3CB1-48A0-86D7-014ACCF7D207</gtr:id><gtr:name>G?lhane Military Medical Academy (GATA), Turkey</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/F463A0E1-E89E-406B-B803-760625885B6C"><gtr:id>F463A0E1-E89E-406B-B803-760625885B6C</gtr:id><gtr:name>Hospital Universitario La Paz</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/B589281B-BE51-4D64-96A8-B62BDE6E23AB"><gtr:id>B589281B-BE51-4D64-96A8-B62BDE6E23AB</gtr:id><gtr:name>Canadian Cancer Society Research Institute (CCSRI)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/1B81D5AE-90EB-42E6-855F-A0F582DA5820"><gtr:id>1B81D5AE-90EB-42E6-855F-A0F582DA5820</gtr:id><gtr:name>Royal North Shore Hospital</gtr:name><gtr:address><gtr:line1>St Lenards</gtr:line1><gtr:postCode>2065</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/191F0D78-2079-48F1-B2D5-7D8526A8EDB4"><gtr:id>191F0D78-2079-48F1-B2D5-7D8526A8EDB4</gtr:id><gtr:name>Hyogo College of Medicine</gtr:name><gtr:address><gtr:line1>Hyogo College of Medicine</gtr:line1><gtr:line2>1-1 Mukogawa-cho</gtr:line2><gtr:line3>Nishinomiya</gtr:line3><gtr:postCode>663-8501</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/E0416AD8-4131-44FC-A547-39F780732240"><gtr:id>E0416AD8-4131-44FC-A547-39F780732240</gtr:id><gtr:name>Thomas Jefferson University</gtr:name><gtr:address><gtr:line1>Thomas Jefferson University</gtr:line1><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/5016B9BE-A15B-4B53-99A3-1DBE28399D47"><gtr:id>5016B9BE-A15B-4B53-99A3-1DBE28399D47</gtr:id><gtr:name>Academy of Medical Royal Colleges</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/344C9D60-ABF6-4230-8E37-2A46E48B1A22"><gtr:id>344C9D60-ABF6-4230-8E37-2A46E48B1A22</gtr:id><gtr:name>Chiba Cancer Center</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/F7B72D66-6B48-471E-8545-F319BE19C9DD"><gtr:id>F7B72D66-6B48-471E-8545-F319BE19C9DD</gtr:id><gtr:name>John H. Stroger Jr. Hospital (formerly Cook County Hospital)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/5A638CD5-2C73-4056-B703-F711C9E0F970"><gtr:id>5A638CD5-2C73-4056-B703-F711C9E0F970</gtr:id><gtr:name>Sun Yat-Sen University</gtr:name><gtr:address><gtr:line1>135 Xingang Xi Road</gtr:line1><gtr:postCode>510275</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>China</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/0E4C8B40-2D9E-4CCE-9A90-EF87DCB2448E"><gtr:id>0E4C8B40-2D9E-4CCE-9A90-EF87DCB2448E</gtr:id><gtr:name>Liverpool Womens NHS Foundation Trust</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/37511276-C1B7-47AF-8663-A244596C825C"><gtr:id>37511276-C1B7-47AF-8663-A244596C825C</gtr:id><gtr:name>Tel Aviv University</gtr:name><gtr:address><gtr:line1>Tel Aviv University</gtr:line1><gtr:line2>PO Box 39040</gtr:line2><gtr:line4>Tel Aviv</gtr:line4><gtr:postCode>69978</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Israel</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/BB51DA9F-7A3E-4A34-8399-58D1F14E5EAE"><gtr:id>BB51DA9F-7A3E-4A34-8399-58D1F14E5EAE</gtr:id><gtr:name>Catalan Institute of Oncology</gtr:name><gtr:address><gtr:line1>Gran Via km 2,7</gtr:line1><gtr:postCode>08907</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/93B13D3A-863C-46E8-A4C7-1EE4759A7E9B"><gtr:id>93B13D3A-863C-46E8-A4C7-1EE4759A7E9B</gtr:id><gtr:name>Cleveland Clinic</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/ADB14AFF-F6DF-4144-A743-0AAE3D33973D"><gtr:id>ADB14AFF-F6DF-4144-A743-0AAE3D33973D</gtr:id><gtr:name>European Organisation for Research and Treatment of Cancer (EORTC)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3606C3ED-A577-408B-B772-36C9080CDAF9"><gtr:id>3606C3ED-A577-408B-B772-36C9080CDAF9</gtr:id><gtr:name>Universite Montpellier</gtr:name><gtr:address><gtr:line1>Service Communication</gtr:line1><gtr:line2>5 bd Henri IV - BP 1017</gtr:line2><gtr:line3>34006 Montpellier Cedex 1</gtr:line3><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/35B1EB39-F65C-4235-983E-475C6967F150"><gtr:id>35B1EB39-F65C-4235-983E-475C6967F150</gtr:id><gtr:name>Tygerberg Children?s Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/51FAE27D-6F57-4089-98B0-E0F4BB1DE196"><gtr:id>51FAE27D-6F57-4089-98B0-E0F4BB1DE196</gtr:id><gtr:name>Piti?-Salp?tri?re Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/2448D059-1C4B-4E76-A4C6-8A3109B8F194"><gtr:id>2448D059-1C4B-4E76-A4C6-8A3109B8F194</gtr:id><gtr:name>University of Gothenburg</gtr:name><gtr:address><gtr:line1>University of Gothenburg</gtr:line1><gtr:line2>PO Box 100</gtr:line2><gtr:line4>Gothenburg</gtr:line4><gtr:line5>SE 405 30</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Sweden</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/CE4FA0EC-37EA-4B26-BA91-4528C959C227"><gtr:id>CE4FA0EC-37EA-4B26-BA91-4528C959C227</gtr:id><gtr:name>Gustave-Roussy Institute</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/645ADF06-01C7-45C1-A485-7102A948B2E5"><gtr:id>645ADF06-01C7-45C1-A485-7102A948B2E5</gtr:id><gtr:name>Smith and Nephew</gtr:name><gtr:address><gtr:line1>York Science Park</gtr:line1><gtr:line2>Heslington</gtr:line2><gtr:line4>York</gtr:line4><gtr:postCode>YO10 5DF</gtr:postCode><gtr:region>Yorkshire and The Humber</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/CB9B10BA-1677-4A30-A18D-A23D972A0C8F"><gtr:id>CB9B10BA-1677-4A30-A18D-A23D972A0C8F</gtr:id><gtr:name>National Kyushu Cancer Center</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/FC59975E-26E8-4A62-ABD8-A570DC6ABF06"><gtr:id>FC59975E-26E8-4A62-ABD8-A570DC6ABF06</gtr:id><gtr:name>Keele University</gtr:name><gtr:address><gtr:line1>Keele</gtr:line1><gtr:line4>Newcastle</gtr:line4><gtr:line5>Staffordshire</gtr:line5><gtr:postCode>ST5 5BG</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/9C932CFE-AAE2-4A8F-A53F-1C7EAC961997"><gtr:id>9C932CFE-AAE2-4A8F-A53F-1C7EAC961997</gtr:id><gtr:name>Harvard University</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/C2EF8978-093D-41F5-98DD-8A459F24C070"><gtr:id>C2EF8978-093D-41F5-98DD-8A459F24C070</gtr:id><gtr:name>Wilhelminen Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/E88920F1-18FE-4D53-8B47-60A86652F503"><gtr:id>E88920F1-18FE-4D53-8B47-60A86652F503</gtr:id><gtr:name>Vejle Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/E9740D79-1063-4735-90E0-EF9CD1DA4587"><gtr:id>E9740D79-1063-4735-90E0-EF9CD1DA4587</gtr:id><gtr:name>Osaka City General Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/A0A585E0-6B0D-4643-A3A6-47943B4CBFEF"><gtr:id>A0A585E0-6B0D-4643-A3A6-47943B4CBFEF</gtr:id><gtr:name>University of Liverpool</gtr:name><gtr:address><gtr:line1>Senate House</gtr:line1><gtr:line2>Abercromby Square</gtr:line2><gtr:line4>Liverpool</gtr:line4><gtr:postCode>L69 3BX</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/CECDEE86-7EB0-4FEC-A2D9-D3B3F8C27F0F"><gtr:id>CECDEE86-7EB0-4FEC-A2D9-D3B3F8C27F0F</gtr:id><gtr:name>Helsinki University Central Hospital</gtr:name><gtr:address><gtr:line1>Stenbackinkatu 9</gtr:line1><gtr:postCode>SF 00290</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/192FC2D6-F07B-4A8F-AEDC-B4BCC69F6367"><gtr:id>192FC2D6-F07B-4A8F-AEDC-B4BCC69F6367</gtr:id><gtr:name>Mansoura University</gtr:name><gtr:address><gtr:line1>Mansoura University</gtr:line1><gtr:postCode>35516</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/C1CE3B13-A79B-48B7-9B8D-97BC9C07DC78"><gtr:id>C1CE3B13-A79B-48B7-9B8D-97BC9C07DC78</gtr:id><gtr:name>Netherlands Cancer Institute</gtr:name><gtr:address><gtr:line1>Plesmanlaan 121</gtr:line1><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/7EA47BE9-7A59-4B93-8E05-D2A186CD8F28"><gtr:id>7EA47BE9-7A59-4B93-8E05-D2A186CD8F28</gtr:id><gtr:name>Chiang Mai University</gtr:name><gtr:address><gtr:line1>Suthep  Muang</gtr:line1><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/856A7EAA-C834-4DBE-8764-98C315C40614"><gtr:id>856A7EAA-C834-4DBE-8764-98C315C40614</gtr:id><gtr:name>Mario Negri Institute for Pharmacological Research</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/202F8631-BFC1-4C0A-BA3E-B8038FDBA639"><gtr:id>202F8631-BFC1-4C0A-BA3E-B8038FDBA639</gtr:id><gtr:name>Oncology Institute of Vojvodina</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/CED0B9B7-1A47-4541-89C2-00CA9E9AF8E4"><gtr:id>CED0B9B7-1A47-4541-89C2-00CA9E9AF8E4</gtr:id><gtr:name>Cedars-Sinai Medical Center</gtr:name><gtr:address><gtr:line1>8700 Beverley BI #8211</gtr:line1><gtr:postCode>90048</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/D3B5235B-CC4A-4B38-8E39-5179BAFB4DE7"><gtr:id>D3B5235B-CC4A-4B38-8E39-5179BAFB4DE7</gtr:id><gtr:name>Birmingham Heartlands Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/B45B1016-314C-4E6E-9977-AF23B544953B"><gtr:id>B45B1016-314C-4E6E-9977-AF23B544953B</gtr:id><gtr:name>Tokyo Medical and Dental University</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/E68BE577-6C17-48CE-B65C-24C477BB8AE9"><gtr:id>E68BE577-6C17-48CE-B65C-24C477BB8AE9</gtr:id><gtr:name>Yeshiva University</gtr:name><gtr:address><gtr:line1>500 West 185th Street</gtr:line1><gtr:postCode>10033</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/AE58F21F-3622-4382-97BB-1359BD183E9F"><gtr:id>AE58F21F-3622-4382-97BB-1359BD183E9F</gtr:id><gtr:name>University of Glasgow</gtr:name><gtr:address><gtr:line1>University Avenue</gtr:line1><gtr:line4>Glasgow</gtr:line4><gtr:postCode>G12 8QQ</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/C3992259-C19F-4FE5-9C01-210C819D7264"><gtr:id>C3992259-C19F-4FE5-9C01-210C819D7264</gtr:id><gtr:name>Yale University</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/4C02B63A-6450-44EE-B38C-5D2C0C38D1E8"><gtr:id>4C02B63A-6450-44EE-B38C-5D2C0C38D1E8</gtr:id><gtr:name>University of Rome II (Tor Vergata)</gtr:name><gtr:address><gtr:line1>via Columbia, 2</gtr:line1><gtr:line4>Roma</gtr:line4><gtr:line5>I-00133</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Italy</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/7DD38B9D-A65B-4D0F-8612-8384BD01394D"><gtr:id>7DD38B9D-A65B-4D0F-8612-8384BD01394D</gtr:id><gtr:name>Tohoku University</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3411CDF4-C540-4081-BAB5-3535A68490D4"><gtr:id>3411CDF4-C540-4081-BAB5-3535A68490D4</gtr:id><gtr:name>Korea Cancer Center Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/A8967420-49D3-4509-9912-25FB3EC75B74"><gtr:id>A8967420-49D3-4509-9912-25FB3EC75B74</gtr:id><gtr:name>University of Sussex</gtr:name><gtr:address><gtr:line1>The Administration</gtr:line1><gtr:line2>Sussex House</gtr:line2><gtr:line3>Falmer</gtr:line3><gtr:line4>Brighton</gtr:line4><gtr:line5>East Sussex</gtr:line5><gtr:postCode>BN1 9RH</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/37B04F53-AFDA-41A8-8216-1EEE7410C7DC"><gtr:id>37B04F53-AFDA-41A8-8216-1EEE7410C7DC</gtr:id><gtr:name>Leicester Royal Infirmary</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/6E068768-8705-4101-8F7E-1B286A2B9B9E"><gtr:id>6E068768-8705-4101-8F7E-1B286A2B9B9E</gtr:id><gtr:name>Strasbourgs University Hospitals</gtr:name><gtr:address><gtr:line1>1 place hopital</gtr:line1><gtr:line2>BP 426, Cedex</gtr:line2><gtr:postCode>cedex67091</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/499467F4-0221-40A6-9DCD-F20F4A09C653"><gtr:id>499467F4-0221-40A6-9DCD-F20F4A09C653</gtr:id><gtr:name>Yokohama City University Medical Centre</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/6721980D-6BE8-41E3-9D78-9F76474E1AAC"><gtr:id>6721980D-6BE8-41E3-9D78-9F76474E1AAC</gtr:id><gtr:name>Cancer Institute of the Loire</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/EF46D1B5-9EE9-459F-8D6D-68C3987370BD"><gtr:id>EF46D1B5-9EE9-459F-8D6D-68C3987370BD</gtr:id><gtr:name>University Hospitals of Leicester NHS</gtr:name><gtr:address><gtr:line1>Leicester Royal Infirmary</gtr:line1><gtr:line2>Infirmary Square</gtr:line2><gtr:line4>Leicester</gtr:line4><gtr:postCode>LE1 5WW</gtr:postCode><gtr:region>East Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/A682D253-DEE6-4EE1-89B0-21F1351C632C"><gtr:id>A682D253-DEE6-4EE1-89B0-21F1351C632C</gtr:id><gtr:name>National Cancer Institute (NCI)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/76CD45AC-378E-4073-94E5-C7DFBA3B4719"><gtr:id>76CD45AC-378E-4073-94E5-C7DFBA3B4719</gtr:id><gtr:name>University of Turku</gtr:name><gtr:address><gtr:line1>Turun yliopisto</gtr:line1><gtr:postCode>FI-20014</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Finland</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/EF8EDD94-E846-412E-B59C-51D4D000D9E2"><gtr:id>EF8EDD94-E846-412E-B59C-51D4D000D9E2</gtr:id><gtr:name>Nagoya University</gtr:name><gtr:address><gtr:line1>Furo-cho</gtr:line1><gtr:line2>Chikusa-ku</gtr:line2><gtr:line4>Nagoya City</gtr:line4><gtr:line5>Aichi Prefecture</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Japan</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/FA04CA23-EB82-46AF-B73D-67FF08E5576E"><gtr:id>FA04CA23-EB82-46AF-B73D-67FF08E5576E</gtr:id><gtr:name>University of Ancona</gtr:name><gtr:address><gtr:line1>Faculty of Medicine</gtr:line1><gtr:postCode>I-60020</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/F44FC935-8229-45D0-832A-AF35C6A449BF"><gtr:id>F44FC935-8229-45D0-832A-AF35C6A449BF</gtr:id><gtr:name>Churchill Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/4051BFFD-1763-4071-82C2-32589D76267C"><gtr:id>4051BFFD-1763-4071-82C2-32589D76267C</gtr:id><gtr:name>Herlev Hospital</gtr:name><gtr:address><gtr:line1>Herlev Ringvej 75</gtr:line1><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/7254835D-A811-460C-ACFC-C345775924B4"><gtr:id>7254835D-A811-460C-ACFC-C345775924B4</gtr:id><gtr:name>The Cochrane Collaboration</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/D5337A10-AC8A-402A-8164-C5F9CC6B0140"><gtr:id>D5337A10-AC8A-402A-8164-C5F9CC6B0140</gtr:id><gtr:name>Queen Mary, University of London</gtr:name><gtr:address><gtr:line1>Mile End Road</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>E1 4NS</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/62C544E8-A6D5-4B0C-9773-7A30B21F968D"><gtr:id>62C544E8-A6D5-4B0C-9773-7A30B21F968D</gtr:id><gtr:name>University of Padua</gtr:name><gtr:address><gtr:line1>Universita di Padova</gtr:line1><gtr:line4>Padova</gtr:line4><gtr:postCode>35129</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Italy</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/C5EA3B28-18A9-4243-9F44-F2A3ADACF4C8"><gtr:id>C5EA3B28-18A9-4243-9F44-F2A3ADACF4C8</gtr:id><gtr:name>Glenfield Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/9C10D78F-6430-4CA7-9528-B96B0762A4C6"><gtr:id>9C10D78F-6430-4CA7-9528-B96B0762A4C6</gtr:id><gtr:name>Cardiff University</gtr:name><gtr:address><gtr:line1>Research &amp; Consultancy</gtr:line1><gtr:line2>PO Box 923</gtr:line2><gtr:line4>Cardiff</gtr:line4><gtr:line5>South Glamorgan</gtr:line5><gtr:postCode>CF10 3TE</gtr:postCode><gtr:region>Wales</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/55AC985A-E874-4B03-85AB-153EAEDAF97E"><gtr:id>55AC985A-E874-4B03-85AB-153EAEDAF97E</gtr:id><gtr:name>Princess Margaret Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/A22A48AB-B677-4DE2-B6ED-8E091A525301"><gtr:id>A22A48AB-B677-4DE2-B6ED-8E091A525301</gtr:id><gtr:name>San Luigi Gonzaga Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/E913F6AA-9FFC-4300-83DB-799EC8F3A4E7"><gtr:id>E913F6AA-9FFC-4300-83DB-799EC8F3A4E7</gtr:id><gtr:name>University of Maryland</gtr:name><gtr:address><gtr:line1>University of Maryland</gtr:line1><gtr:postCode>20742</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/7987E388-1901-4D22-8F24-FA5E3F4D55B5"><gtr:id>7987E388-1901-4D22-8F24-FA5E3F4D55B5</gtr:id><gtr:name>Albany Medical College (AMC)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/2D017FB7-303D-48E6-AAFF-06303F046804"><gtr:id>2D017FB7-303D-48E6-AAFF-06303F046804</gtr:id><gtr:name>Royal Marsden NHS Foundation Trust</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/805FCB03-15BE-4D11-AEF9-8309B623E173"><gtr:id>805FCB03-15BE-4D11-AEF9-8309B623E173</gtr:id><gtr:name>Bordet Institute (Institut Jules Bordet)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/72F4A4EA-BEBF-47BB-AC75-CD8157D7B17C"><gtr:id>72F4A4EA-BEBF-47BB-AC75-CD8157D7B17C</gtr:id><gtr:name>Tata Memorial Hospital</gtr:name><gtr:address><gtr:line1>Cancer Research Centre</gtr:line1><gtr:line2>Dr. E Borges Road</gtr:line2><gtr:postCode>400 012</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/86BA0D2C-1895-41C5-B18C-092178DFFB3E"><gtr:id>86BA0D2C-1895-41C5-B18C-092178DFFB3E</gtr:id><gtr:name>National Institute for Health Research</gtr:name><gtr:address><gtr:line1>NIHR Clinical Research Network CC</gtr:line1><gtr:line2>Fairbairn House</gtr:line2><gtr:line3>71-75 Clarendon Road</gtr:line3><gtr:postCode>LS2 9PH</gtr:postCode><gtr:region>Yorkshire and the Humber</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/6EF3B963-88BD-4EA0-BDFE-60C742501F07"><gtr:id>6EF3B963-88BD-4EA0-BDFE-60C742501F07</gtr:id><gtr:name>Memorial Sloan Kettering Cancer Center</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/C7FBE408-C743-4AAC-9BC6-65E14BC8D2FD"><gtr:id>C7FBE408-C743-4AAC-9BC6-65E14BC8D2FD</gtr:id><gtr:name>Karolinska Institute</gtr:name><gtr:address><gtr:line1>Administration</gtr:line1><gtr:line4>Stockholm</gtr:line4><gtr:postCode>SE-171 77</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Sweden</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/9ACD02BB-EC4C-4346-A6A0-801468590A83"><gtr:id>9ACD02BB-EC4C-4346-A6A0-801468590A83</gtr:id><gtr:name>Tufts University</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/DAC6A24E-71C2-476D-80D2-7CF844CDBA16"><gtr:id>DAC6A24E-71C2-476D-80D2-7CF844CDBA16</gtr:id><gtr:name>Queen Elizabeth Hospital Birmingham</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/9F7C81EF-E4F5-45C5-A902-F4CAB61D4A82"><gtr:id>9F7C81EF-E4F5-45C5-A902-F4CAB61D4A82</gtr:id><gtr:name>NHS Greater Glasgow and Clyde (NHSGGC)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/8319F78A-DCBD-49F6-BE00-78E1CD75CDA9"><gtr:id>8319F78A-DCBD-49F6-BE00-78E1CD75CDA9</gtr:id><gtr:name>University of York</gtr:name><gtr:address><gtr:line1>Heslington</gtr:line1><gtr:line4>York</gtr:line4><gtr:line5>North Yorkshire</gtr:line5><gtr:postCode>YO10 5DD</gtr:postCode><gtr:region>Yorkshire and The Humber</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/78308CAA-8483-45C0-A280-0AB4B6AD9D35"><gtr:id>78308CAA-8483-45C0-A280-0AB4B6AD9D35</gtr:id><gtr:name>Medical Research Council</gtr:name><gtr:address><gtr:line1>Polaris House</gtr:line1><gtr:line2>North Star Avenue</gtr:line2><gtr:postCode>SN2 1FL</gtr:postCode><gtr:region>South West</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/A21478EA-E506-4B64-A8A9-42CD8D97C635"><gtr:id>A21478EA-E506-4B64-A8A9-42CD8D97C635</gtr:id><gtr:name>University College London Hospital (UCLH) NHS Foundation Trust</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/F5B83740-823A-461B-AEB6-0DCFED1739C8"><gtr:id>F5B83740-823A-461B-AEB6-0DCFED1739C8</gtr:id><gtr:name>Kyoto University</gtr:name><gtr:address><gtr:line1>Nishikyo-ku</gtr:line1><gtr:line2>Katsura Campus</gtr:line2><gtr:line4>Kyoto</gtr:line4><gtr:line5>Kyoto, 615-8540</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Japan</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/8C250FB6-4890-4BF9-9C23-69E6B2E02B95"><gtr:id>8C250FB6-4890-4BF9-9C23-69E6B2E02B95</gtr:id><gtr:name>Wake Forest University</gtr:name><gtr:address><gtr:line1>Wake Forest University</gtr:line1><gtr:line2>1834 Wakeforest Road</gtr:line2><gtr:line4>Winston Salem</gtr:line4><gtr:line5>North Carolina</gtr:line5><gtr:postCode>NC 27106</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/80B2EC09-0DBD-4D7B-961C-237A5525F7B0"><gtr:id>80B2EC09-0DBD-4D7B-961C-237A5525F7B0</gtr:id><gtr:name>University of Iowa Hospitals and Clinics</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/A28252F6-AD97-4A7D-82EF-6489C2EB868E"><gtr:id>A28252F6-AD97-4A7D-82EF-6489C2EB868E</gtr:id><gtr:name>Royal Prince Alfred Hospital (RPAH) Sydney</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/E65D5505-6DF9-4801-9019-B9EDE5D0EE5D"><gtr:id>E65D5505-6DF9-4801-9019-B9EDE5D0EE5D</gtr:id><gtr:name>University Medical Center Gronigen</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/DC2AF7CF-815A-42A1-A947-BE95916B963C"><gtr:id>DC2AF7CF-815A-42A1-A947-BE95916B963C</gtr:id><gtr:name>Beijing University of Chinese Medicine</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/F3153B2E-E896-4D49-B647-DFC45287A556"><gtr:id>F3153B2E-E896-4D49-B647-DFC45287A556</gtr:id><gtr:name>Princess Margaret Cancer Centre</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3ED60B49-9C2B-4D71-B644-96CCC7F10194"><gtr:id>3ED60B49-9C2B-4D71-B644-96CCC7F10194</gtr:id><gtr:name>Liverpool School of Tropical Medicine</gtr:name><gtr:address><gtr:line1>School Of Tropical Medicine</gtr:line1><gtr:line2>Pembroke Place</gtr:line2><gtr:postCode>L3 5QA</gtr:postCode><gtr:region>North West</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/C9DA1DA3-D9BD-4897-B554-5181400F24E0"><gtr:id>C9DA1DA3-D9BD-4897-B554-5181400F24E0</gtr:id><gtr:name>University Hospital of Besancon</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/666A7C6D-E59C-4C37-8997-490B93914C41"><gtr:id>666A7C6D-E59C-4C37-8997-490B93914C41</gtr:id><gtr:name>MRC Clinical Trials Unit</gtr:name><gtr:address><gtr:line1>Aviation House</gtr:line1><gtr:line2>125 Kingsway</gtr:line2><gtr:postCode>WC2B 6NH</gtr:postCode><gtr:region>London</gtr:region></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/666A7C6D-E59C-4C37-8997-490B93914C41"><gtr:id>666A7C6D-E59C-4C37-8997-490B93914C41</gtr:id><gtr:name>MRC Clinical Trials Unit</gtr:name><gtr:address><gtr:line1>Aviation House</gtr:line1><gtr:line2>125 Kingsway</gtr:line2><gtr:postCode>WC2B 6NH</gtr:postCode><gtr:region>London</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/2F35F66F-18A8-4A4C-8010-343C2CD2AC41"><gtr:id>2F35F66F-18A8-4A4C-8010-343C2CD2AC41</gtr:id><gtr:name>Shanghai University of Traditional Chinese Medicine</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/0E422C9D-CD3C-4FD8-AAEC-F8E200F9490A"><gtr:id>0E422C9D-CD3C-4FD8-AAEC-F8E200F9490A</gtr:id><gtr:name>University of Yamanashi</gtr:name><gtr:address><gtr:line1>1110 Shimokato</gtr:line1><gtr:line2>Chuo-shi</gtr:line2><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/2DB7ED73-8E89-457A-A395-FAC12F929C1A"><gtr:id>2DB7ED73-8E89-457A-A395-FAC12F929C1A</gtr:id><gtr:name>University of Edinburgh</gtr:name><gtr:address><gtr:line1>Old College</gtr:line1><gtr:line2>South Bridge</gtr:line2><gtr:line3>Mayfield Road</gtr:line3><gtr:line4>Edinburgh</gtr:line4><gtr:postCode>EH8 9YL</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3567C904-98E6-4A2F-8FB5-7463E5617DE3"><gtr:id>3567C904-98E6-4A2F-8FB5-7463E5617DE3</gtr:id><gtr:name>First Teaching Hospital of Tianjin University of Traditional Chinese Medicine (TCM)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/6711BFCB-ACD5-4149-9C97-283269DF2778"><gtr:id>6711BFCB-ACD5-4149-9C97-283269DF2778</gtr:id><gtr:name>Mayo Clinic</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/ECCC96A2-526B-4202-B3E2-547EEB8FE057"><gtr:id>ECCC96A2-526B-4202-B3E2-547EEB8FE057</gtr:id><gtr:name>Newcastle General Hospital</gtr:name><gtr:address><gtr:line1>Westgate Road</gtr:line1><gtr:line2>Newcastle Upon Tyne</gtr:line2><gtr:line3>Tyne and Wear</gtr:line3><gtr:postCode>NE4 6BE</gtr:postCode><gtr:region>Unknown</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/6020EDD4-B3F4-4D08-80DE-E387DD4EB8AB"><gtr:id>6020EDD4-B3F4-4D08-80DE-E387DD4EB8AB</gtr:id><gtr:name>University College London Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/9978E639-9888-4344-B787-1B576D46C6C7"><gtr:id>9978E639-9888-4344-B787-1B576D46C6C7</gtr:id><gtr:name>Radiation Therapy Oncology Group RTOG</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/916B2286-CD84-4805-9E62-358639644585"><gtr:id>916B2286-CD84-4805-9E62-358639644585</gtr:id><gtr:name>Intermountain Medical Centre</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/4A179E2C-FB5E-4836-AA80-6301F4DD5AB6"><gtr:id>4A179E2C-FB5E-4836-AA80-6301F4DD5AB6</gtr:id><gtr:name>University of Sydney</gtr:name><gtr:address><gtr:line1>University of Sydney</gtr:line1><gtr:region>Outside UK</gtr:region><gtr:country>Australia</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/190D7A48-DDE9-433F-A7CE-FF7ED52FE177"><gtr:id>190D7A48-DDE9-433F-A7CE-FF7ED52FE177</gtr:id><gtr:name>Acylbadem Oncology and Neurological Science Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/28DF10CD-6250-442A-804C-A8710CF218D1"><gtr:id>28DF10CD-6250-442A-804C-A8710CF218D1</gtr:id><gtr:name>University of Bern</gtr:name><gtr:address><gtr:line1>Universitat Bern</gtr:line1><gtr:line2>Sidlerstrasse 5</gtr:line2><gtr:line4>Bern</gtr:line4><gtr:line5>CH-3012</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Switzerland</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/660C6724-6599-4A53-98E3-F6B84E80A04E"><gtr:id>660C6724-6599-4A53-98E3-F6B84E80A04E</gtr:id><gtr:name>American College of Radiology (ACR)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/F25BC0C5-5284-441F-B79F-A61707946CA0"><gtr:id>F25BC0C5-5284-441F-B79F-A61707946CA0</gtr:id><gtr:name>University of California Los Angeles</gtr:name><gtr:address><gtr:line1>405 Hillgard Avenue</gtr:line1><gtr:line2>Box 951361</gtr:line2><gtr:postCode>90095</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/F7B8A23C-8C70-4939-AD44-01BA9FEEFDDC"><gtr:id>F7B8A23C-8C70-4939-AD44-01BA9FEEFDDC</gtr:id><gtr:name>Osaka Medical Center for Cancer and Cardiovascular Diseases</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/E09F2D7D-023E-4EBF-9408-DA60760176A7"><gtr:id>E09F2D7D-023E-4EBF-9408-DA60760176A7</gtr:id><gtr:name>International Academy of Environmental Sciences (IAES)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/CF449342-AF1A-4D3F-B833-8F6DB8687F7D"><gtr:id>CF449342-AF1A-4D3F-B833-8F6DB8687F7D</gtr:id><gtr:name>Uppsala University Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/C8C5D55B-121D-41A9-9B83-BA5DA0F0BAB8"><gtr:id>C8C5D55B-121D-41A9-9B83-BA5DA0F0BAB8</gtr:id><gtr:name>SG Moscati Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/473F7B5C-70FE-4079-A7A4-9B33054D3495"><gtr:id>473F7B5C-70FE-4079-A7A4-9B33054D3495</gtr:id><gtr:name>University of Rome I (La Sapienza)</gtr:name><gtr:address><gtr:line1>University of Rome</gtr:line1><gtr:line2>Via Pietro Roselli</gtr:line2><gtr:region>Outside UK</gtr:region><gtr:country>Italy</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/430A04B6-0F63-43BA-B78B-8DD4147CAF43"><gtr:id>430A04B6-0F63-43BA-B78B-8DD4147CAF43</gtr:id><gtr:name>University of Paris South 11</gtr:name><gtr:address><gtr:line1>Batiment 300</gtr:line1><gtr:line4>Orsay cedex</gtr:line4><gtr:line5>F-91405</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>France</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/43BEDA5F-E824-412D-A4AC-ED7F1139F5CC"><gtr:id>43BEDA5F-E824-412D-A4AC-ED7F1139F5CC</gtr:id><gtr:name>University of Turin</gtr:name><gtr:address><gtr:line1>Via Giuseppe Verdi 8</gtr:line1><gtr:postCode>I-10124</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/866F91B4-4A6C-4FD3-9023-600DEE062CED"><gtr:id>866F91B4-4A6C-4FD3-9023-600DEE062CED</gtr:id><gtr:name>Tom Baker Cancer Center</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/E20F47CA-8AB4-4F4D-A90D-A290834C65FF"><gtr:id>E20F47CA-8AB4-4F4D-A90D-A290834C65FF</gtr:id><gtr:name>University Hospital Coventry NHS Trust</gtr:name><gtr:address><gtr:line1>Clifford Bridge Road</gtr:line1><gtr:line2>Walsgrave</gtr:line2><gtr:postCode>CV2 2DX</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/E4E1DAA0-8180-41F1-9351-540577DB2B5F"><gtr:id>E4E1DAA0-8180-41F1-9351-540577DB2B5F</gtr:id><gtr:name>Saarland University</gtr:name><gtr:address><gtr:line1>Main Campus</gtr:line1><gtr:line2>Stuhlsatzenhausweg</gtr:line2><gtr:postCode>D-66123</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Germany</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3AB95F1D-E1ED-4D29-8962-0AFCCC8C3B88"><gtr:id>3AB95F1D-E1ED-4D29-8962-0AFCCC8C3B88</gtr:id><gtr:name>TwoCan Associates</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/9CC0A93E-2E80-48EA-8EEB-B34AF125B454"><gtr:id>9CC0A93E-2E80-48EA-8EEB-B34AF125B454</gtr:id><gtr:name>Cancer and Leukaemia Group B</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/B8E667D9-2ADA-46CF-BCD6-6188767B084A"><gtr:id>B8E667D9-2ADA-46CF-BCD6-6188767B084A</gtr:id><gtr:name>Institute for Oncology and Radiology of Serbia</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/EDB80D14-0821-4499-B1A7-5B12CA49F487"><gtr:id>EDB80D14-0821-4499-B1A7-5B12CA49F487</gtr:id><gtr:name>Gynaecologic Oncology Group GOC</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3B6DCB87-479A-4C53-94E2-B62D0DCE8BB7"><gtr:id>3B6DCB87-479A-4C53-94E2-B62D0DCE8BB7</gtr:id><gtr:name>British Columbia Cancer Agency (BCCA)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/8218E276-85FA-4CD5-86AA-232A830B5037"><gtr:id>8218E276-85FA-4CD5-86AA-232A830B5037</gtr:id><gtr:name>University of Texas at San Antonio</gtr:name><gtr:address><gtr:line1>One UTSA Circle</gtr:line1><gtr:line4>San Antonio</gtr:line4><gtr:line5>TX 78249-1644</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/E93A8558-613B-451F-88F8-964379B61001"><gtr:id>E93A8558-613B-451F-88F8-964379B61001</gtr:id><gtr:name>Auckland City Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/150CE820-6372-414E-9F7F-524E27034E23"><gtr:id>150CE820-6372-414E-9F7F-524E27034E23</gtr:id><gtr:name>University of Colorado at Boulder</gtr:name><gtr:address><gtr:line1>Boulder</gtr:line1><gtr:line4>Colorado</gtr:line4><gtr:line5>80309-0425</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/7FB580F4-0B61-43BD-9C4B-FF74C52464BC"><gtr:id>7FB580F4-0B61-43BD-9C4B-FF74C52464BC</gtr:id><gtr:name>Penn State Milton S. Hershey Medical Center</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/4419EA3A-4FB7-4587-B99E-604A19065313"><gtr:id>4419EA3A-4FB7-4587-B99E-604A19065313</gtr:id><gtr:name>Laval Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/4EBF3DC3-B4A4-4E4E-B13D-284698AA70D7"><gtr:id>4EBF3DC3-B4A4-4E4E-B13D-284698AA70D7</gtr:id><gtr:name>Dana-Farber Cancer Institute</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/4D0DCB45-3ED8-494B-8C55-B5E8DF9DB522"><gtr:id>4D0DCB45-3ED8-494B-8C55-B5E8DF9DB522</gtr:id><gtr:name>UNLISTED</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/6F589F40-E565-4758-ABB8-E5998A94450E"><gtr:id>6F589F40-E565-4758-ABB8-E5998A94450E</gtr:id><gtr:name>Guangdong General Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/6FF9A7D0-4C9E-4FE4-9A31-477B6D9031B1"><gtr:id>6FF9A7D0-4C9E-4FE4-9A31-477B6D9031B1</gtr:id><gtr:name>Trondheim University Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/274F2FB0-27BB-4991-A894-796A2AE916E3"><gtr:id>274F2FB0-27BB-4991-A894-796A2AE916E3</gtr:id><gtr:name>The Christie NHS Foundation Trust</gtr:name><gtr:address><gtr:line1>Wilmslow Road</gtr:line1><gtr:city>Manchester</gtr:city><gtr:postCode>M20 4BX</gtr:postCode><gtr:region>North West</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/696A0A2F-736F-4546-B0F4-F347F0F8488E"><gtr:id>696A0A2F-736F-4546-B0F4-F347F0F8488E</gtr:id><gtr:name>Freeman Hospital</gtr:name><gtr:address><gtr:line1>Liver and Renal Transplant Unit
Freeman Hospital
Freeman Road
High Heaton</gtr:line1><gtr:city>Newcastle Upon Tyne</gtr:city><gtr:postCode>NE7 7DN</gtr:postCode><gtr:region>North East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/4E55B119-02E7-43F3-9B39-DD48A6511372"><gtr:id>4E55B119-02E7-43F3-9B39-DD48A6511372</gtr:id><gtr:name>Addenbrooke's Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/05D69417-BE9F-4C72-B26A-053781697575"><gtr:id>05D69417-BE9F-4C72-B26A-053781697575</gtr:id><gtr:name>Sunnybrook Health Sciences Centre</gtr:name><gtr:address><gtr:line1>Sunnybrook Health Sciences Centre</gtr:line1><gtr:line2>5112-2075 Bayview Ave</gtr:line2><gtr:postCode>M4N 3M5</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/624FC0B7-618B-4A6A-B844-5A775EE3819E"><gtr:id>624FC0B7-618B-4A6A-B844-5A775EE3819E</gtr:id><gtr:name>Duke University Health System</gtr:name><gtr:address><gtr:line1>3100 Tower Blvd. Suite 1008</gtr:line1><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/88B8928E-4F94-4628-BBA4-83727B3185C9"><gtr:id>88B8928E-4F94-4628-BBA4-83727B3185C9</gtr:id><gtr:name>Cross Cancer Institute</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/89833E38-8292-47CC-82C3-394FE46D889E"><gtr:id>89833E38-8292-47CC-82C3-394FE46D889E</gtr:id><gtr:name>University of Arizona</gtr:name><gtr:address><gtr:line1>617 N. Santa Rita Ave.</gtr:line1><gtr:line4>Tucson</gtr:line4><gtr:line5>Arizona</gtr:line5><gtr:postCode>AZ 85721</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/2E9AC78C-5AED-4387-A74B-E8561E9FE1C9"><gtr:id>2E9AC78C-5AED-4387-A74B-E8561E9FE1C9</gtr:id><gtr:name>Velindre Cancer Centre</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/297E114F-009E-4736-A80D-4B51D14BD69B"><gtr:id>297E114F-009E-4736-A80D-4B51D14BD69B</gtr:id><gtr:name>Brussels Saint-Luc University Hospital (UCL)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/4A4090D5-D795-4C4B-8A6B-00D25830130F"><gtr:id>4A4090D5-D795-4C4B-8A6B-00D25830130F</gtr:id><gtr:name>University of Duisburg-Essen</gtr:name><gtr:address><gtr:line1>University of Duisburg-Essen</gtr:line1><gtr:line2>Geibelstrase 41</gtr:line2><gtr:line4>Duisburg</gtr:line4><gtr:line5>D-47057</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Germany</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/F666078A-E9B5-4012-916F-07E418EFFB3D"><gtr:id>F666078A-E9B5-4012-916F-07E418EFFB3D</gtr:id><gtr:name>Rene Gauducheau Centre</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/A86004C8-2B5A-4D93-AFC0-4EC170FE24C6"><gtr:id>A86004C8-2B5A-4D93-AFC0-4EC170FE24C6</gtr:id><gtr:name>Germans University Hospital</gtr:name><gtr:address><gtr:line1>Trias i Pujol</gtr:line1><gtr:line2>Carretera del Canyet</gtr:line2><gtr:region>Unknown</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/1B847C1D-9166-4D93-887B-E57CBE4FAC09"><gtr:id>1B847C1D-9166-4D93-887B-E57CBE4FAC09</gtr:id><gtr:name>Ospedale di Circolo e Fondazione Macchi</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/AE36032A-B18A-496F-A445-75C83AA52EDC"><gtr:id>AE36032A-B18A-496F-A445-75C83AA52EDC</gtr:id><gtr:name>Centre for Research and Implementation of Clinical Practice</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/37EF6C9C-5F51-40DD-BED5-B792981BC119"><gtr:id>37EF6C9C-5F51-40DD-BED5-B792981BC119</gtr:id><gtr:name>Imperial Cancer Research Fund</gtr:name><gtr:address><gtr:line1>44 Lincoln's Inn Fields</gtr:line1><gtr:postCode>WC2A 3PX</gtr:postCode><gtr:region>London</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/7B5B059B-D11D-4216-BAC4-CBFF7E5E3C2C"><gtr:id>7B5B059B-D11D-4216-BAC4-CBFF7E5E3C2C</gtr:id><gtr:name>Academic Medical Center</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/4D413F6A-74CA-41ED-915A-69079B55117F"><gtr:id>4D413F6A-74CA-41ED-915A-69079B55117F</gtr:id><gtr:name>University Hospitals Bristol NHS Foundation Trust</gtr:name><gtr:address><gtr:postCode>BS2 8HW</gtr:postCode><gtr:region>South West</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/E42FE499-D972-48A3-ACFC-4873BA7FAD17"><gtr:id>E42FE499-D972-48A3-ACFC-4873BA7FAD17</gtr:id><gtr:name>Sanjay Gandhi Postgrad Inst Med Sciences</gtr:name><gtr:address><gtr:line1>Sanjay Gandhi Postgrad Inst of Med Sci</gtr:line1><gtr:line2>Raebareli Road</gtr:line2><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/69EC6DC4-ACF4-452D-B2AC-0AD52C33A7B9"><gtr:id>69EC6DC4-ACF4-452D-B2AC-0AD52C33A7B9</gtr:id><gtr:name>Crozer-Keystone Health System</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/95130295-6141-4FEB-B5DA-4EC76F5B5DC0"><gtr:id>95130295-6141-4FEB-B5DA-4EC76F5B5DC0</gtr:id><gtr:name>Christiana Care Health System</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D739677A-6514-46E5-821F-22EEA573D62A"><gtr:id>D739677A-6514-46E5-821F-22EEA573D62A</gtr:id><gtr:name>University of Ghent</gtr:name><gtr:address><gtr:line1>Rectorate Building</gtr:line1><gtr:line2>Sint-Pietersnieuwstraat 25</gtr:line2><gtr:line3>Krijgslaan</gtr:line3><gtr:postCode>B-9000</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Belgium</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D07BED4C-30ED-4568-9697-9F14A111D7DD"><gtr:id>D07BED4C-30ED-4568-9697-9F14A111D7DD</gtr:id><gtr:name>St Woolos Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/F20FFE5B-3DA6-4629-894F-4CE13B49B4E4"><gtr:id>F20FFE5B-3DA6-4629-894F-4CE13B49B4E4</gtr:id><gtr:name>Vanderbilt University</gtr:name><gtr:address><gtr:line1>Vanderbilt University</gtr:line1><gtr:line2>2201 West End Avenue</gtr:line2><gtr:line4>Nashville</gtr:line4><gtr:line5>Tennessee</gtr:line5><gtr:postCode>TN 37235</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/52D361BC-CE18-46F1-8FFD-655C734C9437"><gtr:id>52D361BC-CE18-46F1-8FFD-655C734C9437</gtr:id><gtr:name>Centro Hospitalario Pereira Rossell CHPR</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/8A31C41F-3CB1-48A0-86D7-014ACCF7D207"><gtr:id>8A31C41F-3CB1-48A0-86D7-014ACCF7D207</gtr:id><gtr:name>G?lhane Military Medical Academy (GATA), Turkey</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/F463A0E1-E89E-406B-B803-760625885B6C"><gtr:id>F463A0E1-E89E-406B-B803-760625885B6C</gtr:id><gtr:name>Hospital Universitario La Paz</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/B589281B-BE51-4D64-96A8-B62BDE6E23AB"><gtr:id>B589281B-BE51-4D64-96A8-B62BDE6E23AB</gtr:id><gtr:name>Canadian Cancer Society Research Institute (CCSRI)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/1B81D5AE-90EB-42E6-855F-A0F582DA5820"><gtr:id>1B81D5AE-90EB-42E6-855F-A0F582DA5820</gtr:id><gtr:name>Royal North Shore Hospital</gtr:name><gtr:address><gtr:line1>St Lenards</gtr:line1><gtr:postCode>2065</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/191F0D78-2079-48F1-B2D5-7D8526A8EDB4"><gtr:id>191F0D78-2079-48F1-B2D5-7D8526A8EDB4</gtr:id><gtr:name>Hyogo College of Medicine</gtr:name><gtr:address><gtr:line1>Hyogo College of Medicine</gtr:line1><gtr:line2>1-1 Mukogawa-cho</gtr:line2><gtr:line3>Nishinomiya</gtr:line3><gtr:postCode>663-8501</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/E0416AD8-4131-44FC-A547-39F780732240"><gtr:id>E0416AD8-4131-44FC-A547-39F780732240</gtr:id><gtr:name>Thomas Jefferson University</gtr:name><gtr:address><gtr:line1>Thomas Jefferson University</gtr:line1><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/5016B9BE-A15B-4B53-99A3-1DBE28399D47"><gtr:id>5016B9BE-A15B-4B53-99A3-1DBE28399D47</gtr:id><gtr:name>Academy of Medical Royal Colleges</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/344C9D60-ABF6-4230-8E37-2A46E48B1A22"><gtr:id>344C9D60-ABF6-4230-8E37-2A46E48B1A22</gtr:id><gtr:name>Chiba Cancer Center</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/F7B72D66-6B48-471E-8545-F319BE19C9DD"><gtr:id>F7B72D66-6B48-471E-8545-F319BE19C9DD</gtr:id><gtr:name>John H. Stroger Jr. Hospital (formerly Cook County Hospital)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/5A638CD5-2C73-4056-B703-F711C9E0F970"><gtr:id>5A638CD5-2C73-4056-B703-F711C9E0F970</gtr:id><gtr:name>Sun Yat-Sen University</gtr:name><gtr:address><gtr:line1>135 Xingang Xi Road</gtr:line1><gtr:postCode>510275</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>China</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/0E4C8B40-2D9E-4CCE-9A90-EF87DCB2448E"><gtr:id>0E4C8B40-2D9E-4CCE-9A90-EF87DCB2448E</gtr:id><gtr:name>Liverpool Womens NHS Foundation Trust</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/37511276-C1B7-47AF-8663-A244596C825C"><gtr:id>37511276-C1B7-47AF-8663-A244596C825C</gtr:id><gtr:name>Tel Aviv University</gtr:name><gtr:address><gtr:line1>Tel Aviv University</gtr:line1><gtr:line2>PO Box 39040</gtr:line2><gtr:line4>Tel Aviv</gtr:line4><gtr:postCode>69978</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Israel</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/BB51DA9F-7A3E-4A34-8399-58D1F14E5EAE"><gtr:id>BB51DA9F-7A3E-4A34-8399-58D1F14E5EAE</gtr:id><gtr:name>Catalan Institute of Oncology</gtr:name><gtr:address><gtr:line1>Gran Via km 2,7</gtr:line1><gtr:postCode>08907</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/93B13D3A-863C-46E8-A4C7-1EE4759A7E9B"><gtr:id>93B13D3A-863C-46E8-A4C7-1EE4759A7E9B</gtr:id><gtr:name>Cleveland Clinic</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/ADB14AFF-F6DF-4144-A743-0AAE3D33973D"><gtr:id>ADB14AFF-F6DF-4144-A743-0AAE3D33973D</gtr:id><gtr:name>European Organisation for Research and Treatment of Cancer (EORTC)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3606C3ED-A577-408B-B772-36C9080CDAF9"><gtr:id>3606C3ED-A577-408B-B772-36C9080CDAF9</gtr:id><gtr:name>Universite Montpellier</gtr:name><gtr:address><gtr:line1>Service Communication</gtr:line1><gtr:line2>5 bd Henri IV - BP 1017</gtr:line2><gtr:line3>34006 Montpellier Cedex 1</gtr:line3><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/35B1EB39-F65C-4235-983E-475C6967F150"><gtr:id>35B1EB39-F65C-4235-983E-475C6967F150</gtr:id><gtr:name>Tygerberg Children?s Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/51FAE27D-6F57-4089-98B0-E0F4BB1DE196"><gtr:id>51FAE27D-6F57-4089-98B0-E0F4BB1DE196</gtr:id><gtr:name>Piti?-Salp?tri?re Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/2448D059-1C4B-4E76-A4C6-8A3109B8F194"><gtr:id>2448D059-1C4B-4E76-A4C6-8A3109B8F194</gtr:id><gtr:name>University of Gothenburg</gtr:name><gtr:address><gtr:line1>University of Gothenburg</gtr:line1><gtr:line2>PO Box 100</gtr:line2><gtr:line4>Gothenburg</gtr:line4><gtr:line5>SE 405 30</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Sweden</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/CE4FA0EC-37EA-4B26-BA91-4528C959C227"><gtr:id>CE4FA0EC-37EA-4B26-BA91-4528C959C227</gtr:id><gtr:name>Gustave-Roussy Institute</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/645ADF06-01C7-45C1-A485-7102A948B2E5"><gtr:id>645ADF06-01C7-45C1-A485-7102A948B2E5</gtr:id><gtr:name>Smith and Nephew</gtr:name><gtr:address><gtr:line1>York Science Park</gtr:line1><gtr:line2>Heslington</gtr:line2><gtr:line4>York</gtr:line4><gtr:postCode>YO10 5DF</gtr:postCode><gtr:region>Yorkshire and The Humber</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/CB9B10BA-1677-4A30-A18D-A23D972A0C8F"><gtr:id>CB9B10BA-1677-4A30-A18D-A23D972A0C8F</gtr:id><gtr:name>National Kyushu Cancer Center</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/FC59975E-26E8-4A62-ABD8-A570DC6ABF06"><gtr:id>FC59975E-26E8-4A62-ABD8-A570DC6ABF06</gtr:id><gtr:name>Keele University</gtr:name><gtr:address><gtr:line1>Keele</gtr:line1><gtr:line4>Newcastle</gtr:line4><gtr:line5>Staffordshire</gtr:line5><gtr:postCode>ST5 5BG</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/9C932CFE-AAE2-4A8F-A53F-1C7EAC961997"><gtr:id>9C932CFE-AAE2-4A8F-A53F-1C7EAC961997</gtr:id><gtr:name>Harvard University</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/C2EF8978-093D-41F5-98DD-8A459F24C070"><gtr:id>C2EF8978-093D-41F5-98DD-8A459F24C070</gtr:id><gtr:name>Wilhelminen Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/E88920F1-18FE-4D53-8B47-60A86652F503"><gtr:id>E88920F1-18FE-4D53-8B47-60A86652F503</gtr:id><gtr:name>Vejle Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/E9740D79-1063-4735-90E0-EF9CD1DA4587"><gtr:id>E9740D79-1063-4735-90E0-EF9CD1DA4587</gtr:id><gtr:name>Osaka City General Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/A0A585E0-6B0D-4643-A3A6-47943B4CBFEF"><gtr:id>A0A585E0-6B0D-4643-A3A6-47943B4CBFEF</gtr:id><gtr:name>University of Liverpool</gtr:name><gtr:address><gtr:line1>Senate House</gtr:line1><gtr:line2>Abercromby Square</gtr:line2><gtr:line4>Liverpool</gtr:line4><gtr:postCode>L69 3BX</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/CECDEE86-7EB0-4FEC-A2D9-D3B3F8C27F0F"><gtr:id>CECDEE86-7EB0-4FEC-A2D9-D3B3F8C27F0F</gtr:id><gtr:name>Helsinki University Central Hospital</gtr:name><gtr:address><gtr:line1>Stenbackinkatu 9</gtr:line1><gtr:postCode>SF 00290</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/192FC2D6-F07B-4A8F-AEDC-B4BCC69F6367"><gtr:id>192FC2D6-F07B-4A8F-AEDC-B4BCC69F6367</gtr:id><gtr:name>Mansoura University</gtr:name><gtr:address><gtr:line1>Mansoura University</gtr:line1><gtr:postCode>35516</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/C1CE3B13-A79B-48B7-9B8D-97BC9C07DC78"><gtr:id>C1CE3B13-A79B-48B7-9B8D-97BC9C07DC78</gtr:id><gtr:name>Netherlands Cancer Institute</gtr:name><gtr:address><gtr:line1>Plesmanlaan 121</gtr:line1><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/7EA47BE9-7A59-4B93-8E05-D2A186CD8F28"><gtr:id>7EA47BE9-7A59-4B93-8E05-D2A186CD8F28</gtr:id><gtr:name>Chiang Mai University</gtr:name><gtr:address><gtr:line1>Suthep  Muang</gtr:line1><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/856A7EAA-C834-4DBE-8764-98C315C40614"><gtr:id>856A7EAA-C834-4DBE-8764-98C315C40614</gtr:id><gtr:name>Mario Negri Institute for Pharmacological Research</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/202F8631-BFC1-4C0A-BA3E-B8038FDBA639"><gtr:id>202F8631-BFC1-4C0A-BA3E-B8038FDBA639</gtr:id><gtr:name>Oncology Institute of Vojvodina</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/CED0B9B7-1A47-4541-89C2-00CA9E9AF8E4"><gtr:id>CED0B9B7-1A47-4541-89C2-00CA9E9AF8E4</gtr:id><gtr:name>Cedars-Sinai Medical Center</gtr:name><gtr:address><gtr:line1>8700 Beverley BI #8211</gtr:line1><gtr:postCode>90048</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D3B5235B-CC4A-4B38-8E39-5179BAFB4DE7"><gtr:id>D3B5235B-CC4A-4B38-8E39-5179BAFB4DE7</gtr:id><gtr:name>Birmingham Heartlands Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/B45B1016-314C-4E6E-9977-AF23B544953B"><gtr:id>B45B1016-314C-4E6E-9977-AF23B544953B</gtr:id><gtr:name>Tokyo Medical and Dental University</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/E68BE577-6C17-48CE-B65C-24C477BB8AE9"><gtr:id>E68BE577-6C17-48CE-B65C-24C477BB8AE9</gtr:id><gtr:name>Yeshiva University</gtr:name><gtr:address><gtr:line1>500 West 185th Street</gtr:line1><gtr:postCode>10033</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/AE58F21F-3622-4382-97BB-1359BD183E9F"><gtr:id>AE58F21F-3622-4382-97BB-1359BD183E9F</gtr:id><gtr:name>University of Glasgow</gtr:name><gtr:address><gtr:line1>University Avenue</gtr:line1><gtr:line4>Glasgow</gtr:line4><gtr:postCode>G12 8QQ</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/C3992259-C19F-4FE5-9C01-210C819D7264"><gtr:id>C3992259-C19F-4FE5-9C01-210C819D7264</gtr:id><gtr:name>Yale University</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/4C02B63A-6450-44EE-B38C-5D2C0C38D1E8"><gtr:id>4C02B63A-6450-44EE-B38C-5D2C0C38D1E8</gtr:id><gtr:name>University of Rome II (Tor Vergata)</gtr:name><gtr:address><gtr:line1>via Columbia, 2</gtr:line1><gtr:line4>Roma</gtr:line4><gtr:line5>I-00133</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Italy</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/7DD38B9D-A65B-4D0F-8612-8384BD01394D"><gtr:id>7DD38B9D-A65B-4D0F-8612-8384BD01394D</gtr:id><gtr:name>Tohoku University</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3411CDF4-C540-4081-BAB5-3535A68490D4"><gtr:id>3411CDF4-C540-4081-BAB5-3535A68490D4</gtr:id><gtr:name>Korea Cancer Center Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/A8967420-49D3-4509-9912-25FB3EC75B74"><gtr:id>A8967420-49D3-4509-9912-25FB3EC75B74</gtr:id><gtr:name>University of Sussex</gtr:name><gtr:address><gtr:line1>The Administration</gtr:line1><gtr:line2>Sussex House</gtr:line2><gtr:line3>Falmer</gtr:line3><gtr:line4>Brighton</gtr:line4><gtr:line5>East Sussex</gtr:line5><gtr:postCode>BN1 9RH</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/37B04F53-AFDA-41A8-8216-1EEE7410C7DC"><gtr:id>37B04F53-AFDA-41A8-8216-1EEE7410C7DC</gtr:id><gtr:name>Leicester Royal Infirmary</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/6E068768-8705-4101-8F7E-1B286A2B9B9E"><gtr:id>6E068768-8705-4101-8F7E-1B286A2B9B9E</gtr:id><gtr:name>Strasbourgs University Hospitals</gtr:name><gtr:address><gtr:line1>1 place hopital</gtr:line1><gtr:line2>BP 426, Cedex</gtr:line2><gtr:postCode>cedex67091</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/499467F4-0221-40A6-9DCD-F20F4A09C653"><gtr:id>499467F4-0221-40A6-9DCD-F20F4A09C653</gtr:id><gtr:name>Yokohama City University Medical Centre</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/6721980D-6BE8-41E3-9D78-9F76474E1AAC"><gtr:id>6721980D-6BE8-41E3-9D78-9F76474E1AAC</gtr:id><gtr:name>Cancer Institute of the Loire</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/EF46D1B5-9EE9-459F-8D6D-68C3987370BD"><gtr:id>EF46D1B5-9EE9-459F-8D6D-68C3987370BD</gtr:id><gtr:name>University Hospitals of Leicester NHS</gtr:name><gtr:address><gtr:line1>Leicester Royal Infirmary</gtr:line1><gtr:line2>Infirmary Square</gtr:line2><gtr:line4>Leicester</gtr:line4><gtr:postCode>LE1 5WW</gtr:postCode><gtr:region>East Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/A682D253-DEE6-4EE1-89B0-21F1351C632C"><gtr:id>A682D253-DEE6-4EE1-89B0-21F1351C632C</gtr:id><gtr:name>National Cancer Institute (NCI)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/76CD45AC-378E-4073-94E5-C7DFBA3B4719"><gtr:id>76CD45AC-378E-4073-94E5-C7DFBA3B4719</gtr:id><gtr:name>University of Turku</gtr:name><gtr:address><gtr:line1>Turun yliopisto</gtr:line1><gtr:postCode>FI-20014</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Finland</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/EF8EDD94-E846-412E-B59C-51D4D000D9E2"><gtr:id>EF8EDD94-E846-412E-B59C-51D4D000D9E2</gtr:id><gtr:name>Nagoya University</gtr:name><gtr:address><gtr:line1>Furo-cho</gtr:line1><gtr:line2>Chikusa-ku</gtr:line2><gtr:line4>Nagoya City</gtr:line4><gtr:line5>Aichi Prefecture</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Japan</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/FA04CA23-EB82-46AF-B73D-67FF08E5576E"><gtr:id>FA04CA23-EB82-46AF-B73D-67FF08E5576E</gtr:id><gtr:name>University of Ancona</gtr:name><gtr:address><gtr:line1>Faculty of Medicine</gtr:line1><gtr:postCode>I-60020</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/F44FC935-8229-45D0-832A-AF35C6A449BF"><gtr:id>F44FC935-8229-45D0-832A-AF35C6A449BF</gtr:id><gtr:name>Churchill Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/4051BFFD-1763-4071-82C2-32589D76267C"><gtr:id>4051BFFD-1763-4071-82C2-32589D76267C</gtr:id><gtr:name>Herlev Hospital</gtr:name><gtr:address><gtr:line1>Herlev Ringvej 75</gtr:line1><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/7254835D-A811-460C-ACFC-C345775924B4"><gtr:id>7254835D-A811-460C-ACFC-C345775924B4</gtr:id><gtr:name>The Cochrane Collaboration</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D5337A10-AC8A-402A-8164-C5F9CC6B0140"><gtr:id>D5337A10-AC8A-402A-8164-C5F9CC6B0140</gtr:id><gtr:name>Queen Mary, University of London</gtr:name><gtr:address><gtr:line1>Mile End Road</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>E1 4NS</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/62C544E8-A6D5-4B0C-9773-7A30B21F968D"><gtr:id>62C544E8-A6D5-4B0C-9773-7A30B21F968D</gtr:id><gtr:name>University of Padua</gtr:name><gtr:address><gtr:line1>Universita di Padova</gtr:line1><gtr:line4>Padova</gtr:line4><gtr:postCode>35129</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Italy</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/C5EA3B28-18A9-4243-9F44-F2A3ADACF4C8"><gtr:id>C5EA3B28-18A9-4243-9F44-F2A3ADACF4C8</gtr:id><gtr:name>Glenfield Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/9C10D78F-6430-4CA7-9528-B96B0762A4C6"><gtr:id>9C10D78F-6430-4CA7-9528-B96B0762A4C6</gtr:id><gtr:name>Cardiff University</gtr:name><gtr:address><gtr:line1>Research &amp; Consultancy</gtr:line1><gtr:line2>PO Box 923</gtr:line2><gtr:line4>Cardiff</gtr:line4><gtr:line5>South Glamorgan</gtr:line5><gtr:postCode>CF10 3TE</gtr:postCode><gtr:region>Wales</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/55AC985A-E874-4B03-85AB-153EAEDAF97E"><gtr:id>55AC985A-E874-4B03-85AB-153EAEDAF97E</gtr:id><gtr:name>Princess Margaret Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/A22A48AB-B677-4DE2-B6ED-8E091A525301"><gtr:id>A22A48AB-B677-4DE2-B6ED-8E091A525301</gtr:id><gtr:name>San Luigi Gonzaga Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/E913F6AA-9FFC-4300-83DB-799EC8F3A4E7"><gtr:id>E913F6AA-9FFC-4300-83DB-799EC8F3A4E7</gtr:id><gtr:name>University of Maryland</gtr:name><gtr:address><gtr:line1>University of Maryland</gtr:line1><gtr:postCode>20742</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/7987E388-1901-4D22-8F24-FA5E3F4D55B5"><gtr:id>7987E388-1901-4D22-8F24-FA5E3F4D55B5</gtr:id><gtr:name>Albany Medical College (AMC)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/2D017FB7-303D-48E6-AAFF-06303F046804"><gtr:id>2D017FB7-303D-48E6-AAFF-06303F046804</gtr:id><gtr:name>Royal Marsden NHS Foundation Trust</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/805FCB03-15BE-4D11-AEF9-8309B623E173"><gtr:id>805FCB03-15BE-4D11-AEF9-8309B623E173</gtr:id><gtr:name>Bordet Institute (Institut Jules Bordet)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/72F4A4EA-BEBF-47BB-AC75-CD8157D7B17C"><gtr:id>72F4A4EA-BEBF-47BB-AC75-CD8157D7B17C</gtr:id><gtr:name>Tata Memorial Hospital</gtr:name><gtr:address><gtr:line1>Cancer Research Centre</gtr:line1><gtr:line2>Dr. E Borges Road</gtr:line2><gtr:postCode>400 012</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/86BA0D2C-1895-41C5-B18C-092178DFFB3E"><gtr:id>86BA0D2C-1895-41C5-B18C-092178DFFB3E</gtr:id><gtr:name>National Institute for Health Research</gtr:name><gtr:address><gtr:line1>NIHR Clinical Research Network CC</gtr:line1><gtr:line2>Fairbairn House</gtr:line2><gtr:line3>71-75 Clarendon Road</gtr:line3><gtr:postCode>LS2 9PH</gtr:postCode><gtr:region>Yorkshire and the Humber</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/6EF3B963-88BD-4EA0-BDFE-60C742501F07"><gtr:id>6EF3B963-88BD-4EA0-BDFE-60C742501F07</gtr:id><gtr:name>Memorial Sloan Kettering Cancer Center</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/C7FBE408-C743-4AAC-9BC6-65E14BC8D2FD"><gtr:id>C7FBE408-C743-4AAC-9BC6-65E14BC8D2FD</gtr:id><gtr:name>Karolinska Institute</gtr:name><gtr:address><gtr:line1>Administration</gtr:line1><gtr:line4>Stockholm</gtr:line4><gtr:postCode>SE-171 77</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Sweden</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/9ACD02BB-EC4C-4346-A6A0-801468590A83"><gtr:id>9ACD02BB-EC4C-4346-A6A0-801468590A83</gtr:id><gtr:name>Tufts University</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/DAC6A24E-71C2-476D-80D2-7CF844CDBA16"><gtr:id>DAC6A24E-71C2-476D-80D2-7CF844CDBA16</gtr:id><gtr:name>Queen Elizabeth Hospital Birmingham</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/9F7C81EF-E4F5-45C5-A902-F4CAB61D4A82"><gtr:id>9F7C81EF-E4F5-45C5-A902-F4CAB61D4A82</gtr:id><gtr:name>NHS Greater Glasgow and Clyde (NHSGGC)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/8319F78A-DCBD-49F6-BE00-78E1CD75CDA9"><gtr:id>8319F78A-DCBD-49F6-BE00-78E1CD75CDA9</gtr:id><gtr:name>University of York</gtr:name><gtr:address><gtr:line1>Heslington</gtr:line1><gtr:line4>York</gtr:line4><gtr:line5>North Yorkshire</gtr:line5><gtr:postCode>YO10 5DD</gtr:postCode><gtr:region>Yorkshire and The Humber</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/78308CAA-8483-45C0-A280-0AB4B6AD9D35"><gtr:id>78308CAA-8483-45C0-A280-0AB4B6AD9D35</gtr:id><gtr:name>Medical Research Council</gtr:name><gtr:address><gtr:line1>Polaris House</gtr:line1><gtr:line2>North Star Avenue</gtr:line2><gtr:postCode>SN2 1FL</gtr:postCode><gtr:region>South West</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/A21478EA-E506-4B64-A8A9-42CD8D97C635"><gtr:id>A21478EA-E506-4B64-A8A9-42CD8D97C635</gtr:id><gtr:name>University College London Hospital (UCLH) NHS Foundation Trust</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/F5B83740-823A-461B-AEB6-0DCFED1739C8"><gtr:id>F5B83740-823A-461B-AEB6-0DCFED1739C8</gtr:id><gtr:name>Kyoto University</gtr:name><gtr:address><gtr:line1>Nishikyo-ku</gtr:line1><gtr:line2>Katsura Campus</gtr:line2><gtr:line4>Kyoto</gtr:line4><gtr:line5>Kyoto, 615-8540</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Japan</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/8C250FB6-4890-4BF9-9C23-69E6B2E02B95"><gtr:id>8C250FB6-4890-4BF9-9C23-69E6B2E02B95</gtr:id><gtr:name>Wake Forest University</gtr:name><gtr:address><gtr:line1>Wake Forest University</gtr:line1><gtr:line2>1834 Wakeforest Road</gtr:line2><gtr:line4>Winston Salem</gtr:line4><gtr:line5>North Carolina</gtr:line5><gtr:postCode>NC 27106</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/80B2EC09-0DBD-4D7B-961C-237A5525F7B0"><gtr:id>80B2EC09-0DBD-4D7B-961C-237A5525F7B0</gtr:id><gtr:name>University of Iowa Hospitals and Clinics</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/A28252F6-AD97-4A7D-82EF-6489C2EB868E"><gtr:id>A28252F6-AD97-4A7D-82EF-6489C2EB868E</gtr:id><gtr:name>Royal Prince Alfred Hospital (RPAH) Sydney</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/E65D5505-6DF9-4801-9019-B9EDE5D0EE5D"><gtr:id>E65D5505-6DF9-4801-9019-B9EDE5D0EE5D</gtr:id><gtr:name>University Medical Center Gronigen</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/DC2AF7CF-815A-42A1-A947-BE95916B963C"><gtr:id>DC2AF7CF-815A-42A1-A947-BE95916B963C</gtr:id><gtr:name>Beijing University of Chinese Medicine</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/F3153B2E-E896-4D49-B647-DFC45287A556"><gtr:id>F3153B2E-E896-4D49-B647-DFC45287A556</gtr:id><gtr:name>Princess Margaret Cancer Centre</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3ED60B49-9C2B-4D71-B644-96CCC7F10194"><gtr:id>3ED60B49-9C2B-4D71-B644-96CCC7F10194</gtr:id><gtr:name>Liverpool School of Tropical Medicine</gtr:name><gtr:address><gtr:line1>School Of Tropical Medicine</gtr:line1><gtr:line2>Pembroke Place</gtr:line2><gtr:postCode>L3 5QA</gtr:postCode><gtr:region>North West</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/C9DA1DA3-D9BD-4897-B554-5181400F24E0"><gtr:id>C9DA1DA3-D9BD-4897-B554-5181400F24E0</gtr:id><gtr:name>University Hospital of Besancon</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/5F4BE39D-6ED2-4946-AEB1-C681240D3A57"><gtr:id>5F4BE39D-6ED2-4946-AEB1-C681240D3A57</gtr:id><gtr:firstName>Jayne</gtr:firstName><gtr:surname>Tierney</gtr:surname><gtr:orcidId>0000-0002-4734-3014</gtr:orcidId><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MC_U122861323"><gtr:id>02B0624E-AB03-4360-8E62-CBF8D6EB9A3B</gtr:id><gtr:title>Systematic reviews and meta-analysis</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Intramural</gtr:grantCategory><gtr:grantReference>MC_U122861323</gtr:grantReference><gtr:abstractText>A number of clinical trials comparing the same treatments might not show which treatment is best. In this situation, the CTU Meta-analysis Group searches for all the trials and describes them - a systematic review. Then, we put the results of these trials together in a meta-analysis. This gives a better picture of how good or bad a treatment is, than any single trial.|Most researchers use information written about trials for systematic reviews and meta-analyses. If trials are not written about or not written about in much detail, this method is not so reliable. Instead, we ask all the doctors who did the trials, for all the relevant information on each patient. This so called individual patient data method is much more reliable, but can take much longer. We are one of only a few groups worldwide that do systematic reviews and meta-analyses in this way.|In the past we have looked at treatments in ovarian, lung, oesophageal, bladder, brain, cervical and endometrial cancer, and sarcoma, as well as in pregnancy, human prion disease and venous leg ulcers. Now we have projects in lung and colorectal cancer, and in stroke.|We also research different ways of doing systematic reviews and meta-analyses, to try to improve how they are done.</gtr:abstractText><gtr:technicalSummary>The Meta-analysis Group of the MRC Clinical Trials Unit (CTU) aims to rigorously evaluate the effectiveness of interventions for cancer and other diseases/conditions using systematic reviews and meta-analysis, to inform both clinical practice and research. We also aim to improve the quality and reliability of systematic reviews and meta-analyses through associated methodological research.|Moderate improvements in outcome are often the best that can be expected of new interventions, but these can be clinically worthwhile and important in terms of public health. Where randomised trials recruit too few patients to detect such modest differences reliably, they may have inconclusive results, or by chance, have results in favour of a particular intervention. Collating and appraising such trials in a systematic review, provides an objective summary of all the available evidence. Combining the results of these trials in a meta-analysis, can give sufficient statistical power to obtain a reliable and precise estimate of effect.|The Group predominantly conducts systematic reviews and meta-analyses based on individual patient data (IPD MA). These involve the collection, checking and re-analysis of the original IPD from all the relevant trials worldwide, necessitating extensive collaboration. Compared to standard systematic reviews based on trial-level data extracted from publications or obtained from trial investigators, the collection of IPD can improve the quality of data and breadth of analysis, and so it is considered the gold standard approach. As IPD MAs are resource-intensive and take time to complete, we also use standard systematic reviews to identify questions that require the IPD approach, when a more timely answer is needed, or when resource is limited. We are one of few groups worldwide with expertise in IPD MAs and have an international reputation in their conduct.|The Group has completed IPD MAs and other systematic reviews of therapies for ovarian, lung, oesophageal, bladder, brain and cervical cancer, and soft tissue sarcoma, as well as human prion disease, pre-eclampsia and venous leg ulcers. We have ongoing projects in lung and colorectal cancer, and in stroke. We are piloting consumer involvement in our IPD projects. Methodological projects have included investigations of publication and patient exclusion bias, and the development of methods for analysing published time-to-event data. Ongoing projects include comparing meta-analyses based on summary data with those based on IPD, evaluating the methods for assessing treatment by patient covariate interactions and methods for analysing IPD.|We act as the main CTU link to the Cochrane Collaboration, with members of the Group active in a number of Cochrane Review Groups and Methods Groups. We also co-convene the IPD Meta-analysis Methods Group.</gtr:technicalSummary><gtr:fund><gtr:end>2013-07-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>1998-10-01</gtr:start><gtr:type>EXPENDITURE_ACTUAL</gtr:type><gtr:valuePounds>1512434</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>European Organisation for Research and Treatment of Cancer (EORTC)</gtr:collaboratingOrganisation><gtr:country>European Union (EU)</gtr:country><gtr:description>NSCLC Meta-analyses Colllaborative Group - Adj CT</gtr:description><gtr:id>A5B02FE5-D2A4-4DBE-85B3-94D0F53E40F9</gtr:id><gtr:impact>6 conference presentations and 1 paper (PMID: 20338627). 1 Cochrane review in preparation.
Mixture of different clinical disciplinces, statisticians and other scientists.</gtr:impact><gtr:outcomeId>chkNmQA7hPe-31</gtr:outcomeId><gtr:partnerContribution>Provided advice throughout the project, helped interpret the results and helped write the manuscript. Provided trial data, helped interpret the results and commented on the manuscript.</gtr:partnerContribution><gtr:piContribution>This international collaboration was established to conduct a systematic review and meta-analysis based on the individual participant data (IPD), which is collected directly from the trial investigators. Members of the research team were responsible for protocol development; searching for trials; negotiating and managing collaborations; collecting, managing and analysing data, presenting results at conferences and preparing the final manuscript</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Osaka City General Hospital</gtr:collaboratingOrganisation><gtr:country>Japan</gtr:country><gtr:description>NSCLC Meta-analyses Colllaborative Group - Adj CT</gtr:description><gtr:id>B16D6D9F-AF6B-4D36-89E5-B614CB685B0E</gtr:id><gtr:impact>6 conference presentations and 1 paper (PMID: 20338627). 1 Cochrane review in preparation.
Mixture of different clinical disciplinces, statisticians and other scientists.</gtr:impact><gtr:outcomeId>chkNmQA7hPe-32</gtr:outcomeId><gtr:partnerContribution>Provided advice throughout the project, helped interpret the results and helped write the manuscript. Provided trial data, helped interpret the results and commented on the manuscript.</gtr:partnerContribution><gtr:piContribution>This international collaboration was established to conduct a systematic review and meta-analysis based on the individual participant data (IPD), which is collected directly from the trial investigators. Members of the research team were responsible for protocol development; searching for trials; negotiating and managing collaborations; collecting, managing and analysing data, presenting results at conferences and preparing the final manuscript</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Herlev Hospital</gtr:collaboratingOrganisation><gtr:country>Denmark, Kingdom of</gtr:country><gtr:description>Adjuvant CT for bladder cancer collaborators</gtr:description><gtr:id>7EE3334A-3914-4B50-A28C-EBB934963373</gtr:id><gtr:impact>1 publication (pre-2006) and 1 Cochrane review (PMID:16625650).
Mixture of different clinical disciplinces, statisticians and other scientists.</gtr:impact><gtr:outcomeId>A26515ED15F-19</gtr:outcomeId><gtr:partnerContribution>Provided advice throughout the project, helped interpret the results and helped write the manuscript.</gtr:partnerContribution><gtr:piContribution>This international collaboration was established to conduct a systematic review and meta-analysis based on the individual participant data (IPD), which is collected directly from the trial investigators. Members of the research team were responsible for protocol development; searching for trials; negotiating and managing collaborations; collecting, managing and analysing data, presenting results at conferences and preparing the final manuscript.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Tata Memorial Hospital</gtr:collaboratingOrganisation><gtr:country>India, Republic of</gtr:country><gtr:description>Chemoradiotherapy for Cervical Cancer Meta-analysis Collaboration</gtr:description><gtr:id>93F0E776-8E7B-48EB-B04C-7B3B33129CF6</gtr:id><gtr:impact>2 submitted oral presentations at oncology conferences (1 national, 1 international). 1 paper publication (PMID:19001332) and 1 Cochrane review (PMID: 20091664).
Mixture of different clinical disciplinces, statisticians and other scientists.</gtr:impact><gtr:outcomeId>FBB354ED493-2</gtr:outcomeId><gtr:partnerContribution>Provided advice throughout the project, helped interpret the results and helped write the manuscript</gtr:partnerContribution><gtr:piContribution>This international collaboration was established to conduct a systematic review and meta-analysis based on the individual participant data (IPD) which is collected directly from the trial investigators. This is considered the gold standard approach to systematic review. Members of the research team were responsible for writing the meta-analysis protocol; searching for trials; negotiating and managing collaborations; collecting, managing and analysing data, presenting results at conferences and preparing the final manuscript(s).</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Mansoura University</gtr:collaboratingOrganisation><gtr:country>Egypt, Arab Republic of</gtr:country><gtr:description>Adjuvant CT for bladder cancer collaborators</gtr:description><gtr:id>386D2409-65FB-4451-B699-F7F121E30F00</gtr:id><gtr:impact>1 publication (pre-2006) and 1 Cochrane review (PMID:16625650).
Mixture of different clinical disciplinces, statisticians and other scientists.</gtr:impact><gtr:outcomeId>A26515ED15F-10</gtr:outcomeId><gtr:partnerContribution>Provided advice throughout the project, helped interpret the results and helped write the manuscript.</gtr:partnerContribution><gtr:piContribution>This international collaboration was established to conduct a systematic review and meta-analysis based on the individual participant data (IPD), which is collected directly from the trial investigators. Members of the research team were responsible for protocol development; searching for trials; negotiating and managing collaborations; collecting, managing and analysing data, presenting results at conferences and preparing the final manuscript.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>John H. Stroger Jr. Hospital (formerly Cook County Hospital)</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>NSCLC Meta-analyses Colllaborative Group - Adj CT</gtr:description><gtr:id>193C4EDD-96C2-47FB-A52A-9643B5A81004</gtr:id><gtr:impact>6 conference presentations and 1 paper (PMID: 20338627). 1 Cochrane review in preparation.
Mixture of different clinical disciplinces, statisticians and other scientists.</gtr:impact><gtr:outcomeId>chkNmQA7hPe-20</gtr:outcomeId><gtr:partnerContribution>Provided advice throughout the project, helped interpret the results and helped write the manuscript. Provided trial data, helped interpret the results and commented on the manuscript.</gtr:partnerContribution><gtr:piContribution>This international collaboration was established to conduct a systematic review and meta-analysis based on the individual participant data (IPD), which is collected directly from the trial investigators. Members of the research team were responsible for protocol development; searching for trials; negotiating and managing collaborations; collecting, managing and analysing data, presenting results at conferences and preparing the final manuscript</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Leicester Royal Infirmary</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Department of Oncology</gtr:department><gtr:description>Neoadjuvant CT + S for cervical cancer collaborators</gtr:description><gtr:id>517D39DF-023C-42F7-9B42-B3066B0DCFCD</gtr:id><gtr:impact>2 conference presentations and 1 Cochrane review (PMID: 2091632). Mixture of clinician and scientists.</gtr:impact><gtr:outcomeId>GYfiKpmWGV7-1</gtr:outcomeId><gtr:partnerContribution>Provided advice throughout the project, helped interpret the results and helped write the manuscript</gtr:partnerContribution><gtr:piContribution>This collaboration was established to conduct a systematic review and meta-analysis based. Members of the research team were responsible for protocol development; searching for trials; collecting, managing and analysing data, presenting results at conferences and preparing the final manuscript.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Queen Elizabeth Hospital Birmingham</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Adjuvant CT for bladder cancer collaborators</gtr:description><gtr:id>7108C11A-975E-4D1B-BACB-073EA8E258E7</gtr:id><gtr:impact>1 publication (pre-2006) and 1 Cochrane review (PMID:16625650).
Mixture of different clinical disciplinces, statisticians and other scientists.</gtr:impact><gtr:outcomeId>A26515ED15F-20</gtr:outcomeId><gtr:partnerContribution>Provided advice throughout the project, helped interpret the results and helped write the manuscript.</gtr:partnerContribution><gtr:piContribution>This international collaboration was established to conduct a systematic review and meta-analysis based on the individual participant data (IPD), which is collected directly from the trial investigators. Members of the research team were responsible for protocol development; searching for trials; negotiating and managing collaborations; collecting, managing and analysing data, presenting results at conferences and preparing the final manuscript.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Leicester Royal Infirmary</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Department of Oncology</gtr:department><gtr:description>Chemoradiation audit collaborators</gtr:description><gtr:id>567B7F72-2CBC-4196-9E3B-0F4BF7C479F0</gtr:id><gtr:impact>2 conference presentations and 1 paper (PMID: 20594810). 1 other paper in preparation. Mixed clinical and scientific expertise</gtr:impact><gtr:outcomeId>Wuf7f5195X3-1</gtr:outcomeId><gtr:partnerContribution>Collected the audit data. Provided advice throughout the project, helped interpret the results and helped write the manuscript.</gtr:partnerContribution><gtr:piContribution>This UK collaboration was established to analyse and Royal College of Radiologist Audut of chemoradiotherapy for cervical cancer. Members of the research team were responsible for refining the database; managing and analysing data, and preparing the final manuscript.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>The Cochrane Collaboration</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>UK Cochrane Centre</gtr:department><gtr:description>Time to publication of trials review collaborators</gtr:description><gtr:id>99F595F8-9292-4703-8B6A-25DE2CA4466B</gtr:id><gtr:impact>1 Cochrane review (PMID: 17443632).</gtr:impact><gtr:outcomeId>D73CA76FAB3-1</gtr:outcomeId><gtr:partnerContribution>Responsible for protocol development; searching for trials; exatrcting, managing and analysing data and preparing the final manuscript.</gtr:partnerContribution><gtr:piContribution>This collaboration was established to conduct a systematic review and meta-analysis. Members of our research team provided advice throughout the project, helped interpret the results and helped write the manuscript</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Tel Aviv University</gtr:collaboratingOrganisation><gtr:country>Israel, State of</gtr:country><gtr:department>Sackler Faculty of Medicine</gtr:department><gtr:description>IPD meta-analysis of iron and malaria, feasibility study</gtr:description><gtr:id>A0EE1760-A20F-4CCB-82C7-252ADA2A9178</gtr:id><gtr:impact>We prepared a draft protocol for the meta-analysis and started the feasibility study.</gtr:impact><gtr:outcomeId>XdoSWND9kYa-2</gtr:outcomeId><gtr:partnerContribution>Helped with protocol and feasability study development.</gtr:partnerContribution><gtr:piContribution>This collaboration aims to establish the feasibility of assessing the effect of iron supplementation in malarious areas through and IPD meta-analysis. Members of the research team helped with protocol and feasability study development.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>International Academy of Environmental Sciences (IAES)</gtr:collaboratingOrganisation><gtr:country>Italy, Italian Republic</gtr:country><gtr:description>NSCLC Meta-analyses Collaborative Group - SC</gtr:description><gtr:id>348FD113-5D3C-4A88-A069-E3D2A8898C8D</gtr:id><gtr:impact>2 presentations at international oncology conferences, 1 paper publication (PM: 18678835) and 1 Cochrane Review (PMID 20464750).
Mixture of different clinical disciplinces, statisticians and other scientists.</gtr:impact><gtr:outcomeId>8788CEC157B-8</gtr:outcomeId><gtr:partnerContribution>Provided advice throughout the project, helped interpret the results and helped write the manuscript</gtr:partnerContribution><gtr:piContribution>This international collaboration was established to conduct a systematic review and meta-analysis based on the individual participant data (IPD), which is collected directly from the trial investigators. This is considered the gold standard approach to systematic review. Members of the research team were responsible for writing the meta-analysis protocol; searching for trials; negotiating and managing collaborations; collecting, managing and analysing data, presenting results at conferences and preparing the final mansucript(s).</gtr:piContribution><gtr:sector>Learned Society</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Saarland University</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>Adjuvant CT for bladder cancer collaborators</gtr:description><gtr:id>6A54ACC4-0A88-4795-9871-C6B5CC95A98B</gtr:id><gtr:impact>1 publication (pre-2006) and 1 Cochrane review (PMID:16625650).
Mixture of different clinical disciplinces, statisticians and other scientists.</gtr:impact><gtr:outcomeId>A26515ED15F-9</gtr:outcomeId><gtr:partnerContribution>Provided advice throughout the project, helped interpret the results and helped write the manuscript.</gtr:partnerContribution><gtr:piContribution>This international collaboration was established to conduct a systematic review and meta-analysis based on the individual participant data (IPD), which is collected directly from the trial investigators. Members of the research team were responsible for protocol development; searching for trials; negotiating and managing collaborations; collecting, managing and analysing data, presenting results at conferences and preparing the final manuscript.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Cancer Institute of the Loire</gtr:collaboratingOrganisation><gtr:country>France, French Republic</gtr:country><gtr:description>NSCLC Meta-analyses Collaborative Group - Con vs seq CT + RT</gtr:description><gtr:id>53BFEFF4-5639-4FB8-BFC6-80DCD5FAD492</gtr:id><gtr:impact>1 paper publication (PMID: 20351327).
Mixture of different clinical disciplinces, statisticians and other scientists.</gtr:impact><gtr:outcomeId>LQEbafHZbiJ-3</gtr:outcomeId><gtr:partnerContribution>Provided trial data, helped interpret the results and commented on the manuscript</gtr:partnerContribution><gtr:piContribution>This international collaboration was established to conduct a systematic review and meta-analysis based on the individual participant data (IPD), which is collected directly from the trial investigators. Members of the research team were responsible for protocol development; analysing the final results and preparing the final manuscript</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Yale University</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>School of Medicine</gtr:department><gtr:description>Chemoradiotherapy for Cervical Cancer Meta-analysis Collaboration</gtr:description><gtr:id>DE0CE2FE-EAE8-4846-B3CC-C503BF3AD87A</gtr:id><gtr:impact>2 submitted oral presentations at oncology conferences (1 national, 1 international). 1 paper publication (PMID:19001332) and 1 Cochrane review (PMID: 20091664).
Mixture of different clinical disciplinces, statisticians and other scientists.</gtr:impact><gtr:outcomeId>FBB354ED493-20</gtr:outcomeId><gtr:partnerContribution>Provided advice throughout the project, helped interpret the results and helped write the manuscript</gtr:partnerContribution><gtr:piContribution>This international collaboration was established to conduct a systematic review and meta-analysis based on the individual participant data (IPD) which is collected directly from the trial investigators. This is considered the gold standard approach to systematic review. Members of the research team were responsible for writing the meta-analysis protocol; searching for trials; negotiating and managing collaborations; collecting, managing and analysing data, presenting results at conferences and preparing the final manuscript(s).</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Academic Medical Center</gtr:collaboratingOrganisation><gtr:country>Netherlands, Kingdom of the</gtr:country><gtr:description>NSCLC Meta-analyses Collaborative Group - Con vs seq CT + RT</gtr:description><gtr:id>5DA0DEDE-BF9E-439E-B11D-B3736F4D6B9E</gtr:id><gtr:impact>1 paper publication (PMID: 20351327).
Mixture of different clinical disciplinces, statisticians and other scientists.</gtr:impact><gtr:outcomeId>LQEbafHZbiJ-10</gtr:outcomeId><gtr:partnerContribution>Provided trial data, helped interpret the results and commented on the manuscript</gtr:partnerContribution><gtr:piContribution>This international collaboration was established to conduct a systematic review and meta-analysis based on the individual participant data (IPD), which is collected directly from the trial investigators. Members of the research team were responsible for protocol development; analysing the final results and preparing the final manuscript</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>TwoCan Associates</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Cervical cancer patient research partners</gtr:description><gtr:id>F8473510-DF2A-4446-B0CC-DC92A5CD00FB</gtr:id><gtr:impact>1 editorial published (PMID:20554439) and 1 paper evaluating the project published (PMID 22587912).
Mixture of cervix cancer survivors, a consumer involvement specialist and scientists.</gtr:impact><gtr:outcomeId>HPqPuogUnwj-4</gtr:outcomeId><gtr:partnerContribution>The patient partners provided their views on the results of a UK audit of radiotherapy..</gtr:partnerContribution><gtr:piContribution>This partnership with women who have survived cervical cancer and allowed us to obtain their perspective on the results of a UK radiotherapy audit we conducted. Members of the research team were responsible for obtaining their views drafting an editorial of their perspective.</gtr:piContribution><gtr:sector>Private</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Ancona</gtr:collaboratingOrganisation><gtr:country>Italy, Italian Republic</gtr:country><gtr:description>NSCLC Meta-analyses Collaborative Group - SC</gtr:description><gtr:id>B6528308-EA18-4CDD-810B-F838CC413FCB</gtr:id><gtr:impact>2 presentations at international oncology conferences, 1 paper publication (PM: 18678835) and 1 Cochrane Review (PMID 20464750).
Mixture of different clinical disciplinces, statisticians and other scientists.</gtr:impact><gtr:outcomeId>8788CEC157B-19</gtr:outcomeId><gtr:partnerContribution>Provided advice throughout the project, helped interpret the results and helped write the manuscript</gtr:partnerContribution><gtr:piContribution>This international collaboration was established to conduct a systematic review and meta-analysis based on the individual participant data (IPD), which is collected directly from the trial investigators. This is considered the gold standard approach to systematic review. Members of the research team were responsible for writing the meta-analysis protocol; searching for trials; negotiating and managing collaborations; collecting, managing and analysing data, presenting results at conferences and preparing the final mansucript(s).</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Centro Hospitalario Pereira Rossell CHPR</gtr:collaboratingOrganisation><gtr:country>Uruguay, Eastern Republic of</gtr:country><gtr:department>Instituto de Radiolog?a y Centro de Lucha Contra el C?ncer</gtr:department><gtr:description>Chemoradiotherapy for Cervical Cancer Meta-analysis Collaboration</gtr:description><gtr:id>A27E8231-28E0-4C66-8E1A-0D9BE904B573</gtr:id><gtr:impact>2 submitted oral presentations at oncology conferences (1 national, 1 international). 1 paper publication (PMID:19001332) and 1 Cochrane review (PMID: 20091664).
Mixture of different clinical disciplinces, statisticians and other scientists.</gtr:impact><gtr:outcomeId>FBB354ED493-15</gtr:outcomeId><gtr:partnerContribution>Provided advice throughout the project, helped interpret the results and helped write the manuscript</gtr:partnerContribution><gtr:piContribution>This international collaboration was established to conduct a systematic review and meta-analysis based on the individual participant data (IPD) which is collected directly from the trial investigators. This is considered the gold standard approach to systematic review. Members of the research team were responsible for writing the meta-analysis protocol; searching for trials; negotiating and managing collaborations; collecting, managing and analysing data, presenting results at conferences and preparing the final manuscript(s).</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Chiba Cancer Center</gtr:collaboratingOrganisation><gtr:country>Japan</gtr:country><gtr:department>Chiba Cancer Center Research Institute (CCCRI)</gtr:department><gtr:description>NSCLC Meta-analyses Colllaborative Group - Adj CT</gtr:description><gtr:id>E2693244-019A-4C98-AFDD-86D94A3F01A1</gtr:id><gtr:impact>6 conference presentations and 1 paper (PMID: 20338627). 1 Cochrane review in preparation.
Mixture of different clinical disciplinces, statisticians and other scientists.</gtr:impact><gtr:outcomeId>chkNmQA7hPe-15</gtr:outcomeId><gtr:partnerContribution>Provided advice throughout the project, helped interpret the results and helped write the manuscript. Provided trial data, helped interpret the results and commented on the manuscript.</gtr:partnerContribution><gtr:piContribution>This international collaboration was established to conduct a systematic review and meta-analysis based on the individual participant data (IPD), which is collected directly from the trial investigators. Members of the research team were responsible for protocol development; searching for trials; negotiating and managing collaborations; collecting, managing and analysing data, presenting results at conferences and preparing the final manuscript</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Gustave-Roussy Institute</gtr:collaboratingOrganisation><gtr:country>France, French Republic</gtr:country><gtr:description>IPD meta-analyses of androgen deprivation therapy and docetaxel for prostate cancer</gtr:description><gtr:id>1E2FD3EA-E83C-4121-808F-C656E14190FF</gtr:id><gtr:impact>Protocol currently being drafted, preliminary searches completed.</gtr:impact><gtr:outcomeId>56d9a06cdf39a6.42965273-3</gtr:outcomeId><gtr:partnerContribution>Provided advice and helped with protocol development</gtr:partnerContribution><gtr:piContribution>This collaboration has been established to conduct a systematic review and meta-analysis to investigate the addition of bisphosphonates to standard androgen deprivation therapy for men with non-metastatic and metastatic prostate cancer. Members of the research team have been responsible for protocol development and searching for eligible trials.</gtr:piContribution><gtr:sector>Multiple</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Ghent</gtr:collaboratingOrganisation><gtr:country>Belgium, Kingdom of</gtr:country><gtr:description>NSCLC Meta-analyses Colllaborative Group - Adj CT</gtr:description><gtr:id>303E7D48-70D7-4E38-A4D9-EA7E230C4A5E</gtr:id><gtr:impact>6 conference presentations and 1 paper (PMID: 20338627). 1 Cochrane review in preparation.
Mixture of different clinical disciplinces, statisticians and other scientists.</gtr:impact><gtr:outcomeId>chkNmQA7hPe-4</gtr:outcomeId><gtr:partnerContribution>Provided advice throughout the project, helped interpret the results and helped write the manuscript. Provided trial data, helped interpret the results and commented on the manuscript.</gtr:partnerContribution><gtr:piContribution>This international collaboration was established to conduct a systematic review and meta-analysis based on the individual participant data (IPD), which is collected directly from the trial investigators. Members of the research team were responsible for protocol development; searching for trials; negotiating and managing collaborations; collecting, managing and analysing data, presenting results at conferences and preparing the final manuscript</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Brussels Saint-Luc University Hospital (UCL)</gtr:collaboratingOrganisation><gtr:country>Belgium, Kingdom of</gtr:country><gtr:description>IPD meta-analyses of androgen deprivation therapy and bisphosphonates for prostate cancer</gtr:description><gtr:id>47D3DED7-9D5C-4C40-80C6-F9CFF1D00199</gtr:id><gtr:impact>Protocol currently being drafted, preliminary searches completed</gtr:impact><gtr:outcomeId>56d99f9d2a1dd5.49919358-4</gtr:outcomeId><gtr:partnerContribution>Provided advice and helped with protocol development.</gtr:partnerContribution><gtr:piContribution>This collaboration has been established to conduct a systematic review and meta-analysis to investigate the addition of bisphosphonates to standard androgen deprivation therapy for men with non-metastatic and metastatic prostate cancer. Members of the research team have been responsible for protocol development and searching for eligible trials.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Mario Negri Institute for Pharmacological Research</gtr:collaboratingOrganisation><gtr:country>Italy, Italian Republic</gtr:country><gtr:description>NSCLC Meta-analyses Colllaborative Group - Adj CT</gtr:description><gtr:id>4BB2F6D7-DACA-4CCB-BF0F-3522A9AD7B8C</gtr:id><gtr:impact>6 conference presentations and 1 paper (PMID: 20338627). 1 Cochrane review in preparation.
Mixture of different clinical disciplinces, statisticians and other scientists.</gtr:impact><gtr:outcomeId>chkNmQA7hPe-34</gtr:outcomeId><gtr:partnerContribution>Provided advice throughout the project, helped interpret the results and helped write the manuscript. Provided trial data, helped interpret the results and commented on the manuscript.</gtr:partnerContribution><gtr:piContribution>This international collaboration was established to conduct a systematic review and meta-analysis based on the individual participant data (IPD), which is collected directly from the trial investigators. Members of the research team were responsible for protocol development; searching for trials; negotiating and managing collaborations; collecting, managing and analysing data, presenting results at conferences and preparing the final manuscript</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>National Kyushu Cancer Center</gtr:collaboratingOrganisation><gtr:country>Japan</gtr:country><gtr:description>NSCLC Meta-analyses Collaborative Group - Con vs seq CT + RT</gtr:description><gtr:id>47169707-DB80-4BD6-9BAE-B11C7DAF0488</gtr:id><gtr:impact>1 paper publication (PMID: 20351327).
Mixture of different clinical disciplinces, statisticians and other scientists.</gtr:impact><gtr:outcomeId>LQEbafHZbiJ-8</gtr:outcomeId><gtr:partnerContribution>Provided trial data, helped interpret the results and commented on the manuscript</gtr:partnerContribution><gtr:piContribution>This international collaboration was established to conduct a systematic review and meta-analysis based on the individual participant data (IPD), which is collected directly from the trial investigators. Members of the research team were responsible for protocol development; analysing the final results and preparing the final manuscript</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Padova</gtr:collaboratingOrganisation><gtr:country>Italy, Italian Republic</gtr:country><gtr:department>Department of Paediatrics</gtr:department><gtr:description>Antiretroviral therapy in HIV-infected children</gtr:description><gtr:id>5D02AD5A-565A-4389-B3FC-EFA13D4C1A33</gtr:id><gtr:impact>1 Cochrane Review (PMID: 22786492). Mixed clinical and scientific expertise.</gtr:impact><gtr:outcomeId>jqPULk4PnVg-1</gtr:outcomeId><gtr:partnerContribution>Responsible for protocol development; searching for trials; aseessing trial quality; extracting, managing and analysing data and preparing the final manuscript.</gtr:partnerContribution><gtr:piContribution>This collaboration was established to conduct a systematic review and meta-analysis. Members of the research team helped with protocol development; data extraction, assessing trial quality, analysis and preparing the final manuscript.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Crozer-Keystone Health System</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>Delaware County Memorial Hospital</gtr:department><gtr:description>Chemoradiotherapy for Cervical Cancer Meta-analysis Collaboration</gtr:description><gtr:id>A76B6013-6DB6-484B-8CBC-99CFCEFE8A37</gtr:id><gtr:impact>2 submitted oral presentations at oncology conferences (1 national, 1 international). 1 paper publication (PMID:19001332) and 1 Cochrane review (PMID: 20091664).
Mixture of different clinical disciplinces, statisticians and other scientists.</gtr:impact><gtr:outcomeId>FBB354ED493-14</gtr:outcomeId><gtr:partnerContribution>Provided advice throughout the project, helped interpret the results and helped write the manuscript</gtr:partnerContribution><gtr:piContribution>This international collaboration was established to conduct a systematic review and meta-analysis based on the individual participant data (IPD) which is collected directly from the trial investigators. This is considered the gold standard approach to systematic review. Members of the research team were responsible for writing the meta-analysis protocol; searching for trials; negotiating and managing collaborations; collecting, managing and analysing data, presenting results at conferences and preparing the final manuscript(s).</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Tohoku University</gtr:collaboratingOrganisation><gtr:country>Japan</gtr:country><gtr:description>NSCLC Meta-analyses Colllaborative Group - Adj CT</gtr:description><gtr:id>8E738290-3C90-44F0-A159-AA9742F44F6E</gtr:id><gtr:impact>6 conference presentations and 1 paper (PMID: 20338627). 1 Cochrane review in preparation.
Mixture of different clinical disciplinces, statisticians and other scientists.</gtr:impact><gtr:outcomeId>chkNmQA7hPe-10</gtr:outcomeId><gtr:partnerContribution>Provided advice throughout the project, helped interpret the results and helped write the manuscript. Provided trial data, helped interpret the results and commented on the manuscript.</gtr:partnerContribution><gtr:piContribution>This international collaboration was established to conduct a systematic review and meta-analysis based on the individual participant data (IPD), which is collected directly from the trial investigators. Members of the research team were responsible for protocol development; searching for trials; negotiating and managing collaborations; collecting, managing and analysing data, presenting results at conferences and preparing the final manuscript</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Tygerberg Children?s Hospital</gtr:collaboratingOrganisation><gtr:country>South Africa, Republic of</gtr:country><gtr:description>Antiretroviral therapy in HIV-infected children</gtr:description><gtr:id>4D9EB5F0-727B-4326-8186-E4DB04FB9A9D</gtr:id><gtr:impact>1 Cochrane Review (PMID: 22786492). Mixed clinical and scientific expertise.</gtr:impact><gtr:outcomeId>jqPULk4PnVg-3</gtr:outcomeId><gtr:partnerContribution>Responsible for protocol development; searching for trials; aseessing trial quality; extracting, managing and analysing data and preparing the final manuscript.</gtr:partnerContribution><gtr:piContribution>This collaboration was established to conduct a systematic review and meta-analysis. Members of the research team helped with protocol development; data extraction, assessing trial quality, analysis and preparing the final manuscript.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University Paris Sud</gtr:collaboratingOrganisation><gtr:country>France, French Republic</gtr:country><gtr:description>Surrogate Lung Project Collaborative Group</gtr:description><gtr:id>7EF46BAD-58E5-46D8-84BB-EB37D67445FB</gtr:id><gtr:impact>Presented at Word Conference on Lung Cancer 2011 and ASCO 2011. Published in Lancet 2013</gtr:impact><gtr:outcomeId>KLchf2NAVxL-13</gtr:outcomeId><gtr:partnerContribution>Coordination of project, analyses, supplying trial data and commenting on manuscript</gtr:partnerContribution><gtr:piContribution>Commented on the protocol, supplied some trial data, and commented on manuscript</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Harvard University</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>Harvard T.H. Chan School of Public Health</gtr:department><gtr:description>Surrogate Lung Project Collaborative Group</gtr:description><gtr:id>6652F6CB-9742-4514-909B-B796FFB7F574</gtr:id><gtr:impact>Presented at Word Conference on Lung Cancer 2011 and ASCO 2011. Published in Lancet 2013</gtr:impact><gtr:outcomeId>KLchf2NAVxL-10</gtr:outcomeId><gtr:partnerContribution>Coordination of project, analyses, supplying trial data and commenting on manuscript</gtr:partnerContribution><gtr:piContribution>Commented on the protocol, supplied some trial data, and commented on manuscript</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Texas</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>M. D. Anderson Cancer Center</gtr:department><gtr:description>NSCLC Meta-analyses Colllaborative Group - Adj CT</gtr:description><gtr:id>FD624FFB-D6AE-4A5B-B7F2-63CF9FCA4314</gtr:id><gtr:impact>6 conference presentations and 1 paper (PMID: 20338627). 1 Cochrane review in preparation.
Mixture of different clinical disciplinces, statisticians and other scientists.</gtr:impact><gtr:outcomeId>chkNmQA7hPe-18</gtr:outcomeId><gtr:partnerContribution>Provided advice throughout the project, helped interpret the results and helped write the manuscript. Provided trial data, helped interpret the results and commented on the manuscript.</gtr:partnerContribution><gtr:piContribution>This international collaboration was established to conduct a systematic review and meta-analysis based on the individual participant data (IPD), which is collected directly from the trial investigators. Members of the research team were responsible for protocol development; searching for trials; negotiating and managing collaborations; collecting, managing and analysing data, presenting results at conferences and preparing the final manuscript</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Cross Cancer Institute</gtr:collaboratingOrganisation><gtr:country>Canada</gtr:country><gtr:description>Chemoradiotherapy for Cervical Cancer Meta-analysis Collaboration</gtr:description><gtr:id>E9D015C8-BD4F-4941-8EEA-BFED7B769176</gtr:id><gtr:impact>2 submitted oral presentations at oncology conferences (1 national, 1 international). 1 paper publication (PMID:19001332) and 1 Cochrane review (PMID: 20091664).
Mixture of different clinical disciplinces, statisticians and other scientists.</gtr:impact><gtr:outcomeId>FBB354ED493-18</gtr:outcomeId><gtr:partnerContribution>Provided advice throughout the project, helped interpret the results and helped write the manuscript</gtr:partnerContribution><gtr:piContribution>This international collaboration was established to conduct a systematic review and meta-analysis based on the individual participant data (IPD) which is collected directly from the trial investigators. This is considered the gold standard approach to systematic review. Members of the research team were responsible for writing the meta-analysis protocol; searching for trials; negotiating and managing collaborations; collecting, managing and analysing data, presenting results at conferences and preparing the final manuscript(s).</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Yamanashi</gtr:collaboratingOrganisation><gtr:country>Japan</gtr:country><gtr:description>Chemoradiotherapy for Cervical Cancer Meta-analysis Collaboration</gtr:description><gtr:id>D60D5807-0406-4A34-BAA8-4AC7733F77F3</gtr:id><gtr:impact>2 submitted oral presentations at oncology conferences (1 national, 1 international). 1 paper publication (PMID:19001332) and 1 Cochrane review (PMID: 20091664).
Mixture of different clinical disciplinces, statisticians and other scientists.</gtr:impact><gtr:outcomeId>FBB354ED493-17</gtr:outcomeId><gtr:partnerContribution>Provided advice throughout the project, helped interpret the results and helped write the manuscript</gtr:partnerContribution><gtr:piContribution>This international collaboration was established to conduct a systematic review and meta-analysis based on the individual participant data (IPD) which is collected directly from the trial investigators. This is considered the gold standard approach to systematic review. Members of the research team were responsible for writing the meta-analysis protocol; searching for trials; negotiating and managing collaborations; collecting, managing and analysing data, presenting results at conferences and preparing the final manuscript(s).</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Hyogo College of Medicine</gtr:collaboratingOrganisation><gtr:country>Japan</gtr:country><gtr:description>NSCLC Meta-analyses Colllaborative Group - Adj CT</gtr:description><gtr:id>32DBB04E-A6BF-4747-AD86-4EB739CA6F27</gtr:id><gtr:impact>6 conference presentations and 1 paper (PMID: 20338627). 1 Cochrane review in preparation.
Mixture of different clinical disciplinces, statisticians and other scientists.</gtr:impact><gtr:outcomeId>chkNmQA7hPe-33</gtr:outcomeId><gtr:partnerContribution>Provided advice throughout the project, helped interpret the results and helped write the manuscript. Provided trial data, helped interpret the results and commented on the manuscript.</gtr:partnerContribution><gtr:piContribution>This international collaboration was established to conduct a systematic review and meta-analysis based on the individual participant data (IPD), which is collected directly from the trial investigators. Members of the research team were responsible for protocol development; searching for trials; negotiating and managing collaborations; collecting, managing and analysing data, presenting results at conferences and preparing the final manuscript</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Helsinki University Central Hospital</gtr:collaboratingOrganisation><gtr:country>Finland, Republic of</gtr:country><gtr:description>NSCLC Meta-analyses Colllaborative Group - Adj CT</gtr:description><gtr:id>51AC904B-99A7-43D8-8D11-B4EC8F0FE018</gtr:id><gtr:impact>6 conference presentations and 1 paper (PMID: 20338627). 1 Cochrane review in preparation.
Mixture of different clinical disciplinces, statisticians and other scientists.</gtr:impact><gtr:outcomeId>chkNmQA7hPe-16</gtr:outcomeId><gtr:partnerContribution>Provided advice throughout the project, helped interpret the results and helped write the manuscript. Provided trial data, helped interpret the results and commented on the manuscript.</gtr:partnerContribution><gtr:piContribution>This international collaboration was established to conduct a systematic review and meta-analysis based on the individual participant data (IPD), which is collected directly from the trial investigators. Members of the research team were responsible for protocol development; searching for trials; negotiating and managing collaborations; collecting, managing and analysing data, presenting results at conferences and preparing the final manuscript</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University Duisburg-Essen</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>Adjuvant CT for bladder cancer collaborators</gtr:description><gtr:id>B793FDFF-9E36-4743-80D2-569BA08593FD</gtr:id><gtr:impact>1 publication (pre-2006) and 1 Cochrane review (PMID:16625650).
Mixture of different clinical disciplinces, statisticians and other scientists.</gtr:impact><gtr:outcomeId>A26515ED15F-5</gtr:outcomeId><gtr:partnerContribution>Provided advice throughout the project, helped interpret the results and helped write the manuscript.</gtr:partnerContribution><gtr:piContribution>This international collaboration was established to conduct a systematic review and meta-analysis based on the individual participant data (IPD), which is collected directly from the trial investigators. Members of the research team were responsible for protocol development; searching for trials; negotiating and managing collaborations; collecting, managing and analysing data, presenting results at conferences and preparing the final manuscript.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Christiana Care Health System</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Chemoradiotherapy for Cervical Cancer Meta-analysis Collaboration</gtr:description><gtr:id>A9B9CC61-3247-412D-AEBF-E15EBD047CE3</gtr:id><gtr:impact>2 submitted oral presentations at oncology conferences (1 national, 1 international). 1 paper publication (PMID:19001332) and 1 Cochrane review (PMID: 20091664).
Mixture of different clinical disciplinces, statisticians and other scientists.</gtr:impact><gtr:outcomeId>FBB354ED493-22</gtr:outcomeId><gtr:partnerContribution>Provided advice throughout the project, helped interpret the results and helped write the manuscript</gtr:partnerContribution><gtr:piContribution>This international collaboration was established to conduct a systematic review and meta-analysis based on the individual participant data (IPD) which is collected directly from the trial investigators. This is considered the gold standard approach to systematic review. Members of the research team were responsible for writing the meta-analysis protocol; searching for trials; negotiating and managing collaborations; collecting, managing and analysing data, presenting results at conferences and preparing the final manuscript(s).</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Montpellier</gtr:collaboratingOrganisation><gtr:country>France, French Republic</gtr:country><gtr:department>Graduate Institute of Clinical Research (IURC)</gtr:department><gtr:description>NSCLC Meta-analyses Collaborative Group - Con vs seq CT + RT</gtr:description><gtr:id>470813A8-5C13-47B0-BEC0-8CFA68436A9E</gtr:id><gtr:impact>1 paper publication (PMID: 20351327).
Mixture of different clinical disciplinces, statisticians and other scientists.</gtr:impact><gtr:outcomeId>LQEbafHZbiJ-9</gtr:outcomeId><gtr:partnerContribution>Provided trial data, helped interpret the results and commented on the manuscript</gtr:partnerContribution><gtr:piContribution>This international collaboration was established to conduct a systematic review and meta-analysis based on the individual participant data (IPD), which is collected directly from the trial investigators. Members of the research team were responsible for protocol development; analysing the final results and preparing the final manuscript</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>MRC Prion Unit</gtr:department><gtr:description>Prion review collaborators</gtr:description><gtr:id>97F0D86B-3674-4021-BE98-EA3C2B13CF6A</gtr:id><gtr:impact>1 paper publication (PMID18391159).
Mixture of clinicians and scientists.</gtr:impact><gtr:outcomeId>A60D60838F0-3</gtr:outcomeId><gtr:partnerContribution>Responsible for protocol development; searching for trials; negotiating and managing collaborations; collecting, managing and analysing data, presenting results at conferences and preparing the final manuscript.Provided advice throughout the project, helped interpret the results and helped write the manuscript.</gtr:partnerContribution><gtr:piContribution>This collaboration was established to conduct a systematic review. Members of the research team were responsible for protocol development; searching for trials; extracting and collating data, and preparing the final manuscript.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Edinburgh</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>National CJD Research &amp; Surveillance Unit (NCJDRSU)</gtr:department><gtr:description>Prion review collaborators</gtr:description><gtr:id>D3F56297-BFC8-416D-A61F-1F0DBA06A45B</gtr:id><gtr:impact>1 paper publication (PMID18391159).
Mixture of clinicians and scientists.</gtr:impact><gtr:outcomeId>A60D60838F0-2</gtr:outcomeId><gtr:partnerContribution>Responsible for protocol development; searching for trials; negotiating and managing collaborations; collecting, managing and analysing data, presenting results at conferences and preparing the final manuscript.Provided advice throughout the project, helped interpret the results and helped write the manuscript.</gtr:partnerContribution><gtr:piContribution>This collaboration was established to conduct a systematic review. Members of the research team were responsible for protocol development; searching for trials; extracting and collating data, and preparing the final manuscript.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Intermountain Medical Centre</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Surrogate Lung Project Collaborative Group</gtr:description><gtr:id>293E9D02-9178-4F9D-8EF4-5E6BC6D3899B</gtr:id><gtr:impact>Presented at Word Conference on Lung Cancer 2011 and ASCO 2011. Published in Lancet 2013</gtr:impact><gtr:outcomeId>KLchf2NAVxL-9</gtr:outcomeId><gtr:partnerContribution>Coordination of project, analyses, supplying trial data and commenting on manuscript</gtr:partnerContribution><gtr:piContribution>Commented on the protocol, supplied some trial data, and commented on manuscript</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University Hospitals of Leicester NHS Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>NSCLC Meta-analysis Collaborative Group - Pre op CT</gtr:description><gtr:id>DDE1B5F2-C79D-47DA-869C-E42DB833FEDD</gtr:id><gtr:impact>1 presentation at World Conference on Lung Cancer 2011 and 1 paper in the Lancet (PMID: 24576776)</gtr:impact><gtr:outcomeId>56cdb0ec5aaa28.77180712-13</gtr:outcomeId><gtr:partnerContribution>Provided trial data, advice throughout the project, helped interpret the results and helped write the manuscript. The partners gave permission to use the the data for the secondary staging inaccuracy project.</gtr:partnerContribution><gtr:piContribution>This international collaboration was established to conduct a systematic review and meta-analysis based on the individual participant data (IPD), which is collected directly from the trial investigators. Members of the research team were responsible for protocol development; searching for trials; negotiating and managing collaborations; collecting, managing and analysing data, presenting results at conferences and preparing the final manuscript. We also initiated and did the analysis for a secondary staging inaccuracy project and drafted the manuscript.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Texas</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>M. D. Anderson Cancer Center</gtr:department><gtr:description>Chemoradiotherapy for Cervical Cancer Meta-analysis Collaboration</gtr:description><gtr:id>098F6062-28B4-4E1C-937E-3EBFE15CB71F</gtr:id><gtr:impact>2 submitted oral presentations at oncology conferences (1 national, 1 international). 1 paper publication (PMID:19001332) and 1 Cochrane review (PMID: 20091664).
Mixture of different clinical disciplinces, statisticians and other scientists.</gtr:impact><gtr:outcomeId>FBB354ED493-9</gtr:outcomeId><gtr:partnerContribution>Provided advice throughout the project, helped interpret the results and helped write the manuscript</gtr:partnerContribution><gtr:piContribution>This international collaboration was established to conduct a systematic review and meta-analysis based on the individual participant data (IPD) which is collected directly from the trial investigators. This is considered the gold standard approach to systematic review. Members of the research team were responsible for writing the meta-analysis protocol; searching for trials; negotiating and managing collaborations; collecting, managing and analysing data, presenting results at conferences and preparing the final manuscript(s).</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Vanderbilt University</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>NSCLC Meta-analysis Collaborative Group - Pre op CT</gtr:description><gtr:id>1FE05FC8-9352-4047-AD57-3A131FCDC86F</gtr:id><gtr:impact>1 presentation at World Conference on Lung Cancer 2011 and 1 paper in the Lancet (PMID: 24576776)</gtr:impact><gtr:outcomeId>56cdb0ec5aaa28.77180712-2</gtr:outcomeId><gtr:partnerContribution>Provided trial data, advice throughout the project, helped interpret the results and helped write the manuscript. The partners gave permission to use the the data for the secondary staging inaccuracy project.</gtr:partnerContribution><gtr:piContribution>This international collaboration was established to conduct a systematic review and meta-analysis based on the individual participant data (IPD), which is collected directly from the trial investigators. Members of the research team were responsible for protocol development; searching for trials; negotiating and managing collaborations; collecting, managing and analysing data, presenting results at conferences and preparing the final manuscript. We also initiated and did the analysis for a secondary staging inaccuracy project and drafted the manuscript.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Dana-Farber Cancer Institute</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>IPD meta-analyses of androgen deprivation therapy and bisphosphonates for prostate cancer</gtr:description><gtr:id>5FCA09A9-9BE0-42AA-A54A-9631C95514C4</gtr:id><gtr:impact>Protocol currently being drafted, preliminary searches completed</gtr:impact><gtr:outcomeId>56d99f9d2a1dd5.49919358-3</gtr:outcomeId><gtr:partnerContribution>Provided advice and helped with protocol development.</gtr:partnerContribution><gtr:piContribution>This collaboration has been established to conduct a systematic review and meta-analysis to investigate the addition of bisphosphonates to standard androgen deprivation therapy for men with non-metastatic and metastatic prostate cancer. Members of the research team have been responsible for protocol development and searching for eligible trials.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Wilhelminen Hospital</gtr:collaboratingOrganisation><gtr:country>Austria, Republic of</gtr:country><gtr:description>Venous Leg Ulcers Collaboration</gtr:description><gtr:id>EBF0FF49-A0D3-4445-A128-564AF8BB1583</gtr:id><gtr:impact>1 paper publication (PMID:19376798).
Mixture of clinicians, statisticians and other scientists.</gtr:impact><gtr:outcomeId>4FF6A1579E2-5</gtr:outcomeId><gtr:partnerContribution>The project lead was responsible for writing the meta-analysis protocol; searching for trials; negotiating and managing collaborations; collecting, managing and analysing data, presenting results at conferences and preparing the manuscript. Others contributed trial dat, provided valuable advice in interpreting the findings of the meta-analysis and reviewed the manusucript.</gtr:partnerContribution><gtr:piContribution>This collaboration was established to conduct a systematic review and meta-analysis based on the individual participant data (IPD), which is collected directly from the trial investigators. This is considered the gold standard approach to systematic review. I advised on developing the protocol and collecting, checking, and analysing data, and commented on drafts of the manuscript.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Vanderbilt University</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>Vanderbilt-Ingram Cancer Center</gtr:department><gtr:description>NSCLC Meta-analyses Collaborative Group - SC</gtr:description><gtr:id>59CD77AC-F8E1-44E7-9A19-A1E02AB277CF</gtr:id><gtr:impact>2 presentations at international oncology conferences, 1 paper publication (PM: 18678835) and 1 Cochrane Review (PMID 20464750).
Mixture of different clinical disciplinces, statisticians and other scientists.</gtr:impact><gtr:outcomeId>8788CEC157B-4</gtr:outcomeId><gtr:partnerContribution>Provided advice throughout the project, helped interpret the results and helped write the manuscript</gtr:partnerContribution><gtr:piContribution>This international collaboration was established to conduct a systematic review and meta-analysis based on the individual participant data (IPD), which is collected directly from the trial investigators. This is considered the gold standard approach to systematic review. Members of the research team were responsible for writing the meta-analysis protocol; searching for trials; negotiating and managing collaborations; collecting, managing and analysing data, presenting results at conferences and preparing the final mansucript(s).</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University College London Hospitals NHS Foundation Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Systematic reviews of TKIs for advanced NSCLC</gtr:description><gtr:id>66E478E1-6490-491E-9B1D-3E44FAE1DDF0</gtr:id><gtr:impact>Two systematic reviews and meta-analyses looking at the effect of TKIs in patients with non-small cell lung cancer have been completed, and a manuscript drafted and submitted to a journal.</gtr:impact><gtr:outcomeId>56d99e1d5e8285.75151027-1</gtr:outcomeId><gtr:partnerContribution>Provided advice with protocol development, interpretation of results and finalising the mansucript</gtr:partnerContribution><gtr:piContribution>Conducted two systematic reviews and meta-analyses, including protocol development, assessing trial eligibility, extracting data, conducting analyses, interpreting results and drafting the manuscript</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oxford</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>CRUK/MRC Oxford Institute for Radiation Oncology</gtr:department><gtr:description>Anti-EGFR therapy for advanced colorectal cancer</gtr:description><gtr:id>78CD24AD-D2FF-4731-A9C1-B6C2655A5359</gtr:id><gtr:impact>2 conference presentations and 1 paper (PMID: 22118887). Mixed clinical and scientific expertise</gtr:impact><gtr:outcomeId>NBN99WKBQun-2</gtr:outcomeId><gtr:partnerContribution>Provided advice throughout the project, helped interpret the results and helped write the manuscript</gtr:partnerContribution><gtr:piContribution>This collaboration was established to conduct a systematic review and meta-analysis. Members of the research team were responsible for protocol development; searching for trials; collecting, managing and analysing data, presenting results at conferences and preparing the final manuscript.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Sapienza University of Rome</gtr:collaboratingOrganisation><gtr:country>Italy, Italian Republic</gtr:country><gtr:description>Adjuvant CT for bladder cancer collaborators</gtr:description><gtr:id>011DCFFD-66C6-4A1B-B8FA-FC1DC1386103</gtr:id><gtr:impact>1 publication (pre-2006) and 1 Cochrane review (PMID:16625650).
Mixture of different clinical disciplinces, statisticians and other scientists.</gtr:impact><gtr:outcomeId>A26515ED15F-14</gtr:outcomeId><gtr:partnerContribution>Provided advice throughout the project, helped interpret the results and helped write the manuscript.</gtr:partnerContribution><gtr:piContribution>This international collaboration was established to conduct a systematic review and meta-analysis based on the individual participant data (IPD), which is collected directly from the trial investigators. Members of the research team were responsible for protocol development; searching for trials; negotiating and managing collaborations; collecting, managing and analysing data, presenting results at conferences and preparing the final manuscript.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>The Christie NHS Foundation Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Chemoradiation audit collaborators</gtr:description><gtr:id>9087B70F-B4CF-4811-8610-E0D7B795B678</gtr:id><gtr:impact>2 conference presentations and 1 paper (PMID: 20594810). 1 other paper in preparation. Mixed clinical and scientific expertise</gtr:impact><gtr:outcomeId>Wuf7f5195X3-2</gtr:outcomeId><gtr:partnerContribution>Collected the audit data. Provided advice throughout the project, helped interpret the results and helped write the manuscript.</gtr:partnerContribution><gtr:piContribution>This UK collaboration was established to analyse and Royal College of Radiologist Audut of chemoradiotherapy for cervical cancer. Members of the research team were responsible for refining the database; managing and analysing data, and preparing the final manuscript.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Chiang Mai University</gtr:collaboratingOrganisation><gtr:country>Thailand, Kingdom of</gtr:country><gtr:description>Chemoradiotherapy for Cervical Cancer Meta-analysis Collaboration</gtr:description><gtr:id>54ECA5E0-A35B-460A-BFBF-7E8B61036398</gtr:id><gtr:impact>2 submitted oral presentations at oncology conferences (1 national, 1 international). 1 paper publication (PMID:19001332) and 1 Cochrane review (PMID: 20091664).
Mixture of different clinical disciplinces, statisticians and other scientists.</gtr:impact><gtr:outcomeId>FBB354ED493-16</gtr:outcomeId><gtr:partnerContribution>Provided advice throughout the project, helped interpret the results and helped write the manuscript</gtr:partnerContribution><gtr:piContribution>This international collaboration was established to conduct a systematic review and meta-analysis based on the individual participant data (IPD) which is collected directly from the trial investigators. This is considered the gold standard approach to systematic review. Members of the research team were responsible for writing the meta-analysis protocol; searching for trials; negotiating and managing collaborations; collecting, managing and analysing data, presenting results at conferences and preparing the final manuscript(s).</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Padova</gtr:collaboratingOrganisation><gtr:country>Italy, Italian Republic</gtr:country><gtr:department>Medical School Padua</gtr:department><gtr:description>Adjuvant CT for bladder cancer collaborators</gtr:description><gtr:id>99C8BF44-E4BB-4153-B1D7-53F4145330E6</gtr:id><gtr:impact>1 publication (pre-2006) and 1 Cochrane review (PMID:16625650).
Mixture of different clinical disciplinces, statisticians and other scientists.</gtr:impact><gtr:outcomeId>A26515ED15F-11</gtr:outcomeId><gtr:partnerContribution>Provided advice throughout the project, helped interpret the results and helped write the manuscript.</gtr:partnerContribution><gtr:piContribution>This international collaboration was established to conduct a systematic review and meta-analysis based on the individual participant data (IPD), which is collected directly from the trial investigators. Members of the research team were responsible for protocol development; searching for trials; negotiating and managing collaborations; collecting, managing and analysing data, presenting results at conferences and preparing the final manuscript.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Turku</gtr:collaboratingOrganisation><gtr:country>Finland, Republic of</gtr:country><gtr:description>NSCLC Meta-analyses Colllaborative Group - Adj CT</gtr:description><gtr:id>12EDCD47-2B63-45CC-8CC9-FDC13B695948</gtr:id><gtr:impact>6 conference presentations and 1 paper (PMID: 20338627). 1 Cochrane review in preparation.
Mixture of different clinical disciplinces, statisticians and other scientists.</gtr:impact><gtr:outcomeId>chkNmQA7hPe-24</gtr:outcomeId><gtr:partnerContribution>Provided advice throughout the project, helped interpret the results and helped write the manuscript. Provided trial data, helped interpret the results and commented on the manuscript.</gtr:partnerContribution><gtr:piContribution>This international collaboration was established to conduct a systematic review and meta-analysis based on the individual participant data (IPD), which is collected directly from the trial investigators. Members of the research team were responsible for protocol development; searching for trials; negotiating and managing collaborations; collecting, managing and analysing data, presenting results at conferences and preparing the final manuscript</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Texas</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>NSCLC Meta-analysis Collaborative Group - Pre op CT</gtr:description><gtr:id>D492D4BE-EEC3-4B89-BA91-0B1591AED9BC</gtr:id><gtr:impact>1 presentation at World Conference on Lung Cancer 2011 and 1 paper in the Lancet (PMID: 24576776)</gtr:impact><gtr:outcomeId>56cdb0ec5aaa28.77180712-9</gtr:outcomeId><gtr:partnerContribution>Provided trial data, advice throughout the project, helped interpret the results and helped write the manuscript. The partners gave permission to use the the data for the secondary staging inaccuracy project.</gtr:partnerContribution><gtr:piContribution>This international collaboration was established to conduct a systematic review and meta-analysis based on the individual participant data (IPD), which is collected directly from the trial investigators. Members of the research team were responsible for protocol development; searching for trials; negotiating and managing collaborations; collecting, managing and analysing data, presenting results at conferences and preparing the final manuscript. We also initiated and did the analysis for a secondary staging inaccuracy project and drafted the manuscript.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of California, Los Angeles (UCLA)</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>NSCLC Meta-analyses Collaborative Group - SC</gtr:description><gtr:id>BEF61D77-8554-4EC3-8A04-8F0A98CBAE4F</gtr:id><gtr:impact>2 presentations at international oncology conferences, 1 paper publication (PM: 18678835) and 1 Cochrane Review (PMID 20464750).
Mixture of different clinical disciplinces, statisticians and other scientists.</gtr:impact><gtr:outcomeId>8788CEC157B-11</gtr:outcomeId><gtr:partnerContribution>Provided advice throughout the project, helped interpret the results and helped write the manuscript</gtr:partnerContribution><gtr:piContribution>This international collaboration was established to conduct a systematic review and meta-analysis based on the individual participant data (IPD), which is collected directly from the trial investigators. This is considered the gold standard approach to systematic review. Members of the research team were responsible for writing the meta-analysis protocol; searching for trials; negotiating and managing collaborations; collecting, managing and analysing data, presenting results at conferences and preparing the final mansucript(s).</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Gothenburg</gtr:collaboratingOrganisation><gtr:country>Sweden, Kingdom of</gtr:country><gtr:department>Sahlgrenska Academy</gtr:department><gtr:description>NSCLC Meta-analyses Colllaborative Group - Adj CT</gtr:description><gtr:id>3AC7DF2A-5CD1-4090-977F-A18D137E5FED</gtr:id><gtr:impact>6 conference presentations and 1 paper (PMID: 20338627). 1 Cochrane review in preparation.
Mixture of different clinical disciplinces, statisticians and other scientists.</gtr:impact><gtr:outcomeId>chkNmQA7hPe-6</gtr:outcomeId><gtr:partnerContribution>Provided advice throughout the project, helped interpret the results and helped write the manuscript. Provided trial data, helped interpret the results and commented on the manuscript.</gtr:partnerContribution><gtr:piContribution>This international collaboration was established to conduct a systematic review and meta-analysis based on the individual participant data (IPD), which is collected directly from the trial investigators. Members of the research team were responsible for protocol development; searching for trials; negotiating and managing collaborations; collecting, managing and analysing data, presenting results at conferences and preparing the final manuscript</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Oncology Institute of Vojvodina</gtr:collaboratingOrganisation><gtr:country>Serbia, Republic of</gtr:country><gtr:description>Chemoradiotherapy for Cervical Cancer Meta-analysis Collaboration</gtr:description><gtr:id>A2002D81-716E-4757-B5DA-303AF6EAFDAF</gtr:id><gtr:impact>2 submitted oral presentations at oncology conferences (1 national, 1 international). 1 paper publication (PMID:19001332) and 1 Cochrane review (PMID: 20091664).
Mixture of different clinical disciplinces, statisticians and other scientists.</gtr:impact><gtr:outcomeId>FBB354ED493-12</gtr:outcomeId><gtr:partnerContribution>Provided advice throughout the project, helped interpret the results and helped write the manuscript</gtr:partnerContribution><gtr:piContribution>This international collaboration was established to conduct a systematic review and meta-analysis based on the individual participant data (IPD) which is collected directly from the trial investigators. This is considered the gold standard approach to systematic review. Members of the research team were responsible for writing the meta-analysis protocol; searching for trials; negotiating and managing collaborations; collecting, managing and analysing data, presenting results at conferences and preparing the final manuscript(s).</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Medical Research Council (MRC)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>MRC Clinical Trials Unit</gtr:department><gtr:description>NSCLC Meta-analyses Colllaborative Group - Adj CT</gtr:description><gtr:id>E7F5DC71-5EAD-4EB4-957D-4EC595E451D9</gtr:id><gtr:impact>6 conference presentations and 1 paper (PMID: 20338627). 1 Cochrane review in preparation.
Mixture of different clinical disciplinces, statisticians and other scientists.</gtr:impact><gtr:outcomeId>chkNmQA7hPe-11</gtr:outcomeId><gtr:partnerContribution>Provided advice throughout the project, helped interpret the results and helped write the manuscript. Provided trial data, helped interpret the results and commented on the manuscript.</gtr:partnerContribution><gtr:piContribution>This international collaboration was established to conduct a systematic review and meta-analysis based on the individual participant data (IPD), which is collected directly from the trial investigators. Members of the research team were responsible for protocol development; searching for trials; negotiating and managing collaborations; collecting, managing and analysing data, presenting results at conferences and preparing the final manuscript</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Trondheim University Hospital</gtr:collaboratingOrganisation><gtr:country>Norway, Kingdom of</gtr:country><gtr:description>NSCLC Meta-analyses Collaborative Group - SC</gtr:description><gtr:id>EEEEBFD8-BD70-414C-8B0A-FE84DA5ED55C</gtr:id><gtr:impact>2 presentations at international oncology conferences, 1 paper publication (PM: 18678835) and 1 Cochrane Review (PMID 20464750).
Mixture of different clinical disciplinces, statisticians and other scientists.</gtr:impact><gtr:outcomeId>8788CEC157B-13</gtr:outcomeId><gtr:partnerContribution>Provided advice throughout the project, helped interpret the results and helped write the manuscript</gtr:partnerContribution><gtr:piContribution>This international collaboration was established to conduct a systematic review and meta-analysis based on the individual participant data (IPD), which is collected directly from the trial investigators. This is considered the gold standard approach to systematic review. Members of the research team were responsible for writing the meta-analysis protocol; searching for trials; negotiating and managing collaborations; collecting, managing and analysing data, presenting results at conferences and preparing the final mansucript(s).</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University Hospitals of Strasbourg</gtr:collaboratingOrganisation><gtr:country>France, French Republic</gtr:country><gtr:department>Department of Pneumology</gtr:department><gtr:description>NSCLC Meta-analyses Collaborative Group - SC</gtr:description><gtr:id>21D69CD4-EE26-4E31-B6A9-385104B343B1</gtr:id><gtr:impact>2 presentations at international oncology conferences, 1 paper publication (PM: 18678835) and 1 Cochrane Review (PMID 20464750).
Mixture of different clinical disciplinces, statisticians and other scientists.</gtr:impact><gtr:outcomeId>8788CEC157B-14</gtr:outcomeId><gtr:partnerContribution>Provided advice throughout the project, helped interpret the results and helped write the manuscript</gtr:partnerContribution><gtr:piContribution>This international collaboration was established to conduct a systematic review and meta-analysis based on the individual participant data (IPD), which is collected directly from the trial investigators. This is considered the gold standard approach to systematic review. Members of the research team were responsible for writing the meta-analysis protocol; searching for trials; negotiating and managing collaborations; collecting, managing and analysing data, presenting results at conferences and preparing the final mansucript(s).</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Vejle Hospital</gtr:collaboratingOrganisation><gtr:country>Denmark, Kingdom of</gtr:country><gtr:description>Chemoradiotherapy for Cervical Cancer Meta-analysis Collaboration</gtr:description><gtr:id>2AED634E-EB5C-4FF5-9CDD-68154D6E0CA9</gtr:id><gtr:impact>2 submitted oral presentations at oncology conferences (1 national, 1 international). 1 paper publication (PMID:19001332) and 1 Cochrane review (PMID: 20091664).
Mixture of different clinical disciplinces, statisticians and other scientists.</gtr:impact><gtr:outcomeId>FBB354ED493-3</gtr:outcomeId><gtr:partnerContribution>Provided advice throughout the project, helped interpret the results and helped write the manuscript</gtr:partnerContribution><gtr:piContribution>This international collaboration was established to conduct a systematic review and meta-analysis based on the individual participant data (IPD) which is collected directly from the trial investigators. This is considered the gold standard approach to systematic review. Members of the research team were responsible for writing the meta-analysis protocol; searching for trials; negotiating and managing collaborations; collecting, managing and analysing data, presenting results at conferences and preparing the final manuscript(s).</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Tom Baker Cancer Center</gtr:collaboratingOrganisation><gtr:country>Canada</gtr:country><gtr:description>NSCLC Meta-analyses Collaborative Group - SC</gtr:description><gtr:id>3E3527F7-CE86-4AE8-A213-3A5591BF7C48</gtr:id><gtr:impact>2 presentations at international oncology conferences, 1 paper publication (PM: 18678835) and 1 Cochrane Review (PMID 20464750).
Mixture of different clinical disciplinces, statisticians and other scientists.</gtr:impact><gtr:outcomeId>8788CEC157B-15</gtr:outcomeId><gtr:partnerContribution>Provided advice throughout the project, helped interpret the results and helped write the manuscript</gtr:partnerContribution><gtr:piContribution>This international collaboration was established to conduct a systematic review and meta-analysis based on the individual participant data (IPD), which is collected directly from the trial investigators. This is considered the gold standard approach to systematic review. Members of the research team were responsible for writing the meta-analysis protocol; searching for trials; negotiating and managing collaborations; collecting, managing and analysing data, presenting results at conferences and preparing the final mansucript(s).</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>G?lhane Military Medical Academy (GATA), Turkey</gtr:collaboratingOrganisation><gtr:country>Turkey, Republic of</gtr:country><gtr:department>Radiation Oncology Department (GATA) Turkey</gtr:department><gtr:description>NSCLC Meta-analyses Collaborative Group - Con vs seq CT + RT</gtr:description><gtr:id>B26BE73C-A05E-4017-B145-C607134D4C6C</gtr:id><gtr:impact>1 paper publication (PMID: 20351327).
Mixture of different clinical disciplinces, statisticians and other scientists.</gtr:impact><gtr:outcomeId>LQEbafHZbiJ-6</gtr:outcomeId><gtr:partnerContribution>Provided trial data, helped interpret the results and commented on the manuscript</gtr:partnerContribution><gtr:piContribution>This international collaboration was established to conduct a systematic review and meta-analysis based on the individual participant data (IPD), which is collected directly from the trial investigators. Members of the research team were responsible for protocol development; analysing the final results and preparing the final manuscript</gtr:piContribution><gtr:sector>Public</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>British Columbia Cancer Agency (BCCA)</gtr:collaboratingOrganisation><gtr:country>Canada</gtr:country><gtr:department>Fraser Valley Cancer Centre</gtr:department><gtr:description>Adjuvant CT for bladder cancer collaborators</gtr:description><gtr:id>88F778D1-879F-482E-9D54-41F43EC3E41A</gtr:id><gtr:impact>1 publication (pre-2006) and 1 Cochrane review (PMID:16625650).
Mixture of different clinical disciplinces, statisticians and other scientists.</gtr:impact><gtr:outcomeId>A26515ED15F-13</gtr:outcomeId><gtr:partnerContribution>Provided advice throughout the project, helped interpret the results and helped write the manuscript.</gtr:partnerContribution><gtr:piContribution>This international collaboration was established to conduct a systematic review and meta-analysis based on the individual participant data (IPD), which is collected directly from the trial investigators. Members of the research team were responsible for protocol development; searching for trials; negotiating and managing collaborations; collecting, managing and analysing data, presenting results at conferences and preparing the final manuscript.</gtr:piContribution><gtr:sector>Public</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>National Institute for Health Research</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>NIHR Cambridge Biomedical Research Centre</gtr:department><gtr:description>Surrogate Lung Project Collaborative Group</gtr:description><gtr:id>7180C485-DCC5-466B-B82B-549C8001345A</gtr:id><gtr:impact>Presented at Word Conference on Lung Cancer 2011 and ASCO 2011. Published in Lancet 2013</gtr:impact><gtr:outcomeId>KLchf2NAVxL-6</gtr:outcomeId><gtr:partnerContribution>Coordination of project, analyses, supplying trial data and commenting on manuscript</gtr:partnerContribution><gtr:piContribution>Commented on the protocol, supplied some trial data, and commented on manuscript</gtr:piContribution><gtr:sector>Public</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Royal North Shore Hospital</gtr:collaboratingOrganisation><gtr:country>Australia, Commonwealth of</gtr:country><gtr:department>Northern Sydney Cancer Centre</gtr:department><gtr:description>IPD meta-analysis of adjuvant RT for prostate cancer (ARTISTIC)</gtr:description><gtr:id>E2582FD0-7C02-4124-9A8F-D0C8C1E3C777</gtr:id><gtr:impact>Published a letter to the editor of European Urology about the project</gtr:impact><gtr:outcomeId>56d99da298ee20.30438230-1</gtr:outcomeId><gtr:partnerContribution>Provided information on their ongoing trials, agreed to collaborate on the meta-analysis and helped draft a joint letter published about the project</gtr:partnerContribution><gtr:piContribution>Initiated a prospective collaborative IPD meta-analysis. Published a joint letter in European Urology about the project with our trialist collaborators.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Southern California</gtr:collaboratingOrganisation><gtr:country>Unknown</gtr:country><gtr:department>Keck School of Medicine</gtr:department><gtr:description>Adjuvant CT for bladder cancer collaborators</gtr:description><gtr:id>1A6704A8-8EF1-4BBF-87D0-DA95DE32249F</gtr:id><gtr:impact>1 publication (pre-2006) and 1 Cochrane review (PMID:16625650).
Mixture of different clinical disciplinces, statisticians and other scientists.</gtr:impact><gtr:outcomeId>A26515ED15F-6</gtr:outcomeId><gtr:partnerContribution>Provided advice throughout the project, helped interpret the results and helped write the manuscript.</gtr:partnerContribution><gtr:piContribution>This international collaboration was established to conduct a systematic review and meta-analysis based on the individual participant data (IPD), which is collected directly from the trial investigators. Members of the research team were responsible for protocol development; searching for trials; negotiating and managing collaborations; collecting, managing and analysing data, presenting results at conferences and preparing the final manuscript.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>San Luigi Gonzaga Hospital</gtr:collaboratingOrganisation><gtr:country>Italy, Italian Republic</gtr:country><gtr:description>NSCLC Meta-analyses Colllaborative Group - Adj CT</gtr:description><gtr:id>5F2A639A-405C-41C5-BA24-1861167EF46C</gtr:id><gtr:impact>6 conference presentations and 1 paper (PMID: 20338627). 1 Cochrane review in preparation.
Mixture of different clinical disciplinces, statisticians and other scientists.</gtr:impact><gtr:outcomeId>chkNmQA7hPe-26</gtr:outcomeId><gtr:partnerContribution>Provided advice throughout the project, helped interpret the results and helped write the manuscript. Provided trial data, helped interpret the results and commented on the manuscript.</gtr:partnerContribution><gtr:piContribution>This international collaboration was established to conduct a systematic review and meta-analysis based on the individual participant data (IPD), which is collected directly from the trial investigators. Members of the research team were responsible for protocol development; searching for trials; negotiating and managing collaborations; collecting, managing and analysing data, presenting results at conferences and preparing the final manuscript</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Trondheim University Hospital</gtr:collaboratingOrganisation><gtr:country>Norway, Kingdom of</gtr:country><gtr:description>NSCLC Meta-analyses Collaborative Group - SC</gtr:description><gtr:id>8ADC4FCD-61CA-445C-8DCE-D4FBD88F6755</gtr:id><gtr:impact>2 presentations at international oncology conferences, 1 paper publication (PM: 18678835) and 1 Cochrane Review (PMID 20464750).
Mixture of different clinical disciplinces, statisticians and other scientists.</gtr:impact><gtr:outcomeId>8788CEC157B-22</gtr:outcomeId><gtr:partnerContribution>Provided advice throughout the project, helped interpret the results and helped write the manuscript</gtr:partnerContribution><gtr:piContribution>This international collaboration was established to conduct a systematic review and meta-analysis based on the individual participant data (IPD), which is collected directly from the trial investigators. This is considered the gold standard approach to systematic review. Members of the research team were responsible for writing the meta-analysis protocol; searching for trials; negotiating and managing collaborations; collecting, managing and analysing data, presenting results at conferences and preparing the final mansucript(s).</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Institute for Oncology and Radiology of Serbia</gtr:collaboratingOrganisation><gtr:country>Serbia, Republic of</gtr:country><gtr:description>Chemoradiotherapy for Cervical Cancer Meta-analysis Collaboration</gtr:description><gtr:id>611AD165-5F9E-4879-936C-F34876B4BA8B</gtr:id><gtr:impact>2 submitted oral presentations at oncology conferences (1 national, 1 international). 1 paper publication (PMID:19001332) and 1 Cochrane review (PMID: 20091664).
Mixture of different clinical disciplinces, statisticians and other scientists.</gtr:impact><gtr:outcomeId>FBB354ED493-8</gtr:outcomeId><gtr:partnerContribution>Provided advice throughout the project, helped interpret the results and helped write the manuscript</gtr:partnerContribution><gtr:piContribution>This international collaboration was established to conduct a systematic review and meta-analysis based on the individual participant data (IPD) which is collected directly from the trial investigators. This is considered the gold standard approach to systematic review. Members of the research team were responsible for writing the meta-analysis protocol; searching for trials; negotiating and managing collaborations; collecting, managing and analysing data, presenting results at conferences and preparing the final manuscript(s).</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Liverpool Womens NHS Foundation Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Liverpool Women's Hospital</gtr:department><gtr:description>CT for endometrial cancer collaborators</gtr:description><gtr:id>4A5603ED-17C2-4E72-9D21-01A2148EE4CC</gtr:id><gtr:impact>1 Cochrane Review (pre-2006), 1 update of the Cochrane review (PMID: 22895938), and 1 paper publication (PMID: 17150999). Mixture of different clinical disciplinces and scientists.</gtr:impact><gtr:outcomeId>93A61F77E4F-4</gtr:outcomeId><gtr:partnerContribution>Responsible for protocol development; searching for trials; extracting, managing and analysing data and preparing the final manuscript.Involved in protocol development; helped interpret the results and helped write the manuscript.Involved in protocol development and searching for trials. Provided advice throughout the project, helped interpret the results and helped write the manuscript.</gtr:partnerContribution><gtr:piContribution>This collaboration was established to conduct a systematic review and meta-analysis. We were involved in protocol development; searching for trials; extracting, managing and analysing data and preparing the final manuscript.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>The Christie NHS Foundation Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>IPD meta-analyses of androgen deprivation therapy and docetaxel for prostate cancer</gtr:description><gtr:id>CC386040-7BC3-4936-8088-9F6447C5B1C3</gtr:id><gtr:impact>Protocol currently being drafted, preliminary searches completed.</gtr:impact><gtr:outcomeId>56d9a06cdf39a6.42965273-1</gtr:outcomeId><gtr:partnerContribution>Provided advice and helped with protocol development</gtr:partnerContribution><gtr:piContribution>This collaboration has been established to conduct a systematic review and meta-analysis to investigate the addition of bisphosphonates to standard androgen deprivation therapy for men with non-metastatic and metastatic prostate cancer. Members of the research team have been responsible for protocol development and searching for eligible trials.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Cleveland Clinic</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>Lerner Research Institute</gtr:department><gtr:description>Chemoradiotherapy for Cervical Cancer Meta-analysis Collaboration</gtr:description><gtr:id>162B2320-B943-49A1-BE9B-000C3D694E5E</gtr:id><gtr:impact>2 submitted oral presentations at oncology conferences (1 national, 1 international). 1 paper publication (PMID:19001332) and 1 Cochrane review (PMID: 20091664).
Mixture of different clinical disciplinces, statisticians and other scientists.</gtr:impact><gtr:outcomeId>FBB354ED493-21</gtr:outcomeId><gtr:partnerContribution>Provided advice throughout the project, helped interpret the results and helped write the manuscript</gtr:partnerContribution><gtr:piContribution>This international collaboration was established to conduct a systematic review and meta-analysis based on the individual participant data (IPD) which is collected directly from the trial investigators. This is considered the gold standard approach to systematic review. Members of the research team were responsible for writing the meta-analysis protocol; searching for trials; negotiating and managing collaborations; collecting, managing and analysing data, presenting results at conferences and preparing the final manuscript(s).</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Laval Hospital</gtr:collaboratingOrganisation><gtr:country>Canada</gtr:country><gtr:description>NSCLC Meta-analyses Collaborative Group - SC</gtr:description><gtr:id>55235B9F-3458-43CC-B22A-FFD36A807555</gtr:id><gtr:impact>2 presentations at international oncology conferences, 1 paper publication (PM: 18678835) and 1 Cochrane Review (PMID 20464750).
Mixture of different clinical disciplinces, statisticians and other scientists.</gtr:impact><gtr:outcomeId>8788CEC157B-9</gtr:outcomeId><gtr:partnerContribution>Provided advice throughout the project, helped interpret the results and helped write the manuscript</gtr:partnerContribution><gtr:piContribution>This international collaboration was established to conduct a systematic review and meta-analysis based on the individual participant data (IPD), which is collected directly from the trial investigators. This is considered the gold standard approach to systematic review. Members of the research team were responsible for writing the meta-analysis protocol; searching for trials; negotiating and managing collaborations; collecting, managing and analysing data, presenting results at conferences and preparing the final mansucript(s).</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Arizona</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>University of Arizona Cancer Center</gtr:department><gtr:description>Chemoradiotherapy for Cervical Cancer Meta-analysis Collaboration</gtr:description><gtr:id>6C3B0587-4FDC-4611-9C6A-690FC30941AF</gtr:id><gtr:impact>2 submitted oral presentations at oncology conferences (1 national, 1 international). 1 paper publication (PMID:19001332) and 1 Cochrane review (PMID: 20091664).
Mixture of different clinical disciplinces, statisticians and other scientists.</gtr:impact><gtr:outcomeId>FBB354ED493-6</gtr:outcomeId><gtr:partnerContribution>Provided advice throughout the project, helped interpret the results and helped write the manuscript</gtr:partnerContribution><gtr:piContribution>This international collaboration was established to conduct a systematic review and meta-analysis based on the individual participant data (IPD) which is collected directly from the trial investigators. This is considered the gold standard approach to systematic review. Members of the research team were responsible for writing the meta-analysis protocol; searching for trials; negotiating and managing collaborations; collecting, managing and analysing data, presenting results at conferences and preparing the final manuscript(s).</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Osaka Medical Center for Cancer and Cardiovascular Diseases</gtr:collaboratingOrganisation><gtr:country>Japan</gtr:country><gtr:description>NSCLC Meta-analyses Colllaborative Group - Adj CT</gtr:description><gtr:id>1FF6DCE7-2DC5-4987-A49A-C691DFE4886A</gtr:id><gtr:impact>6 conference presentations and 1 paper (PMID: 20338627). 1 Cochrane review in preparation.
Mixture of different clinical disciplinces, statisticians and other scientists.</gtr:impact><gtr:outcomeId>chkNmQA7hPe-17</gtr:outcomeId><gtr:partnerContribution>Provided advice throughout the project, helped interpret the results and helped write the manuscript. Provided trial data, helped interpret the results and commented on the manuscript.</gtr:partnerContribution><gtr:piContribution>This international collaboration was established to conduct a systematic review and meta-analysis based on the individual participant data (IPD), which is collected directly from the trial investigators. Members of the research team were responsible for protocol development; searching for trials; negotiating and managing collaborations; collecting, managing and analysing data, presenting results at conferences and preparing the final manuscript</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Tufts University</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>NSCLC Meta-analyses Colllaborative Group - Adj CT</gtr:description><gtr:id>99A8C365-7BDA-47B8-A615-0DF04B1F1BA0</gtr:id><gtr:impact>6 conference presentations and 1 paper (PMID: 20338627). 1 Cochrane review in preparation.
Mixture of different clinical disciplinces, statisticians and other scientists.</gtr:impact><gtr:outcomeId>chkNmQA7hPe-30</gtr:outcomeId><gtr:partnerContribution>Provided advice throughout the project, helped interpret the results and helped write the manuscript. Provided trial data, helped interpret the results and commented on the manuscript.</gtr:partnerContribution><gtr:piContribution>This international collaboration was established to conduct a systematic review and meta-analysis based on the individual participant data (IPD), which is collected directly from the trial investigators. Members of the research team were responsible for protocol development; searching for trials; negotiating and managing collaborations; collecting, managing and analysing data, presenting results at conferences and preparing the final manuscript</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University Hospital of Besancon</gtr:collaboratingOrganisation><gtr:country>France, French Republic</gtr:country><gtr:description>NSCLC Meta-analysis Collaborative Group - Pre op CT</gtr:description><gtr:id>FED411F8-375A-41A3-8976-AC6533C82001</gtr:id><gtr:impact>1 presentation at World Conference on Lung Cancer 2011 and 1 paper in the Lancet (PMID: 24576776)</gtr:impact><gtr:outcomeId>56cdb0ec5aaa28.77180712-14</gtr:outcomeId><gtr:partnerContribution>Provided trial data, advice throughout the project, helped interpret the results and helped write the manuscript. The partners gave permission to use the the data for the secondary staging inaccuracy project.</gtr:partnerContribution><gtr:piContribution>This international collaboration was established to conduct a systematic review and meta-analysis based on the individual participant data (IPD), which is collected directly from the trial investigators. Members of the research team were responsible for protocol development; searching for trials; negotiating and managing collaborations; collecting, managing and analysing data, presenting results at conferences and preparing the final manuscript. We also initiated and did the analysis for a secondary staging inaccuracy project and drafted the manuscript.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Liverpool</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>CT for endometrial cancer collaborators</gtr:description><gtr:id>03864132-9381-449B-995D-891FDF0CBC66</gtr:id><gtr:impact>1 Cochrane Review (pre-2006), 1 update of the Cochrane review (PMID: 22895938), and 1 paper publication (PMID: 17150999). Mixture of different clinical disciplinces and scientists.</gtr:impact><gtr:outcomeId>93A61F77E4F-6</gtr:outcomeId><gtr:partnerContribution>Responsible for protocol development; searching for trials; extracting, managing and analysing data and preparing the final manuscript.Involved in protocol development; helped interpret the results and helped write the manuscript.Involved in protocol development and searching for trials. Provided advice throughout the project, helped interpret the results and helped write the manuscript.</gtr:partnerContribution><gtr:piContribution>This collaboration was established to conduct a systematic review and meta-analysis. We were involved in protocol development; searching for trials; extracting, managing and analysing data and preparing the final manuscript.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Birmingham Heartlands Hospital</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Venous Leg Ulcers Collaboration</gtr:description><gtr:id>2EB22772-FFE3-4EE8-A8D8-5FF2119590EE</gtr:id><gtr:impact>1 paper publication (PMID:19376798).
Mixture of clinicians, statisticians and other scientists.</gtr:impact><gtr:outcomeId>4FF6A1579E2-3</gtr:outcomeId><gtr:partnerContribution>The project lead was responsible for writing the meta-analysis protocol; searching for trials; negotiating and managing collaborations; collecting, managing and analysing data, presenting results at conferences and preparing the manuscript. Others contributed trial dat, provided valuable advice in interpreting the findings of the meta-analysis and reviewed the manusucript.</gtr:partnerContribution><gtr:piContribution>This collaboration was established to conduct a systematic review and meta-analysis based on the individual participant data (IPD), which is collected directly from the trial investigators. This is considered the gold standard approach to systematic review. I advised on developing the protocol and collecting, checking, and analysing data, and commented on drafts of the manuscript.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Maryland</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Acupuncture for pregnancy outcomes during IVF</gtr:description><gtr:id>9C804193-99BF-43F6-93A4-B69CDB6C4AD5</gtr:id><gtr:impact>1 paper published (PMID: 23814102). Mixed clinical and scientific expertise</gtr:impact><gtr:outcomeId>T9x3NyJK43b-1</gtr:outcomeId><gtr:partnerContribution>They were responsible for protocol development; searching for trials; aseessing trial quality; extracting, managing and analysing data, presenting results at conferences and preparing the final manuscript. Others helped with protocol development and preparing the final manuscript.</gtr:partnerContribution><gtr:piContribution>This collaboration was established to conduct a systematic review and meta-analysis. Members of the research team helped with protocol development and preparing the final manuscript.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University Hospitals Bristol NHS Foundation Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Bristol Haematology and Oncology Centre</gtr:department><gtr:description>NSCLC Meta-analyses Collaborative Group - SC</gtr:description><gtr:id>C22BCBD4-3DE8-4534-AF80-FAA72F42960A</gtr:id><gtr:impact>2 presentations at international oncology conferences, 1 paper publication (PM: 18678835) and 1 Cochrane Review (PMID 20464750).
Mixture of different clinical disciplinces, statisticians and other scientists.</gtr:impact><gtr:outcomeId>8788CEC157B-20</gtr:outcomeId><gtr:partnerContribution>Provided advice throughout the project, helped interpret the results and helped write the manuscript</gtr:partnerContribution><gtr:piContribution>This international collaboration was established to conduct a systematic review and meta-analysis based on the individual participant data (IPD), which is collected directly from the trial investigators. This is considered the gold standard approach to systematic review. Members of the research team were responsible for writing the meta-analysis protocol; searching for trials; negotiating and managing collaborations; collecting, managing and analysing data, presenting results at conferences and preparing the final mansucript(s).</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Ghent</gtr:collaboratingOrganisation><gtr:country>Belgium, Kingdom of</gtr:country><gtr:description>NSCLC Meta-analyses Collaborative Group - SC</gtr:description><gtr:id>C5546D75-3415-48B0-9889-C49136124602</gtr:id><gtr:impact>2 presentations at international oncology conferences, 1 paper publication (PM: 18678835) and 1 Cochrane Review (PMID 20464750).
Mixture of different clinical disciplinces, statisticians and other scientists.</gtr:impact><gtr:outcomeId>8788CEC157B-5</gtr:outcomeId><gtr:partnerContribution>Provided advice throughout the project, helped interpret the results and helped write the manuscript</gtr:partnerContribution><gtr:piContribution>This international collaboration was established to conduct a systematic review and meta-analysis based on the individual participant data (IPD), which is collected directly from the trial investigators. This is considered the gold standard approach to systematic review. Members of the research team were responsible for writing the meta-analysis protocol; searching for trials; negotiating and managing collaborations; collecting, managing and analysing data, presenting results at conferences and preparing the final mansucript(s).</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Gynaecologic Oncology Group GOC</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Chemoradiotherapy for Cervical Cancer Meta-analysis Collaboration</gtr:description><gtr:id>B3532714-1F4C-4BC0-ABB6-AA289531DA83</gtr:id><gtr:impact>2 submitted oral presentations at oncology conferences (1 national, 1 international). 1 paper publication (PMID:19001332) and 1 Cochrane review (PMID: 20091664).
Mixture of different clinical disciplinces, statisticians and other scientists.</gtr:impact><gtr:outcomeId>FBB354ED493-1</gtr:outcomeId><gtr:partnerContribution>Provided advice throughout the project, helped interpret the results and helped write the manuscript</gtr:partnerContribution><gtr:piContribution>This international collaboration was established to conduct a systematic review and meta-analysis based on the individual participant data (IPD) which is collected directly from the trial investigators. This is considered the gold standard approach to systematic review. Members of the research team were responsible for writing the meta-analysis protocol; searching for trials; negotiating and managing collaborations; collecting, managing and analysing data, presenting results at conferences and preparing the final manuscript(s).</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Dana-Farber Cancer Institute</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>Department of Radiation Oncology</gtr:department><gtr:description>IPD meta-analysis of adjuvant RT for prostate cancer (ARTISTIC)</gtr:description><gtr:id>C78A2437-9551-4E5D-976B-97EECF58BDC5</gtr:id><gtr:impact>Published a letter to the editor of European Urology about the project</gtr:impact><gtr:outcomeId>56d99da298ee20.30438230-3</gtr:outcomeId><gtr:partnerContribution>Provided information on their ongoing trials, agreed to collaborate on the meta-analysis and helped draft a joint letter published about the project</gtr:partnerContribution><gtr:piContribution>Initiated a prospective collaborative IPD meta-analysis. Published a joint letter in European Urology about the project with our trialist collaborators.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Sunnybrook Health Sciences Centre</gtr:collaboratingOrganisation><gtr:country>Canada</gtr:country><gtr:department>The Odette Cancer Centre (OCC)</gtr:department><gtr:description>Chemoradiotherapy for Cervical Cancer Meta-analysis Collaboration</gtr:description><gtr:id>ED2A4372-3CCB-4EAC-BFE4-78FFB37C3955</gtr:id><gtr:impact>2 submitted oral presentations at oncology conferences (1 national, 1 international). 1 paper publication (PMID:19001332) and 1 Cochrane review (PMID: 20091664).
Mixture of different clinical disciplinces, statisticians and other scientists.</gtr:impact><gtr:outcomeId>FBB354ED493-4</gtr:outcomeId><gtr:partnerContribution>Provided advice throughout the project, helped interpret the results and helped write the manuscript</gtr:partnerContribution><gtr:piContribution>This international collaboration was established to conduct a systematic review and meta-analysis based on the individual participant data (IPD) which is collected directly from the trial investigators. This is considered the gold standard approach to systematic review. Members of the research team were responsible for writing the meta-analysis protocol; searching for trials; negotiating and managing collaborations; collecting, managing and analysing data, presenting results at conferences and preparing the final manuscript(s).</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>NHS Greater Glasgow and Clyde (NHSGGC)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>General Medicine</gtr:department><gtr:description>Non-pharmacological interventions for caregivers of stroke survivors collaborators</gtr:description><gtr:id>B0ED7414-C93E-4538-8DD3-5B42C35B17ED</gtr:id><gtr:impact>1 published Cohrane Review (PMID:21975778) and 1 paper in press. Mixed clinical and scientific expertise.</gtr:impact><gtr:outcomeId>oStBf8CLXNv-3</gtr:outcomeId><gtr:partnerContribution>1 responsible for protocol development; searching for trials; aseessing trial quality; extracting, managing and analysing data, presenting results at conferences and preparing the final manuscript. Others helped with protocol development; assessing trial quality and preparing the final manuscript.</gtr:partnerContribution><gtr:piContribution>This collaboration was established to conduct a systematic review and meta-analysis. Members of the research team helped with protocol development; assessing trial quality and preparing the final manuscript.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>St Woolos Hospital</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Newport Chest Clinic</gtr:department><gtr:description>NSCLC Meta-analyses Collaborative Group - SC</gtr:description><gtr:id>D090F6DA-A10A-42FE-8020-4C7D46F3AC76</gtr:id><gtr:impact>2 presentations at international oncology conferences, 1 paper publication (PM: 18678835) and 1 Cochrane Review (PMID 20464750).
Mixture of different clinical disciplinces, statisticians and other scientists.</gtr:impact><gtr:outcomeId>8788CEC157B-21</gtr:outcomeId><gtr:partnerContribution>Provided advice throughout the project, helped interpret the results and helped write the manuscript</gtr:partnerContribution><gtr:piContribution>This international collaboration was established to conduct a systematic review and meta-analysis based on the individual participant data (IPD), which is collected directly from the trial investigators. This is considered the gold standard approach to systematic review. Members of the research team were responsible for writing the meta-analysis protocol; searching for trials; negotiating and managing collaborations; collecting, managing and analysing data, presenting results at conferences and preparing the final mansucript(s).</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Royal Prince Alfred Hospital (RPAH) Sydney</gtr:collaboratingOrganisation><gtr:country>Australia, Commonwealth of</gtr:country><gtr:department>Sydney Cancer Centre</gtr:department><gtr:description>Adjuvant CT for bladder cancer collaborators</gtr:description><gtr:id>3BA1AD84-3A5B-4C2C-A650-E4E7B87CFBC9</gtr:id><gtr:impact>1 publication (pre-2006) and 1 Cochrane review (PMID:16625650).
Mixture of different clinical disciplinces, statisticians and other scientists.</gtr:impact><gtr:outcomeId>A26515ED15F-12</gtr:outcomeId><gtr:partnerContribution>Provided advice throughout the project, helped interpret the results and helped write the manuscript.</gtr:partnerContribution><gtr:piContribution>This international collaboration was established to conduct a systematic review and meta-analysis based on the individual participant data (IPD), which is collected directly from the trial investigators. Members of the research team were responsible for protocol development; searching for trials; negotiating and managing collaborations; collecting, managing and analysing data, presenting results at conferences and preparing the final manuscript.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Vanderbilt University</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>Vanderbilt-Ingram Cancer Center</gtr:department><gtr:description>NSCLC Meta-analyses Colllaborative Group - Adj CT</gtr:description><gtr:id>AC1CEC77-6B61-4F1F-B709-50347BF1AEFD</gtr:id><gtr:impact>6 conference presentations and 1 paper (PMID: 20338627). 1 Cochrane review in preparation.
Mixture of different clinical disciplinces, statisticians and other scientists.</gtr:impact><gtr:outcomeId>chkNmQA7hPe-3</gtr:outcomeId><gtr:partnerContribution>Provided advice throughout the project, helped interpret the results and helped write the manuscript. Provided trial data, helped interpret the results and commented on the manuscript.</gtr:partnerContribution><gtr:piContribution>This international collaboration was established to conduct a systematic review and meta-analysis based on the individual participant data (IPD), which is collected directly from the trial investigators. Members of the research team were responsible for protocol development; searching for trials; negotiating and managing collaborations; collecting, managing and analysing data, presenting results at conferences and preparing the final manuscript</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Uppsala University Hospital</gtr:collaboratingOrganisation><gtr:country>Sweden, Kingdom of</gtr:country><gtr:description>Adjuvant CT for bladder cancer collaborators</gtr:description><gtr:id>37E42D88-40A3-4BD2-AB95-7133DD5D2DDF</gtr:id><gtr:impact>1 publication (pre-2006) and 1 Cochrane review (PMID:16625650).
Mixture of different clinical disciplinces, statisticians and other scientists.</gtr:impact><gtr:outcomeId>A26515ED15F-17</gtr:outcomeId><gtr:partnerContribution>Provided advice throughout the project, helped interpret the results and helped write the manuscript.</gtr:partnerContribution><gtr:piContribution>This international collaboration was established to conduct a systematic review and meta-analysis based on the individual participant data (IPD), which is collected directly from the trial investigators. Members of the research team were responsible for protocol development; searching for trials; negotiating and managing collaborations; collecting, managing and analysing data, presenting results at conferences and preparing the final manuscript.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Gustave-Roussy Institute</gtr:collaboratingOrganisation><gtr:country>France, French Republic</gtr:country><gtr:description>IPD meta-analyses of androgen deprivation therapy and bisphosphonates for prostate cancer</gtr:description><gtr:id>85894350-CCDF-4D1B-B477-4DAB07636917</gtr:id><gtr:impact>Protocol currently being drafted, preliminary searches completed</gtr:impact><gtr:outcomeId>56d99f9d2a1dd5.49919358-2</gtr:outcomeId><gtr:partnerContribution>Provided advice and helped with protocol development.</gtr:partnerContribution><gtr:piContribution>This collaboration has been established to conduct a systematic review and meta-analysis to investigate the addition of bisphosphonates to standard androgen deprivation therapy for men with non-metastatic and metastatic prostate cancer. Members of the research team have been responsible for protocol development and searching for eligible trials.</gtr:piContribution><gtr:sector>Multiple</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Cardiff University</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>School of Medicine</gtr:department><gtr:description>IPD meta-analyses of androgen deprivation therapy and bisphosphonates for prostate cancer</gtr:description><gtr:id>22D4F1E4-E4A1-4C9B-A0E0-683CA2FDC52A</gtr:id><gtr:impact>Protocol currently being drafted, preliminary searches completed</gtr:impact><gtr:outcomeId>56d99f9d2a1dd5.49919358-5</gtr:outcomeId><gtr:partnerContribution>Provided advice and helped with protocol development.</gtr:partnerContribution><gtr:piContribution>This collaboration has been established to conduct a systematic review and meta-analysis to investigate the addition of bisphosphonates to standard androgen deprivation therapy for men with non-metastatic and metastatic prostate cancer. Members of the research team have been responsible for protocol development and searching for eligible trials.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Helsinki University Central Hospital</gtr:collaboratingOrganisation><gtr:country>Finland, Republic of</gtr:country><gtr:description>NSCLC Meta-analysis Collaborative Group - Pre op CT</gtr:description><gtr:id>1650CF2A-6C58-4FC4-9570-66893090049F</gtr:id><gtr:impact>1 presentation at World Conference on Lung Cancer 2011 and 1 paper in the Lancet (PMID: 24576776)</gtr:impact><gtr:outcomeId>56cdb0ec5aaa28.77180712-8</gtr:outcomeId><gtr:partnerContribution>Provided trial data, advice throughout the project, helped interpret the results and helped write the manuscript. The partners gave permission to use the the data for the secondary staging inaccuracy project.</gtr:partnerContribution><gtr:piContribution>This international collaboration was established to conduct a systematic review and meta-analysis based on the individual participant data (IPD), which is collected directly from the trial investigators. Members of the research team were responsible for protocol development; searching for trials; negotiating and managing collaborations; collecting, managing and analysing data, presenting results at conferences and preparing the final manuscript. We also initiated and did the analysis for a secondary staging inaccuracy project and drafted the manuscript.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Canadian Cancer Society Research Institute (CCSRI)</gtr:collaboratingOrganisation><gtr:country>Canada</gtr:country><gtr:description>NSCLC Meta-analyses Collaborative Group - SC</gtr:description><gtr:id>8290D158-6B5E-4BA0-A034-ACA29B84BBC7</gtr:id><gtr:impact>2 presentations at international oncology conferences, 1 paper publication (PM: 18678835) and 1 Cochrane Review (PMID 20464750).
Mixture of different clinical disciplinces, statisticians and other scientists.</gtr:impact><gtr:outcomeId>8788CEC157B-16</gtr:outcomeId><gtr:partnerContribution>Provided advice throughout the project, helped interpret the results and helped write the manuscript</gtr:partnerContribution><gtr:piContribution>This international collaboration was established to conduct a systematic review and meta-analysis based on the individual participant data (IPD), which is collected directly from the trial investigators. This is considered the gold standard approach to systematic review. Members of the research team were responsible for writing the meta-analysis protocol; searching for trials; negotiating and managing collaborations; collecting, managing and analysing data, presenting results at conferences and preparing the final mansucript(s).</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Guangdong General Hospital</gtr:collaboratingOrganisation><gtr:country>China, People's Republic of</gtr:country><gtr:description>NSCLC Meta-analysis Collaborative Group - Pre op CT</gtr:description><gtr:id>062B6DE5-94FC-462B-850D-36BA2AD40957</gtr:id><gtr:impact>1 presentation at World Conference on Lung Cancer 2011 and 1 paper in the Lancet (PMID: 24576776)</gtr:impact><gtr:outcomeId>56cdb0ec5aaa28.77180712-15</gtr:outcomeId><gtr:partnerContribution>Provided trial data, advice throughout the project, helped interpret the results and helped write the manuscript. The partners gave permission to use the the data for the secondary staging inaccuracy project.</gtr:partnerContribution><gtr:piContribution>This international collaboration was established to conduct a systematic review and meta-analysis based on the individual participant data (IPD), which is collected directly from the trial investigators. Members of the research team were responsible for protocol development; searching for trials; negotiating and managing collaborations; collecting, managing and analysing data, presenting results at conferences and preparing the final manuscript. We also initiated and did the analysis for a secondary staging inaccuracy project and drafted the manuscript.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Beijing University of Chinese Medicine</gtr:collaboratingOrganisation><gtr:country>China, People's Republic of</gtr:country><gtr:description>Acupuncture for pregnancy outcomes during IVF</gtr:description><gtr:id>3D2BA721-7937-4F71-AC7D-544F2DC751AC</gtr:id><gtr:impact>1 paper published (PMID: 23814102). Mixed clinical and scientific expertise</gtr:impact><gtr:outcomeId>T9x3NyJK43b-4</gtr:outcomeId><gtr:partnerContribution>They were responsible for protocol development; searching for trials; aseessing trial quality; extracting, managing and analysing data, presenting results at conferences and preparing the final manuscript. Others helped with protocol development and preparing the final manuscript.</gtr:partnerContribution><gtr:piContribution>This collaboration was established to conduct a systematic review and meta-analysis. Members of the research team helped with protocol development and preparing the final manuscript.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oxford</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Oxford Health Services Research Unit</gtr:department><gtr:description>PARIS Collaborative Group</gtr:description><gtr:id>524C679B-012A-4168-99F0-2D93688FA9D3</gtr:id><gtr:impact>1 paper publication (Lancet, PMID: 17512048).
Mixture of different clinical disciplinces, statisticians and other scientists.</gtr:impact><gtr:outcomeId>589F5C4E93E-3</gtr:outcomeId><gtr:partnerContribution>Responsible for protocol development; searching for trials; negotiating and managing collaborations; collecting, managing and analysing data (from 57 trials and 25 countries), presenting results at conferences and preparing the final manuscript.Provided advice throughout the project, helped interpret the results and helped write the manuscript.</gtr:partnerContribution><gtr:piContribution>This international collaboration was established to conduct a systematic review and meta-analysis based on the individual participant data (IPD), which is collected directly from the trial investigators. Members of the research team were involved in protocol development; searching for trials; negotiating and managing collaborations; collecting, managing and analysing data, presenting results at conferences and helped preparing the final manuscripts(s).</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Acylbadem Oncology and Neurological Science Hospital</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Chemoradiotherapy for Cervical Cancer Meta-analysis Collaboration</gtr:description><gtr:id>C76F85CA-380D-4322-ACA9-0EC539DA2FC9</gtr:id><gtr:impact>2 submitted oral presentations at oncology conferences (1 national, 1 international). 1 paper publication (PMID:19001332) and 1 Cochrane review (PMID: 20091664).
Mixture of different clinical disciplinces, statisticians and other scientists.</gtr:impact><gtr:outcomeId>FBB354ED493-10</gtr:outcomeId><gtr:partnerContribution>Provided advice throughout the project, helped interpret the results and helped write the manuscript</gtr:partnerContribution><gtr:piContribution>This international collaboration was established to conduct a systematic review and meta-analysis based on the individual participant data (IPD) which is collected directly from the trial investigators. This is considered the gold standard approach to systematic review. Members of the research team were responsible for writing the meta-analysis protocol; searching for trials; negotiating and managing collaborations; collecting, managing and analysing data, presenting results at conferences and preparing the final manuscript(s).</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Korea Cancer Center Hospital</gtr:collaboratingOrganisation><gtr:country>Korea, Republic of</gtr:country><gtr:description>NSCLC Meta-analyses Colllaborative Group - Adj CT</gtr:description><gtr:id>C04D2D7D-9400-472C-8023-3CB2033001E4</gtr:id><gtr:impact>6 conference presentations and 1 paper (PMID: 20338627). 1 Cochrane review in preparation.
Mixture of different clinical disciplinces, statisticians and other scientists.</gtr:impact><gtr:outcomeId>chkNmQA7hPe-22</gtr:outcomeId><gtr:partnerContribution>Provided advice throughout the project, helped interpret the results and helped write the manuscript. Provided trial data, helped interpret the results and commented on the manuscript.</gtr:partnerContribution><gtr:piContribution>This international collaboration was established to conduct a systematic review and meta-analysis based on the individual participant data (IPD), which is collected directly from the trial investigators. Members of the research team were responsible for protocol development; searching for trials; negotiating and managing collaborations; collecting, managing and analysing data, presenting results at conferences and preparing the final manuscript</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>The Christie NHS Foundation Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>IPD meta-analyses of androgen deprivation therapy and bisphosphonates for prostate cancer</gtr:description><gtr:id>408093DA-FEA4-41AA-BC29-B48D5C228484</gtr:id><gtr:impact>Protocol currently being drafted, preliminary searches completed</gtr:impact><gtr:outcomeId>56d99f9d2a1dd5.49919358-1</gtr:outcomeId><gtr:partnerContribution>Provided advice and helped with protocol development.</gtr:partnerContribution><gtr:piContribution>This collaboration has been established to conduct a systematic review and meta-analysis to investigate the addition of bisphosphonates to standard androgen deprivation therapy for men with non-metastatic and metastatic prostate cancer. Members of the research team have been responsible for protocol development and searching for eligible trials.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Royal Marsden NHS Foundation Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Surrogate Lung Project Collaborative Group</gtr:description><gtr:id>06FEFA6C-D919-4491-B87A-08823AA9191C</gtr:id><gtr:impact>Presented at Word Conference on Lung Cancer 2011 and ASCO 2011. Published in Lancet 2013</gtr:impact><gtr:outcomeId>KLchf2NAVxL-11</gtr:outcomeId><gtr:partnerContribution>Coordination of project, analyses, supplying trial data and commenting on manuscript</gtr:partnerContribution><gtr:piContribution>Commented on the protocol, supplied some trial data, and commented on manuscript</gtr:piContribution><gtr:sector>Public</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Cambridge</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>MRC Biostatistics Unit</gtr:department><gtr:description>NSCLC Meta-analyses Collaborative Group - SC</gtr:description><gtr:id>DF01E33C-04D2-444F-9BF4-6D755399ABD1</gtr:id><gtr:impact>2 presentations at international oncology conferences, 1 paper publication (PM: 18678835) and 1 Cochrane Review (PMID 20464750).
Mixture of different clinical disciplinces, statisticians and other scientists.</gtr:impact><gtr:outcomeId>8788CEC157B-3</gtr:outcomeId><gtr:partnerContribution>Provided advice throughout the project, helped interpret the results and helped write the manuscript</gtr:partnerContribution><gtr:piContribution>This international collaboration was established to conduct a systematic review and meta-analysis based on the individual participant data (IPD), which is collected directly from the trial investigators. This is considered the gold standard approach to systematic review. Members of the research team were responsible for writing the meta-analysis protocol; searching for trials; negotiating and managing collaborations; collecting, managing and analysing data, presenting results at conferences and preparing the final mansucript(s).</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Sanjay Gandhi Post Graduate Institute of Medical Sciences</gtr:collaboratingOrganisation><gtr:country>India, Republic of</gtr:country><gtr:description>Chemoradiotherapy for Cervical Cancer Meta-analysis Collaboration</gtr:description><gtr:id>91A220EE-2C6E-4851-B0A4-B4C967FD567C</gtr:id><gtr:impact>2 submitted oral presentations at oncology conferences (1 national, 1 international). 1 paper publication (PMID:19001332) and 1 Cochrane review (PMID: 20091664).
Mixture of different clinical disciplinces, statisticians and other scientists.</gtr:impact><gtr:outcomeId>FBB354ED493-13</gtr:outcomeId><gtr:partnerContribution>Provided advice throughout the project, helped interpret the results and helped write the manuscript</gtr:partnerContribution><gtr:piContribution>This international collaboration was established to conduct a systematic review and meta-analysis based on the individual participant data (IPD) which is collected directly from the trial investigators. This is considered the gold standard approach to systematic review. Members of the research team were responsible for writing the meta-analysis protocol; searching for trials; negotiating and managing collaborations; collecting, managing and analysing data, presenting results at conferences and preparing the final manuscript(s).</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Albany Medical College (AMC)</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Chemoradiotherapy for Cervical Cancer Meta-analysis Collaboration</gtr:description><gtr:id>43CFDA2B-9467-43ED-A139-6296DB481282</gtr:id><gtr:impact>2 submitted oral presentations at oncology conferences (1 national, 1 international). 1 paper publication (PMID:19001332) and 1 Cochrane review (PMID: 20091664).
Mixture of different clinical disciplinces, statisticians and other scientists.</gtr:impact><gtr:outcomeId>FBB354ED493-11</gtr:outcomeId><gtr:partnerContribution>Provided advice throughout the project, helped interpret the results and helped write the manuscript</gtr:partnerContribution><gtr:piContribution>This international collaboration was established to conduct a systematic review and meta-analysis based on the individual participant data (IPD) which is collected directly from the trial investigators. This is considered the gold standard approach to systematic review. Members of the research team were responsible for writing the meta-analysis protocol; searching for trials; negotiating and managing collaborations; collecting, managing and analysing data, presenting results at conferences and preparing the final manuscript(s).</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Yokohama City University Medical Centre</gtr:collaboratingOrganisation><gtr:country>Japan</gtr:country><gtr:description>NSCLC Meta-analysis Collaborative Group - Pre op CT</gtr:description><gtr:id>47B9A4BB-B7CB-4431-93A6-68734F11F791</gtr:id><gtr:impact>1 presentation at World Conference on Lung Cancer 2011 and 1 paper in the Lancet (PMID: 24576776)</gtr:impact><gtr:outcomeId>56cdb0ec5aaa28.77180712-12</gtr:outcomeId><gtr:partnerContribution>Provided trial data, advice throughout the project, helped interpret the results and helped write the manuscript. The partners gave permission to use the the data for the secondary staging inaccuracy project.</gtr:partnerContribution><gtr:piContribution>This international collaboration was established to conduct a systematic review and meta-analysis based on the individual participant data (IPD), which is collected directly from the trial investigators. Members of the research team were responsible for protocol development; searching for trials; negotiating and managing collaborations; collecting, managing and analysing data, presenting results at conferences and preparing the final manuscript. We also initiated and did the analysis for a secondary staging inaccuracy project and drafted the manuscript.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Newcastle General Hospital</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Adjuvant CT for bladder cancer collaborators</gtr:description><gtr:id>533D4EEB-AEC7-4389-BBF0-81073811A6B6</gtr:id><gtr:impact>1 publication (pre-2006) and 1 Cochrane review (PMID:16625650).
Mixture of different clinical disciplinces, statisticians and other scientists.</gtr:impact><gtr:outcomeId>A26515ED15F-2</gtr:outcomeId><gtr:partnerContribution>Provided advice throughout the project, helped interpret the results and helped write the manuscript.</gtr:partnerContribution><gtr:piContribution>This international collaboration was established to conduct a systematic review and meta-analysis based on the individual participant data (IPD), which is collected directly from the trial investigators. Members of the research team were responsible for protocol development; searching for trials; negotiating and managing collaborations; collecting, managing and analysing data, presenting results at conferences and preparing the final manuscript.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Nagoya University</gtr:collaboratingOrganisation><gtr:country>Japan</gtr:country><gtr:department>Graduate School of Medicine</gtr:department><gtr:description>NSCLC Meta-analyses Colllaborative Group - Adj CT</gtr:description><gtr:id>DA41B2A7-D342-439A-B357-4658BD39479B</gtr:id><gtr:impact>6 conference presentations and 1 paper (PMID: 20338627). 1 Cochrane review in preparation.
Mixture of different clinical disciplinces, statisticians and other scientists.</gtr:impact><gtr:outcomeId>chkNmQA7hPe-12</gtr:outcomeId><gtr:partnerContribution>Provided advice throughout the project, helped interpret the results and helped write the manuscript. Provided trial data, helped interpret the results and commented on the manuscript.</gtr:partnerContribution><gtr:piContribution>This international collaboration was established to conduct a systematic review and meta-analysis based on the individual participant data (IPD), which is collected directly from the trial investigators. Members of the research team were responsible for protocol development; searching for trials; negotiating and managing collaborations; collecting, managing and analysing data, presenting results at conferences and preparing the final manuscript</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>European Organisation for Research and Treatment of Cancer (EORTC)</gtr:collaboratingOrganisation><gtr:country>European Union (EU)</gtr:country><gtr:description>Surrogate Lung Project Collaborative Group</gtr:description><gtr:id>63A6EDE6-51DA-4E2E-A3A3-4C5E9FBF6482</gtr:id><gtr:impact>Presented at Word Conference on Lung Cancer 2011 and ASCO 2011. Published in Lancet 2013</gtr:impact><gtr:outcomeId>KLchf2NAVxL-8</gtr:outcomeId><gtr:partnerContribution>Coordination of project, analyses, supplying trial data and commenting on manuscript</gtr:partnerContribution><gtr:piContribution>Commented on the protocol, supplied some trial data, and commented on manuscript</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of York</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Department of Health Sciences</gtr:department><gtr:description>Venous Leg Ulcers Collaboration</gtr:description><gtr:id>C6307D23-198E-4C34-91EE-684B394D6FBA</gtr:id><gtr:impact>1 paper publication (PMID:19376798).
Mixture of clinicians, statisticians and other scientists.</gtr:impact><gtr:outcomeId>4FF6A1579E2-1</gtr:outcomeId><gtr:partnerContribution>The project lead was responsible for writing the meta-analysis protocol; searching for trials; negotiating and managing collaborations; collecting, managing and analysing data, presenting results at conferences and preparing the manuscript. Others contributed trial dat, provided valuable advice in interpreting the findings of the meta-analysis and reviewed the manusucript.</gtr:partnerContribution><gtr:piContribution>This collaboration was established to conduct a systematic review and meta-analysis based on the individual participant data (IPD), which is collected directly from the trial investigators. This is considered the gold standard approach to systematic review. I advised on developing the protocol and collecting, checking, and analysing data, and commented on drafts of the manuscript.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Churchill Hospital</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>CT for endometrial cancer collaborators</gtr:description><gtr:id>4B9908DA-4778-4A66-94B2-716214ABF682</gtr:id><gtr:impact>1 Cochrane Review (pre-2006), 1 update of the Cochrane review (PMID: 22895938), and 1 paper publication (PMID: 17150999). Mixture of different clinical disciplinces and scientists.</gtr:impact><gtr:outcomeId>93A61F77E4F-3</gtr:outcomeId><gtr:partnerContribution>Responsible for protocol development; searching for trials; extracting, managing and analysing data and preparing the final manuscript.Involved in protocol development; helped interpret the results and helped write the manuscript.Involved in protocol development and searching for trials. Provided advice throughout the project, helped interpret the results and helped write the manuscript.</gtr:partnerContribution><gtr:piContribution>This collaboration was established to conduct a systematic review and meta-analysis. We were involved in protocol development; searching for trials; extracting, managing and analysing data and preparing the final manuscript.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Keele University</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Research Institute for Primary Care and Health Sciences</gtr:department><gtr:description>Acupuncture for pregnancy outcomes during IVF</gtr:description><gtr:id>A7B314B4-95BE-46A1-B000-0EA5FBBB8FBF</gtr:id><gtr:impact>1 paper published (PMID: 23814102). Mixed clinical and scientific expertise</gtr:impact><gtr:outcomeId>T9x3NyJK43b-2</gtr:outcomeId><gtr:partnerContribution>They were responsible for protocol development; searching for trials; aseessing trial quality; extracting, managing and analysing data, presenting results at conferences and preparing the final manuscript. Others helped with protocol development and preparing the final manuscript.</gtr:partnerContribution><gtr:piContribution>This collaboration was established to conduct a systematic review and meta-analysis. Members of the research team helped with protocol development and preparing the final manuscript.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Gustave-Roussy Institute</gtr:collaboratingOrganisation><gtr:country>France, French Republic</gtr:country><gtr:description>NSCLC Meta-analysis Collaborative Group - Pre op CT</gtr:description><gtr:id>CE0F827F-DEA2-4864-99F8-319F97F1656C</gtr:id><gtr:impact>1 presentation at World Conference on Lung Cancer 2011 and 1 paper in the Lancet (PMID: 24576776)</gtr:impact><gtr:outcomeId>56cdb0ec5aaa28.77180712-1</gtr:outcomeId><gtr:partnerContribution>Provided trial data, advice throughout the project, helped interpret the results and helped write the manuscript. The partners gave permission to use the the data for the secondary staging inaccuracy project.</gtr:partnerContribution><gtr:piContribution>This international collaboration was established to conduct a systematic review and meta-analysis based on the individual participant data (IPD), which is collected directly from the trial investigators. Members of the research team were responsible for protocol development; searching for trials; negotiating and managing collaborations; collecting, managing and analysing data, presenting results at conferences and preparing the final manuscript. We also initiated and did the analysis for a secondary staging inaccuracy project and drafted the manuscript.</gtr:piContribution><gtr:sector>Multiple</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Memorial Sloan Kettering Cancer Center</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>NSCLC Meta-analyses Colllaborative Group - Adj CT</gtr:description><gtr:id>D96F1A37-DA39-4B6A-8831-64AC44017073</gtr:id><gtr:impact>6 conference presentations and 1 paper (PMID: 20338627). 1 Cochrane review in preparation.
Mixture of different clinical disciplinces, statisticians and other scientists.</gtr:impact><gtr:outcomeId>chkNmQA7hPe-19</gtr:outcomeId><gtr:partnerContribution>Provided advice throughout the project, helped interpret the results and helped write the manuscript. Provided trial data, helped interpret the results and commented on the manuscript.</gtr:partnerContribution><gtr:piContribution>This international collaboration was established to conduct a systematic review and meta-analysis based on the individual participant data (IPD), which is collected directly from the trial investigators. Members of the research team were responsible for protocol development; searching for trials; negotiating and managing collaborations; collecting, managing and analysing data, presenting results at conferences and preparing the final manuscript</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Glasgow</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Institute of Cardiovascular and Medical Sciences (ICAMS)</gtr:department><gtr:description>Non-pharmacological interventions for caregivers of stroke survivors collaborators</gtr:description><gtr:id>0183793D-7D7D-4FCE-AC1D-773A5643F7BB</gtr:id><gtr:impact>1 published Cohrane Review (PMID:21975778) and 1 paper in press. Mixed clinical and scientific expertise.</gtr:impact><gtr:outcomeId>oStBf8CLXNv-1</gtr:outcomeId><gtr:partnerContribution>1 responsible for protocol development; searching for trials; aseessing trial quality; extracting, managing and analysing data, presenting results at conferences and preparing the final manuscript. Others helped with protocol development; assessing trial quality and preparing the final manuscript.</gtr:partnerContribution><gtr:piContribution>This collaboration was established to conduct a systematic review and meta-analysis. Members of the research team helped with protocol development; assessing trial quality and preparing the final manuscript.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Glenfield Hospital</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>NSCLC Meta-analyses Colllaborative Group - Adj CT</gtr:description><gtr:id>1AAA119E-9C14-47DF-847F-C484CB70B954</gtr:id><gtr:impact>6 conference presentations and 1 paper (PMID: 20338627). 1 Cochrane review in preparation.
Mixture of different clinical disciplinces, statisticians and other scientists.</gtr:impact><gtr:outcomeId>chkNmQA7hPe-36</gtr:outcomeId><gtr:partnerContribution>Provided advice throughout the project, helped interpret the results and helped write the manuscript. Provided trial data, helped interpret the results and commented on the manuscript.</gtr:partnerContribution><gtr:piContribution>This international collaboration was established to conduct a systematic review and meta-analysis based on the individual participant data (IPD), which is collected directly from the trial investigators. Members of the research team were responsible for protocol development; searching for trials; negotiating and managing collaborations; collecting, managing and analysing data, presenting results at conferences and preparing the final manuscript</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Rene Gauducheau Centre</gtr:collaboratingOrganisation><gtr:country>France, French Republic</gtr:country><gtr:description>NSCLC Meta-analyses Colllaborative Group - Adj CT</gtr:description><gtr:id>76F4C430-8CF0-4762-8FA6-DF6094BBD665</gtr:id><gtr:impact>6 conference presentations and 1 paper (PMID: 20338627). 1 Cochrane review in preparation.
Mixture of different clinical disciplinces, statisticians and other scientists.</gtr:impact><gtr:outcomeId>chkNmQA7hPe-8</gtr:outcomeId><gtr:partnerContribution>Provided advice throughout the project, helped interpret the results and helped write the manuscript. Provided trial data, helped interpret the results and commented on the manuscript.</gtr:partnerContribution><gtr:piContribution>This international collaboration was established to conduct a systematic review and meta-analysis based on the individual participant data (IPD), which is collected directly from the trial investigators. Members of the research team were responsible for protocol development; searching for trials; negotiating and managing collaborations; collecting, managing and analysing data, presenting results at conferences and preparing the final manuscript</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>European Organisation for Research and Treatment of Cancer (EORTC)</gtr:collaboratingOrganisation><gtr:country>European Union (EU)</gtr:country><gtr:description>Adjuvant CT for bladder cancer collaborators</gtr:description><gtr:id>071EBDC2-2EC0-4E8E-8D0F-5B72CCE44CFB</gtr:id><gtr:impact>1 publication (pre-2006) and 1 Cochrane review (PMID:16625650).
Mixture of different clinical disciplinces, statisticians and other scientists.</gtr:impact><gtr:outcomeId>A26515ED15F-3</gtr:outcomeId><gtr:partnerContribution>Provided advice throughout the project, helped interpret the results and helped write the manuscript.</gtr:partnerContribution><gtr:piContribution>This international collaboration was established to conduct a systematic review and meta-analysis based on the individual participant data (IPD), which is collected directly from the trial investigators. Members of the research team were responsible for protocol development; searching for trials; negotiating and managing collaborations; collecting, managing and analysing data, presenting results at conferences and preparing the final manuscript.</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of York</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Centre for Reviews and Dissemination (CRD)</gtr:department><gtr:description>Prion review collaborators</gtr:description><gtr:id>9C31A06A-3FE3-4294-A7D1-78699F4B2AAB</gtr:id><gtr:impact>1 paper publication (PMID18391159).
Mixture of clinicians and scientists.</gtr:impact><gtr:outcomeId>A60D60838F0-1</gtr:outcomeId><gtr:partnerContribution>Responsible for protocol development; searching for trials; negotiating and managing collaborations; collecting, managing and analysing data, presenting results at conferences and preparing the final manuscript.Provided advice throughout the project, helped interpret the results and helped write the manuscript.</gtr:partnerContribution><gtr:piContribution>This collaboration was established to conduct a systematic review. Members of the research team were responsible for protocol development; searching for trials; extracting and collating data, and preparing the final manuscript.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Brussels Saint-Luc University Hospital (UCL)</gtr:collaboratingOrganisation><gtr:country>Belgium, Kingdom of</gtr:country><gtr:description>IPD meta-analyses of androgen deprivation therapy and docetaxel for prostate cancer</gtr:description><gtr:id>9502DF90-F427-4237-96B1-AB567763EB34</gtr:id><gtr:impact>Protocol currently being drafted, preliminary searches completed.</gtr:impact><gtr:outcomeId>56d9a06cdf39a6.42965273-5</gtr:outcomeId><gtr:partnerContribution>Provided advice and helped with protocol development</gtr:partnerContribution><gtr:piContribution>This collaboration has been established to conduct a systematic review and meta-analysis to investigate the addition of bisphosphonates to standard androgen deprivation therapy for men with non-metastatic and metastatic prostate cancer. Members of the research team have been responsible for protocol development and searching for eligible trials.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Cancer and Leukaemia Group B</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Surrogate Lung Project Collaborative Group</gtr:description><gtr:id>8C312058-379C-4C5B-80E0-491786147EFA</gtr:id><gtr:impact>Presented at Word Conference on Lung Cancer 2011 and ASCO 2011. Published in Lancet 2013</gtr:impact><gtr:outcomeId>KLchf2NAVxL-7</gtr:outcomeId><gtr:partnerContribution>Coordination of project, analyses, supplying trial data and commenting on manuscript</gtr:partnerContribution><gtr:piContribution>Commented on the protocol, supplied some trial data, and commented on manuscript</gtr:piContribution><gtr:sector>Public</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Cancer Research UK</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>NSCLC Meta-analyses Colllaborative Group - Adj CT</gtr:description><gtr:id>0000E9F6-A66B-4BCA-AE7C-E459F2E00956</gtr:id><gtr:impact>6 conference presentations and 1 paper (PMID: 20338627). 1 Cochrane review in preparation.
Mixture of different clinical disciplinces, statisticians and other scientists.</gtr:impact><gtr:outcomeId>chkNmQA7hPe-5</gtr:outcomeId><gtr:partnerContribution>Provided advice throughout the project, helped interpret the results and helped write the manuscript. Provided trial data, helped interpret the results and commented on the manuscript.</gtr:partnerContribution><gtr:piContribution>This international collaboration was established to conduct a systematic review and meta-analysis based on the individual participant data (IPD), which is collected directly from the trial investigators. Members of the research team were responsible for protocol development; searching for trials; negotiating and managing collaborations; collecting, managing and analysing data, presenting results at conferences and preparing the final manuscript</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Dana-Farber Cancer Institute</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Intermediate Clinical Endpoint in Cancer of the Prostate (ICECaP) Initiative</gtr:description><gtr:id>BC0E25AF-0A4E-4D96-9499-2649AA4BC03E</gtr:id><gtr:impact>Ongoing</gtr:impact><gtr:outcomeId>56d9a0c252e871.22655242-1</gtr:outcomeId><gtr:partnerContribution>Dana-Farber are leading this initiative</gtr:partnerContribution><gtr:piContribution>Collaborating with the ICECaP initiative to establish a repository of RCTs in non-metastatic prostate cancer with the primary aim of identifying surrogate outcomes for survival. Will lead the planned repository of RCTs in metastatic prostate cancer.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University Hospitals Bristol NHS Foundation Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Bristol Haematology and Oncology Centre</gtr:department><gtr:description>CT for endometrial cancer collaborators</gtr:description><gtr:id>E419AE0C-404E-43B4-AAEC-77E259B2C379</gtr:id><gtr:impact>1 Cochrane Review (pre-2006), 1 update of the Cochrane review (PMID: 22895938), and 1 paper publication (PMID: 17150999). Mixture of different clinical disciplinces and scientists.</gtr:impact><gtr:outcomeId>93A61F77E4F-5</gtr:outcomeId><gtr:partnerContribution>Responsible for protocol development; searching for trials; extracting, managing and analysing data and preparing the final manuscript.Involved in protocol development; helped interpret the results and helped write the manuscript.Involved in protocol development and searching for trials. Provided advice throughout the project, helped interpret the results and helped write the manuscript.</gtr:partnerContribution><gtr:piContribution>This collaboration was established to conduct a systematic review and meta-analysis. We were involved in protocol development; searching for trials; extracting, managing and analysing data and preparing the final manuscript.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Colorado</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>Cancer Centre</gtr:department><gtr:description>NSCLC Meta-analysis Collaborative Group - Pre op CT</gtr:description><gtr:id>E358361B-9255-4F25-8996-EDB6394BA350</gtr:id><gtr:impact>1 presentation at World Conference on Lung Cancer 2011 and 1 paper in the Lancet (PMID: 24576776)</gtr:impact><gtr:outcomeId>56cdb0ec5aaa28.77180712-4</gtr:outcomeId><gtr:partnerContribution>Provided trial data, advice throughout the project, helped interpret the results and helped write the manuscript. The partners gave permission to use the the data for the secondary staging inaccuracy project.</gtr:partnerContribution><gtr:piContribution>This international collaboration was established to conduct a systematic review and meta-analysis based on the individual participant data (IPD), which is collected directly from the trial investigators. Members of the research team were responsible for protocol development; searching for trials; negotiating and managing collaborations; collecting, managing and analysing data, presenting results at conferences and preparing the final manuscript. We also initiated and did the analysis for a secondary staging inaccuracy project and drafted the manuscript.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Germans Trias i Pujol University Hospital</gtr:collaboratingOrganisation><gtr:country>Spain, Kingdom of</gtr:country><gtr:description>NSCLC Meta-analysis Collaborative Group - Pre op CT</gtr:description><gtr:id>BBAA0FEC-6593-45BF-AC54-5BD923C39A0E</gtr:id><gtr:impact>1 presentation at World Conference on Lung Cancer 2011 and 1 paper in the Lancet (PMID: 24576776)</gtr:impact><gtr:outcomeId>56cdb0ec5aaa28.77180712-10</gtr:outcomeId><gtr:partnerContribution>Provided trial data, advice throughout the project, helped interpret the results and helped write the manuscript. The partners gave permission to use the the data for the secondary staging inaccuracy project.</gtr:partnerContribution><gtr:piContribution>This international collaboration was established to conduct a systematic review and meta-analysis based on the individual participant data (IPD), which is collected directly from the trial investigators. Members of the research team were responsible for protocol development; searching for trials; negotiating and managing collaborations; collecting, managing and analysing data, presenting results at conferences and preparing the final manuscript. We also initiated and did the analysis for a secondary staging inaccuracy project and drafted the manuscript.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Duke University Medical Centre</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>NSCLC Meta-analyses Collaborative Group - Con vs seq CT + RT</gtr:description><gtr:id>A77A5076-303F-4B1A-BC8E-33172ADB01C5</gtr:id><gtr:impact>1 paper publication (PMID: 20351327).
Mixture of different clinical disciplinces, statisticians and other scientists.</gtr:impact><gtr:outcomeId>LQEbafHZbiJ-11</gtr:outcomeId><gtr:partnerContribution>Provided trial data, helped interpret the results and commented on the manuscript</gtr:partnerContribution><gtr:piContribution>This international collaboration was established to conduct a systematic review and meta-analysis based on the individual participant data (IPD), which is collected directly from the trial investigators. Members of the research team were responsible for protocol development; analysing the final results and preparing the final manuscript</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Tokyo Medical and Dental University</gtr:collaboratingOrganisation><gtr:country>Japan</gtr:country><gtr:description>NSCLC Meta-analyses Colllaborative Group - Adj CT</gtr:description><gtr:id>FD91B27D-EC67-4EB5-AE5F-972417FE63DA</gtr:id><gtr:impact>6 conference presentations and 1 paper (PMID: 20338627). 1 Cochrane review in preparation.
Mixture of different clinical disciplinces, statisticians and other scientists.</gtr:impact><gtr:outcomeId>chkNmQA7hPe-13</gtr:outcomeId><gtr:partnerContribution>Provided advice throughout the project, helped interpret the results and helped write the manuscript. Provided trial data, helped interpret the results and commented on the manuscript.</gtr:partnerContribution><gtr:piContribution>This international collaboration was established to conduct a systematic review and meta-analysis based on the individual participant data (IPD), which is collected directly from the trial investigators. Members of the research team were responsible for protocol development; searching for trials; negotiating and managing collaborations; collecting, managing and analysing data, presenting results at conferences and preparing the final manuscript</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Netherlands Cancer Institute (NKI)</gtr:collaboratingOrganisation><gtr:country>Netherlands, Kingdom of the</gtr:country><gtr:description>NSCLC Meta-analyses Collaborative Group - Con vs seq CT + RT</gtr:description><gtr:id>9382DA38-577D-4F74-A753-AA4018A3D193</gtr:id><gtr:impact>1 paper publication (PMID: 20351327).
Mixture of different clinical disciplinces, statisticians and other scientists.</gtr:impact><gtr:outcomeId>LQEbafHZbiJ-4</gtr:outcomeId><gtr:partnerContribution>Provided trial data, helped interpret the results and commented on the manuscript</gtr:partnerContribution><gtr:piContribution>This international collaboration was established to conduct a systematic review and meta-analysis based on the individual participant data (IPD), which is collected directly from the trial investigators. Members of the research team were responsible for protocol development; analysing the final results and preparing the final manuscript</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Turin</gtr:collaboratingOrganisation><gtr:country>Italy, Italian Republic</gtr:country><gtr:description>NSCLC Meta-analysis Collaborative Group - Pre op CT</gtr:description><gtr:id>360BD464-CEAA-4622-BB40-BDF8E8150069</gtr:id><gtr:impact>1 presentation at World Conference on Lung Cancer 2011 and 1 paper in the Lancet (PMID: 24576776)</gtr:impact><gtr:outcomeId>56cdb0ec5aaa28.77180712-11</gtr:outcomeId><gtr:partnerContribution>Provided trial data, advice throughout the project, helped interpret the results and helped write the manuscript. The partners gave permission to use the the data for the secondary staging inaccuracy project.</gtr:partnerContribution><gtr:piContribution>This international collaboration was established to conduct a systematic review and meta-analysis based on the individual participant data (IPD), which is collected directly from the trial investigators. Members of the research team were responsible for protocol development; searching for trials; negotiating and managing collaborations; collecting, managing and analysing data, presenting results at conferences and preparing the final manuscript. We also initiated and did the analysis for a secondary staging inaccuracy project and drafted the manuscript.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Bern</gtr:collaboratingOrganisation><gtr:country>Switzerland, Swiss Confederation</gtr:country><gtr:description>Adjuvant CT for bladder cancer collaborators</gtr:description><gtr:id>23852E18-B11F-4B65-A0DB-2FC5D4E81FF1</gtr:id><gtr:impact>1 publication (pre-2006) and 1 Cochrane review (PMID:16625650).
Mixture of different clinical disciplinces, statisticians and other scientists.</gtr:impact><gtr:outcomeId>A26515ED15F-7</gtr:outcomeId><gtr:partnerContribution>Provided advice throughout the project, helped interpret the results and helped write the manuscript.</gtr:partnerContribution><gtr:piContribution>This international collaboration was established to conduct a systematic review and meta-analysis based on the individual participant data (IPD), which is collected directly from the trial investigators. Members of the research team were responsible for protocol development; searching for trials; negotiating and managing collaborations; collecting, managing and analysing data, presenting results at conferences and preparing the final manuscript.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>American College of Radiology (ACR)</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>NSCLC Meta-analyses Collaborative Group - Con vs seq CT + RT</gtr:description><gtr:id>D860723A-0679-4DCD-A64D-81132FA61084</gtr:id><gtr:impact>1 paper publication (PMID: 20351327).
Mixture of different clinical disciplinces, statisticians and other scientists.</gtr:impact><gtr:outcomeId>LQEbafHZbiJ-7</gtr:outcomeId><gtr:partnerContribution>Provided trial data, helped interpret the results and commented on the manuscript</gtr:partnerContribution><gtr:piContribution>This international collaboration was established to conduct a systematic review and meta-analysis based on the individual participant data (IPD), which is collected directly from the trial investigators. Members of the research team were responsible for protocol development; analysing the final results and preparing the final manuscript</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Penn State Milton S. Hershey Medical Center</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>Cancer Institute</gtr:department><gtr:description>Surrogate Lung Project Collaborative Group</gtr:description><gtr:id>CF9F51A3-26C5-4FE0-BA1F-9A27F501FF9B</gtr:id><gtr:impact>Presented at Word Conference on Lung Cancer 2011 and ASCO 2011. Published in Lancet 2013</gtr:impact><gtr:outcomeId>KLchf2NAVxL-4</gtr:outcomeId><gtr:partnerContribution>Coordination of project, analyses, supplying trial data and commenting on manuscript</gtr:partnerContribution><gtr:piContribution>Commented on the protocol, supplied some trial data, and commented on manuscript</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Shanghai University of Traditional Chinese Medicine</gtr:collaboratingOrganisation><gtr:country>China, People's Republic of</gtr:country><gtr:description>Acupuncture for pregnancy outcomes during IVF</gtr:description><gtr:id>F3952E2A-0396-4B22-8670-762ECB9FAE5A</gtr:id><gtr:impact>1 paper published (PMID: 23814102). Mixed clinical and scientific expertise</gtr:impact><gtr:outcomeId>T9x3NyJK43b-3</gtr:outcomeId><gtr:partnerContribution>They were responsible for protocol development; searching for trials; aseessing trial quality; extracting, managing and analysing data, presenting results at conferences and preparing the final manuscript. Others helped with protocol development and preparing the final manuscript.</gtr:partnerContribution><gtr:piContribution>This collaboration was established to conduct a systematic review and meta-analysis. Members of the research team helped with protocol development and preparing the final manuscript.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>The Cochrane Collaboration</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>UK Cochrane Centre</gtr:department><gtr:description>PARIS Collaborative Group</gtr:description><gtr:id>709066D4-ED12-4028-A48F-6B13AE8D2A5E</gtr:id><gtr:impact>1 paper publication (Lancet, PMID: 17512048).
Mixture of different clinical disciplinces, statisticians and other scientists.</gtr:impact><gtr:outcomeId>589F5C4E93E-2</gtr:outcomeId><gtr:partnerContribution>Responsible for protocol development; searching for trials; negotiating and managing collaborations; collecting, managing and analysing data (from 57 trials and 25 countries), presenting results at conferences and preparing the final manuscript.Provided advice throughout the project, helped interpret the results and helped write the manuscript.</gtr:partnerContribution><gtr:piContribution>This international collaboration was established to conduct a systematic review and meta-analysis based on the individual participant data (IPD), which is collected directly from the trial investigators. Members of the research team were involved in protocol development; searching for trials; negotiating and managing collaborations; collecting, managing and analysing data, presenting results at conferences and helped preparing the final manuscripts(s).</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University College London Hospitals NHS Foundation Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>NSCLC Meta-analyses Collaborative Group - SC</gtr:description><gtr:id>0A020058-72BA-47CA-8892-E790680CC54F</gtr:id><gtr:impact>2 presentations at international oncology conferences, 1 paper publication (PM: 18678835) and 1 Cochrane Review (PMID 20464750).
Mixture of different clinical disciplinces, statisticians and other scientists.</gtr:impact><gtr:outcomeId>8788CEC157B-17</gtr:outcomeId><gtr:partnerContribution>Provided advice throughout the project, helped interpret the results and helped write the manuscript</gtr:partnerContribution><gtr:piContribution>This international collaboration was established to conduct a systematic review and meta-analysis based on the individual participant data (IPD), which is collected directly from the trial investigators. This is considered the gold standard approach to systematic review. Members of the research team were responsible for writing the meta-analysis protocol; searching for trials; negotiating and managing collaborations; collecting, managing and analysing data, presenting results at conferences and preparing the final mansucript(s).</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>National Cancer Institute (NCI)</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Chemoradiotherapy for Cervical Cancer Meta-analysis Collaboration</gtr:description><gtr:id>9ABE46F6-108B-4161-B3D3-002F133159DC</gtr:id><gtr:impact>2 submitted oral presentations at oncology conferences (1 national, 1 international). 1 paper publication (PMID:19001332) and 1 Cochrane review (PMID: 20091664).
Mixture of different clinical disciplinces, statisticians and other scientists.</gtr:impact><gtr:outcomeId>FBB354ED493-5</gtr:outcomeId><gtr:partnerContribution>Provided advice throughout the project, helped interpret the results and helped write the manuscript</gtr:partnerContribution><gtr:piContribution>This international collaboration was established to conduct a systematic review and meta-analysis based on the individual participant data (IPD) which is collected directly from the trial investigators. This is considered the gold standard approach to systematic review. Members of the research team were responsible for writing the meta-analysis protocol; searching for trials; negotiating and managing collaborations; collecting, managing and analysing data, presenting results at conferences and preparing the final manuscript(s).</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Liverpool School of Tropical Medicine</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>IPD meta-analysis of iron and malaria, feasibility study</gtr:description><gtr:id>E639F809-A0FA-44A4-90EC-77496F80C96E</gtr:id><gtr:impact>We prepared a draft protocol for the meta-analysis and started the feasibility study.</gtr:impact><gtr:outcomeId>XdoSWND9kYa-1</gtr:outcomeId><gtr:partnerContribution>Helped with protocol and feasability study development.</gtr:partnerContribution><gtr:piContribution>This collaboration aims to establish the feasibility of assessing the effect of iron supplementation in malarious areas through and IPD meta-analysis. Members of the research team helped with protocol and feasability study development.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of York</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>NSCLC Meta-analysis Collaborative Group - Pre op CT</gtr:description><gtr:id>7B4CE4BC-1FFB-4AA8-A2B3-753E10C3A983</gtr:id><gtr:impact>1 presentation at World Conference on Lung Cancer 2011 and 1 paper in the Lancet (PMID: 24576776)</gtr:impact><gtr:outcomeId>56cdb0ec5aaa28.77180712-3</gtr:outcomeId><gtr:partnerContribution>Provided trial data, advice throughout the project, helped interpret the results and helped write the manuscript. The partners gave permission to use the the data for the secondary staging inaccuracy project.</gtr:partnerContribution><gtr:piContribution>This international collaboration was established to conduct a systematic review and meta-analysis based on the individual participant data (IPD), which is collected directly from the trial investigators. Members of the research team were responsible for protocol development; searching for trials; negotiating and managing collaborations; collecting, managing and analysing data, presenting results at conferences and preparing the final manuscript. We also initiated and did the analysis for a secondary staging inaccuracy project and drafted the manuscript.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University Medical Center Gronigen</gtr:collaboratingOrganisation><gtr:country>Netherlands, Kingdom of the</gtr:country><gtr:description>Chemoradiotherapy for Cervical Cancer Meta-analysis Collaboration</gtr:description><gtr:id>3494715D-D547-4F2A-BA04-E83DFCA8808E</gtr:id><gtr:impact>2 submitted oral presentations at oncology conferences (1 national, 1 international). 1 paper publication (PMID:19001332) and 1 Cochrane review (PMID: 20091664).
Mixture of different clinical disciplinces, statisticians and other scientists.</gtr:impact><gtr:outcomeId>FBB354ED493-19</gtr:outcomeId><gtr:partnerContribution>Provided advice throughout the project, helped interpret the results and helped write the manuscript</gtr:partnerContribution><gtr:piContribution>This international collaboration was established to conduct a systematic review and meta-analysis based on the individual participant data (IPD) which is collected directly from the trial investigators. This is considered the gold standard approach to systematic review. Members of the research team were responsible for writing the meta-analysis protocol; searching for trials; negotiating and managing collaborations; collecting, managing and analysing data, presenting results at conferences and preparing the final manuscript(s).</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Sun Yat-Sen University</gtr:collaboratingOrganisation><gtr:country>China, People's Republic of</gtr:country><gtr:department>Sun Yat-Sen University Cancer Center SYSUCC</gtr:department><gtr:description>NSCLC Meta-analyses Colllaborative Group - Adj CT</gtr:description><gtr:id>767671C4-C3AC-4AA7-BADB-FF7CBD6456B0</gtr:id><gtr:impact>6 conference presentations and 1 paper (PMID: 20338627). 1 Cochrane review in preparation.
Mixture of different clinical disciplinces, statisticians and other scientists.</gtr:impact><gtr:outcomeId>chkNmQA7hPe-37</gtr:outcomeId><gtr:partnerContribution>Provided advice throughout the project, helped interpret the results and helped write the manuscript. Provided trial data, helped interpret the results and commented on the manuscript.</gtr:partnerContribution><gtr:piContribution>This international collaboration was established to conduct a systematic review and meta-analysis based on the individual participant data (IPD), which is collected directly from the trial investigators. Members of the research team were responsible for protocol development; searching for trials; negotiating and managing collaborations; collecting, managing and analysing data, presenting results at conferences and preparing the final manuscript</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Karolinska Institute</gtr:collaboratingOrganisation><gtr:country>Sweden, Kingdom of</gtr:country><gtr:description>NSCLC Meta-analyses Collaborative Group - SC</gtr:description><gtr:id>642372DC-4A6B-4892-A639-A22EAEF0201B</gtr:id><gtr:impact>2 presentations at international oncology conferences, 1 paper publication (PM: 18678835) and 1 Cochrane Review (PMID 20464750).
Mixture of different clinical disciplinces, statisticians and other scientists.</gtr:impact><gtr:outcomeId>8788CEC157B-1</gtr:outcomeId><gtr:partnerContribution>Provided advice throughout the project, helped interpret the results and helped write the manuscript</gtr:partnerContribution><gtr:piContribution>This international collaboration was established to conduct a systematic review and meta-analysis based on the individual participant data (IPD), which is collected directly from the trial investigators. This is considered the gold standard approach to systematic review. Members of the research team were responsible for writing the meta-analysis protocol; searching for trials; negotiating and managing collaborations; collecting, managing and analysing data, presenting results at conferences and preparing the final mansucript(s).</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Bordet Institute (Institut Jules Bordet)</gtr:collaboratingOrganisation><gtr:country>Belgium, Kingdom of</gtr:country><gtr:description>Surrogate Lung Project Collaborative Group</gtr:description><gtr:id>79F0BA55-4A59-4F13-805F-61C178111299</gtr:id><gtr:impact>Presented at Word Conference on Lung Cancer 2011 and ASCO 2011. Published in Lancet 2013</gtr:impact><gtr:outcomeId>KLchf2NAVxL-12</gtr:outcomeId><gtr:partnerContribution>Coordination of project, analyses, supplying trial data and commenting on manuscript</gtr:partnerContribution><gtr:piContribution>Commented on the protocol, supplied some trial data, and commented on manuscript</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Centre for Research and Implementation of Clinical Practice</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Venous Leg Ulcers Collaboration</gtr:description><gtr:id>0DD29ABB-2BA5-410B-80E0-287C4FE26083</gtr:id><gtr:impact>1 paper publication (PMID:19376798).
Mixture of clinicians, statisticians and other scientists.</gtr:impact><gtr:outcomeId>4FF6A1579E2-2</gtr:outcomeId><gtr:partnerContribution>The project lead was responsible for writing the meta-analysis protocol; searching for trials; negotiating and managing collaborations; collecting, managing and analysing data, presenting results at conferences and preparing the manuscript. Others contributed trial dat, provided valuable advice in interpreting the findings of the meta-analysis and reviewed the manusucript.</gtr:partnerContribution><gtr:piContribution>This collaboration was established to conduct a systematic review and meta-analysis based on the individual participant data (IPD), which is collected directly from the trial investigators. This is considered the gold standard approach to systematic review. I advised on developing the protocol and collecting, checking, and analysing data, and commented on drafts of the manuscript.</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Thomas Jefferson University</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>Bodine Center for Cancer Treatment</gtr:department><gtr:description>NSCLC Meta-analyses Collaborative Group - Con vs seq CT + RT</gtr:description><gtr:id>1A38EE94-F299-4840-BC20-DA54EAB59C7A</gtr:id><gtr:impact>1 paper publication (PMID: 20351327).
Mixture of different clinical disciplinces, statisticians and other scientists.</gtr:impact><gtr:outcomeId>LQEbafHZbiJ-1</gtr:outcomeId><gtr:partnerContribution>Provided trial data, helped interpret the results and commented on the manuscript</gtr:partnerContribution><gtr:piContribution>This international collaboration was established to conduct a systematic review and meta-analysis based on the individual participant data (IPD), which is collected directly from the trial investigators. Members of the research team were responsible for protocol development; analysing the final results and preparing the final manuscript</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Hospital Universitario La Paz</gtr:collaboratingOrganisation><gtr:country>Spain, Kingdom of</gtr:country><gtr:description>Adjuvant CT for bladder cancer collaborators</gtr:description><gtr:id>F2BF3237-4B1D-4759-BC0C-724E1BD7EFAA</gtr:id><gtr:impact>1 publication (pre-2006) and 1 Cochrane review (PMID:16625650).
Mixture of different clinical disciplinces, statisticians and other scientists.</gtr:impact><gtr:outcomeId>A26515ED15F-18</gtr:outcomeId><gtr:partnerContribution>Provided advice throughout the project, helped interpret the results and helped write the manuscript.</gtr:partnerContribution><gtr:piContribution>This international collaboration was established to conduct a systematic review and meta-analysis based on the individual participant data (IPD), which is collected directly from the trial investigators. Members of the research team were responsible for protocol development; searching for trials; negotiating and managing collaborations; collecting, managing and analysing data, presenting results at conferences and preparing the final manuscript.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Ospedale di Circolo e Fondazione Macchi</gtr:collaboratingOrganisation><gtr:country>Italy, Italian Republic</gtr:country><gtr:description>Adjuvant CT for bladder cancer collaborators</gtr:description><gtr:id>75C70472-F87C-4E43-A424-27A66337733E</gtr:id><gtr:impact>1 publication (pre-2006) and 1 Cochrane review (PMID:16625650).
Mixture of different clinical disciplinces, statisticians and other scientists.</gtr:impact><gtr:outcomeId>A26515ED15F-4</gtr:outcomeId><gtr:partnerContribution>Provided advice throughout the project, helped interpret the results and helped write the manuscript.</gtr:partnerContribution><gtr:piContribution>This international collaboration was established to conduct a systematic review and meta-analysis based on the individual participant data (IPD), which is collected directly from the trial investigators. Members of the research team were responsible for protocol development; searching for trials; negotiating and managing collaborations; collecting, managing and analysing data, presenting results at conferences and preparing the final manuscript.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University College London Hospital</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>University College London Hospitals Charity (UCLH)</gtr:department><gtr:description>A review of RCTs in recurrent ovarian cancer</gtr:description><gtr:id>FF5FAF81-BF29-48E8-A673-4C6CC424DC12</gtr:id><gtr:impact>Project initiated</gtr:impact><gtr:outcomeId>545a10f2f2cc96.29741868-1</gtr:outcomeId><gtr:partnerContribution>Reviewed results of searches and early stage protocol developement</gtr:partnerContribution><gtr:piContribution>Carried out searches for trials, reviewed the results, and begin to develop an protocol.</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Gustave-Roussy Institute</gtr:collaboratingOrganisation><gtr:country>France, French Republic</gtr:country><gtr:description>NSCLC Meta-analyses Colllaborative Group - Adj CT</gtr:description><gtr:id>4288A6A1-3CF5-4564-8375-FDBBB67E223B</gtr:id><gtr:impact>6 conference presentations and 1 paper (PMID: 20338627). 1 Cochrane review in preparation.
Mixture of different clinical disciplinces, statisticians and other scientists.</gtr:impact><gtr:outcomeId>chkNmQA7hPe-9</gtr:outcomeId><gtr:partnerContribution>Provided advice throughout the project, helped interpret the results and helped write the manuscript. Provided trial data, helped interpret the results and commented on the manuscript.</gtr:partnerContribution><gtr:piContribution>This international collaboration was established to conduct a systematic review and meta-analysis based on the individual participant data (IPD), which is collected directly from the trial investigators. Members of the research team were responsible for protocol development; searching for trials; negotiating and managing collaborations; collecting, managing and analysing data, presenting results at conferences and preparing the final manuscript</gtr:piContribution><gtr:sector>Multiple</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Queen Elizabeth Hospital Birmingham</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>NSCLC Meta-analyses Collaborative Group - SC</gtr:description><gtr:id>896A3845-BE90-488C-8468-BEB642D688AD</gtr:id><gtr:impact>2 presentations at international oncology conferences, 1 paper publication (PM: 18678835) and 1 Cochrane Review (PMID 20464750).
Mixture of different clinical disciplinces, statisticians and other scientists.</gtr:impact><gtr:outcomeId>8788CEC157B-10</gtr:outcomeId><gtr:partnerContribution>Provided advice throughout the project, helped interpret the results and helped write the manuscript</gtr:partnerContribution><gtr:piContribution>This international collaboration was established to conduct a systematic review and meta-analysis based on the individual participant data (IPD), which is collected directly from the trial investigators. This is considered the gold standard approach to systematic review. Members of the research team were responsible for writing the meta-analysis protocol; searching for trials; negotiating and managing collaborations; collecting, managing and analysing data, presenting results at conferences and preparing the final mansucript(s).</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Albert Einstein College of Medicine</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>Montefiore Medical Center</gtr:department><gtr:description>NSCLC Meta-analyses Colllaborative Group - Adj CT</gtr:description><gtr:id>92F02119-CD52-4FE8-8D68-8AE3C2EB9F0E</gtr:id><gtr:impact>6 conference presentations and 1 paper (PMID: 20338627). 1 Cochrane review in preparation.
Mixture of different clinical disciplinces, statisticians and other scientists.</gtr:impact><gtr:outcomeId>chkNmQA7hPe-14</gtr:outcomeId><gtr:partnerContribution>Provided advice throughout the project, helped interpret the results and helped write the manuscript. Provided trial data, helped interpret the results and commented on the manuscript.</gtr:partnerContribution><gtr:piContribution>This international collaboration was established to conduct a systematic review and meta-analysis based on the individual participant data (IPD), which is collected directly from the trial investigators. Members of the research team were responsible for protocol development; searching for trials; negotiating and managing collaborations; collecting, managing and analysing data, presenting results at conferences and preparing the final manuscript</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Cardiff University</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>School of Medicine</gtr:department><gtr:description>IPD meta-analyses of androgen deprivation therapy and docetaxel for prostate cancer</gtr:description><gtr:id>CBC0D8C9-D20A-4E0C-BFB0-B5CA53D6FED3</gtr:id><gtr:impact>Protocol currently being drafted, preliminary searches completed.</gtr:impact><gtr:outcomeId>56d9a06cdf39a6.42965273-4</gtr:outcomeId><gtr:partnerContribution>Provided advice and helped with protocol development</gtr:partnerContribution><gtr:piContribution>This collaboration has been established to conduct a systematic review and meta-analysis to investigate the addition of bisphosphonates to standard androgen deprivation therapy for men with non-metastatic and metastatic prostate cancer. Members of the research team have been responsible for protocol development and searching for eligible trials.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Karolinska Institute</gtr:collaboratingOrganisation><gtr:country>Sweden, Kingdom of</gtr:country><gtr:description>NSCLC Meta-analyses Colllaborative Group - Adj CT</gtr:description><gtr:id>FA37DE97-7334-4A7C-9F8C-82918039B770</gtr:id><gtr:impact>6 conference presentations and 1 paper (PMID: 20338627). 1 Cochrane review in preparation.
Mixture of different clinical disciplinces, statisticians and other scientists.</gtr:impact><gtr:outcomeId>chkNmQA7hPe-1</gtr:outcomeId><gtr:partnerContribution>Provided advice throughout the project, helped interpret the results and helped write the manuscript. Provided trial data, helped interpret the results and commented on the manuscript.</gtr:partnerContribution><gtr:piContribution>This international collaboration was established to conduct a systematic review and meta-analysis based on the individual participant data (IPD), which is collected directly from the trial investigators. Members of the research team were responsible for protocol development; searching for trials; negotiating and managing collaborations; collecting, managing and analysing data, presenting results at conferences and preparing the final manuscript</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Royal North Shore Hospital</gtr:collaboratingOrganisation><gtr:country>Australia, Commonwealth of</gtr:country><gtr:description>NSCLC Meta-analyses Collaborative Group - SC</gtr:description><gtr:id>DBDBEED9-2A5D-4292-9F40-74C822D498C8</gtr:id><gtr:impact>2 presentations at international oncology conferences, 1 paper publication (PM: 18678835) and 1 Cochrane Review (PMID 20464750).
Mixture of different clinical disciplinces, statisticians and other scientists.</gtr:impact><gtr:outcomeId>8788CEC157B-7</gtr:outcomeId><gtr:partnerContribution>Provided advice throughout the project, helped interpret the results and helped write the manuscript</gtr:partnerContribution><gtr:piContribution>This international collaboration was established to conduct a systematic review and meta-analysis based on the individual participant data (IPD), which is collected directly from the trial investigators. This is considered the gold standard approach to systematic review. Members of the research team were responsible for writing the meta-analysis protocol; searching for trials; negotiating and managing collaborations; collecting, managing and analysing data, presenting results at conferences and preparing the final mansucript(s).</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Iowa Hospitals and Clinics</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>NSCLC Meta-analyses Collaborative Group - Con vs seq CT + RT</gtr:description><gtr:id>1B20756F-FE78-4554-AC18-6B408C386579</gtr:id><gtr:impact>1 paper publication (PMID: 20351327).
Mixture of different clinical disciplinces, statisticians and other scientists.</gtr:impact><gtr:outcomeId>LQEbafHZbiJ-5</gtr:outcomeId><gtr:partnerContribution>Provided trial data, helped interpret the results and commented on the manuscript</gtr:partnerContribution><gtr:piContribution>This international collaboration was established to conduct a systematic review and meta-analysis based on the individual participant data (IPD), which is collected directly from the trial investigators. Members of the research team were responsible for protocol development; analysing the final results and preparing the final manuscript</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Sydney</gtr:collaboratingOrganisation><gtr:country>Australia, Commonwealth of</gtr:country><gtr:department>NHMRC Clinical Trials Centre</gtr:department><gtr:description>PARIS Collaborative Group</gtr:description><gtr:id>7F6F1720-EF5B-4B30-A60B-B7D1425D2037</gtr:id><gtr:impact>1 paper publication (Lancet, PMID: 17512048).
Mixture of different clinical disciplinces, statisticians and other scientists.</gtr:impact><gtr:outcomeId>589F5C4E93E-1</gtr:outcomeId><gtr:partnerContribution>Responsible for protocol development; searching for trials; negotiating and managing collaborations; collecting, managing and analysing data (from 57 trials and 25 countries), presenting results at conferences and preparing the final manuscript.Provided advice throughout the project, helped interpret the results and helped write the manuscript.</gtr:partnerContribution><gtr:piContribution>This international collaboration was established to conduct a systematic review and meta-analysis based on the individual participant data (IPD), which is collected directly from the trial investigators. Members of the research team were involved in protocol development; searching for trials; negotiating and managing collaborations; collecting, managing and analysing data, presenting results at conferences and helped preparing the final manuscripts(s).</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Cedars-Sinai Medical Center</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>NSCLC Meta-analyses Colllaborative Group - Adj CT</gtr:description><gtr:id>09BD27FE-5F4F-48DE-8544-B373B9A5D602</gtr:id><gtr:impact>6 conference presentations and 1 paper (PMID: 20338627). 1 Cochrane review in preparation.
Mixture of different clinical disciplinces, statisticians and other scientists.</gtr:impact><gtr:outcomeId>chkNmQA7hPe-23</gtr:outcomeId><gtr:partnerContribution>Provided advice throughout the project, helped interpret the results and helped write the manuscript. Provided trial data, helped interpret the results and commented on the manuscript.</gtr:partnerContribution><gtr:piContribution>This international collaboration was established to conduct a systematic review and meta-analysis based on the individual participant data (IPD), which is collected directly from the trial investigators. Members of the research team were responsible for protocol development; searching for trials; negotiating and managing collaborations; collecting, managing and analysing data, presenting results at conferences and preparing the final manuscript</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University College London Hospitals NHS Foundation Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>NSCLC Meta-analyses Colllaborative Group - Adj CT</gtr:description><gtr:id>D76509C8-D7DB-48BE-8343-59D19002D72D</gtr:id><gtr:impact>6 conference presentations and 1 paper (PMID: 20338627). 1 Cochrane review in preparation.
Mixture of different clinical disciplinces, statisticians and other scientists.</gtr:impact><gtr:outcomeId>chkNmQA7hPe-29</gtr:outcomeId><gtr:partnerContribution>Provided advice throughout the project, helped interpret the results and helped write the manuscript. Provided trial data, helped interpret the results and commented on the manuscript.</gtr:partnerContribution><gtr:piContribution>This international collaboration was established to conduct a systematic review and meta-analysis based on the individual participant data (IPD), which is collected directly from the trial investigators. Members of the research team were responsible for protocol development; searching for trials; negotiating and managing collaborations; collecting, managing and analysing data, presenting results at conferences and preparing the final manuscript</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Piti?-Salp?tri?re Hospital</gtr:collaboratingOrganisation><gtr:country>France, French Republic</gtr:country><gtr:description>NSCLC Meta-analysis Collaborative Group - Pre op CT</gtr:description><gtr:id>B14EF1C7-6CF1-49D9-9726-0173E76DA2E5</gtr:id><gtr:impact>1 presentation at World Conference on Lung Cancer 2011 and 1 paper in the Lancet (PMID: 24576776)</gtr:impact><gtr:outcomeId>56cdb0ec5aaa28.77180712-5</gtr:outcomeId><gtr:partnerContribution>Provided trial data, advice throughout the project, helped interpret the results and helped write the manuscript. The partners gave permission to use the the data for the secondary staging inaccuracy project.</gtr:partnerContribution><gtr:piContribution>This international collaboration was established to conduct a systematic review and meta-analysis based on the individual participant data (IPD), which is collected directly from the trial investigators. Members of the research team were responsible for protocol development; searching for trials; negotiating and managing collaborations; collecting, managing and analysing data, presenting results at conferences and preparing the final manuscript. We also initiated and did the analysis for a secondary staging inaccuracy project and drafted the manuscript.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Velindre Cancer Centre</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Anti-EGFR therapy for advanced colorectal cancer</gtr:description><gtr:id>06D14A86-3A58-4C9E-8BD1-5A503F8FC8F4</gtr:id><gtr:impact>2 conference presentations and 1 paper (PMID: 22118887). Mixed clinical and scientific expertise</gtr:impact><gtr:outcomeId>NBN99WKBQun-1</gtr:outcomeId><gtr:partnerContribution>Provided advice throughout the project, helped interpret the results and helped write the manuscript</gtr:partnerContribution><gtr:piContribution>This collaboration was established to conduct a systematic review and meta-analysis. Members of the research team were responsible for protocol development; searching for trials; collecting, managing and analysing data, presenting results at conferences and preparing the final manuscript.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Gustave-Roussy Institute</gtr:collaboratingOrganisation><gtr:country>France, French Republic</gtr:country><gtr:department>Meta Analysis Unit Gustave-Roussy</gtr:department><gtr:description>Surrogate Lung Project Collaborative Group</gtr:description><gtr:id>83F678CB-F036-4103-A5B1-6B7C0E0465C5</gtr:id><gtr:impact>Presented at Word Conference on Lung Cancer 2011 and ASCO 2011. Published in Lancet 2013</gtr:impact><gtr:outcomeId>KLchf2NAVxL-1</gtr:outcomeId><gtr:partnerContribution>Coordination of project, analyses, supplying trial data and commenting on manuscript</gtr:partnerContribution><gtr:piContribution>Commented on the protocol, supplied some trial data, and commented on manuscript</gtr:piContribution><gtr:sector>Multiple</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Catalan Institute of Oncology (ICO)</gtr:collaboratingOrganisation><gtr:country>Spain, Kingdom of</gtr:country><gtr:description>NSCLC Meta-analyses Colllaborative Group - Adj CT</gtr:description><gtr:id>E0BCEDA5-0663-45D7-BB39-09B032560FF6</gtr:id><gtr:impact>6 conference presentations and 1 paper (PMID: 20338627). 1 Cochrane review in preparation.
Mixture of different clinical disciplinces, statisticians and other scientists.</gtr:impact><gtr:outcomeId>chkNmQA7hPe-25</gtr:outcomeId><gtr:partnerContribution>Provided advice throughout the project, helped interpret the results and helped write the manuscript. Provided trial data, helped interpret the results and commented on the manuscript.</gtr:partnerContribution><gtr:piContribution>This international collaboration was established to conduct a systematic review and meta-analysis based on the individual participant data (IPD), which is collected directly from the trial investigators. Members of the research team were responsible for protocol development; searching for trials; negotiating and managing collaborations; collecting, managing and analysing data, presenting results at conferences and preparing the final manuscript</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Piti?-Salp?tri?re Hospital</gtr:collaboratingOrganisation><gtr:country>France, French Republic</gtr:country><gtr:description>NSCLC Meta-analyses Colllaborative Group - Adj CT</gtr:description><gtr:id>AE4831BE-90EF-48F9-B4E4-6A484B455EE4</gtr:id><gtr:impact>6 conference presentations and 1 paper (PMID: 20338627). 1 Cochrane review in preparation.
Mixture of different clinical disciplinces, statisticians and other scientists.</gtr:impact><gtr:outcomeId>chkNmQA7hPe-7</gtr:outcomeId><gtr:partnerContribution>Provided advice throughout the project, helped interpret the results and helped write the manuscript. Provided trial data, helped interpret the results and commented on the manuscript.</gtr:partnerContribution><gtr:piContribution>This international collaboration was established to conduct a systematic review and meta-analysis based on the individual participant data (IPD), which is collected directly from the trial investigators. Members of the research team were responsible for protocol development; searching for trials; negotiating and managing collaborations; collecting, managing and analysing data, presenting results at conferences and preparing the final manuscript</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Cancer Research UK</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>NSCLC Meta-analyses Collaborative Group - SC</gtr:description><gtr:id>EE969006-3E87-44F9-AB1F-B088F231BCF4</gtr:id><gtr:impact>2 presentations at international oncology conferences, 1 paper publication (PM: 18678835) and 1 Cochrane Review (PMID 20464750).
Mixture of different clinical disciplinces, statisticians and other scientists.</gtr:impact><gtr:outcomeId>8788CEC157B-6</gtr:outcomeId><gtr:partnerContribution>Provided advice throughout the project, helped interpret the results and helped write the manuscript</gtr:partnerContribution><gtr:piContribution>This international collaboration was established to conduct a systematic review and meta-analysis based on the individual participant data (IPD), which is collected directly from the trial investigators. This is considered the gold standard approach to systematic review. Members of the research team were responsible for writing the meta-analysis protocol; searching for trials; negotiating and managing collaborations; collecting, managing and analysing data, presenting results at conferences and preparing the final mansucript(s).</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Academy of Medical Royal Colleges</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Royal College of Radiologists</gtr:department><gtr:description>Chemoradiation audit collaborators</gtr:description><gtr:id>D48010E6-BF80-411E-AC82-7AFFE667C22E</gtr:id><gtr:impact>2 conference presentations and 1 paper (PMID: 20594810). 1 other paper in preparation. Mixed clinical and scientific expertise</gtr:impact><gtr:outcomeId>Wuf7f5195X3-3</gtr:outcomeId><gtr:partnerContribution>Collected the audit data. Provided advice throughout the project, helped interpret the results and helped write the manuscript.</gtr:partnerContribution><gtr:piContribution>This UK collaboration was established to analyse and Royal College of Radiologist Audut of chemoradiotherapy for cervical cancer. Members of the research team were responsible for refining the database; managing and analysing data, and preparing the final manuscript.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Sussex</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Brighton and Sussex Medical School</gtr:department><gtr:description>Vitamin D as a Cancer Therapy</gtr:description><gtr:id>D0B97374-5073-425D-A598-2E8897128BB9</gtr:id><gtr:impact>A manuscript has been drafted</gtr:impact><gtr:outcomeId>5459f9a15b8015.89928194-1</gtr:outcomeId><gtr:partnerContribution>Carrying out the 'mini-review'</gtr:partnerContribution><gtr:piContribution>Input into a 'mini-review' of the potential to repurpose Vitamin D as a cancer treatment</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Gustave-Roussy Institute</gtr:collaboratingOrganisation><gtr:country>France, French Republic</gtr:country><gtr:description>NSCLC Meta-analyses Collaborative Group - SC</gtr:description><gtr:id>A7AA6E2A-25D7-4290-94BB-5F08837405D8</gtr:id><gtr:impact>2 presentations at international oncology conferences, 1 paper publication (PM: 18678835) and 1 Cochrane Review (PMID 20464750).
Mixture of different clinical disciplinces, statisticians and other scientists.</gtr:impact><gtr:outcomeId>8788CEC157B-2</gtr:outcomeId><gtr:partnerContribution>Provided advice throughout the project, helped interpret the results and helped write the manuscript</gtr:partnerContribution><gtr:piContribution>This international collaboration was established to conduct a systematic review and meta-analysis based on the individual participant data (IPD), which is collected directly from the trial investigators. This is considered the gold standard approach to systematic review. Members of the research team were responsible for writing the meta-analysis protocol; searching for trials; negotiating and managing collaborations; collecting, managing and analysing data, presenting results at conferences and preparing the final mansucript(s).</gtr:piContribution><gtr:sector>Multiple</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Kyoto</gtr:collaboratingOrganisation><gtr:country>Japan</gtr:country><gtr:description>NSCLC Meta-analyses Colllaborative Group - Adj CT</gtr:description><gtr:id>F9FACB05-74A2-4677-8454-AF7A16015455</gtr:id><gtr:impact>6 conference presentations and 1 paper (PMID: 20338627). 1 Cochrane review in preparation.
Mixture of different clinical disciplinces, statisticians and other scientists.</gtr:impact><gtr:outcomeId>chkNmQA7hPe-35</gtr:outcomeId><gtr:partnerContribution>Provided advice throughout the project, helped interpret the results and helped write the manuscript. Provided trial data, helped interpret the results and commented on the manuscript.</gtr:partnerContribution><gtr:piContribution>This international collaboration was established to conduct a systematic review and meta-analysis based on the individual participant data (IPD), which is collected directly from the trial investigators. Members of the research team were responsible for protocol development; searching for trials; negotiating and managing collaborations; collecting, managing and analysing data, presenting results at conferences and preparing the final manuscript</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Smith and Nephew</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Smith and Nephew Wound Management</gtr:department><gtr:description>Venous Leg Ulcers Collaboration</gtr:description><gtr:id>F311B4F1-1B9D-48D8-8142-E1D9E811709E</gtr:id><gtr:impact>1 paper publication (PMID:19376798).
Mixture of clinicians, statisticians and other scientists.</gtr:impact><gtr:outcomeId>4FF6A1579E2-4</gtr:outcomeId><gtr:partnerContribution>The project lead was responsible for writing the meta-analysis protocol; searching for trials; negotiating and managing collaborations; collecting, managing and analysing data, presenting results at conferences and preparing the manuscript. Others contributed trial dat, provided valuable advice in interpreting the findings of the meta-analysis and reviewed the manusucript.</gtr:partnerContribution><gtr:piContribution>This collaboration was established to conduct a systematic review and meta-analysis based on the individual participant data (IPD), which is collected directly from the trial investigators. This is considered the gold standard approach to systematic review. I advised on developing the protocol and collecting, checking, and analysing data, and commented on drafts of the manuscript.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Freeman Hospital</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Adjuvant CT for bladder cancer collaborators</gtr:description><gtr:id>ABA8CD98-4FA2-421A-BC4B-A2A5FA7389C0</gtr:id><gtr:impact>1 publication (pre-2006) and 1 Cochrane review (PMID:16625650).
Mixture of different clinical disciplinces, statisticians and other scientists.</gtr:impact><gtr:outcomeId>A26515ED15F-15</gtr:outcomeId><gtr:partnerContribution>Provided advice throughout the project, helped interpret the results and helped write the manuscript.</gtr:partnerContribution><gtr:piContribution>This international collaboration was established to conduct a systematic review and meta-analysis based on the individual participant data (IPD), which is collected directly from the trial investigators. Members of the research team were responsible for protocol development; searching for trials; negotiating and managing collaborations; collecting, managing and analysing data, presenting results at conferences and preparing the final manuscript.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Rome Tor Vergata</gtr:collaboratingOrganisation><gtr:country>Italy, Italian Republic</gtr:country><gtr:description>NSCLC Meta-analyses Colllaborative Group - Adj CT</gtr:description><gtr:id>C0B45756-2BAB-417F-937A-5C73AB7F2F96</gtr:id><gtr:impact>6 conference presentations and 1 paper (PMID: 20338627). 1 Cochrane review in preparation.
Mixture of different clinical disciplinces, statisticians and other scientists.</gtr:impact><gtr:outcomeId>chkNmQA7hPe-21</gtr:outcomeId><gtr:partnerContribution>Provided advice throughout the project, helped interpret the results and helped write the manuscript. Provided trial data, helped interpret the results and commented on the manuscript.</gtr:partnerContribution><gtr:piContribution>This international collaboration was established to conduct a systematic review and meta-analysis based on the individual participant data (IPD), which is collected directly from the trial investigators. Members of the research team were responsible for protocol development; searching for trials; negotiating and managing collaborations; collecting, managing and analysing data, presenting results at conferences and preparing the final manuscript</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>SG Moscati Hospital</gtr:collaboratingOrganisation><gtr:country>Italy, Italian Republic</gtr:country><gtr:description>NSCLC Meta-analyses Collaborative Group - SC</gtr:description><gtr:id>C93477AA-0CCD-433E-B348-A8BBB32641F5</gtr:id><gtr:impact>2 presentations at international oncology conferences, 1 paper publication (PM: 18678835) and 1 Cochrane Review (PMID 20464750).
Mixture of different clinical disciplinces, statisticians and other scientists.</gtr:impact><gtr:outcomeId>8788CEC157B-12</gtr:outcomeId><gtr:partnerContribution>Provided advice throughout the project, helped interpret the results and helped write the manuscript</gtr:partnerContribution><gtr:piContribution>This international collaboration was established to conduct a systematic review and meta-analysis based on the individual participant data (IPD), which is collected directly from the trial investigators. This is considered the gold standard approach to systematic review. Members of the research team were responsible for writing the meta-analysis protocol; searching for trials; negotiating and managing collaborations; collecting, managing and analysing data, presenting results at conferences and preparing the final mansucript(s).</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Radiation Therapy Oncology Group RTOG</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>Statistical Center</gtr:department><gtr:description>Surrogate Lung Project Collaborative Group</gtr:description><gtr:id>0EF55C25-C239-423B-9302-137CDC3DE866</gtr:id><gtr:impact>Presented at Word Conference on Lung Cancer 2011 and ASCO 2011. Published in Lancet 2013</gtr:impact><gtr:outcomeId>KLchf2NAVxL-2</gtr:outcomeId><gtr:partnerContribution>Coordination of project, analyses, supplying trial data and commenting on manuscript</gtr:partnerContribution><gtr:piContribution>Commented on the protocol, supplied some trial data, and commented on manuscript</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Queen Mary University of London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Paediatrics</gtr:department><gtr:description>Antiretroviral therapy in HIV-infected children</gtr:description><gtr:id>B969591E-DDC7-4E8B-943C-7B88A017112C</gtr:id><gtr:impact>1 Cochrane Review (PMID: 22786492). Mixed clinical and scientific expertise.</gtr:impact><gtr:outcomeId>jqPULk4PnVg-2</gtr:outcomeId><gtr:partnerContribution>Responsible for protocol development; searching for trials; aseessing trial quality; extracting, managing and analysing data and preparing the final manuscript.</gtr:partnerContribution><gtr:piContribution>This collaboration was established to conduct a systematic review and meta-analysis. Members of the research team helped with protocol development; data extraction, assessing trial quality, analysis and preparing the final manuscript.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Medical Research Council (MRC)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Network of Hubs for Trials Methodology Research (HTMR)</gtr:department><gtr:description>Non-pharmacological interventions for caregivers of stroke survivors collaborators</gtr:description><gtr:id>3648307B-B6E4-46FB-A7FD-80284C4406CA</gtr:id><gtr:impact>1 published Cohrane Review (PMID:21975778) and 1 paper in press. Mixed clinical and scientific expertise.</gtr:impact><gtr:outcomeId>oStBf8CLXNv-4</gtr:outcomeId><gtr:partnerContribution>1 responsible for protocol development; searching for trials; aseessing trial quality; extracting, managing and analysing data, presenting results at conferences and preparing the final manuscript. Others helped with protocol development; assessing trial quality and preparing the final manuscript.</gtr:partnerContribution><gtr:piContribution>This collaboration was established to conduct a systematic review and meta-analysis. Members of the research team helped with protocol development; assessing trial quality and preparing the final manuscript.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Wake Forest University</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Adjuvant CT for bladder cancer collaborators</gtr:description><gtr:id>92CD5F40-D3D2-45B0-A10B-0C3DF9D796C0</gtr:id><gtr:impact>1 publication (pre-2006) and 1 Cochrane review (PMID:16625650).
Mixture of different clinical disciplinces, statisticians and other scientists.</gtr:impact><gtr:outcomeId>A26515ED15F-8</gtr:outcomeId><gtr:partnerContribution>Provided advice throughout the project, helped interpret the results and helped write the manuscript.</gtr:partnerContribution><gtr:piContribution>This international collaboration was established to conduct a systematic review and meta-analysis based on the individual participant data (IPD), which is collected directly from the trial investigators. Members of the research team were responsible for protocol development; searching for trials; negotiating and managing collaborations; collecting, managing and analysing data, presenting results at conferences and preparing the final manuscript.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>The Christie NHS Foundation Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Adjuvant CT for bladder cancer collaborators</gtr:description><gtr:id>E0F0040B-025D-4054-BD62-686D17810DE6</gtr:id><gtr:impact>1 publication (pre-2006) and 1 Cochrane review (PMID:16625650).
Mixture of different clinical disciplinces, statisticians and other scientists.</gtr:impact><gtr:outcomeId>A26515ED15F-1</gtr:outcomeId><gtr:partnerContribution>Provided advice throughout the project, helped interpret the results and helped write the manuscript.</gtr:partnerContribution><gtr:piContribution>This international collaboration was established to conduct a systematic review and meta-analysis based on the individual participant data (IPD), which is collected directly from the trial investigators. Members of the research team were responsible for protocol development; searching for trials; negotiating and managing collaborations; collecting, managing and analysing data, presenting results at conferences and preparing the final manuscript.</gtr:piContribution><gtr:sector>Public</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University Hospitals Coventry and Warwickshire NHS Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Oncology Coventry and Warwickshire</gtr:department><gtr:description>CT for endometrial cancer collaborators</gtr:description><gtr:id>37FF87DE-B909-4B7B-BE2F-A9FCB22FADF2</gtr:id><gtr:impact>1 Cochrane Review (pre-2006), 1 update of the Cochrane review (PMID: 22895938), and 1 paper publication (PMID: 17150999). Mixture of different clinical disciplinces and scientists.</gtr:impact><gtr:outcomeId>93A61F77E4F-1</gtr:outcomeId><gtr:partnerContribution>Responsible for protocol development; searching for trials; extracting, managing and analysing data and preparing the final manuscript.Involved in protocol development; helped interpret the results and helped write the manuscript.Involved in protocol development and searching for trials. Provided advice throughout the project, helped interpret the results and helped write the manuscript.</gtr:partnerContribution><gtr:piContribution>This collaboration was established to conduct a systematic review and meta-analysis. We were involved in protocol development; searching for trials; extracting, managing and analysing data and preparing the final manuscript.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Mayo Clinic</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Surrogate Lung Project Collaborative Group</gtr:description><gtr:id>0A3C4264-1657-45F0-BAA4-2B516E337784</gtr:id><gtr:impact>Presented at Word Conference on Lung Cancer 2011 and ASCO 2011. Published in Lancet 2013</gtr:impact><gtr:outcomeId>KLchf2NAVxL-3</gtr:outcomeId><gtr:partnerContribution>Coordination of project, analyses, supplying trial data and commenting on manuscript</gtr:partnerContribution><gtr:piContribution>Commented on the protocol, supplied some trial data, and commented on manuscript</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>First Teaching Hospital of Tianjin University of Traditional Chinese Medicine (TCM)</gtr:collaboratingOrganisation><gtr:country>China, People's Republic of</gtr:country><gtr:description>Chemoradiotherapy for Cervical Cancer Meta-analysis Collaboration</gtr:description><gtr:id>863CEC1E-E66D-41CE-BED8-884A59D140E3</gtr:id><gtr:impact>2 submitted oral presentations at oncology conferences (1 national, 1 international). 1 paper publication (PMID:19001332) and 1 Cochrane review (PMID: 20091664).
Mixture of different clinical disciplinces, statisticians and other scientists.</gtr:impact><gtr:outcomeId>FBB354ED493-7</gtr:outcomeId><gtr:partnerContribution>Provided advice throughout the project, helped interpret the results and helped write the manuscript</gtr:partnerContribution><gtr:piContribution>This international collaboration was established to conduct a systematic review and meta-analysis based on the individual participant data (IPD) which is collected directly from the trial investigators. This is considered the gold standard approach to systematic review. Members of the research team were responsible for writing the meta-analysis protocol; searching for trials; negotiating and managing collaborations; collecting, managing and analysing data, presenting results at conferences and preparing the final manuscript(s).</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Princess Margaret Hospital</gtr:collaboratingOrganisation><gtr:country>Australia, Commonwealth of</gtr:country><gtr:description>NSCLC Meta-analyses Colllaborative Group - Adj CT</gtr:description><gtr:id>5FC94AD7-88D8-40A6-B18C-55DC68E70C24</gtr:id><gtr:impact>6 conference presentations and 1 paper (PMID: 20338627). 1 Cochrane review in preparation.
Mixture of different clinical disciplinces, statisticians and other scientists.</gtr:impact><gtr:outcomeId>chkNmQA7hPe-28</gtr:outcomeId><gtr:partnerContribution>Provided advice throughout the project, helped interpret the results and helped write the manuscript. Provided trial data, helped interpret the results and commented on the manuscript.</gtr:partnerContribution><gtr:piContribution>This international collaboration was established to conduct a systematic review and meta-analysis based on the individual participant data (IPD), which is collected directly from the trial investigators. Members of the research team were responsible for protocol development; searching for trials; negotiating and managing collaborations; collecting, managing and analysing data, presenting results at conferences and preparing the final manuscript</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Cambridge</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>MRC Biostatistics Unit</gtr:department><gtr:description>NSCLC Meta-analyses Colllaborative Group - Adj CT</gtr:description><gtr:id>DFB9015D-A37F-4677-8871-BA472CA08989</gtr:id><gtr:impact>6 conference presentations and 1 paper (PMID: 20338627). 1 Cochrane review in preparation.
Mixture of different clinical disciplinces, statisticians and other scientists.</gtr:impact><gtr:outcomeId>chkNmQA7hPe-2</gtr:outcomeId><gtr:partnerContribution>Provided advice throughout the project, helped interpret the results and helped write the manuscript. Provided trial data, helped interpret the results and commented on the manuscript.</gtr:partnerContribution><gtr:piContribution>This international collaboration was established to conduct a systematic review and meta-analysis based on the individual participant data (IPD), which is collected directly from the trial investigators. Members of the research team were responsible for protocol development; searching for trials; negotiating and managing collaborations; collecting, managing and analysing data, presenting results at conferences and preparing the final manuscript</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Dana-Farber Cancer Institute</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>IPD meta-analyses of androgen deprivation therapy and docetaxel for prostate cancer</gtr:description><gtr:id>14303C97-0232-4678-AB4C-77FC0A74B4AE</gtr:id><gtr:impact>Protocol currently being drafted, preliminary searches completed.</gtr:impact><gtr:outcomeId>56d9a06cdf39a6.42965273-2</gtr:outcomeId><gtr:partnerContribution>Provided advice and helped with protocol development</gtr:partnerContribution><gtr:piContribution>This collaboration has been established to conduct a systematic review and meta-analysis to investigate the addition of bisphosphonates to standard androgen deprivation therapy for men with non-metastatic and metastatic prostate cancer. Members of the research team have been responsible for protocol development and searching for eligible trials.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Leicester Royal Infirmary</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>CT for endometrial cancer collaborators</gtr:description><gtr:id>C2D27E8B-3148-4CA9-B13E-483F9E89EF2C</gtr:id><gtr:impact>1 Cochrane Review (pre-2006), 1 update of the Cochrane review (PMID: 22895938), and 1 paper publication (PMID: 17150999). Mixture of different clinical disciplinces and scientists.</gtr:impact><gtr:outcomeId>93A61F77E4F-2</gtr:outcomeId><gtr:partnerContribution>Responsible for protocol development; searching for trials; extracting, managing and analysing data and preparing the final manuscript.Involved in protocol development; helped interpret the results and helped write the manuscript.Involved in protocol development and searching for trials. Provided advice throughout the project, helped interpret the results and helped write the manuscript.</gtr:partnerContribution><gtr:piContribution>This collaboration was established to conduct a systematic review and meta-analysis. We were involved in protocol development; searching for trials; extracting, managing and analysing data and preparing the final manuscript.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University College London Hospitals NHS Foundation Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>NSCLC Meta-analysis Collaborative Group - Pre op CT</gtr:description><gtr:id>29A4D0A0-174C-4747-911A-2E76E64E7E04</gtr:id><gtr:impact>1 presentation at World Conference on Lung Cancer 2011 and 1 paper in the Lancet (PMID: 24576776)</gtr:impact><gtr:outcomeId>56cdb0ec5aaa28.77180712-16</gtr:outcomeId><gtr:partnerContribution>Provided trial data, advice throughout the project, helped interpret the results and helped write the manuscript. The partners gave permission to use the the data for the secondary staging inaccuracy project.</gtr:partnerContribution><gtr:piContribution>This international collaboration was established to conduct a systematic review and meta-analysis based on the individual participant data (IPD), which is collected directly from the trial investigators. Members of the research team were responsible for protocol development; searching for trials; negotiating and managing collaborations; collecting, managing and analysing data, presenting results at conferences and preparing the final manuscript. We also initiated and did the analysis for a secondary staging inaccuracy project and drafted the manuscript.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Princess Margaret Cancer Centre</gtr:collaboratingOrganisation><gtr:country>Canada</gtr:country><gtr:department>NCIC Clinical Trials Group</gtr:department><gtr:description>Surrogate Lung Project Collaborative Group</gtr:description><gtr:id>5E081F80-A72C-473F-8390-B91F38DFCE8A</gtr:id><gtr:impact>Presented at Word Conference on Lung Cancer 2011 and ASCO 2011. Published in Lancet 2013</gtr:impact><gtr:outcomeId>KLchf2NAVxL-5</gtr:outcomeId><gtr:partnerContribution>Coordination of project, analyses, supplying trial data and commenting on manuscript</gtr:partnerContribution><gtr:piContribution>Commented on the protocol, supplied some trial data, and commented on manuscript</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Addenbrooke's Hospital</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Department of Oncology</gtr:department><gtr:description>NSCLC Meta-analysis Collaborative Group - Pre op CT</gtr:description><gtr:id>CDFC208F-0C63-471A-850E-C5E66EA30A1B</gtr:id><gtr:impact>1 presentation at World Conference on Lung Cancer 2011 and 1 paper in the Lancet (PMID: 24576776)</gtr:impact><gtr:outcomeId>56cdb0ec5aaa28.77180712-6</gtr:outcomeId><gtr:partnerContribution>Provided trial data, advice throughout the project, helped interpret the results and helped write the manuscript. The partners gave permission to use the the data for the secondary staging inaccuracy project.</gtr:partnerContribution><gtr:piContribution>This international collaboration was established to conduct a systematic review and meta-analysis based on the individual participant data (IPD), which is collected directly from the trial investigators. Members of the research team were responsible for protocol development; searching for trials; negotiating and managing collaborations; collecting, managing and analysing data, presenting results at conferences and preparing the final manuscript. We also initiated and did the analysis for a secondary staging inaccuracy project and drafted the manuscript.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Auckland City Hospital</gtr:collaboratingOrganisation><gtr:country>New Zealand</gtr:country><gtr:description>IPD meta-analysis of adjuvant RT for prostate cancer (ARTISTIC)</gtr:description><gtr:id>E6CAC7F7-2EA8-42C3-A7FE-96B49D4D184C</gtr:id><gtr:impact>Published a letter to the editor of European Urology about the project</gtr:impact><gtr:outcomeId>56d99da298ee20.30438230-2</gtr:outcomeId><gtr:partnerContribution>Provided information on their ongoing trials, agreed to collaborate on the meta-analysis and helped draft a joint letter published about the project</gtr:partnerContribution><gtr:piContribution>Initiated a prospective collaborative IPD meta-analysis. Published a joint letter in European Urology about the project with our trialist collaborators.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University Medical Center Gronigen</gtr:collaboratingOrganisation><gtr:country>Netherlands, Kingdom of the</gtr:country><gtr:description>NSCLC Meta-analysis Collaborative Group - Pre op CT</gtr:description><gtr:id>5D6F55A8-1788-4620-812E-6BF6B834E1E9</gtr:id><gtr:impact>1 presentation at World Conference on Lung Cancer 2011 and 1 paper in the Lancet (PMID: 24576776)</gtr:impact><gtr:outcomeId>56cdb0ec5aaa28.77180712-7</gtr:outcomeId><gtr:partnerContribution>Provided trial data, advice throughout the project, helped interpret the results and helped write the manuscript. The partners gave permission to use the the data for the secondary staging inaccuracy project.</gtr:partnerContribution><gtr:piContribution>This international collaboration was established to conduct a systematic review and meta-analysis based on the individual participant data (IPD), which is collected directly from the trial investigators. Members of the research team were responsible for protocol development; searching for trials; negotiating and managing collaborations; collecting, managing and analysing data, presenting results at conferences and preparing the final manuscript. We also initiated and did the analysis for a secondary staging inaccuracy project and drafted the manuscript.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Glasgow</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Institute of Health and Wellbeing</gtr:department><gtr:description>Non-pharmacological interventions for caregivers of stroke survivors collaborators</gtr:description><gtr:id>66AB8929-783B-4A8C-A41E-2F4B94397117</gtr:id><gtr:impact>1 published Cohrane Review (PMID:21975778) and 1 paper in press. Mixed clinical and scientific expertise.</gtr:impact><gtr:outcomeId>oStBf8CLXNv-2</gtr:outcomeId><gtr:partnerContribution>1 responsible for protocol development; searching for trials; aseessing trial quality; extracting, managing and analysing data, presenting results at conferences and preparing the final manuscript. Others helped with protocol development; assessing trial quality and preparing the final manuscript.</gtr:partnerContribution><gtr:piContribution>This collaboration was established to conduct a systematic review and meta-analysis. Members of the research team helped with protocol development; assessing trial quality and preparing the final manuscript.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Royal Marsden NHS Foundation Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Adjuvant CT for bladder cancer collaborators</gtr:description><gtr:id>160B5356-9B48-4DD8-9647-9EE663C988FD</gtr:id><gtr:impact>1 publication (pre-2006) and 1 Cochrane review (PMID:16625650).
Mixture of different clinical disciplinces, statisticians and other scientists.</gtr:impact><gtr:outcomeId>A26515ED15F-16</gtr:outcomeId><gtr:partnerContribution>Provided advice throughout the project, helped interpret the results and helped write the manuscript.</gtr:partnerContribution><gtr:piContribution>This international collaboration was established to conduct a systematic review and meta-analysis based on the individual participant data (IPD), which is collected directly from the trial investigators. Members of the research team were responsible for protocol development; searching for trials; negotiating and managing collaborations; collecting, managing and analysing data, presenting results at conferences and preparing the final manuscript.</gtr:piContribution><gtr:sector>Public</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>The Christie NHS Foundation Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>NSCLC Meta-analyses Collaborative Group - SC</gtr:description><gtr:id>EA0879D3-856C-462D-A3F7-88642AD8B0DF</gtr:id><gtr:impact>2 presentations at international oncology conferences, 1 paper publication (PM: 18678835) and 1 Cochrane Review (PMID 20464750).
Mixture of different clinical disciplinces, statisticians and other scientists.</gtr:impact><gtr:outcomeId>8788CEC157B-18</gtr:outcomeId><gtr:partnerContribution>Provided advice throughout the project, helped interpret the results and helped write the manuscript</gtr:partnerContribution><gtr:piContribution>This international collaboration was established to conduct a systematic review and meta-analysis based on the individual participant data (IPD), which is collected directly from the trial investigators. This is considered the gold standard approach to systematic review. Members of the research team were responsible for writing the meta-analysis protocol; searching for trials; negotiating and managing collaborations; collecting, managing and analysing data, presenting results at conferences and preparing the final mansucript(s).</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Presentation of evaluation of consumer involvement</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>1D8242A5-E07E-4BDA-AA14-23CAC9DD2BE4</gtr:id><gtr:impact>Presented initial results of an evaluation of our involvement of consumers, from the researchers and consumers perspective, at the Involve Conference. Involve promotes public involvement in research, and the biennial conference includes sevice users, carers, voluntary organisations, and health and social services managers and researchers

Not sure</gtr:impact><gtr:outcomeId>oVje7UmVPES</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Paper Presentation</gtr:presentationType><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Engaging with guideline developers</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>8C202ADB-F2BB-4BB2-AD83-C484146257E0</gtr:id><gtr:impact>We aimed to engage more directly with guideline developers, with the aim of ensuring that the most up-to-date evidence is included in clinical practice guidelines.


The results of our research were actively included in, and provided key evidence for, updated clinical practice guidelines in Lung Cancer. An informal collaboration has also been formed with the Scottish Intercollegiate Guidelines Network (SIGN) in order to ensure that our research work (where appropriate and relevant) is included in future guideline updates.</gtr:impact><gtr:outcomeId>5450c6d0c0ca83.24767963</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Policymakers/politicians</gtr:primaryAudience><gtr:year>2013,2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Presentation of cervical cancer research results to patients</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>2AA3AAFC-07DD-47F7-B064-1C85CECD4C5A</gtr:id><gtr:impact>We worked with women treated for cervical cancer alongside 2 research projects in cervical cancer. We have presented methodology and research results to them and sought their advice.

Helped us: improve our lay decriptions of projects; prepare patient-friendly summaries of our results, improve how we involve patients and the public in the future. Helped them understand the research process.</gtr:impact><gtr:outcomeId>EC004114A84</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2006,2007,2008</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Presentation of research results on consumer involvement to consumers</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>F900E743-7AFC-46A6-ABD4-27E8F5848721</gtr:id><gtr:impact>Presented results of our research on consumer involvement at the Involve Conference. Involve promotes public involvemnet in research, and the biennial conference includes sevice users, carers, voluntary organisations, and health and social services managers and researchers

Not sure</gtr:impact><gtr:outcomeId>E9F920561F0</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Paper Presentation</gtr:presentationType><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2006</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>1900000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Hubs for Trial Methodology Research (HTMR)</gtr:description><gtr:end>2013-08-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>3CE7619B-8D0C-4743-8C24-5703D20C5735</gtr:id><gtr:outcomeId>9E02C60D8A10</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>9500</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Cochrane Collaboration Methodological Improvement Project</gtr:description><gtr:fundingOrg>National Institute for Health Research</gtr:fundingOrg><gtr:id>D35FEDE4-57DE-42F0-BC2E-8D3185DBD239</gtr:id><gtr:outcomeId>FD27FFCBB570</gtr:outcomeId><gtr:sector>Public</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>160500</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Population Health Sciences Research Network (PHSRN) cross Unit Appointment with MRC GPRF</gtr:description><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>404D27B2-CD35-4A7B-8DD9-F8CCDBFFD308</gtr:id><gtr:outcomeId>3EB2B187F5B0</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>8600</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>NIHR No specific scheme/Prion1</gtr:description><gtr:fundingOrg>National Institute for Health Research</gtr:fundingOrg><gtr:id>11D85783-DEBA-4433-9CEF-3D6E064EB2A1</gtr:id><gtr:outcomeId>281A7D9CDCE0</gtr:outcomeId><gtr:sector>Public</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>174517</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>NCC RCD Research Scientist in Evidence Synthesis Awards 2004</gtr:description><gtr:fundingOrg>National Institute for Health Research</gtr:fundingOrg><gtr:id>762CF325-90EE-4FB5-B2C3-B6F0682FB035</gtr:id><gtr:outcomeId>4F7290C34240</gtr:outcomeId><gtr:sector>Public</gtr:sector></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Glioma CT IPD (PMID:11937180) AHS guideline 2012</gtr:description><gtr:geographicReach>North America</gtr:geographicReach><gtr:guidelineTitle>Anaplastic Astrocytomas and Oligodendrogliomas</gtr:guidelineTitle><gtr:id>290388D1-2045-45AB-9E30-B9E110767E6F</gtr:id><gtr:impact>&amp;quot;In a thorough systematic review and meta-analysis published by the Glioma Meta-analysis Trialists Group in 2002, individual patient data from 12 randomized controlled trials that compared radiotherapy alone with radiotherapy plus chemotherapy over a 30 year period were analyzed. In total, data from 3004 patients, 706 of which were patients with anaplastic astrocytomas, were included in the analysis, and the majority of the trials involved nitrosourea-based chemotherapy regimens. The group reported a small but statistically significant improvement in overall survival associated with the administration of adjuvant chemotherapy (HR=0.85, 95% CI 0.78 - 0.91; p&amp;lt;0.0001)&amp;quot;, based on our systematic review and meta-analysis of IPD (PMID:11937180)</gtr:impact><gtr:outcomeId>degF7QiyvbZ</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type><gtr:url>http://europepmc.org/abstract/MED/11937180</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Cervix CTRT SR (PMID:16034873) BHKC guideline 2011</gtr:description><gtr:geographicReach>Europe</gtr:geographicReach><gtr:guidelineTitle>A national clinical practice guideline for the management of cervical cancer</gtr:guidelineTitle><gtr:id>B7A0CDBD-F2DE-44ED-AC1C-55C8EC92C956</gtr:id><gtr:impact>Our systematic review and meta-analysis of summary data was cited as evidence in this guideline (PMID:16034873)</gtr:impact><gtr:outcomeId>GDLd2itNJw8</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type><gtr:url>http://europepmc.org/abstract/MED/16034873</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Sarcoma CT SR (PMID:7640234) NCCN Soft Tissue Sarcoma 2014</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:guidelineTitle>NCCN Clinical Practice Guidelines in Oncology v.2.2014 Soft Tissue Sarcoma</gtr:guidelineTitle><gtr:id>3EF20CB2-563D-476F-9B06-DCE037B5743B</gtr:id><gtr:impact>Our systematic review and meta-analysis of summary data was cited as key evidence in this guideline (PMID: 7640234)</gtr:impact><gtr:outcomeId>544fc64deb7a25.86498556</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Endometrial CT SR (PMID:17150999) ESMO guideline 2013</gtr:description><gtr:geographicReach>Europe</gtr:geographicReach><gtr:guidelineTitle>Endometrial cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up</gtr:guidelineTitle><gtr:id>33FEAD88-E59C-48D5-ABF2-836C9EA87E64</gtr:id><gtr:impact>Our systematic review and meta-analysis of summary data was cited as evidence in this guideline (PMID: 17150999)</gtr:impact><gtr:outcomeId>pfzxaCh61jn</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Lung PORT IPD (PMID:9690404) IAEA guideline 2007</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:guidelineTitle>Lung cancer management in limited resource settings: Guidelines for appropriate good care</gtr:guidelineTitle><gtr:id>90D6460F-5F47-465A-9513-310DB23D700A</gtr:id><gtr:impact>Our systematic review and meta-analysis of IPD was cited as evidence in this guideline (PMID: 9690404)</gtr:impact><gtr:outcomeId>MQqQGWnPofT</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type><gtr:url>http://europepmc.org/abstract/MED/9690404</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Bladder Neo CT IPD (PMID: 15939524) BCCA guideline 2008</gtr:description><gtr:geographicReach>North America</gtr:geographicReach><gtr:guidelineTitle>Cancer Management Guidelines. Genitourinary. Bladder</gtr:guidelineTitle><gtr:id>57B5A003-2EE8-4549-B96E-5A5D1D80F2AD</gtr:id><gtr:impact>Our systematic review and meta-analysis of IPD was cited as evidence in this guideline (PMID: 15939524)</gtr:impact><gtr:outcomeId>56617E9F9FD</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type><gtr:url>http://europepmc.org/abstract/MED/15939524</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Lung CT 95 IPD (PMID:7580546) NCCN guideline 2013</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:guidelineTitle>NCCN Practice Guidelines in Oncology v.2.2013. Non-Small Cell Lung Cancer</gtr:guidelineTitle><gtr:id>6293E314-D273-4051-8D7E-2CDD86694E8A</gtr:id><gtr:impact>&amp;quot;For patients with stage IV disease who have a good PS,
platinum-based chemotherapy is beneficial&amp;quot;, based on our systematic review and meta-analysis of IPD (PMID: 7580546)</gtr:impact><gtr:outcomeId>eAGznQc3KS1</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Lung PORT IPD (PMID:15846628) CCA guideline stage I RT after operable 2014</gtr:description><gtr:geographicReach>Australia</gtr:geographicReach><gtr:guidelineTitle>Clinical practice guidelines for the treatment of lung cancer. What is the role of radiotherapy after surgery in the treatment of operable stage I NSCLC?</gtr:guidelineTitle><gtr:id>261444A8-F60E-4E9B-89C4-F794555F691F</gtr:id><gtr:impact>&amp;quot;There is strong evidence, based on an individual patient data meta-analysis and recently updated, that the use of postoperative radiotherapy following complete resection of stage I NSCLC is detrimental, and is associated with worse survival. In patients who have had complete resection of stage I NSCLC, postoperative radiotherapy is not recommended&amp;quot;, based on our systematic review and meta-analysis of IPD (PMID: 15846628)</gtr:impact><gtr:outcomeId>544fc130ef4563.34672516</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Cervix Neo CT SR (PMID:20091632) NCCN guideline 2014</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:guidelineTitle>NCCN Practice Guidelines in Oncology - v.1.2014 Cervical Cancer</gtr:guidelineTitle><gtr:id>69907B34-7815-4A93-A616-79F585FC5521</gtr:id><gtr:impact>&amp;quot;Although neoadjuvant chemotherapy followed by surgery has been used in areas where RT is not available, data suggest no improvement in survival when compared with surgery alone for early-stage cervical cancer. The panel does not recommend the use of neoadjuvant chemotherapy&amp;quot;, based on our systematic review and meta-analysis of summary data (PMID: 20091632)</gtr:impact><gtr:outcomeId>544f9889973da2.34729677</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Glioma CT IPD (PMID:11937180) NICE guideline 2006</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:guidelineTitle>Improving Outcomes for People with Brain and Other CNS Tumours</gtr:guidelineTitle><gtr:id>1B27D7FD-93CD-40BA-9F41-444B49E61EB6</gtr:id><gtr:impact>&amp;quot;Chemotherapy in an adjuvant setting has been the subject of a recent, high-quality meta-analysis. The meta-analysis included 12 RCTs, representing numerous chemotherapy regimens and demonstrated a 2-month median survival advantage for chemotherapy plus radiotherapy compared with radiotherapy alone (hazard ratio [HR] 0.85; 95% confidence interval [CI] 0.78 to 0.91; p = 0.00004) and a 5% increase in 2-year survival&amp;quot;, based on our systematic review and meta-analysis of IPD (PMID: 11937180)</gtr:impact><gtr:outcomeId>544f92afaf11d7.67037406</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Lung PORT IPD (PMID:9690404) SCA guideline 2011</gtr:description><gtr:geographicReach>North America</gtr:geographicReach><gtr:guidelineTitle>Provincial non-small cell lung cancer guidelines</gtr:guidelineTitle><gtr:id>9094E1EB-CDE6-4917-9D14-B775DA7585DF</gtr:id><gtr:impact>Our systematic review and meta-analysis of IPD was cited as evidence in this guideline (PMID: 9690404)</gtr:impact><gtr:outcomeId>Z4Qw3St5No6</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Pre-eclampsia PARIS IPD (PMID:17512048) NICE/RCOG joint guideline 2010</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:guidelineTitle>CG107 Hypertension in pregnancy: the management of hypertensive disorders during pregnancy</gtr:guidelineTitle><gtr:id>17C56501-3304-44AC-9913-956BC25FE676</gtr:id><gtr:impact>&amp;quot;A meta-analysis of individual-patient data [EL = 1++] that included women with chronic hypertension showed antiplatelet agents to be effective in reducing the risk of developing preeclampsia (RR 0.90; 95% CI 0.84 to 0.97)&amp;quot;, based on our systematic review and meta-analysis of IPD (PMID: 17512048)</gtr:impact><gtr:outcomeId>b9v8RgbDCHu</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type><gtr:url>http://www.nice.org.uk/CG107</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Glioma CT IPD (PMID:11937180; 12519620) NCCN guideline 2010</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:guidelineTitle>NCCN Clinical Practice Guidelines in Oncology - v.1.2010 Central Nervous System Cancers</gtr:guidelineTitle><gtr:id>CFEEB705-1A75-489C-80B4-33F33CA561F5</gtr:id><gtr:impact>Our systematic review and meta-analysis of IPD was cited as evidence in this guideline (PMID:11937180, PMID:12519620)</gtr:impact><gtr:outcomeId>Hf1tTu3wW53</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type><gtr:url>http://europepmc.org/abstract/MED/11937180</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Bladder Adj CT IPD (PMID:15939530) AURO.it guideline 2009</gtr:description><gtr:geographicReach>Europe</gtr:geographicReach><gtr:guidelineTitle>Guidelines on Bladder and Upper Urinary Tract Cancer</gtr:guidelineTitle><gtr:id>F0AFE1D1-E527-45A1-AEFD-BAF9C0D0D7C2</gtr:id><gtr:impact>&amp;quot;Si suggerisce di non eseguire la chemioterapia adiuvante&amp;quot;

&amp;quot;Nel 2005 il gruppo ABC ha condotto una metanalisi dei dati individuali di 491 pazienti dai sei studi clinici randomizzati condotti fino ad allora (di cui uno non pubblicato). Nonostante la limitazione della metanalisi dovuta al numero ridotto dei pazienti, al fatto che quattro dei 6 studi inclusi erano stati interrotti al momento della analisi ad interim, non permettendo cos&amp;igrave; di trarre conclusioni definitive, &amp;egrave; stata evidenziata una riduzione del rischio di morte del 25% (hazard ratio: 0.75; p=0.019) a favore del gruppo trattato con chemioterapia ma il dato &amp;egrave; ancora controverso.&amp;quot;

Translation:
&amp;quot;Use of adjuvant chemotherapy is not advised&amp;quot;

&amp;quot;In 2005, the ABC group conducted an analysis of 491 patients from 6 RCTs, 5 published and 1 unpublished. Despite the limited number of patients and the early stopping of included trials, making it difficult to draw definitive conclusions, a 25% reduction in the risk of death was observed (HR: 0.75; p=0.019) in the group treated with adjuvant chemotherapy&amp;quot;, based on our systematic review and meta-analysis of IPD (PMID: 15939530)</gtr:impact><gtr:outcomeId>544f80de5ce649.30976316</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>VenousUlcers IPD (PMID:19376798) AWMA/NZWCS guideline 2011</gtr:description><gtr:geographicReach>Australia</gtr:geographicReach><gtr:guidelineTitle>Australian and New Zealand clinical practice guideline for prevention and management of venous leg ulcers</gtr:guidelineTitle><gtr:id>436D93FE-9E95-424A-8B67-CAFBB6AE65E3</gtr:id><gtr:impact>&amp;quot;There is minimal evidence to suggest that there is a superior compression system to prevent recurrence of VLUs.118,142 Moderate- and low -quality RCTs suggest that medical-grade compression hosiery may be more effective than compression bandages in preventing ulcer recurrence (24% vs 53%, p&amp;lt;0.05).&amp;quot;, based on our systematic review and meta-analysis of IPD (PMID: 19376798)</gtr:impact><gtr:outcomeId>56cda6cfb66b75.31213268</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Lung Adj CT IPD (PMID:20338628) CCA guideline stage II after 2013</gtr:description><gtr:geographicReach>Oceania</gtr:geographicReach><gtr:guidelineTitle>Clinical practice guidelines for the treatment of lung cancer. &amp;quot;What is the role of chemotherapy after surgery in the treatment of operable stage II NSCLC?&amp;quot;</gtr:guidelineTitle><gtr:id>23D018E4-C738-442A-8DA8-B8E066D6E725</gtr:id><gtr:impact>In patients with operable stage II NSCLC, the evidence supports the use of 3-4 cycles of adjuvant cisplatin based chemotherapy&amp;quot;, based on our systematic review and meta-analysis of IPD (PMID: 20338628)</gtr:impact><gtr:outcomeId>izXsCzs13R5</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Glioma CT IPD (PMID:11937180) CCA guideline 2009</gtr:description><gtr:geographicReach>Australia</gtr:geographicReach><gtr:guidelineTitle>Clinical practice guidelines for the management of adult gliomas: astrocytomas and oligodendrogliomas</gtr:guidelineTitle><gtr:id>BE2FDBB7-49A2-41DB-9F7A-765CBC06C283</gtr:id><gtr:impact>&amp;quot;Adjuvant chemotherapy after surgery and radiotherapy provides modest improvement in progression free survival and overall survival for patients with GBM. Adjuvant chemotherapy after surgery and radiotherapy improves survival and is recommended for patients with anaplastic astrocytoma (AA).&amp;quot;, based on our systematic review and meta-analysis of IPD (PMID:11937180)</gtr:impact><gtr:outcomeId>544f95830310f7.28461648</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Lung Neo CT SR (PMID:17409927) CCO guideline 2012</gtr:description><gtr:geographicReach>North America</gtr:geographicReach><gtr:guidelineTitle>Use of Preoperative Chemotherapy With or Without Postoperative Radiotherapy in Technically Resectable Stage IIIA Non-Small Cell Lung Cancer. Evidence-based Series #7-4 Version 2</gtr:guidelineTitle><gtr:id>428B4CFD-F6BE-4FF6-A9F8-931BBA39D43D</gtr:id><gtr:impact>Our systematic review and meta-analysis of summary data was cited as evidence in this guideline (PMID: 17409927)</gtr:impact><gtr:outcomeId>544fb1c5078af2.31640004</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Lung SC IPD (PMID: 18678835) NCCN guideline 2014</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:guidelineTitle>NCCN Practice Guidelines in Oncology v.1.2014. Non-Small Cell Lung Cancer</gtr:guidelineTitle><gtr:id>FDE8634F-D839-4229-9A0B-51050B24500C</gtr:id><gtr:impact>&amp;quot;Patients with stage IV disease who have a good PS, benefit from chemotherapy, usually with a platinum-based regimen&amp;quot;, based on our systematic review and meta-analysis of IPD (PMID: 18678835)</gtr:impact><gtr:outcomeId>544fad2a5a1d82.45945657</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Lung SC IPD (PMID:18678835) NCCN guideline 2012</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:guidelineTitle>NCCN Practice Guidelines in Oncology v.2.2012. Non-Small Cell Lung Cancer</gtr:guidelineTitle><gtr:id>E32FEE1B-611A-490E-BBDF-A9B92EE6B337</gtr:id><gtr:impact>&amp;quot;Patients with stage IV disease who have a good PS, benefit from chemotherapy, usually with a platinum-based regimen&amp;quot;, based on our systematic review and meta-analysis of IPD (PMID: 18678835)</gtr:impact><gtr:outcomeId>sp5hje2V58H</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type><gtr:url>http://europepmc.org/abstract/MED/18678835</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Lung CT 95 IPD (PMID:7580546) AIOT guideline Stage IIIb-IV 2012</gtr:description><gtr:geographicReach>Europe</gtr:geographicReach><gtr:guidelineTitle>Linee guida per la gestione integrata del paziente con tumore polmonare: NSCLC - Stadio IIIb-IV</gtr:guidelineTitle><gtr:id>144A7BAF-01B7-49D6-8BDA-C3FFED2B76A6</gtr:id><gtr:impact>Our systematic review and meta-analysis of IPD was cited as evidence in this guideline (PMID: 7580546)</gtr:impact><gtr:outcomeId>56cda984930d56.56080297</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Lung CT 95 IPD (PMID: 7580546) NCCN guideline 2010</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:guidelineTitle>NCCN Practice Guidelines in Oncology v.2.2010. Non-Small Cell Lung Cancer</gtr:guidelineTitle><gtr:id>006182C4-DB17-483D-BE70-145F5EDFE094</gtr:id><gtr:impact>Our systematic review and meta-analysis of IPD was cited as evidence in this guideline (PMID: 7580546)</gtr:impact><gtr:outcomeId>FUv94yTQU3F</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type><gtr:url>http://europepmc.org/abstract/MED/7580546</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Lung PORT IPD (PMID:9690404) ACCP guideline Stage IIIA 2007</gtr:description><gtr:geographicReach>North America</gtr:geographicReach><gtr:guidelineTitle>Treatment of non-small cell lung cancer, stage IIIA. ACCP evidence-based clinical practice guidelines (2nd edition)</gtr:guidelineTitle><gtr:id>9BF4E486-F2C5-4672-B9D3-DD2A7F097144</gtr:id><gtr:impact>&amp;quot;At present post-operative radiotherapy cannot be recommended on the basis of any proof of improved survival&amp;quot;, based on our systematic review and meta-analysis of IPD (PMID: 9690404)</gtr:impact><gtr:outcomeId>30D2EAFAFF5</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type><gtr:url>http://europepmc.org/abstract/MED/9690404</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Lung CT 95 IPD (PMID:7580546) AHS guideline stage IV 2013</gtr:description><gtr:geographicReach>North America</gtr:geographicReach><gtr:guidelineTitle>Non-Small Cell Lung Cancer Stage IV</gtr:guidelineTitle><gtr:id>CDA1DF09-C3CD-4966-AA30-C4AE91FFE1D4</gtr:id><gtr:impact>Our systematic review and meta-analysis of IPD was cited as evidence in this guideline (PMID: 7580546)</gtr:impact><gtr:outcomeId>hSyXhHp5rbU</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Glioma CT IPD (PMID:11937180) ESMO guideline 2009</gtr:description><gtr:geographicReach>Europe</gtr:geographicReach><gtr:guidelineTitle>Malignant glioma: ESMO clinical recommendations for diagnosis, treatment and follow-up</gtr:guidelineTitle><gtr:id>231F9159-C93E-49D4-BA2D-DCE2DAE44AC5</gtr:id><gtr:impact>&amp;quot;Based on a large meta-analysis [Evidence level:IA] nitrosourea-based chemotherapy may marginally improve survival in selected patients&amp;quot;, based on our systematic review and meta-analysis of IPD (PMID:11937180)</gtr:impact><gtr:outcomeId>ARu6uLwzH23</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type><gtr:url>http://europepmc.org/abstract/MED/11937180</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Bladder Neo CT IPD (PMID:12801735; 15939524) SOS guideline 2011</gtr:description><gtr:geographicReach>Asia</gtr:geographicReach><gtr:guidelineTitle>Saudi Oncology Society clinical management guidelines for urinary bladder cancer</gtr:guidelineTitle><gtr:id>B4E13D2C-83A6-4433-A652-C5E56F7875C1</gtr:id><gtr:impact>&amp;quot;Neoadjuvant cisplatin-based chemotherapy improved overall survival by 5-7% at 5 years and this option should be offered to patients especially with locally advanced disease (T3,T4)&amp;quot;, based on our systematic review and meta-analysis of IPD (PMID:12801735; PMID:15939524)</gtr:impact><gtr:outcomeId>rW24YA9SH3A</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type><gtr:url>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3099485/</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Oesophagus RT IPD (PMID:9635705) NCCN guideline 2013</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:guidelineTitle>NCCN Guidelines Version 2.2013 Esophageal and Esophagogastric Junction Cancers</gtr:guidelineTitle><gtr:id>333CFD45-B7A4-451B-B829-52EAA9E14122</gtr:id><gtr:impact>&amp;quot;A meta-analysis from the Oesophageal Cancer Collaborative Group also showed no clear evidence of a survival advantage with preoperative radiation&amp;quot;, based on our systematic review and meta-analysis of IPD. (PMID: 9635705)</gtr:impact><gtr:outcomeId>i6oyFHmLyVj</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Cervix CTRT IPD (PMID: 19001332) NCCN guideline 2010</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:guidelineTitle>NCCN Practice Gudelines in Oncology - v.1.2010 Cervical Cancer</gtr:guidelineTitle><gtr:id>2A0D07F9-2BBF-48B0-BC40-916A8D4A4AB6</gtr:id><gtr:impact>The NCCN panel agrees that RT and concurrent cisplatin-based chemotherapy (either cisplatin alone or cisplatin/5-fluorouracil [5-FU]) are the treatment of choice for stages IIB, IIIA, IIIB and IVA disease, based on our systematic review and meta-analysis of IPD (PMID: 19001332)</gtr:impact><gtr:outcomeId>kuRVFZctjzn</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type><gtr:url>http://europepmc.org/abstract/MED/19001332</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Lung CT 95 IPD (PMID:7580546) ESMO guideline 2010</gtr:description><gtr:geographicReach>Europe</gtr:geographicReach><gtr:guidelineTitle>Early stage and locally advanced (non-metastatic) non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up</gtr:guidelineTitle><gtr:id>B3DCA663-A3DC-4ADD-A06F-379CE111FC18</gtr:id><gtr:impact>&amp;quot;Constitute a rational basis for the ESMO Clinical Practice Guidelines in favour of adjuvant chemotherapy in the stage II-III radically resected NSCLC patient&amp;quot;, based on our systematic review and meta-analysis of IPD (PMID: 7580546)</gtr:impact><gtr:outcomeId>TaeGk9XxNGy</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type><gtr:url>http://europepmc.org/abstract/MED/7580546</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Lung Neo CT SR (PMID:17409927) ESMO guideline 2010</gtr:description><gtr:geographicReach>Europe</gtr:geographicReach><gtr:guidelineTitle>Early stage and locally advanced (non-metastatic) non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up</gtr:guidelineTitle><gtr:id>5B631A50-B890-4B6E-B8AD-D41CAC58922F</gtr:id><gtr:impact>&amp;quot;With the present status of knowledge, neoadjuvant regimens should be platinum based and at least three cycles of chemotherapy should be administered. As in advanced NSCLC, a two-drug combination of platinum and a third-generation drug seems preferable: preoperative cisplatin-based combination chemotherapy can be considered in patients with stage IIIA-N2 disease.&amp;quot;, based on our systematic review and meta-analysis of summary data. (PMID: 17409927)</gtr:impact><gtr:outcomeId>oaPn8oTfQnU</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type><gtr:url>http://europepmc.org/abstract/MED/17409927</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Lung CT 95 IPD (PMID:7580546) NCCN guideline 2011</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:guidelineTitle>NCCN Practice Guidelines in Oncology v.3.2011. Non-Small Cell Lung Cancer</gtr:guidelineTitle><gtr:id>E2CC0E1D-DD3B-4FB0-88B9-A63C72844823</gtr:id><gtr:impact>&amp;quot;For patients with stage IV disease who have a good PS, platinum based chemotherapy is beneficial&amp;quot;, based on our systematic review and meta-analysis of IPD (PMID: 7580546)</gtr:impact><gtr:outcomeId>n2PwDTjfYDV</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type><gtr:url>http://europepmc.org/abstract/MED/7580546</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Sarcoma CT SR (PMID: 7640234) NCCN guideline SoftTissueSarcoma 2010</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:guidelineTitle>NCCN Clinical Practice Guidelines in Oncology v.2.2010 Soft Tissue Sarcoma</gtr:guidelineTitle><gtr:id>52167019-4C48-48D9-9E2C-70F7D81E8471</gtr:id><gtr:impact>Our systematic review and meta-analysis was cited as evidence in this guideline (PMID: 7640234)</gtr:impact><gtr:outcomeId>e6PSPmhGuVe</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type><gtr:url>http://europepmc.org/abstract/MED/7640234</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Lung CT 95 IPD (PMID:7580546) CCA guideline stage II after 2012</gtr:description><gtr:geographicReach>Oceania</gtr:geographicReach><gtr:guidelineTitle>Clinical practice guidelines for the treatment of lung cancer. &amp;quot;What is the role of chemotherapy after surgery in the treatment of operable stage II NSCLC?&amp;quot;</gtr:guidelineTitle><gtr:id>11C285CD-795A-4D24-AD12-441304D95FC1</gtr:id><gtr:impact>In patients with operable stage II NSCLC, the evidence supports the use of 3-4 cycles of adjuvant cisplatin based chemotherapy; analysis. This study also revealed combination of alkylating agents with Cisplatin to be detrimental and this combination is no longer recommended&amp;quot;, based on our systematic review and meta-analysis of IPD (PMID: 7580546)</gtr:impact><gtr:outcomeId>ruHFyw2VZEr</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Bladder Neo CT IPD (PMID:12801735; 15939524) AURO guideline 2010</gtr:description><gtr:geographicReach>Europe</gtr:geographicReach><gtr:guidelineTitle>New Italian guidelines on bladder cancer, based on the World Health Organization 2004 classification</gtr:guidelineTitle><gtr:id>2382A525-1AB6-4F05-870B-D0452E57AEE4</gtr:id><gtr:impact>&amp;quot;High-quality clinical evidence
shows that neoadjuvant cisplatin-based chemotherapy has acceptable toxicity and increases the survival rate by 5-6.5% in patients with T2-T2/N0-N2/M0 clinical stage disease&amp;quot;, based on our systematic review and meta-analysis of IPD (PMID:12801735; PMID:15939524)</gtr:impact><gtr:outcomeId>rsKEF2A8Z5J</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type><gtr:url>http://europepmc.org/abstract/MED/12801735</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Lung Neo CT SR (PMID: 17409927) BCCA guideline 2008</gtr:description><gtr:geographicReach>North America</gtr:geographicReach><gtr:guidelineTitle>Cancer Management Guidelines. Lung (including Mesothelioma &amp;amp; Thymoma)</gtr:guidelineTitle><gtr:id>ACF4A3B3-C190-4D01-AD15-359C12142947</gtr:id><gtr:impact>&amp;quot;This data demonstrates the benefit of chemotherapy when added to definitive surgical management&amp;quot;, based on our systematic review and meta-analysis of summary data (PMID: 17409927)</gtr:impact><gtr:outcomeId>A398B0CFBC5</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type><gtr:url>http://europepmc.org/abstract/MED/17409927</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Lung Adj CT IPD (PMID:20338628) ESMO guideline 2013</gtr:description><gtr:geographicReach>Europe</gtr:geographicReach><gtr:guidelineTitle>Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up</gtr:guidelineTitle><gtr:id>B8620F91-757B-4BE5-BC9F-AB92E3123383</gtr:id><gtr:impact>&amp;quot;Chemotherapy is an integral part in the treatment of locally advanced NSCLC (LA-NSCLC) as it improves survival in all subgroups of patients, whether treated with surgery or radiotherapy, as shown in meta-analyses based on individual patient data [I, A]&amp;quot; &amp;quot;Adjuvant chemotherapy should be offered to patients with resected stage II or III NSCLC [I, A]&amp;quot;, based on our systematic review and meta-analysis of IPD (PMID: 20338628)</gtr:impact><gtr:outcomeId>AXV9o6YNFSw</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Bladder Neo CT IPD (PMID:15939524) NCCN guideline 2010</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:guidelineTitle>NCCN Clinical Practice Guidelines in Oncology - v.2.2010 Bladder Cancer</gtr:guidelineTitle><gtr:id>EA15F0D7-D7D5-45E4-99F4-73F6BE107268</gtr:id><gtr:impact>&amp;quot;In the most recent meta-analysis, a statistically significant decrease in the death rate was seen corresponding to an improvement in overall survival. The NCCN Bladder Cancer panel members recommend considering cisplatin-based neoadjuvant combination chemotherapy&amp;quot;, based on our systematic review and meta-analysis of IPD (PMID:15939524)</gtr:impact><gtr:outcomeId>pMJYqrSt5JR</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type><gtr:url>http://europepmc.org/abstract/MED/15939524</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Sarcoma CT IPD (PMID:9400508) NCCN guideline SoftTissueSarcoma 2011</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:guidelineTitle>NCCN Clinical Practice Guidelines in Oncology v.2.2011 Soft Tissue Sarcoma</gtr:guidelineTitle><gtr:id>521A4504-714A-42D3-847C-D99703762858</gtr:id><gtr:impact>&amp;quot;Doxorubicin-based chemotherapy prolongs relapse-free survival (RFS) in adults with localized, resectable STS of the extremity and was associated with decreased recurrence rates.&amp;quot;, based on our systematic review and meta-analysis of IPD (PMID: 9400508)</gtr:impact><gtr:outcomeId>s9RQXVj8Ecn</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type><gtr:url>http://europepmc.org/abstract/MED/9400508</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Lung Neo CT SR (PMID:17409927) ACR guideline N2 2013</gtr:description><gtr:geographicReach>North America</gtr:geographicReach><gtr:guidelineTitle>American College of Radiology ACR Appropriateness Criteria&amp;reg; INDUCTION AND ADJUVANT THERAPY FOR N2 NON-SMALL-CELL LUNG CANCER</gtr:guidelineTitle><gtr:id>61485619-AFC1-424A-9BA9-EDA0CC84C50F</gtr:id><gtr:impact>Our systematic review and meta-analysis of summary data was cited as evidence in this guideline (PMID: 17409927)</gtr:impact><gtr:outcomeId>544fb223e33185.21853839</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Prion SR (PMID:18391159) ENFS/ENS guideline 2012</gtr:description><gtr:geographicReach>Europe</gtr:geographicReach><gtr:guidelineTitle>EFNS-ENS Guidelines on the diagnosis and management of disorders associated with dementia</gtr:guidelineTitle><gtr:id>772B823B-0FDE-40B4-A4F7-9072290B202F</gtr:id><gtr:impact>No specific treatment for prion diseases can be recommended at the present time, based on our systematic review (PMID: 18391159)</gtr:impact><gtr:outcomeId>RCS81XBRVKC</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type><gtr:url>http://europepmc.org/abstract/MED/18391159</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Lung PORT IPD (PMID:15846628) CCA guideline stage III PORT 2012</gtr:description><gtr:geographicReach>Oceania</gtr:geographicReach><gtr:guidelineTitle>Clinical practice guidelines for the treatment of lung cancer. &amp;quot;What is the role of postoperative radiotherapy (PORT) in resected stage III NSCLC?&amp;quot;</gtr:guidelineTitle><gtr:id>2E524D85-8012-475B-A4E4-588B1FB1BAD6</gtr:id><gtr:impact>&amp;quot;Post-operative radiation therapy in patients with pN2 disease is not recommended for routine use because of the lack of prospective randomised clinical trial data demonstrating an improvement in survival&amp;quot;, based on our systematic review and meta-analysis of IPD (PMID: 15846628)</gtr:impact><gtr:outcomeId>ivBdX2sBwWP</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Lung SeqCon CTRT IPD (PMID:20351327) SIGN 137 guideline 2014</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:guidelineTitle>SIGN 137: Management of Lung cancer</gtr:guidelineTitle><gtr:id>C616E836-AC8C-434F-8049-90390FCACAA6</gtr:id><gtr:impact>&amp;quot;Concurrent chemoradiotherapy should be administered to patients with locally advanced NSCLC
(suitable for radical radiotherapy) who have a good performance status (PS 0-1).&amp;quot;

&amp;quot;In patients with locally advanced NSCLC, concurrent SACT and radiotherapy confers a significant survival
benefit over sequential treatment (HR 0.84, 95% CI, 0.74 to 0.95; p=0.004; absolute survival benefit 4.5% at
five years) or radiotherapy alone&amp;quot;, based on our systematic review and meta-analysis of IPD (PMID: 20351327)</gtr:impact><gtr:outcomeId>544fb5932db050.35044740</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Lung Adj CT IPD (PMID:20338628) NICE guideline 2011</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:guidelineTitle>NICE guideline CG121:The diagnosis and treatment of lung cancer (update of NICE clinical guideline 24).</gtr:guidelineTitle><gtr:id>EFFE0ECC-1DB2-4683-BA83-299B32DF8F44</gtr:id><gtr:impact>&amp;quot;Surgery in combination with adjuvant chemotherapy was associated with longer survival (hazard ratio = .86) than surgery alone. The results also suggest that patients who received adjuvant chemotherapy experienced longer recurrence-free survival with longer time to both loco-regional and distant recurrence&amp;quot;; &amp;quot;Consider postoperative chemotherapy in patients with good performance status (WHO 0 or 1) and T2-3 N0 M0 NSCLC with tumours greater than 4 cm in diameter&amp;quot;, based on our systematic review and meta-analysis of IPD (PMID: 20338628)</gtr:impact><gtr:outcomeId>LJMYHYq9buX</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type><gtr:url>http://www.nice.org.uk/CG121</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Lung PORT IPD (PMID:9690404) NCCN guideline 2012</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:guidelineTitle>NCCN Practice Guidelines in Oncology v.2.2012. Non-Small Cell Lung Cancer</gtr:guidelineTitle><gtr:id>1B4435EB-1A75-4FB9-AC46-6400FE8E4029</gtr:id><gtr:impact>Our systematic review and meta-analysis of IPD was cited as evidence in this guideline (PMID: 9690404)</gtr:impact><gtr:outcomeId>RLx6dib3iom</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type><gtr:url>http://europepmc.org/abstract/MED/9690404</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Colorectal Anti-EGFR SR (PMID:22118887) NCCN guideline 2014</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:guidelineTitle>NCCN Practice Guidelines in Oncology v.2.2013. Colon Cancer</gtr:guidelineTitle><gtr:id>5619F90C-FC5D-47AA-A697-C50C998B87BC</gtr:id><gtr:impact>&amp;quot;A recent meta-analysis concluded there was a clear benefit to the use of EGFR inhibitors in patients with KRAS-wild-type metastatic colorectal cancer&amp;quot;, based on our systematic review and meta-analysis of summary data (PMID: 22118887)</gtr:impact><gtr:outcomeId>544f98f0a90db5.70346445</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Lung CT 95 IPD (PMID:7580546) IATO guideline 2010</gtr:description><gtr:geographicReach>Europe</gtr:geographicReach><gtr:guidelineTitle>Recent issues in first-line treatment of advanced non-small-cell lung cancer</gtr:guidelineTitle><gtr:id>F155967D-51C8-4017-B7D0-B45925442782</gtr:id><gtr:impact>Our systematic review and meta-analysis of IPD was cited as evidence in this guideline (PMID: 7580546)</gtr:impact><gtr:outcomeId>SCUiYeRQKjH</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type><gtr:url>http://europepmc.org/abstract/MED/7580546</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Lung CT 95 IPD (PMID:7580546) ACCP guideline stage III 2013</gtr:description><gtr:geographicReach>North America</gtr:geographicReach><gtr:guidelineTitle>Treatment of Stage III Non-small Cell Lung Cancer. Diagnosis and Management of Lung Cancer, 3rd ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines</gtr:guidelineTitle><gtr:id>69608B8E-B37E-4B0E-BD64-9FAF6C8883E5</gtr:id><gtr:impact>&amp;quot;We recommend adjuvant chemotherapy for patients with completely resected NSCLC with incidentally detected stage III disease unless there is reason to believe the risk of chemotherapy related complications is unusually high on the basis of performance status or comorbidities&amp;quot;, based on our systematic review and meta-analysis of IPD (PMID: 7580546)</gtr:impact><gtr:outcomeId>ZmQ6HspPdQ7</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Bladder Adj CT IPD (PMID:15939530) EAU guideline 2013</gtr:description><gtr:geographicReach>Europe</gtr:geographicReach><gtr:guidelineTitle>Guidelines on Bladder Cancer: Muscle-Invasive and Metastatic</gtr:guidelineTitle><gtr:id>D525FFE6-EF1D-4982-BD19-2EA42C253437</gtr:id><gtr:impact>Our systematic review and meta-analysis of IPD was cited as key evidence in this guideline (PMID: 15939530)</gtr:impact><gtr:outcomeId>EG18pjGskjv</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Lung CT 95 IPD (PMID:7580546) ACR guideline NonSurgGoodPS 2010</gtr:description><gtr:geographicReach>North America</gtr:geographicReach><gtr:guidelineTitle>ACR Appropriateness Criteria NONSURGICAL TREATMENT FOR NON-SMALL-CELL LUNG CANCER: GOOD PERFORMANCE STATUS/DEFINITIVE INTENT</gtr:guidelineTitle><gtr:id>69E8DFF5-9DC7-47A2-8B8D-CD1B08483FA3</gtr:id><gtr:impact>&amp;quot;These analyses have provided the evidence that has established combined platinum-based chemotherapy and radiation as the standard of care for the good-performance-status patient with unresectable stage IIIA and IIIB NSCLC and minimal weight loss&amp;quot;, based on our systematic review and meta-analysis of IPD (PMID: 7580546)</gtr:impact><gtr:outcomeId>aExsS7J26wa</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type><gtr:url>http://europepmc.org/abstract/MED/7580546</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Lung PORT IPD (PMID: 15846628 AIOT guideline Stage IIIa 2012</gtr:description><gtr:geographicReach>Europe</gtr:geographicReach><gtr:guidelineTitle>Linee guida per la gestione integrata del paziente con tumore polmonare: NSCLC - Stadio IIIa</gtr:guidelineTitle><gtr:id>E5F98D39-B867-46B2-BB11-66DC31373F60</gtr:id><gtr:impact>&amp;quot;Nei pazienti affetti da NSClC allo stadio IIIa-N2 radicalmente operati, il ruolo della radioterapia post-operatoria, anche se non ancora supportato da evidenze di fase III, &amp;egrave; un trattamento che trova larga condivisione nel mondo oncologico. le dosi impiegate non dovrebbero essere superiori ai 50 Gy erogati con frazionamento convenzionale e non in concomitanza alla chemioterapia.&amp;quot;, based on our systematic review and meta-analysis of IPD (PMID: 15846628)</gtr:impact><gtr:outcomeId>56cdaac7b6dc45.45680718</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Endometrial CT SR (PMID:17150999) CCA guideline 2014</gtr:description><gtr:geographicReach>Australia</gtr:geographicReach><gtr:guidelineTitle>Clinical practice guidelines for the treatment and management of endometrial cancer</gtr:guidelineTitle><gtr:id>02FBF18C-3DCC-4B18-B9EE-C725A5B701FA</gtr:id><gtr:impact>Our systematic review and meta-analysis of summary data was cited as evidence in this guideline (PMID: 17150999)</gtr:impact><gtr:outcomeId>544f9a638d7ef3.05109225</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Lung PORT IPD (PMID: 9690404; 15846628; 15603857) AIOT guideline Stage I&amp;amp;II 2012</gtr:description><gtr:geographicReach>Europe</gtr:geographicReach><gtr:guidelineTitle>Linee guida per la gestione integrata del paziente con tumore polmonare: NSCLC - Stadio I e II</gtr:guidelineTitle><gtr:id>1CF06943-773C-4B4E-980A-182509ACC5C9</gtr:id><gtr:impact>&amp;quot;Nei pazienti affetti da NSCLC allo stadio I-II radicalmente operati la radioterapia post-operatoria non &amp;egrave; raccomandata.&amp;quot;, based on our systematic review and meta-analysis of IPD (PMID: 9690404; PMID: 15846628; PMID: 15603857)</gtr:impact><gtr:outcomeId>56cdabba5858f1.91906508</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Cervix Neo CT SR (PMID:20091632) ACR guideline early 2012</gtr:description><gtr:geographicReach>North America</gtr:geographicReach><gtr:guidelineTitle>ACR Appropriateness Criteria Definitive therapy for early stage cervical cancer</gtr:guidelineTitle><gtr:id>0275B031-CC2C-43FA-9A84-66A7D41045A8</gtr:id><gtr:impact>&amp;quot;The appropriateness of induction chemotherapy followed by surgery remains uncertain, and it should be performed only in the context of a clinical trial&amp;quot;, based on our systematic review and meta-analysis of summary data (PMID: 20091632)</gtr:impact><gtr:outcomeId>MnZpgNxF37H</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type><gtr:url>http://europepmc.org/abstract/MED/20091632</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Oesophagus RT IPD (PMID:9635705) NCCN guideline 2010</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:guidelineTitle>NCCN Practice Guidelines in Oncology - v.1.2010 Esophageal Cancer</gtr:guidelineTitle><gtr:id>2502FC97-7A8C-43F6-8BF3-BF096A5A960F</gtr:id><gtr:impact>&amp;quot;The panel recommends that RT alone should generally be reserved for palliation or for patients who are medically unable to receive chemotherapy&amp;quot;, based in part on our systematic review and meta-analysis of IPD (PMID: 9635705)</gtr:impact><gtr:outcomeId>swsdXnjpueW</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type><gtr:url>http://europepmc.org/abstract/MED/9635705</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Bladder Adj CT IPD (PMID:15939530) EAU guideline 2010</gtr:description><gtr:geographicReach>Europe</gtr:geographicReach><gtr:guidelineTitle>Guidelines on Bladder Cancer: Muscle-Invasive and Metastatic</gtr:guidelineTitle><gtr:id>791FF693-1182-487A-AECF-AB17F1E65C85</gtr:id><gtr:impact>&amp;quot;There is not enough evidence in favour of the routine use of adjuvant chemotherapy. The data are not convincing enough to give an unequivocal recommendation for the use of
adjuvant chemotherapy&amp;quot;, based on our systematic review and meta-analysis of IPD (PMID:15939530)</gtr:impact><gtr:outcomeId>Pmw5333t99d</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type><gtr:url>http://europepmc.org/abstract/MED/15939530</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Bladder Neo CT IPD (PMID: 15939524) NCCN guideline 2014</gtr:description><gtr:geographicReach>North America</gtr:geographicReach><gtr:guidelineTitle>NCCN Clinical Practice Guidelines in Oncology - v.1.2013 Bladder Cancer</gtr:guidelineTitle><gtr:id>B5E81523-8032-484B-A596-02981CDF4CB8</gtr:id><gtr:impact>&amp;quot;Randomized trials and meta-analyses show a survival benefit for cisplatin-based neoadjuvant chemotherapy in patients with muscle invasive bladder cancer. Meta-analysis suggests a survival benefit to adjuvant therapy for pathologic T3, T4 or N+ disease at cystectomy. Neoadjuvant chemotherapy is preferred over adjuvant-based chemotherapy on a higher level of evidence data&amp;quot;, based on our systematic review and meta-analysis of IPD (PMID: 15939524)</gtr:impact><gtr:outcomeId>544e2ee9d7d9f5.78145188</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Bladder Adj CT IPD (PMID:16625650) ESMO guideline 2014</gtr:description><gtr:geographicReach>Europe</gtr:geographicReach><gtr:guidelineTitle>Bladder cancer: ESMO Practice Guidelines for diagnosis, treatment and follow-up</gtr:guidelineTitle><gtr:id>CD2C8C60-5311-4C44-8451-D349194AC7CE</gtr:id><gtr:impact>&amp;quot;While there is still insufficient evidence for the routine use of adjuvant chemotherapy in clinical practice [I, A], it is likely that high-risk patients, such as those with extravesical and/or node-positive disease that have not received neoadjuvant chemotherapy, will benefit most from adjuvant chemotherapy&amp;quot;, based on our systematic review and meta-analysis of IPD (PMID:16625650)</gtr:impact><gtr:outcomeId>544f92155f1b56.04437512</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Sarcoma CT IPD (PMID:10796873) NCCN guideline UterineNeoplasms 2013</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:guidelineTitle>NCCN Clinical Practice Guidelines in Oncology v.1.2013 Uterine Neoplasms</gtr:guidelineTitle><gtr:id>39497594-8C0D-4240-94F7-64EA477D7827</gtr:id><gtr:impact>&amp;quot;Doxorubicin is an active single agent for LMS and is less toxic than combination regimens&amp;quot; , based on our systematic review and meta-analysis of IPD (PMID: 10796873)</gtr:impact><gtr:outcomeId>bvxWWFiTgnZ</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Lung PORT IPD (PMID:15846628) AHS guideline stage III 2012</gtr:description><gtr:geographicReach>North America</gtr:geographicReach><gtr:guidelineTitle>Non-small Cell Lung Cancer - Stage III</gtr:guidelineTitle><gtr:id>8547FF12-BB7A-411F-9A3D-8D4772F74A25</gtr:id><gtr:impact>&amp;quot;The Post-Operative Radiotherapy (PORT) Meta-analysis Trialists Group (2010) found evidence that post-operative radiotherapy in patients with completely resected NSCLC had a detrimental effect on overall survival. An exploratory analysis by stage and nodal status suggested that this effect was more pronounced in earlier stage patients and those with lower nodal status. Considering the results for stage III patients by themselves, there was no clear evidence of a detrimental effect of PORT (trend across all stages p=0.004)&amp;quot; , based on our systematic review and meta-analysis of IPD (PMID: 15846628)</gtr:impact><gtr:outcomeId>qzCyAJPJmEH</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type><gtr:url>http://europepmc.org/abstract/MED/15846628</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Lung CT 95 IPD (PMID:7580546) ACR guideline NonSurgGoodPS 2014</gtr:description><gtr:geographicReach>North America</gtr:geographicReach><gtr:guidelineTitle>American College of Radiology ACR Appropriateness Criteria&amp;reg; NONSURGICAL TREATMENT FOR LOCALLY ADVANCED NON-SMALL-CELL LUNG CANCER: GOOD PERFORMANCE STATUS/DEFINITIVE INTENT</gtr:guidelineTitle><gtr:id>525FBF21-2F14-4F17-A9E4-923805568AE6</gtr:id><gtr:impact>&amp;quot;Several meta-analyses have now examined the benefit of adding chemotherapy to radiation for stage IIIA and IIIB NSCLC. The Non-small Cell Lung Cancer Collaborative Group analyzed updated individual patient data from 22 trials including 3,033 patients. The group excluded all trials in which chemotherapy was given only during RT. Five trials used long-term alkylating agents, mainly cyclophosphamide or nitrosourea in combination with methotrexate. Three used vinca alkaloids or etoposide, and 3 used &amp;quot;other&amp;quot; regimens, mostly based on doxorubicin. Eleven trials used chemotherapy regimens containing cisplatin. The group found a significant overall benefit of chemotherapy, which resulted in a 10% reduction in the risk of death, corresponding to absolute benefits of 3% at 2 years and 2% at 5 years. Trials using cisplatin-based chemotherapy gave the strongest evidence in favor of chemotherapy, with absolute benefits of 4% at 2 years and 2% at 5 years&amp;quot;, based on our systematic review and meta-analysis of IPD (PMID: 7580546)</gtr:impact><gtr:outcomeId>544fa1e2249758.69392614</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Lung CT 95 IPD (PMID:7580546; 10796867) IAEA guideline 2007</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:guidelineTitle>Lung cancer management in limited resource settings: Guidelines for appropriate good care</gtr:guidelineTitle><gtr:id>7E78B300-0F7B-4D00-94F4-977D17FB1A35</gtr:id><gtr:impact>&amp;quot;A meta-analysis has shown that cisplatin-based chemotherapy results in a modest survival benefit in patients with Stage III and IV disease and good PS (WHO PS 0,1); there is a 6-8 week increase in median survival and a 10% increase in 1-year survival compared to 'best supportive care&amp;quot; , based on our systematic review and meta-analysis of IPD (PMID: 7580546; PMID: 10796867)</gtr:impact><gtr:outcomeId>fzCoFNB7PcT</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type><gtr:url>http://europepmc.org/abstract/MED/7580546</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Endometrial CT SR (PMID:17150999) AOSCG guideline 2009</gtr:description><gtr:geographicReach>Asia</gtr:geographicReach><gtr:guidelineTitle>Management of endometrial cancer in Asia: consensus statement from the Asian Oncology Summit</gtr:guidelineTitle><gtr:id>ADBF3F7F-0CF0-4FEA-8005-6ED0907D1D22</gtr:id><gtr:impact>Our systematic review and meta-analysis of summary data was cited as evidence in this guideline (PMID: 17150999)</gtr:impact><gtr:outcomeId>bs7cZXT5xer</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type><gtr:url>http://europepmc.org/abstract/MED/17150999</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Lung PORT IPD (PMID:9690404; 15603857) CCO guideline 7-1-1 2012</gtr:description><gtr:geographicReach>North America</gtr:geographicReach><gtr:guidelineTitle>Postoperative Adjuvant Radiation Therapy in Stage II or IIIA Completely Resected Non-Small Cell Lung Cancer. Evidence-based Series 7-1-1 Version 2</gtr:guidelineTitle><gtr:id>7F686D77-A050-4810-8E94-A3808C8D3EA4</gtr:id><gtr:impact>&amp;quot;Postoperative radiation therapy is not recommended for use following complete resection of stage II non-small cell lung cancer......There is evidence from a meta-analysis of individual patient data from ten randomized controlled trials that postoperative thoracic irradiation in patients with completely resected non-small cell lung cancer significantly reduces overall survival (mortality hazard ratio, 1.18; 95% confidence interval, 1.07 to 1.31; p=0.002)&amp;quot;, based on our systematic review and meta-analysis of IPD (PMID: 9690404; PMID: 15603857)</gtr:impact><gtr:outcomeId>544fb97f114676.59008327</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Bladder Neo CT IPD (PMID: 12801735; PMID: 15939524) EAU guideline 2008</gtr:description><gtr:geographicReach>Europe</gtr:geographicReach><gtr:guidelineTitle>Guidelines on bladder cancer. Muscle invasive and metastatic</gtr:guidelineTitle><gtr:id>03670388-6954-4D3C-A18A-86CD9C350190</gtr:id><gtr:impact>&amp;quot;Cisplatin containing combination neoadjuvant chemotherapy should be considered for muscle invasive bladder cancer irrespective of definitive treatment&amp;quot; based on our systematic review and meta-analysis of IPD (PMID: 12801735; PMID: 15939524)</gtr:impact><gtr:outcomeId>73B0DF0B3CD</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type><gtr:url>http://europepmc.org/abstract/MED/12801735</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Lung SeqCon CTRT IPD (PMID:20351327) AHS guideline Stage III 2012</gtr:description><gtr:geographicReach>North America</gtr:geographicReach><gtr:guidelineTitle>Non-small Cell Lung Cancer - Stage III</gtr:guidelineTitle><gtr:id>D7AA0102-C179-4BA8-B431-5C951453C761</gtr:id><gtr:impact>&amp;quot;Auperin et al. (2010) also observed a significant benefit of concurrent chemoradiotherapy (HR 0.84; p=0.004) as compared with sequential, with an absolute survival benefit of 5.7% at 3 years, increasing survival from 18.1% in the sequential arm to 23.8% in the concurrent arm.16 However, the increase in esophageal toxicity (Grade 3-4) was significant when comparing sequential with concurrent chemoradiotherapy (4% versus 18%)&amp;quot;, based on our systematic review and meta-analysis of IPD (PMID: 20351327)</gtr:impact><gtr:outcomeId>ra4ta6s1PYW</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type><gtr:url>http://europepmc.org/abstract/MED/20351327</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Lung SC IPD (PMID:18678835) AOSCG guideline 2009</gtr:description><gtr:geographicReach>Asia</gtr:geographicReach><gtr:guidelineTitle>First-line systemic treatment of advanced stage non-small-cell lung cancer in Asia: consensus statement from the Asian Oncology Summit 2009</gtr:guidelineTitle><gtr:id>23E932FF-D590-4261-B475-EBECC611BCAE</gtr:id><gtr:impact>&amp;quot;1-year survival was 29% for chemotherapy and 20% for best supportive care (HR 0?77, 95% CI 0?71-0?83)&amp;quot;, based on our systematic review and meta-analysis of IPD (PMID: 18678835)</gtr:impact><gtr:outcomeId>qAtEyzUxajr</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type><gtr:url>http://europepmc.org/abstract/MED/18678835</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Bladder Adj CT IPD (PMID: 16625650) ESMO guideline 2008</gtr:description><gtr:geographicReach>Europe</gtr:geographicReach><gtr:guidelineTitle>Invasive bladder cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up</gtr:guidelineTitle><gtr:id>9ECB22A3-C3C2-484F-8119-D933B24E98E3</gtr:id><gtr:impact>&amp;quot;Insufficient evidence for the routine use of adjuvant chemotherapy in clinical practice&amp;quot;, based on our systematic review and meta-analysis of IPD (PMID: 16625650)</gtr:impact><gtr:outcomeId>66C84477B78</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type><gtr:url>http://europepmc.org/abstract/MED/16625650</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Bladder Neo CT IPD (PMID: 15939524) NCCN guideline 2013</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:guidelineTitle>NCCN Clinical Practice Guidelines in Oncology - v.1.2013 Bladder Cancer</gtr:guidelineTitle><gtr:id>8FCDA6D3-537B-41AF-9484-78BD3ED2F560</gtr:id><gtr:impact>&amp;quot;Randomized trials and meta-analyses show a survival benefit for cisplatin-based neoadjuvant chemotherapy in patients with muscle invasive bladder cancer. Meta-analysis suggests a survival benefit to adjuvant therapy for pathologic T3, T4 or N+ disease at cystectomy. Neoadjuvant chemotherapy is preferred over adjuvant-based chemotherapy on a higher level of evidence data&amp;quot;, based on our systematic review and meta-analysis of IPD (PMID: 15939524)</gtr:impact><gtr:outcomeId>eM5w5LhY7ZQ</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Pre-eclampsia PARIS IPD (PMID:17512048) CCS guideline 2011</gtr:description><gtr:geographicReach>North America</gtr:geographicReach><gtr:guidelineTitle>The Use of Antiplatelet Therapy in the Outpatient Setting: Canadian Cardiovascular Society Guidelines Executive Summary</gtr:guidelineTitle><gtr:id>74D41EA6-6873-46C6-9D6F-E0A2DA7FFA38</gtr:id><gtr:impact>Our systematic review and meta-analysis of IPD was cited as key evidence in this guideline (PMID: 17512048)</gtr:impact><gtr:outcomeId>jRDcjb5erLk</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type><gtr:url>http://europepmc.org/abstract/MED/17512048</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Sarcoma CT SR (PMID:7640234) NCCN guideline SoftTissueSarcoma 2012</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:guidelineTitle>NCCN Clinical Practice Guidelines in Oncology v.2.2012 Soft Tissue Sarcoma</gtr:guidelineTitle><gtr:id>6AF1E0FE-AA5A-4751-AA5F-A30E9F51E7B4</gtr:id><gtr:impact>&amp;quot;Evidence from meta-analyses suggest that post-operative chemotherapy improves relapse-free survival in patients with STS of extremities&amp;quot;, based on our systematic review and meta-analysis of summary data (PMID: 7640234)</gtr:impact><gtr:outcomeId>tMkQM6Ci8rh</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type><gtr:url>http://europepmc.org/abstract/MED/7640234</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Bladder Neo CT IPD (PMID: 15846746) AHS guideline 2013</gtr:description><gtr:geographicReach>North America</gtr:geographicReach><gtr:guidelineTitle>Clinical Practice Guideline: GU-002 Bladder Cancer</gtr:guidelineTitle><gtr:id>1945DA9C-A4A0-439D-8996-E9555740314D</gtr:id><gtr:impact>&amp;quot;All patients who are eligible for cisplatinum-based combination chemotherapy should have the opportunity to discuss neoadjuvant therapy with a medical oncologist either before surgery or as combined modality therapy&amp;quot;, based on our systematic review and meta-analysis of IPD (PMID:15846746)</gtr:impact><gtr:outcomeId>sYFsQCkvfy1</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Lung SC IPD (PMID:18678835) NCCN guideline 2013</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:guidelineTitle>NCCN Practice Guidelines in Oncology v.2.2013. Non-Small Cell Lung Cancer</gtr:guidelineTitle><gtr:id>2A310569-3BB3-4E92-B541-B6A6FC3EBB53</gtr:id><gtr:impact>&amp;quot;Patients with stage IV disease who have a good PS, benefit from chemotherapy, usually with a platinum-based regimen&amp;quot;, based on our systematic review and meta-analysis of IPD (PMID: 18678835)</gtr:impact><gtr:outcomeId>qoT87iFC7f4</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Lung CT 95 IPD (PMID:7580546) BCCA guideline 2014</gtr:description><gtr:geographicReach>North America</gtr:geographicReach><gtr:guidelineTitle>BCCA Cancer Management Guidelines; 6.1 Non-Small Cell Lung Cancer (NSCLC) - 14) Palliative Chemotherapy of Advanced NSCLC</gtr:guidelineTitle><gtr:id>8C7952D4-B5EB-428B-8492-6A15C29E406A</gtr:id><gtr:impact>Our systematic review and meta-analysis of IPD was cited as evidence in this guideline (PMID: 7580546)</gtr:impact><gtr:outcomeId>544fa6efafbc92.31738000</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Glioma CT IPD (PMID:11937180) ACCC guideline 2007</gtr:description><gtr:geographicReach>Europe</gtr:geographicReach><gtr:guidelineTitle>Gliomas: Nation-wide guideline, Version: 2.0</gtr:guidelineTitle><gtr:id>7C2BBE64-5561-4B8D-88F7-0ABB5E2EF33D</gtr:id><gtr:impact>Our systematic review and meta-analysis of IPD was cited as evidence in this guideline (PMID: 11937180)</gtr:impact><gtr:outcomeId>WUEvfmkS9U4</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type><gtr:url>http://europepmc.org/abstract/MED/11937180</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Lung CT 95 IPD (PMID: 7580546) ESMO guideline 2009</gtr:description><gtr:geographicReach>Europe</gtr:geographicReach><gtr:guidelineTitle>Non-small-cell lung cancer: ESMO Clinical Recommendations for diagnosis, treatment and follow-up.</gtr:guidelineTitle><gtr:id>70E1F1AB-0A09-42FE-8E25-8D3285FD3B5B</gtr:id><gtr:impact>Our systematic review and meta-analysis of IPD was cited as evidence in this guideline (PMID: 7580546)</gtr:impact><gtr:outcomeId>ALiDYJCeVJX</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type><gtr:url>http://europepmc.org/abstract/MED/7580546</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Cervix Neo CT IPD (PMID:15106161) ESMO guideline 2012</gtr:description><gtr:geographicReach>Europe</gtr:geographicReach><gtr:guidelineTitle>Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up</gtr:guidelineTitle><gtr:id>2D90231F-C9F7-4A7B-B259-E6CF55C5CA3D</gtr:id><gtr:impact>Our systematic review and meta-analysis of IPD was cited as evidence in this guideline (PMID: 15106161)</gtr:impact><gtr:outcomeId>PCHbmRLKzBn</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type><gtr:url>http://europepmc.org/abstract/MED/15106161</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Lung Adj CT IPD (PMID:20338628) ACCP guideline stage I&amp;amp;II 2013</gtr:description><gtr:geographicReach>North America</gtr:geographicReach><gtr:guidelineTitle>Treatment of Stage I &amp;amp; II Non-small Cell Lung Cancer. Diagnosis and Management of Lung Cancer, 3rd ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines</gtr:guidelineTitle><gtr:id>99AAFA01-8563-4C11-A4BF-93ABB86E6D52</gtr:id><gtr:impact>Our systematic review and meta-analysis of IPD was cited as evidence in this guideline (PMID: 20338628)</gtr:impact><gtr:outcomeId>TLQexUJEp3E</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Cervix Neo CT SR (PMID:20091632) BHKC guideline 2011</gtr:description><gtr:geographicReach>Europe</gtr:geographicReach><gtr:guidelineTitle>A national clinical practice guideline for the management of cervical cancer</gtr:guidelineTitle><gtr:id>8DC972E5-67CD-4BB7-9BC3-0EE427C962EE</gtr:id><gtr:impact>Our systematic review and meta-analysis of summary data was cited as evidence in this guideline (PMID: 20091632)</gtr:impact><gtr:outcomeId>MEmCzGp1Wqp</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type><gtr:url>http://europepmc.org/abstract/MED/20091632</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Bladder Neo CT IPD (PMID: 15846746) ESMO guideline 2008</gtr:description><gtr:geographicReach>Europe</gtr:geographicReach><gtr:guidelineTitle>Invasive bladder cancer: ESMO clinical recommendations of diagnosis, treatment and follow-up</gtr:guidelineTitle><gtr:id>FF7DE7AF-BECC-4F68-8797-E4796444E25E</gtr:id><gtr:impact>&amp;quot;The demonstrated survival benefit encourages the use of platinum-based combination chemotherapy for patients with invasive bladder cancer before radical cystectomy or definitive radiotherapy&amp;quot; based on our systematic review and meta-analysis of IPD (PMID: 15846746)</gtr:impact><gtr:outcomeId>1D1EC944804</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type><gtr:url>http://europepmc.org/abstract/MED/15846746</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Lung PORT IPD (PMID:9690404; 15603857) NCCN guideline 2013</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:guidelineTitle>NCCN Practice Guidelines in Oncology v.2.2013. Non-Small Cell Lung Cancer</gtr:guidelineTitle><gtr:id>8F1B4968-255B-4E81-8986-893A4F0A706D</gtr:id><gtr:impact>&amp;quot;PORT is not recommended for patients with pathologic stage N0-1 disease, because it has been associated with increased mortality, at least when using older RT techniques. In patients treated with surgery, postoperative radiotherapy (PORT) is not recommended unless there are positive margins or upstaging to N2&amp;quot;, based on our systematic review and meta-analysis of IPD (PMID: 9690404; PMID: 15603857)</gtr:impact><gtr:outcomeId>TK5WXRhDoc5</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Lung PORT IPD (PMID:15603857) ESMO guideline 2009</gtr:description><gtr:geographicReach>Europe</gtr:geographicReach><gtr:guidelineTitle>Non-small-cell lung cancer: ESMO Clinical Recommendations for diagnosis, treatment and follow-up</gtr:guidelineTitle><gtr:id>791FBE52-362C-4923-A42A-24DEC074139C</gtr:id><gtr:impact>Our systematic review and meta-analysis of IPD was cited as evidence in this guideline (PMID: 15603857)</gtr:impact><gtr:outcomeId>JcassLGLHNy</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type><gtr:url>http://europepmc.org/abstract/MED/15603857</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Lung CT 95 IPD (PMID:7580546) AIOT guideline Stage IIIa 2012</gtr:description><gtr:geographicReach>Europe</gtr:geographicReach><gtr:guidelineTitle>Linee guida per la gestione integrata del paziente con tumore polmonare: NSCLC - Stadio IIIa</gtr:guidelineTitle><gtr:id>BA585EE7-2C57-4E49-9A53-1BF73252A161</gtr:id><gtr:impact>Our systematic review and meta-analysis of IPD was cited as evidence in this guideline (PMID: 7580546)</gtr:impact><gtr:outcomeId>56cda8c5c2cf18.43862892</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Lung CT 95 IPD (PMID:7580546) IATO guideline 2011</gtr:description><gtr:geographicReach>Europe</gtr:geographicReach><gtr:guidelineTitle>Treatment of advanced non-small-cell lung cancer</gtr:guidelineTitle><gtr:id>68B610AA-5B99-4832-A3AF-D47A94764006</gtr:id><gtr:impact>&amp;quot;In 1995, an individual patient data meta-analysis demonstrated a significant benefit in overall survival for the addition of platinum based chemotherapy to best supportive care (BSC) as first-line treatment of advanced NSCLC. There are no trials comparing chemotherapy versus BSC alone, but important evidence supporting the role of chemotherapy in these patients come from the individual patient data meta-analyses, demonstrating a significant benefit with chemotherapy in patients with advanced NSCLC&amp;quot;, based on our systematic review and meta-analysis of IPD(PMID: 7580546)</gtr:impact><gtr:outcomeId>Mdm7SBAMP5s</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type><gtr:url>http://europepmc.org/abstract/MED/7580546</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Lung CT 95 IPD (PMID:7580546) NCCN guideline 2012</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:guidelineTitle>NCCN Practice Guidelines in Oncology v.2.2012. Non-Small Cell Lung Cancer</gtr:guidelineTitle><gtr:id>FDA6A946-7606-456D-93F5-6A7B439FACEE</gtr:id><gtr:impact>&amp;quot;For patients with stage IV disease who have good PS, platinum-based chemotherapy is beneficial&amp;quot;, based on our systematic review and meta-analysis of IPD (PMID: 7580546)</gtr:impact><gtr:outcomeId>KW3JY9h5uA7</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type><gtr:url>http://europepmc.org/abstract/MED/7580546</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Oesophagus RT IPD (PMID:10796823) CCO guideline 2008</gtr:description><gtr:geographicReach>North America</gtr:geographicReach><gtr:guidelineTitle>Preoperative or Postoperative Therapy for Resectable Esophageal Cancer. Evidence-based Series 2-11 Version 3</gtr:guidelineTitle><gtr:id>26F40752-89A9-482F-8875-EBD8575949D5</gtr:id><gtr:impact>Our systematic review and meta-analysis of IPD was cited as evidence in this guideline (PMID: 10796823)</gtr:impact><gtr:outcomeId>EQmLwNWDNju</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Cervix CTRT IPD (PMID:19001332) AHS guideline 2013</gtr:description><gtr:geographicReach>North America</gtr:geographicReach><gtr:guidelineTitle>Cancer of the Uterine Cervix</gtr:guidelineTitle><gtr:id>61E90494-420B-4C79-9CFB-5ADA3E72F0A6</gtr:id><gtr:impact>&amp;quot;Cisplatin should be administered at a dose of 40 mg/m2 (max = 80) intravenously over one hour weekly for 5 - 6 cycles during EBRT&amp;quot;, based on our systematic review and meta-analysis of IPD (PMID: 19001332)</gtr:impact><gtr:outcomeId>fpSsEsNaNYW</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Oesophagus RT IPD (PMID:10796823) ESMO guideline 2013</gtr:description><gtr:geographicReach>Europe</gtr:geographicReach><gtr:guidelineTitle>Oesophageal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up</gtr:guidelineTitle><gtr:id>F02459FF-3845-4743-8324-035E6076B75D</gtr:id><gtr:impact>&amp;quot;Preoperative or post-operative radiation alone (without
chemotherapy) does not add any survival benefit to surgery
alone [9]. This treatment is not recommended for curative
intent in localised tumours [I, A]&amp;quot;, based on our systematic review and meta-analysis of IPD (PMID: 10796823)</gtr:impact><gtr:outcomeId>njZCzmyGsYY</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Cervix CTRT IPD (PMID:19001332) ACR guideline advanced 2012</gtr:description><gtr:geographicReach>North America</gtr:geographicReach><gtr:guidelineTitle>ACR Appropriateness Criteria ADVANCED CERVICAL CANCER</gtr:guidelineTitle><gtr:id>A59D010B-855E-4D88-8BB0-4BF7C37072FC</gtr:id><gtr:impact>&amp;quot;The addition of chemotherapy concurrently with RT has resulted in a large improvement in overall survival&amp;quot;, based on our systematic review and meta-analysis of IPD (PMID: 19001332)</gtr:impact><gtr:outcomeId>bGCtcHkEfR4</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Cervix CTRT IPD (PMID:19001332) ACR guideline early 2012</gtr:description><gtr:geographicReach>North America</gtr:geographicReach><gtr:guidelineTitle>ACR Appropriateness Criteria Definitive therapy for early stage cervical cancer</gtr:guidelineTitle><gtr:id>89E54400-BEB7-44C5-81B5-F852AB03E6FC</gtr:id><gtr:impact>Our systematic review and meta-analysis of IPD was cited as evidence in this guideline (PMID: 19001332)</gtr:impact><gtr:outcomeId>tB71uwunAaa</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type><gtr:url>http://europepmc.org/abstract/MED/19001332</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Lung CT 95 IPD (PMID:7580546) ASCO/CCO joint guideline 2007</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:guidelineTitle>Cancer Care Ontario and American Society of Clinical Oncology Adjuvant Chemotherapy and Adjuvant Radiation Therapy for Stages I-IIIA Resectable Non-Small-Cell Lung Cancer Guideline</gtr:guidelineTitle><gtr:id>0E33FB10-351D-4516-BFC9-FB1526585E14</gtr:id><gtr:impact>&amp;quot;The 1995 NSCLC Collaborative Group individual-patient meta-analysis (n_9,387) found a statistically significant survival disadvantage associated with the use of postoperative chemotherapy involving alkylating agents&amp;quot;, based on our systematic review and meta-analysis of IPD (PMID: 7580546)</gtr:impact><gtr:outcomeId>kBeStaMKTVq</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type><gtr:url>http://europepmc.org/abstract/MED/7580546</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Lung CT 95 IPD (PMID:7580546; 10796867) CCO guideline 7-3 2006</gtr:description><gtr:geographicReach>North America</gtr:geographicReach><gtr:guidelineTitle>Management of Unresected Stage III Non-Small Cell Lung Cancer: Practice Guideline No 7-3</gtr:guidelineTitle><gtr:id>D05F619F-C45B-404B-8009-8192CBD71487</gtr:id><gtr:impact>Our systematic review and meta-analysis of IPD was cited as evidence in this guideline (PMID: 7580546; PMID: 10796867)</gtr:impact><gtr:outcomeId>kxijXej77Ep</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type><gtr:url>http://europepmc.org/abstract/MED/7580546</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Lung PORT IPD (PMID:9690404; 15603857) CCO guideline 7-1-2 2006</gtr:description><gtr:geographicReach>North America</gtr:geographicReach><gtr:guidelineTitle>Postoperative adjuvant chemotherapy with or without radiotherapy in completely resected non-small cell lung cancer. Practice guideline No 7-1-2</gtr:guidelineTitle><gtr:id>8DEF2271-8D00-4742-993A-11BD48CFAC83</gtr:id><gtr:impact>Our systematic review and meta-analysis of IPD was cited as evidence in this guideline (PMID: 9690404; PMID: 15603857)</gtr:impact><gtr:outcomeId>Sw5xWUoszjt</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type><gtr:url>http://europepmc.org/abstract/MED/9690404</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Lung CT 95 IPD (PMID:7580546) CCA guideline stage II CT after operable 2014</gtr:description><gtr:geographicReach>Australia</gtr:geographicReach><gtr:guidelineTitle>Clinical practice guidelines for the treatment of lung cancer. What is the role of chemotherapy after surgery in the treatment of operable stage II NSCLC?</gtr:guidelineTitle><gtr:id>EB3BCBAA-1348-43DF-BBAC-F0795139AD7E</gtr:id><gtr:impact>Our systematic review and meta-analysis of IPD was cited as evidence in this guideline (PMID: 7580546)</gtr:impact><gtr:outcomeId>544fa84480a137.73159676</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Bladder Adj CT IPD (PMID:15939530) NCCN guideline 2013</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:guidelineTitle>NCCN Clinical Practice Guidelines in Oncology - v.1.2013 Bladder Cancer</gtr:guidelineTitle><gtr:id>A4650CF0-08FC-4520-AFA4-C7E004E3C812</gtr:id><gtr:impact>&amp;quot;Meta-analysis suggests a survival benefit to adjuvant therapy for pathologic T3, T4 or N+ disease at cystectomy&amp;quot;, based on our systematic review and meta-analysis of IPD (PMID: 15939530)</gtr:impact><gtr:outcomeId>AWfP2er4yEK</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Bladder Neo CT IPD (PMID:12801735; 15939524) EAU guideline 2012</gtr:description><gtr:geographicReach>Europe</gtr:geographicReach><gtr:guidelineTitle>Guidelines on Bladder Cancer: Muscle-Invasive and Metastatic</gtr:guidelineTitle><gtr:id>D40EFD76-BC96-41B8-B534-EFB3064A5726</gtr:id><gtr:impact>&amp;quot;Neoadjuvant cisplatin-containing combination chemotherapy improves overall survival, irrespective of
the type of definitive treatment used&amp;quot;, based on our systematic review and meta-analysis of IPD (PMID:12801735; PMID:15939524)</gtr:impact><gtr:outcomeId>QLqAZ2zKRus</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type><gtr:url>http://europepmc.org/abstract/MED/12801735</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Cervix Neo CT IPD (PMID:14602133) ESMO guideline 2010</gtr:description><gtr:geographicReach>Europe</gtr:geographicReach><gtr:guidelineTitle>Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up</gtr:guidelineTitle><gtr:id>714FB5A6-E64F-47ED-8DE1-489DC0A1D5F8</gtr:id><gtr:impact>Our systematic review and meta-analysis of IPD was cited as evidence in this guideline (PMID: 14602133)</gtr:impact><gtr:outcomeId>RNXxe3WAK7g</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type><gtr:url>http://europepmc.org/abstract/MED/14602133</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Bladder Neo CT IPD (PMID: 15939524) ESMO guideline 2014</gtr:description><gtr:geographicReach>Europe</gtr:geographicReach><gtr:guidelineTitle>Bladder cancer: ESMO Practice Guidelines for diagnosis, treatment and follow-up</gtr:guidelineTitle><gtr:id>C977C6E6-9230-4E64-ABC1-04FD9B210943</gtr:id><gtr:impact>&amp;quot;The use of cisplatin-based neoadjuvant chemotherapy for bladder cancer is supported by a meta-analysis of 11 randomised trials including 3005 patients. There was a 5% absolute increase in 5-year OS and a 9% absolute increase in 5-year disease-free survival (DFS) compared with RC alone. This demonstrated survival benefit encourages the use of platinum-based combination chemotherapy before RC or definitive radiotherapy [I, A]&amp;quot;, based on our systematic review and meta-analysis of IPD (PMID: 15939524)</gtr:impact><gtr:outcomeId>544f795c0cb599.36014392</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Oesophagus RT IPD (PMID:10796823) AHS guideline 2011</gtr:description><gtr:geographicReach>North America</gtr:geographicReach><gtr:guidelineTitle>Clinical Practice Guideline: GI-009: Esophageal Cancer</gtr:guidelineTitle><gtr:id>B71AD443-40F0-478F-AE23-6AAFB600A889</gtr:id><gtr:impact>Our systematic review and meta-analysis of IPD was cited as evidence in this guideline (PMID: 10796823)</gtr:impact><gtr:outcomeId>FfiQw1RGAZD</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type><gtr:url>http://europepmc.org/abstract/MED/10796823</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Glioma CT IPD (PMID:11937180) NCCN guideline 2011</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:guidelineTitle>NCCN Clinical Practice Guidelines in Oncology - v.2.2011 Central Nervous System Cancers</gtr:guidelineTitle><gtr:id>E232F90B-2AD7-467F-875A-BD28E1113E4B</gtr:id><gtr:impact>Our systematic review and meta-analysis of IPD was cited as evidence in this guideline (PMID:11937180)</gtr:impact><gtr:outcomeId>g2ybj7F67v2</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type><gtr:url>http://europepmc.org/abstract/MED/11937180</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Lung Neo CT SR (PMID:17409927) AIOT guideline Stage IIIa 2012</gtr:description><gtr:geographicReach>Europe</gtr:geographicReach><gtr:guidelineTitle>Linee guida per la gestione integrata del paziente con tumore polmonare: NSCLC - Stadio IIIa</gtr:guidelineTitle><gtr:id>AA36EBE3-5A7A-4F53-A0C0-36A8F421447F</gtr:id><gtr:impact>Our systematic review and meta-analysis of summary data was cited as evidence in this guideline (PMID: 7580546)</gtr:impact><gtr:outcomeId>56cdaa5a255490.40051179</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Cervix CTRT IPD (PMID:19001332) NCCN guideline 2011</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:guidelineTitle>NCCN Practice Guidelines in Oncology - v.1.2011 Cervical Cancer</gtr:guidelineTitle><gtr:id>44EE7292-4691-4434-BFAD-18F36202D5A4</gtr:id><gtr:impact>Our systematic review and meta-analysis of IPD was cited as evidence in this guideline (PMID: 19001332)</gtr:impact><gtr:outcomeId>sfxXP9L6p6n</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type><gtr:url>http://europepmc.org/abstract/MED/19001332</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Lung CT 95 IPD (PMID:7580546) BCCA guideline 6.1.06 2008</gtr:description><gtr:geographicReach>North America</gtr:geographicReach><gtr:guidelineTitle>Cancer Management Guidelines. Lung (including Mesothelioma &amp;amp; Thymoma): Combined Modality Therapy for Unresectable Stage III (6.1.06)</gtr:guidelineTitle><gtr:id>3E684C48-B7C8-4F9B-AE7C-EF4E6294B03A</gtr:id><gtr:impact>&amp;quot;The strongest evidence regarding combined modality therapy is derived from a meta-analysis of 52 randomized trials conducted by the Non-small Cell Lung Cancer Collaborative Group.1 Twenty-two trials were identified that compared radical radiation to radical radiation plus chemotherapy, of which eleven employed chemotherapy regimens including cisplatin. The addition of cisplatin-based chemotherapy to thoracic irradiation led to a 13% reduction in the risk of death, although the absolute survival advantage at 2 years was a modest 4%.&amp;quot;, based on our systematic review and meta-analysis of IPD (PMID: 7580546)</gtr:impact><gtr:outcomeId>DuvBHKRsbFG</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type><gtr:url>http://europepmc.org/abstract/MED/7580546</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Bladder Neo CT IPD (PMID:15939524) EAU guideline 2009</gtr:description><gtr:geographicReach>Europe</gtr:geographicReach><gtr:guidelineTitle>The Updated EAU Guidelines on Muscle-Invasive and Metastatic Bladder Cancer</gtr:guidelineTitle><gtr:id>C5BA3952-5FD4-4D7A-B90C-AF329F4A098B</gtr:id><gtr:impact>&amp;quot;As a result of a 5-8 % overall survival (OS) advantage in recently published studies and meta-analyses, it has therefore been recommended that neoadjuvant cisplatin containing combination chemotherapy should be considered in muscle-invasive BCa irrespective of definitive treatment (grade of recommendation: A)&amp;quot;, based on our systematic review and meta-analysis of IPD (PMID:15939524)</gtr:impact><gtr:outcomeId>oTy6SKJtFf2</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type><gtr:url>http://europepmc.org/abstract/MED/15939524</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Cervix CTRT SR (PMID: 16034873) GGPO guideline 2014</gtr:description><gtr:geographicReach>Europe</gtr:geographicReach><gtr:guidelineTitle>S3-Leitlinie Diagnostik, Therapie und Nachsorge der Patientin mit Zervixkarzinom v1.0 2014</gtr:guidelineTitle><gtr:id>B181DFE2-F1BC-4CA7-9D62-74CA6360A6E8</gtr:id><gtr:impact>&amp;quot;Bei der Patientin mit Zervixkarzinom soll bei Indikationsstellung zu einer prim&amp;auml;ren Radiotherapie ab Stadium IB2 diese in Kombination mit einer cisplatinbasierten Chemotherapie erfolgen.&amp;quot;, based on our systematic review and meta-analysis of summary data (PMID: 16034873)</gtr:impact><gtr:outcomeId>56cdcac857fc76.98765923</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Lung PORT IPD (PMID:7580546) ASCO guideline 2007</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:guidelineTitle>Cancer Care Ontario and American Society of Clinical Oncology Adjuvant Chemotherapy and Adjuvant Radiation Therapy for Stages I-IIIA Resectable Non-Small-Cell Lung Cancer Guideline</gtr:guidelineTitle><gtr:id>A2BFCDF4-7505-4FDB-86B0-15C908CEE93F</gtr:id><gtr:impact>&amp;quot;Postoperative thoracic radiation is not recommended for patients with completely resected stage I or II NSCLC.&amp;quot;, based on our systematic review and meta-analysis of IPD (PMID: 7580546)</gtr:impact><gtr:outcomeId>W3EAZNXgPbd</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type><gtr:url>http://europepmc.org/abstract/MED/7580546</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Bladder Adj CT IPD (PMID:15939530) EAU guideline 2011</gtr:description><gtr:geographicReach>Europe</gtr:geographicReach><gtr:guidelineTitle>Guidelines on Bladder Cancer: Muscle-Invasive and Metastatic</gtr:guidelineTitle><gtr:id>C32A976C-D9CA-4F1C-9261-80F33F62F342</gtr:id><gtr:impact>&amp;quot;Adjuvant chemotherapy is advised within clinical trials, but not for routine use&amp;quot;, based on our systematic review and meta-analysis of IPD (PMID:15939530)</gtr:impact><gtr:outcomeId>db87t8Q8f82</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type><gtr:url>http://europepmc.org/abstract/MED/15939530</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Cervix CTRT IPD (PMID:19001332) NCCN guideline 2012</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:guidelineTitle>NCCN Practice Guidelines in Oncology - v.1.2012 Cervical Cancer</gtr:guidelineTitle><gtr:id>74A67522-00E4-488E-9F40-EC38E2CAD03C</gtr:id><gtr:impact>Our systematic review and meta-analysis of IPD was cited as evidence in this guideline (PMID: 19001332)</gtr:impact><gtr:outcomeId>b5YSSqsYndY</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type><gtr:url>http://europepmc.org/abstract/MED/19001332</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Bladder Neo CT IPD (PMID: 12801735; 15939524) EAU guideline 2013</gtr:description><gtr:geographicReach>Europe</gtr:geographicReach><gtr:guidelineTitle>Guidelines on Bladder Cancer: Muscle-Invasive and Metastatic</gtr:guidelineTitle><gtr:id>8FB90467-8E60-441C-BD3E-6D8EC6FDB663</gtr:id><gtr:impact>Our systematic review and meta-analysis of IPD was cited as key evidence in this guideline (PMID:12801735; PMID:15939524)</gtr:impact><gtr:outcomeId>szuvJZRfgTZ</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Lung CT 95 IPD (PMID:7580546) ACCP guideline stage IIIA 2007</gtr:description><gtr:geographicReach>North America</gtr:geographicReach><gtr:guidelineTitle>Treatment of non-small cell lung cancer, stage IIIA. ACCP evidence-based clinical practice guidelines (2nd edition)</gtr:guidelineTitle><gtr:id>898D14B8-2A73-467A-871F-0AC2261CDB8E</gtr:id><gtr:impact>&amp;quot;In patients with resected NSCLC who were found to have incidental (occult) N2 disease (IIIA1-2) and who have good performance status, adjuvant platinum- based chemotherapy is recommended&amp;quot;, based on our systematic review and meta-analysis of IPD (PMID: 7580546) and subsequent large trials</gtr:impact><gtr:outcomeId>2DD84CCB460</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type><gtr:url>http://europepmc.org/abstract/MED/7580546</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Cervix CTRT SR (PMID:11564482) SIGN guideline 2008</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:guidelineTitle>SIGN99 Management of cervical cancer. A national clinical guideline</gtr:guidelineTitle><gtr:id>D2F1E025-5519-4A85-B664-21DE991D3563</gtr:id><gtr:impact>&amp;quot;Any patient with cervical cancer considered suitable for radical radiotherapy treatment should have concurrent chemoradiotherapy with a platinum based chemotherapy, if fit enough&amp;quot; based on our systematic review and meta-analysis of summary data (PMID: 11564482)</gtr:impact><gtr:outcomeId>0E9933C901F</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type><gtr:url>http://www.sign.ac.uk/pdf/sign99.pdf</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Lung CT 95 IPD (PMID:7580546) CCA guideline stage II before 2012</gtr:description><gtr:geographicReach>Oceania</gtr:geographicReach><gtr:guidelineTitle>Clinical practice guidelines for the treatment of lung cancer. &amp;quot;What is the role of chemotherapy before surgery in the treatment of operable stage II NSCLC?&amp;quot;</gtr:guidelineTitle><gtr:id>46AC2870-7811-439D-9CF1-6D0DAA326430</gtr:id><gtr:impact>Our systematic review and meta-analysis of IPD was cited as evidence in this guideline (PMID: 7580546)</gtr:impact><gtr:outcomeId>GBKdhhDSSXi</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Lung PORT IPD (PMID:9690404; 15603857; 10796868) BCCA guideline 2013</gtr:description><gtr:geographicReach>North America</gtr:geographicReach><gtr:guidelineTitle>BCCA Cancer Management Guidelines; 6.1 Non-Small Cell Lung Cancer (NSCLC) - 02) Adjuvant Radical Radiotherapy Following Surgical Resection</gtr:guidelineTitle><gtr:id>35C31B65-884D-48E3-BA0D-F02BB87C2453</gtr:id><gtr:impact>&amp;quot;Post-operative adjuvant radiotherapy should not be used after complete resection of Stage I or II NSCLC, due to an increased risk of non-cancer deaths.&amp;quot;, based on our systematic review and meta-analysis of IPD (PMID: 9690404; PMID: 10796868; PMID: 15603857</gtr:impact><gtr:outcomeId>544fba11849024.65183152</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Lung CT 95 IPD (PMID:7580546) CCO guideline 2014</gtr:description><gtr:geographicReach>North America</gtr:geographicReach><gtr:guidelineTitle>First-line Systemic Chemotherapy in the Treatment of Advanced Non-Small Cell Lung Cancer. Evidence-Based Series 7-10 Version 2</gtr:guidelineTitle><gtr:id>4D6FA747-200E-4DA3-8D22-543D736875D4</gtr:id><gtr:impact>Our systematic review and meta-analysis of IPD was cited as evidence in this guideline (PMID: 7580546)</gtr:impact><gtr:outcomeId>544fa7c908ec68.83035896</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Cervix CTRT IPD (PMID:19001332) SEOM guideline 2012</gtr:description><gtr:geographicReach>Europe</gtr:geographicReach><gtr:guidelineTitle>SEOM guidelines for cervical cancer</gtr:guidelineTitle><gtr:id>B54C662F-CC41-465E-89C5-2E010C58E68A</gtr:id><gtr:impact>&amp;quot;Stages IIB, III and IVA: This category has traditionally included patients with stage IIB-IVA disease. However, currently patients with IB2 and IIA2 disease are also included in this category. Concomitant chemoradiation represents the standard treatment. This modality is superior to RT alone for local control, metastasis rate, disease-free and overall survival. A meta-analysis based on 18 trials with individual patient data was recently performed. Cisplatin-based chemotherapy was used in 85% of the patients. The most common regimen was cisplatin monotherapy 40 mg/m2 on a weekly schedule.The results demonstrated a 6% and 8% improvement in absolute 5-year survival and disease-free survival with chemoradiotherapy respectively. In addition a decreasing relative effect of chemoradiotherapy on survival with increasing tumour stage was observed, with estimated absolute survival benefits of 10% (stage Ia to IIA), 7% (stage IIB) and 3% (stage III to IVA) at 5 years&amp;quot;, based on our systematic review and meta-analysis of IPD (PMID: 19001332)</gtr:impact><gtr:outcomeId>544f9797a8ac61.97521716</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Bladder Adj CT IPD (PMID:16625650) ESMO guideline 2009</gtr:description><gtr:geographicReach>Europe</gtr:geographicReach><gtr:guidelineTitle>Invasive bladder cancer: ESMO Clinical Recommendations for diagnosis, treatment and follow-up</gtr:guidelineTitle><gtr:id>F3D72B2E-1950-4602-BE73-0B7E3978596E</gtr:id><gtr:impact>Our systematic review and meta-analysis of IPD was cited as key evidence in this guideline (PMID:16625650)</gtr:impact><gtr:outcomeId>fqRqCv21ieh</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type><gtr:url>http://europepmc.org/abstract/MED/16625650</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Lung CT 95 IPD (PMID:7580546) BCCA guideline 2011</gtr:description><gtr:geographicReach>North America</gtr:geographicReach><gtr:guidelineTitle>BCCA Cancer Management Guidelines; 6.1 Non-Small Cell Lung Cancer (NSCLC) - 04) Post-operative Adjuvant Chemotherapy for Resected NSCLC</gtr:guidelineTitle><gtr:id>9C1BCAA2-30D1-457B-96C5-40E45886DE36</gtr:id><gtr:impact>Our systematic review and meta-analysis of IPD was cited as evidence in this guideline (PMID: 7580546)</gtr:impact><gtr:outcomeId>544f9efd9e3ad5.72919251</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Sarcoma CT SR (PMID:7640234) CCO guideline 2011</gtr:description><gtr:geographicReach>North America</gtr:geographicReach><gtr:guidelineTitle>Adjuvant Chemotherapy Following Complete Resection of Soft Tissue Sarcoma in Adults: Practice Guideline Report 11-2</gtr:guidelineTitle><gtr:id>BE631447-318E-484E-8C4B-3F184D68C7EF</gtr:id><gtr:impact>Our systematic review and meta-analysis of summary data was cited as key evidence in this guideline (PMID: 7640234)</gtr:impact><gtr:outcomeId>b6M6qbKNrrD</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type><gtr:url>http://europepmc.org/abstract/MED/7640234</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Lung PORT IPD (PMID:15603857) NCCN guideline 2014</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:guidelineTitle>NCCN Practice Guidelines in Oncology v.1.2014. Non-Small Cell Lung Cancer</gtr:guidelineTitle><gtr:id>0646622D-3121-4619-90F9-596093DB0890</gtr:id><gtr:impact>&amp;quot;PORT is not recommended for patients with pathologic stage N0-1 disease, because it has been associated with increased mortality, at least when using older RT techniques. In patients treated with surgery, postoperative radiotherapy (PORT) is not recommended unless there are positive margins or upstaging to N2&amp;quot;, based on our systematic review and meta-analysis of IPD (PMID: 9690404; PMID: 15603857)</gtr:impact><gtr:outcomeId>544fc0b8628be5.74610057</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Lung CT 95 IPD (PMID:7580546) ACR guideline Induction/Adjuvant 2010</gtr:description><gtr:geographicReach>North America</gtr:geographicReach><gtr:guidelineTitle>ACR Appropriateness Criteria INDUCTION AND ADJUVANT THERAPY FOR N2 NON-SMALL-CELL LUNG CANCER</gtr:guidelineTitle><gtr:id>8142D740-A3A4-461A-B13A-1D3A07D624D8</gtr:id><gtr:impact>Our systematic review and meta-analysis of IPD was cited as evidence in this guideline (PMID: 7580546)</gtr:impact><gtr:outcomeId>qhtWdoZFZ1P</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type><gtr:url>http://europepmc.org/abstract/MED/7580546</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Lung PORT IPD (PMID:10796868) BCCA guideline 2011</gtr:description><gtr:geographicReach>North America</gtr:geographicReach><gtr:guidelineTitle>BCCA Cancer Management Guidelines; 6.1 Non-Small Cell Lung Cancer (NSCLC) - 04) Post-operative Adjuvant Chemotherapy for Resected NSCLC</gtr:guidelineTitle><gtr:id>DC49C592-950D-4A0C-A586-BAA53AB30D43</gtr:id><gtr:impact>Our systematic review and meta-analysis of IPD was cited as evidence in this guideline (PMID: 10796868)</gtr:impact><gtr:outcomeId>544fb8fc7c8b16.52282189</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Bladder Neo CT IPD (PMID:15939524) JUA guideline 2010</gtr:description><gtr:geographicReach>Asia</gtr:geographicReach><gtr:guidelineTitle>Evidence-based clinical practice guidelines for bladder cancer</gtr:guidelineTitle><gtr:id>F4316215-945D-463A-BE5D-63150003C4A4</gtr:id><gtr:impact>&amp;quot;Perioperative chemotherapy might improve the therapeutic results for muscle-invasive bladder cancer. Preoperative and postoperative chemotherapy have their respective merits and demerits. At present, a definite improvement in survival rates has been shown only for preoperative cisplatin-based combination chemotherapy.(Grade of recommendation A.)&amp;quot;, based on our systematic review and meta-analysis of IPD (PMID: 15939524)</gtr:impact><gtr:outcomeId>jzRRSv7bcwh</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type><gtr:url>http://europepmc.org/abstract/MED/15939524</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Bladder Neo CT IPD (PMID:15846746) ESMO guideline 2010</gtr:description><gtr:geographicReach>Europe</gtr:geographicReach><gtr:guidelineTitle>Bladder cancer: ESMO Practice Guidelines for diagnosis, treatment and follow-up</gtr:guidelineTitle><gtr:id>A5B2ACEA-C7D2-4768-B181-4E6EC343FD86</gtr:id><gtr:impact>&amp;quot;A meta-analysis supports the use of neoadjuvant chemotherapy before cystectomy for T2 and T3 disease. The demonstrated survival benefit encourages the use of platinum-based combination chemotherapy before radical cystectomy or definitive radiotherapy [I, A].&amp;quot;, based on our systematic review and meta-analysis of IPD (PMID:15846746)</gtr:impact><gtr:outcomeId>fR6BwaT7GHC</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type><gtr:url>http://europepmc.org/abstract/MED/15846746</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Lung SeqCon CTRT IPD (PMID:20351327) CCA guideline stage II CTRT inoperable 2014</gtr:description><gtr:geographicReach>Australia</gtr:geographicReach><gtr:guidelineTitle>Clinical practice guidelines for the treatment of lung cancer. What is the role of chemotherapy when added to radiotherapy in the treatment of inoperable stage II NSCLC?</gtr:guidelineTitle><gtr:id>8786ABF3-9364-4472-9478-95243BB52A4A</gtr:id><gtr:impact>Our systematic review and meta-analysis of IPD was cited as evidence in this guideline (PMID: 20351327)</gtr:impact><gtr:outcomeId>544fb673c24b96.41668658</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Lung CT 95 IPD (PMID:7580546) CCA guideline stage II CT before operable 2014</gtr:description><gtr:geographicReach>Australia</gtr:geographicReach><gtr:guidelineTitle>Clinical practice guidelines for the treatment of lung cancer. What is the role of chemotherapy before surgery in the treatment of operable stage II NSCLC?</gtr:guidelineTitle><gtr:id>6BE41621-7E40-430A-9984-812844F2786F</gtr:id><gtr:impact>Our systematic review and meta-analysis of IPD was cited as evidence in this guideline (PMID: 7580546)</gtr:impact><gtr:outcomeId>544fa758dda077.80050322</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Lung SC IPD (PMID:18678835) ERS/ESTS guideline 2009</gtr:description><gtr:geographicReach>Europe</gtr:geographicReach><gtr:guidelineTitle>ERS/ESTS Clinical Guidelines on Fitness for Radical Therapy in Lung Cancer Patients (surgery and chemo-radiotherapy)</gtr:guidelineTitle><gtr:id>D2D16D95-0EF8-434C-89FF-B760670E1CEA</gtr:id><gtr:impact>Our systematic review and meta-analysis of IPD was cited as evidence in this guideline (PMID: 18678835)</gtr:impact><gtr:outcomeId>S53yKxEDWkh</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type><gtr:url>http://europepmc.org/abstract/MED/18678835</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Endometrial CT SR (PMID:17150999) NCCN guideline 2014</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:guidelineTitle>NCCN Practice Guidelines in Oncology v.1.2014. Uterine Neoplasms</gtr:guidelineTitle><gtr:id>6E7D6075-AC03-4092-8E9F-06F459835520</gtr:id><gtr:impact>&amp;quot;Based on the current data, multiagent chemotherapy regimens are preferred for metastatic, recurrent, or high-risk disease, if tolerated&amp;quot;, based on our systematic review and meta-analysis of summary data (PMID: 17150999)</gtr:impact><gtr:outcomeId>544f9b3fe31535.25805315</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Bladder Neo CT IPD (PMID:15846746) ESMO guideline 2011</gtr:description><gtr:geographicReach>Europe</gtr:geographicReach><gtr:guidelineTitle>Bladder cancer: ESMO Practice Guidelines for diagnosis, treatment and follow-up</gtr:guidelineTitle><gtr:id>638196C9-E035-41FD-9844-FBF57672635B</gtr:id><gtr:impact>&amp;quot;A meta-analysis supports the use of neoadjuvant chemotherapy before cystectomy for T2 and T3 disease. The demonstrated survival benefit encourages the use of platinum-based combination chemotherapy before radical cystectomy or definitive radiotherapy [I, A].&amp;quot;, based on our systematic review and meta-analysis of IPD (PMID:15846746)</gtr:impact><gtr:outcomeId>XspbZABmGBB</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type><gtr:url>http://europepmc.org/abstract/MED/15846746</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Lung Neo CT SR (PMID:17409927) BHKC guideline 2013</gtr:description><gtr:geographicReach>Europe</gtr:geographicReach><gtr:guidelineTitle>SMALL CELL AND NON-SMALL CELL LUNG CANCER: DIAGNOSIS, TREATMENT AND FOLLOW-UP</gtr:guidelineTitle><gtr:id>736DB00A-828E-4AF4-AF0E-BEB09AB35BDD</gtr:id><gtr:impact>Our systematic review and meta-analysis of summary data was cited as evidence in this guideline (PMID: 17409927)</gtr:impact><gtr:outcomeId>544fb2928df2b9.60346419</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Lung SC IPD (PMID: 20464750) CCA guideline stage II CT after operable 2014</gtr:description><gtr:geographicReach>Australia</gtr:geographicReach><gtr:guidelineTitle>Clinical practice guidelines for the treatment of lung cancer. What is the role of chemotherapy after surgery in the treatment of operable stage II NSCLC?</gtr:guidelineTitle><gtr:id>9B0F1F3B-53FE-435F-9CD0-4E340CEA5849</gtr:id><gtr:impact>Our systematic review and meta-analysis of IPD was cited as evidence in this guideline (PMID: 20464750)</gtr:impact><gtr:outcomeId>544fadfcdd3bd7.08030084</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Cervix Neo CT SR (PMID:20091632) NICE QIPP topic 2011</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>E5C04544-BBBF-4267-90B1-726A6EDC642E</gtr:id><gtr:impact>This case study, published by NICE is aimed at informing the decisions of local initiatives about patient care or the use of resources, and is based on our systematic review and meta-analysis of summary data (PMID: 20091632)</gtr:impact><gtr:outcomeId>ts9P8N7Jtp4</gtr:outcomeId><gtr:type>Citation in other policy documents</gtr:type><gtr:url>http://europepmc.org/abstract/MED/20091632</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Lung SeqCon CTRT IPD (PMID:20351327) NCCN guideline 2014</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:guidelineTitle>NCCN Practice Guidelines in Oncology v.1.2014. Non-Small Cell Lung Cancer</gtr:guidelineTitle><gtr:id>B5E72EE4-BCC9-45B6-B783-3741D53ABE8E</gtr:id><gtr:impact>&amp;quot;When distant metastases are not present, the NCCN Panel recommends that the patient be treated with definitive concurrent chemoradiation therapy&amp;quot; , based on our systematic review and meta-analysis of IPD (PMID: 20351327)</gtr:impact><gtr:outcomeId>544fb5126bd264.53537078</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Lung Adj CT IPD (PMID:20338628) BHKC guideline 2013</gtr:description><gtr:geographicReach>Europe</gtr:geographicReach><gtr:guidelineTitle>SMALL CELL AND NON-SMALL CELL LUNG CANCER: DIAGNOSIS, TREATMENT AND FOLLOW-UP</gtr:guidelineTitle><gtr:id>B70B4D26-47A7-4A1B-A63E-B6C729C36364</gtr:id><gtr:impact>&amp;quot;NICE recommends to offer postoperative chemotherapy to patients with good performance status (WHO 0 or 1) and T1-3 N1-2 M0 NSCLC and to consider postoperative chemotherapy in patients with good performance status (WHO 0 or 1) and T2-3 N0 M0 NSCLC with tumours greater than 4 cm in diameter. They also recommend to offer a cisplatin-based combination chemotherapy regimen for adjuvant chemotherapy and to ensure eligible patients have the benefit of detailed discussion of the risks and benefits of adjuvant chemotherapy They base their conclusions on five systematic reviews with meta-analyses&amp;quot;, based on our systematic review and meta-analysis of IPD (PMID: 20338628)</gtr:impact><gtr:outcomeId>544fae89ce2a67.06109028</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Oesophagus RT IPD (PMID:9635705) NCCN guideline 2014</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:guidelineTitle>NCCN Guidelines Version 2.2014 Esophageal and Esophagogastric Junction Cancers</gtr:guidelineTitle><gtr:id>95754A0E-8B29-4791-AE42-4A42B03F3404</gtr:id><gtr:impact>&amp;quot;In the adjuvant setting, randomized trials have not shown a survival advantage for preoperative or postoperative RT alone. A meta-analysis from the Oesophageal Cancer Collaborative Group also showed no clear evidence of a survival advantage with preoperative RT&amp;quot;, based on our systematic review and meta-analysis of IPD. (PMID: 9635705)</gtr:impact><gtr:outcomeId>544fc5584840f1.99711302</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Lung PORT IPD (PMID:15846628) ESMO guideline 2010</gtr:description><gtr:geographicReach>Europe</gtr:geographicReach><gtr:guidelineTitle>Early stage and locally advanced (non-metastatic) non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up</gtr:guidelineTitle><gtr:id>BF80B8A3-2ED1-40FC-98D6-2ED9E9FBBB8D</gtr:id><gtr:impact>Our systematic review and meta-analysis of IPD was cited as evidence in this guideline (PMID: 15846628)</gtr:impact><gtr:outcomeId>Aix4YUauM2F</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type><gtr:url>http://europepmc.org/abstract/MED/15846628</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Bladder Neo CT IPD (PMID:12801735; 15939524) EAU guideline 2010</gtr:description><gtr:geographicReach>Europe</gtr:geographicReach><gtr:guidelineTitle>Guidelines on Bladder Cancer: Muscle-Invasive and Metastatic</gtr:guidelineTitle><gtr:id>6423D1F2-8FC5-46E5-8D37-DA651072E008</gtr:id><gtr:impact>&amp;quot;Neoadjuvant cisplatin-containing combination chemotherapy should be considered in muscleinvasive bladder cancer, irrespective of definitive treatment&amp;quot;, based on our systematic review and meta-analysis of IPD (PMID:12801735; PMID:15939524)</gtr:impact><gtr:outcomeId>pM1DoQJCghM</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type><gtr:url>http://europepmc.org/abstract/MED/12801735</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Sarcoma CT IPD (PMID:9400508) NCCN guideline SoftTissueSarcoma 2009</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:guidelineTitle>NCCN Practice Guidelines in Oncology - v.2.2009 Soft Tissue Sarcoma</gtr:guidelineTitle><gtr:id>CB8ADF2C-D311-4A23-A0E5-61EECD644788</gtr:id><gtr:impact>Our systematic review and meta-analysis of IPD was cited as evidence in this guideline (PMID: 9400508)</gtr:impact><gtr:outcomeId>X3uhRAvVo5q</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type><gtr:url>http://europepmc.org/abstract/MED/9400508</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Lung CT 95 IPD (PMID:7580546; 10796867) AIOT guideline Stage IIIb 2012</gtr:description><gtr:geographicReach>Europe</gtr:geographicReach><gtr:guidelineTitle>Linee guida per la gestione integrata del paziente con tumore polmonare: NSCLC - Stadio IIIb</gtr:guidelineTitle><gtr:id>ADE895DA-102B-4DCB-9932-6B375BDC60AC</gtr:id><gtr:impact>Our systematic review and meta-analysis of IPD was cited as evidence in this guideline (PMID: 7580546; PMID: 10796867)</gtr:impact><gtr:outcomeId>56cda9df5853a3.77292242</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Cervix Neo CT IPD (PMID:14602133) BHKC guideline 2011</gtr:description><gtr:geographicReach>Europe</gtr:geographicReach><gtr:guidelineTitle>A national clinical practice guideline for the management of cervical cancer</gtr:guidelineTitle><gtr:id>024DC57F-8879-4A00-BC3F-E0EE93444351</gtr:id><gtr:impact>&amp;quot;If NACT prior to surgery is chosen to treat patients with FIGO stage IB2, IIA, or IIB cervical cancer, then short cycle (= 14 days) and dose-intensive regimens (cisplatin = 25 mg/m2) are recommended (1B)&amp;quot;, based on our systematic review and meta-analysis of IPD (PMID: 14602133)</gtr:impact><gtr:outcomeId>j1QntosTgTL</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type><gtr:url>http://europepmc.org/abstract/MED/14602133</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Bladder Adj CT IPD (PMID:15939530) EAU guideline 2014</gtr:description><gtr:geographicReach>Europe</gtr:geographicReach><gtr:guidelineTitle>Guidelines on Bladder Cancer: Muscle-Invasive and Metastatic</gtr:guidelineTitle><gtr:id>09EE3C61-78C1-4B70-97A7-E23B5EC9EB00</gtr:id><gtr:impact>Our systematic review and meta-analysis of IPD was cited as key evidence in this guideline (PMID: 15939530)</gtr:impact><gtr:outcomeId>544f91a7eeca30.41467181</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Systematic review training for Oncologists (MSc)</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>09C334C8-8603-4F08-ABC9-E772E53F6F9C</gtr:id><gtr:outcomeId>YcDiXdhtyTS</gtr:outcomeId><gtr:type>Influenced training of practitioners or researchers</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Cervix CTRT IPD (PMID:19001332) ACR guideline 2010</gtr:description><gtr:geographicReach>North America</gtr:geographicReach><gtr:guidelineTitle>ACR Appropriateness Criteria ADVANCED CERVICAL CANCER</gtr:guidelineTitle><gtr:id>A177EF0C-51C2-424D-A4BC-AB3F118A5438</gtr:id><gtr:impact>Our systematic review and meta-analysis of summary data was cited as evidence in this guideline (PMID: 19001332)</gtr:impact><gtr:outcomeId>AR6BUYPPGvs</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type><gtr:url>http://europepmc.org/abstract/MED/19001332</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Glioma CT IPD (PMID: 11937180) CCO guideline 2006</gtr:description><gtr:geographicReach>North America</gtr:geographicReach><gtr:guidelineTitle>Adjuvant systemic chemotherapy following surgery and external beam radiotherapy for adults with newly diagnosed malignant glioma</gtr:guidelineTitle><gtr:id>C5B9A17F-1D1E-4D81-8FEE-3086AEB87D6D</gtr:id><gtr:impact>Our systematic review and meta-analysis of IPD was cited as evidence in this guideline (PMID: 11937180)</gtr:impact><gtr:outcomeId>7E21368574E</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type><gtr:url>http://europepmc.org/abstract/MED/11937180</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Lung PORT IPD (PMID:15603857) ESMO guideline 2008</gtr:description><gtr:geographicReach>Europe</gtr:geographicReach><gtr:guidelineTitle>Non-small cell lung cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up</gtr:guidelineTitle><gtr:id>56CE083D-6FC4-4D7A-8844-43FAD1AB18DE</gtr:id><gtr:impact>&amp;quot;Post-operative radiotherapy is not recommended for patients with radically resected stage I and II diease and should only be considred for patients with stage III disease/mediastinal involvelment&amp;quot;, based on our systematic review and meta-analysis of IPD (PMID: 15603857)</gtr:impact><gtr:outcomeId>1F39AA39321</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type><gtr:url>http://europepmc.org/abstract/MED/15603857</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Sarcoma CT IPD (PMID:10796873) NCCN guideline UterineNeoplasms 2011</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:guidelineTitle>NCCN Practice Guidelines in Oncology v.2.2011. Uterine Neoplasms</gtr:guidelineTitle><gtr:id>44F9F731-91EF-455A-9E54-2E93B6859794</gtr:id><gtr:impact>&amp;quot;Doxorubicin is an active single agent for LMS and is less toxic than combination regimens&amp;quot;, based on our systematic review and meta-analysis of IPD (PMID: 10796873)</gtr:impact><gtr:outcomeId>pCbBn8tHDpW</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type><gtr:url>http://europepmc.org/abstract/MED/10796873</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Lung Adj CT IPD (PMID:20338628) NCCN guideline 2012</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:guidelineTitle>NCCN Practice Guidelines in Oncology v.2.2012. Non-Small Cell Lung Cancer</gtr:guidelineTitle><gtr:id>0C034BA7-C477-4FF7-B347-97006A903CDF</gtr:id><gtr:impact>&amp;quot;The panel recommends chemotherapy (category I ) for patients with negative surgical margins and stage II disease 1) Tlab-2a, N1; 2) T2b, N1; or 3) T3, NO disease&amp;quot;, based on our systematic review and meta-analysis of IPD (PMID: 20338628)</gtr:impact><gtr:outcomeId>cbDv9nCkxdC</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type><gtr:url>http://europepmc.org/abstract/MED/20338628</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Lung Adj CT IPD (PMID:20338628) NCCN guideline 2014</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:guidelineTitle>NCCN Practice Guidelines in Oncology v.1.2014. Non-Small Cell Lung Cancer</gtr:guidelineTitle><gtr:id>7F13BC66-DDA4-4346-A663-7BEDD802C322</gtr:id><gtr:impact>&amp;quot;The panel recommends chemotherapy (category I) for patients with negative surgical margins and stage II disease 1) Tlab-2a, N1; 2) T2b, N1; or 3) T3, NO disease&amp;quot;, based on our systematic review and meta-analysis of IPD (PMID: 20338628)</gtr:impact><gtr:outcomeId>544faf83b398d5.05126515</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Glioma CT IPD (PMID:11937180) NCCN guideline 2013</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:guidelineTitle>NCCN Clinical Practice Guidelines in Oncology - v.1.2012 Central Nervous System Cancers</gtr:guidelineTitle><gtr:id>E150563F-A36C-4E1C-9F2C-01184188737B</gtr:id><gtr:impact>Our systematic review and meta-analysis of IPD was cited as evidence in this guideline (PMID:11937180)</gtr:impact><gtr:outcomeId>544f9717ed0d61.47947623</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Cervix Neo CT IPD (PMID:14602133) ACR guideline early 2012</gtr:description><gtr:geographicReach>North America</gtr:geographicReach><gtr:guidelineTitle>ACR Appropriateness Criteria Definitive therapy for early stage cervical cancer</gtr:guidelineTitle><gtr:id>23E814C8-781D-4D7B-9D3B-BFE1814FDED0</gtr:id><gtr:impact>Our systematic review and meta-analysis of summary data was cited as evidence in this guideline (PMID: 14602133)</gtr:impact><gtr:outcomeId>DoomYXgUFe2</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type><gtr:url>http://europepmc.org/abstract/MED/14602133</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Pre-eclampsia PARIS IPD (PMID:17512048) NICE/RCOG joint guideline 2011</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:guidelineTitle>CG107 Hypertension in pregnancy: the management of hypertensive disorders during pregnancy</gtr:guidelineTitle><gtr:id>54E28B5A-BA65-47AD-B9FA-A79C63DB1A6A</gtr:id><gtr:impact>&amp;quot;A meta-analysis of individual-patient data [EL = 1++] that included women with chronic hypertension showed antiplatelet agents to be effective in reducing the risk of developing preeclampsia (RR 0.90; 95% CI 0.84 to 0.97)&amp;quot;, based on our systematic review and meta-analysis of IPD (PMID: 17512048)</gtr:impact><gtr:outcomeId>WuGSHRz9MBU</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type><gtr:url>http://www.nice.org.uk/CG107</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Lung PORT IPD (PMID:15846628) BHKC guideline 2013</gtr:description><gtr:geographicReach>Europe</gtr:geographicReach><gtr:guidelineTitle>SMALL CELL AND NON-SMALL CELL LUNG CANCER: DIAGNOSIS, TREATMENT AND FOLLOW-UP</gtr:guidelineTitle><gtr:id>DFA8A63C-B9E6-490E-9EE6-68E737EE913F</gtr:id><gtr:impact>&amp;quot;An update of the Cochrane review on postoperative radiotherapy for completely resected NSCLC was published in 2010. Combined results of the analysis based on individual patient data shows a detrimental effect of postoperative radiotherapy on overall survival (HR 1.17; 95%CI 1.02-1.34, p=0.02). Recurrence-free survival was also adversely affected by postoperative radiotherapy but that effect was not statistically significant (HR 1.09; 95%CI 0.95-1.25). Subgroup analyses for predefined factors shows no evidence that the effect of postoperative radiotherapy is different for any group of patients defined by age, sex or histology. Results for stage III disease (for the meta-analysis defined as any T-stage with N2,3 disease) show no clear evidence for neither a detrimental nor a beneficial effect of postoperative radiotherapy. For completely resected N2 disease, HR was 0.97; 95%CI 0.81 to 1.16. No further RCTs on the use of postoperative radiotherapy in completely resected lung tumours were identified.&amp;quot;, based ou our systematic review and meta-analysis of IPD (PMID: 15846628)</gtr:impact><gtr:outcomeId>544fc047d96245.77665832</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Bladder Adj CT IPD (PMID: 15939530) BCCA guideline 2008</gtr:description><gtr:geographicReach>North America</gtr:geographicReach><gtr:guidelineTitle>Cancer Management Guidelines. Genitourinary. Bladder</gtr:guidelineTitle><gtr:id>D32FEE89-C019-4344-8C6E-998D314C52CB</gtr:id><gtr:impact>&amp;quot;Adjuvant chemotherapy is not routinely recommended&amp;quot;. based on our systematic review and meta-analysis of IPD (PMID: 15939530)</gtr:impact><gtr:outcomeId>269B92EFF70</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type><gtr:url>http://europepmc.org/abstract/MED/15939530</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Lung CT 95 IPD (PMID:7580546) NCCN guideline 2014</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:guidelineTitle>NCCN Practice Guidelines in Oncology v.1.2014. Non-Small Cell Lung Cancer</gtr:guidelineTitle><gtr:id>9A2F4A43-000B-4221-AC34-77154BEEA671</gtr:id><gtr:impact>&amp;quot;For patients with stage IV disease who have a good PS, platinum-based chemotherapy is beneficial&amp;quot;, based on our systematic review and meta-analysis of IPD (PMID: 7580546)</gtr:impact><gtr:outcomeId>544fa121ed0af1.74069587</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Lung PORT IPD (PMID:9690404) GRS/GCS guideline 2010</gtr:description><gtr:geographicReach>Europe</gtr:geographicReach><gtr:guidelineTitle>Prevention, Diagnosis, Therapy and Follow-up of Lung Cancer</gtr:guidelineTitle><gtr:id>13CD7657-190C-441C-8BD8-A29D555A29CE</gtr:id><gtr:impact>Our systematic review and meta-analysis of IPD was cited as evidence in this guideline (PMID: 9690404)</gtr:impact><gtr:outcomeId>et2UQgRTycF</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type><gtr:url>http://europepmc.org/abstract/MED/9690404</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Lung PORT IPD (PMID:10796868) SIGN 137 guideline 2014</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:guidelineTitle>SIGN 137: Management of Lung cancer</gtr:guidelineTitle><gtr:id>83C1FE06-11E1-4F53-9C51-CE0EAC4D6106</gtr:id><gtr:impact>&amp;quot;Postoperative radiotherapy (PORT) has been shown to reduce local recurrence in the radiotherapy arm. The PORT meta-analysis suggests an adverse effect of radiotherapy on survival with a hazard ratio of 1.21 (95% CI 1.08 to 1.34), favouring surgery; two year survival with adjuvant radiotherapy was 48% versus 50% in the surgery alone group. Patients with NSCLC who have had complete tumour resection should not receive postoperative radiotherapy, except as part of a randomised trial&amp;quot;, based on our systematic review and meta-analysis of IPD (PMID: 10796868)</gtr:impact><gtr:outcomeId>544fc18c87f6d4.25612535</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Glioma CT IPD (PMID:11937180) NCCN guideline 2012</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:guidelineTitle>NCCN Clinical Practice Guidelines in Oncology - v.2.2012 Central Nervous System Cancers</gtr:guidelineTitle><gtr:id>61ADF308-5597-4CEA-8760-E6F74E1674E2</gtr:id><gtr:impact>&amp;quot;The Glioma Meta-Analysis Trialists Group reviewed 12 studies involving approximately 3000 patients and reported an absolute increase in 1-year survival from 40% to 46% and a 2-month increase in median survival when chemotherapy was added to postoperative radiation (HR, 0.85; 95% CI, 0.78-0.91; P&amp;lt;0.0001)&amp;quot;, based on our systematic review and meta-analysis of IPD (PMID:11937180)</gtr:impact><gtr:outcomeId>HS41gc9pUMQ</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type><gtr:url>http://europepmc.org/abstract/MED/11937180</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Oesophagus RT IPD (PMID:10796823) CCO guideline 2012</gtr:description><gtr:geographicReach>North America</gtr:geographicReach><gtr:guidelineTitle>Preoperative or Postoperative Therapy for Resectable Esophageal Cancer</gtr:guidelineTitle><gtr:id>56B13D20-2D44-4424-8AD2-38D674CF666C</gtr:id><gtr:impact>&amp;quot;A Cochrane review with meta-analysis published in 2005 using updated individual patient data on 1147 patients from five trials reported ahazard ratio for death of 0.89 (95% CI, 0.78 to 1.01; p=0.062) for preoperative radiotherapy compared with surgery alone using a fixed effects model&amp;quot;, based on our systematic review and meta-analysis of IPD (PMID: 10796823)</gtr:impact><gtr:outcomeId>544fc29577ad93.64407916</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Endometrial CT SR (PMID:17150999) NCCN guideline UterineNeoplasms 2011</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:guidelineTitle>NCCN Practice Guidelines in Oncology v.2.2011. Uterine Neoplasms</gtr:guidelineTitle><gtr:id>514B3EC5-3876-47CE-A2A7-93303C80ACDB</gtr:id><gtr:impact>Our systematic review and meta-analysis of summary data was cited as evidence in this guideline (PMID: 17150999)</gtr:impact><gtr:outcomeId>jQa2LpidReV</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type><gtr:url>http://europepmc.org/abstract/MED/17150999</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Endometrial CT SR (PMID:17150999) AHS guideline 2013</gtr:description><gtr:geographicReach>North America</gtr:geographicReach><gtr:guidelineTitle>ENDOMETRIAL CANCER CLINICAL PRACTICE GUIDELINE GYNE-002</gtr:guidelineTitle><gtr:id>87CF7308-FA2E-406B-9C4D-B57E3A748059</gtr:id><gtr:impact>&amp;quot;..a meta-analysis by Humber, et al.in 2007 concluded that combination chemotherapy was superior to single agent chemotherapy, with the addition of anthracyclines and taxanes to cisplatin giving the best response.&amp;quot;, based on our systematic review and meta-analysis of summary data (PMID: 17150999)</gtr:impact><gtr:outcomeId>544f99f1aec198.96568465</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Cervix CTRT IPD (PMID:19001332) AHS guideline 2012</gtr:description><gtr:geographicReach>North America</gtr:geographicReach><gtr:guidelineTitle>Cancer of the Uterine Cervix</gtr:guidelineTitle><gtr:id>392CBEAC-CEFB-4BDE-AF62-91AAF0A40368</gtr:id><gtr:impact>&amp;quot;A meta-analysis of 13 trials showed that chemoradiotherapy (versus radiotherapy alone) increased the disease free survival rate at five years by eight percent.&amp;quot;; &amp;quot;Cisplatin should be administered at a dose of 40 mg/m2 (max = 80) intravenously over one hour weekly for 5 - 6 cycles during EBRT&amp;quot;, based on our systematic review and meta-analysis of summary data (PMID: 19001332)</gtr:impact><gtr:outcomeId>MGo6XF95DN8</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type><gtr:url>http://europepmc.org/abstract/MED/19001332</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Lung PORT IPD (PMID: 9690404; 15603857) ACR guideline PostOpAdj 2010</gtr:description><gtr:geographicReach>North America</gtr:geographicReach><gtr:guidelineTitle>ACR Appropriateness Criteria NONSURGICAL TREATMENT FOR NON-SMALL-CELL LUNG CANCER: POSTOPERATIVE ADJUVANT THERAPY IN NON-SMALL CELL LUNG CANCER</gtr:guidelineTitle><gtr:id>B5610842-C6FD-42FE-BE45-F5CC1C749B1D</gtr:id><gtr:impact>Our systematic review and meta-analysis of IPD was cited as evidence in this guideline (PMID: 9690404; PMID: 15603857)</gtr:impact><gtr:outcomeId>TiaLnxNHmtb</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type><gtr:url>http://europepmc.org/abstract/MED/9690404</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Lung PORT IPD (PMID:9690404) NCCN guideline 2011</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:guidelineTitle>NCCN Practice Guidelines in Oncology v.3.2011. Non-Small Cell Lung Cancer</gtr:guidelineTitle><gtr:id>ED997382-808E-4CC8-8510-E2E4F1A85114</gtr:id><gtr:impact>Our systematic review and meta-analysis of IPD was cited as evidence in this guideline (PMID: 9690404)</gtr:impact><gtr:outcomeId>Us3s8b7jAZE</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type><gtr:url>http://europepmc.org/abstract/MED/9690404</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Oesophagus RT IPD (PMID:10796823) GASTSG guideline 2011</gtr:description><gtr:geographicReach>Europe</gtr:geographicReach><gtr:guidelineTitle>Diagnostic evaluation, surgical technique, and perioperative management after esophagectomy</gtr:guidelineTitle><gtr:id>CE3FABDB-696F-4CB2-AEB4-6BB830915BF3</gtr:id><gtr:impact>Our systematic review and meta-analysis of IPD was cited as evidence in this guideline (PMID: 10796823)</gtr:impact><gtr:outcomeId>LUQKnam56Te</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type><gtr:url>http://europepmc.org/abstract/MED/10796823</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Endometrial CT SR (PMID:17150999) ESMO guideline 2011</gtr:description><gtr:geographicReach>Europe</gtr:geographicReach><gtr:guidelineTitle>Endometrial cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up</gtr:guidelineTitle><gtr:id>B59AE7DD-99B2-4329-BE54-400F6C6888DB</gtr:id><gtr:impact>Our systematic review and meta-analysis of summary data was cited as evidence in this guideline (PMID: 17150999)</gtr:impact><gtr:outcomeId>GxmMLT1dRaF</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type><gtr:url>http://europepmc.org/abstract/MED/17150999</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Cervix CTRT IPD (PMID:19001332) ESMO guideline 2012</gtr:description><gtr:geographicReach>Europe</gtr:geographicReach><gtr:guidelineTitle>Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up</gtr:guidelineTitle><gtr:id>A8C07C48-0687-4E32-B456-34B0EE6DEAC3</gtr:id><gtr:impact>Our systematic review and meta-analysis of IPD was cited as evidence in this guideline (PMID: 19001332)</gtr:impact><gtr:outcomeId>FnTe38EMvrb</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type><gtr:url>http://europepmc.org/abstract/MED/19001332</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Sarcoma CT SR (PMID:7640234) NCCN guideline SoftTissueSarcoma 2013</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:guidelineTitle>NCCN Clinical Practice Guidelines in Oncology v.1.2013 Soft Tissue Sarcoma</gtr:guidelineTitle><gtr:id>C08BE915-0EAB-476D-A682-B0B50235DA9E</gtr:id><gtr:impact>Our systematic review and meta-analysis of summary data was cited as key evidence in this guideline (PMID: 7640234)</gtr:impact><gtr:outcomeId>544fc5e4d06b18.60431794</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Bladder Neo CT IPD (PMID:15939524) NCCN guideline 2012</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:guidelineTitle>NCCN Clinical Practice Guidelines in Oncology - v.2.2012 Bladder Cancer</gtr:guidelineTitle><gtr:id>F302E1FB-E4B8-470B-B2A4-54F3AB089510</gtr:id><gtr:impact>Our systematic review and meta-analysis of IPD was cited as key evidence in this guideline (PMID: 15939524)</gtr:impact><gtr:outcomeId>ZJCBcUVjYdk</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type><gtr:url>http://europepmc.org/abstract/MED/15939524</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Sarcoma CT IPD (PMID:9400508; 10796873) BSG guideline 2010</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:guidelineTitle>Guidelines for the Management of Soft Tissue Sarcomas</gtr:guidelineTitle><gtr:id>CC42DE37-B2A0-40AB-ACDD-5B2624A9DD6A</gtr:id><gtr:impact>Our systematic review and meta-analysis of IPD was cited as evidence in this guideline (PMID: 9400508, PMID: 10796873)</gtr:impact><gtr:outcomeId>nqnsaL2C6WB</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type><gtr:url>http://europepmc.org/abstract/MED/9400508</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Endometrial CT SR (PMID:16034916) ESMO guideline 2010</gtr:description><gtr:geographicReach>Europe</gtr:geographicReach><gtr:guidelineTitle>Endometrial cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up</gtr:guidelineTitle><gtr:id>67AC3400-EC39-40F1-8E74-2AA9A527E316</gtr:id><gtr:impact>&amp;quot;Reasonable to consider adjuvant chemotherapy for high-grade (grade 3) tumours&amp;quot;, based on our systematic review and meta-analysis of summary data (PMID: 16034916)</gtr:impact><gtr:outcomeId>dy1E8aDHtqJ</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type><gtr:url>http://europepmc.org/abstract/MED/16034916</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Cervix CTRT IPD (PMID:19001332) BHKC guideline 2011</gtr:description><gtr:geographicReach>Europe</gtr:geographicReach><gtr:guidelineTitle>A national clinical practice guideline for the management of cervical cancer</gtr:guidelineTitle><gtr:id>BB9A2ADE-9D1F-4D87-8636-F35AACAEE2EC</gtr:id><gtr:impact>Our systematic review and meta-analysis of IPD was cited as evidence in this guideline (PMID: 19001332)</gtr:impact><gtr:outcomeId>grymjxLvP3z</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type><gtr:url>http://europepmc.org/abstract/MED/19001332</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Regular Cochrane workshops and handbook chapter on meta-analyses of individual patient data</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>0D9309D6-606A-405F-8C4C-A92069C86371</gtr:id><gtr:outcomeId>K3w5PewJc4i</gtr:outcomeId><gtr:type>Influenced training of practitioners or researchers</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Bladder Adj CT IPD (PMID:15939530) NCCN guideline 2012</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:guidelineTitle>NCCN Clinical Practice Guidelines in Oncology - v.2.2012 Bladder Cancer</gtr:guidelineTitle><gtr:id>DA5C9A47-D6A0-45AE-AA2F-6F63BC591E0A</gtr:id><gtr:impact>Our systematic review and meta-analysis of IPD was cited as key evidence in this guideline (PMID:15939530)</gtr:impact><gtr:outcomeId>XKKNJG4r2p8</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type><gtr:url>http://europepmc.org/abstract/MED/15939530</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Lung SeqCon CTRT IPD (PMID:20351327) ESMO guideline 2010</gtr:description><gtr:geographicReach>Europe</gtr:geographicReach><gtr:guidelineTitle>Early stage and locally advanced (non-metastatic) non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up</gtr:guidelineTitle><gtr:id>821894B5-AED6-4920-8A33-9B363C78E1F8</gtr:id><gtr:impact>&amp;quot;Concomitant chemotherapy at systemic doses results in superior outcome to sequential chemoradiotherapy&amp;quot;, based on our systematic review and meta-analysis of IPD (PMID: 20351327)</gtr:impact><gtr:outcomeId>ThL48MUYywG</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type><gtr:url>http://europepmc.org/abstract/MED/20351327</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Bladder Adj CT IPD (PMID:15939530; 16625650) ESMO guideline 2010</gtr:description><gtr:geographicReach>Europe</gtr:geographicReach><gtr:guidelineTitle>Bladder cancer: ESMO Practice Guidelines for diagnosis, treatment and follow-up</gtr:guidelineTitle><gtr:id>D4F476EA-6FE6-40E9-94E9-E0F0ED144EA2</gtr:id><gtr:impact>&amp;quot;Available trials provide insufficient evidence for the routine use of adjuvant chemotherapy in clinical practice [I, A].&amp;quot;, based on our systematic review and meta-analysis of IPD (PMID:15939530; PMID:16625650)</gtr:impact><gtr:outcomeId>cuC6NSws1Nf</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type><gtr:url>http://europepmc.org/abstract/MED/16625650</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Endometrial CT SR (PMID:17150999) NCCN guideline UterineNeoplasms 2012</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:guidelineTitle>NCCN Practice Guidelines in Oncology v.2.2012. Uterine Neoplasms</gtr:guidelineTitle><gtr:id>64BF8B90-2335-4C60-A5B9-11268EEC67DF</gtr:id><gtr:impact>Our systematic review and meta-analysis of summary data was cited as evidence in this guideline (PMID: 17150999)</gtr:impact><gtr:outcomeId>nbMAn3NK8Za</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type><gtr:url>http://europepmc.org/abstract/MED/17150999</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Sarcoma CT SR (PMID:7640234) NCCN guideline SoftTissueSarcoma 2011</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:guidelineTitle>NCCN Clinical Practice Guidelines in Oncology v.2.2011 Soft Tissue Sarcoma</gtr:guidelineTitle><gtr:id>A6EAB104-6AA6-46A3-8657-546B1DAA2FD8</gtr:id><gtr:impact>&amp;quot;Available evidence suggests that anthracycline-based postoperative chemotherapy would improve DFS in selected patients who are at high risk of recurrence but otherwise are in good performance status.&amp;quot;, based on our systematic review and meta-analysis of summary data (PMID: 7640234)</gtr:impact><gtr:outcomeId>R7bYh1Jw6Kn</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type><gtr:url>http://europepmc.org/abstract/MED/7640234</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Lung PORT IPD (PMID:15846628) CCA guideline stage I after 2012</gtr:description><gtr:geographicReach>Oceania</gtr:geographicReach><gtr:guidelineTitle>Clinical practice guidelines for the treatment of lung cancer. &amp;quot;What is the role of radiotherapy after surgery in the treatment of operable stage I NSCLC?&amp;quot;</gtr:guidelineTitle><gtr:id>638CE621-1E47-4620-833B-DCCE8344259E</gtr:id><gtr:impact>&amp;quot;In patients who have had complete resection of stage I NSCLC, postoperative radiotherapy is not recommended. There is strong evidence, based on an individual patient data meta-analysis and recently updated, that the use of postoperative radiotherapy following complete resection of stage I NSCLC is detrimental, and is associated with worse survival. In 665 patients with stage I disease randomised to PORT or no PORT, there was an increased risk of death with a hazard ratio of 1.42 (95% C.I.: 1.16, 1.75) in patients randomised to PORT&amp;quot;, based on our systematic review and meta-analysis of IPD (PMID: 15846628)</gtr:impact><gtr:outcomeId>nQZCrGqvY3y</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Sarcoma CT IPD (PMID:9400508) NCCN Soft Tissue Sarcoma 2014</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:guidelineTitle>NCCN Clinical Practice Guidelines in Oncology v.2.2014 Soft Tissue Sarcoma</gtr:guidelineTitle><gtr:id>F4CAE6A9-F28A-491E-883A-A384C55D08C6</gtr:id><gtr:impact>&amp;quot;The Sarcoma Meta Analysis Collaboration (SMAC) performed a meta-analysis of 14 randomized trials (1,568 patients) which compared adjuvant chemotherapy to follow-up and in some cases RT after surgery with a variety of sarcomas. The result of the meta-analysis showed that doxorubicin-based chemotherapy prolongs local and distant recurrence and overall RFS in adults with localized, resectable STS of the extremity and was associated with decreased recurrence rates. The OS advantage was not significant, although there was a trend in favor of postoperative chemotherapy&amp;quot;, based on our systematic review and meta-analysis of IPD (PMID: 9400508)</gtr:impact><gtr:outcomeId>544fc6caab1325.46125196</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Lung PORT IPD (PMID: 9690404) BCCA guideline 2008</gtr:description><gtr:geographicReach>North America</gtr:geographicReach><gtr:guidelineTitle>Cancer Management Guidelines. Lung (including Mesothelioma &amp;amp; Thymoma)</gtr:guidelineTitle><gtr:id>9C56DB69-FDE0-4B66-BF73-96DD83CECD87</gtr:id><gtr:impact>&amp;quot;Radical radiotherapy after surgical resection is not routinely recommended&amp;quot;, based on our systematic review and meta-analysis of IPD (PMID: 9690404)</gtr:impact><gtr:outcomeId>59A4B9C8BCE</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type><gtr:url>http://europepmc.org/abstract/MED/9690404</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Bladder Neo CT IPD (PMID: 12801735; 15939524) SOS/SUA guideline 2014</gtr:description><gtr:geographicReach>Asia</gtr:geographicReach><gtr:guidelineTitle>Saudi Oncology Society and Saudi Urology Association combined clinical management guidelines for urothelial urinary bladder cancer</gtr:guidelineTitle><gtr:id>2053A915-2B59-4C21-A612-ED913C7258F3</gtr:id><gtr:impact>&amp;quot;Neo-adjuvant cisplatin based chemotherapy improved overall survival by 5-7% at 5 years and this option should be offered to patients especially with locally advanced disease (T3, T4)(EL-1)&amp;quot;, based on our systematic review and meta-analysis of IPD (PMID:12801735; PMID:15939524)</gtr:impact><gtr:outcomeId>56cdc4c655d980.98846775</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Sarcoma CT IPD (PMID:10796873) NCCN UterineNeoplasms 2012</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:guidelineTitle>NCCN Practice Guidelines in Oncology v.2.2012. Uterine Neoplasms</gtr:guidelineTitle><gtr:id>17A98FE1-F33B-4970-B51E-538809727CA7</gtr:id><gtr:impact>&amp;quot;Doxorubicin is an active single agent for LMS and is less toxic than combination regimens&amp;quot;, based on our systematic review and meta-analysis of IPD (PMID: 10796873)</gtr:impact><gtr:outcomeId>nh78saGeSbE</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type><gtr:url>http://europepmc.org/abstract/MED/10796873</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Lung SeqCon CTRT IPD (PMID:20351327) EORTC guideline 2010</gtr:description><gtr:geographicReach>Europe</gtr:geographicReach><gtr:guidelineTitle>EORTC Recommendations for Planning and Delivery of High-Dose, High-Precision Radiotherapy for Lung Cancer</gtr:guidelineTitle><gtr:id>2A72954E-88A9-40F7-BE7B-F328EB24FDE4</gtr:id><gtr:impact>Our systematic review and meta-analysis of IPD was cited as evidence throughout this guideline (PMID: 20351327)</gtr:impact><gtr:outcomeId>Jzj3HKhwWCc</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type><gtr:url>http://europepmc.org/abstract/MED/20351327</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Lung CT 95 IPD (PMID:7580546) BCCA guideline 6.1.14 2008</gtr:description><gtr:geographicReach>North America</gtr:geographicReach><gtr:guidelineTitle>Cancer Management Guidelines. Lung (including Mesothelioma &amp;amp; Thymoma): Palliative Chemotherapy of Advanced NSCLC (6.1.14)</gtr:guidelineTitle><gtr:id>EF89E69B-F473-4EDD-913E-E74B94071B96</gtr:id><gtr:impact>&amp;quot;There is evidence from meta-analyses of a small survival benefit of chemotherapy over best supportive care in performance status 0-2 NSCLC patients&amp;quot;, based on our systematic review and meta-analysis of IPD (PMID: 7580546)</gtr:impact><gtr:outcomeId>hqfxxcTcwjz</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type><gtr:url>http://europepmc.org/abstract/MED/7580546</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Bladder Neo CT IPD (PMID:15846746) ESMO guideline 2009</gtr:description><gtr:geographicReach>Europe</gtr:geographicReach><gtr:guidelineTitle>Invasive bladder cancer: ESMO Clinical Recommendations for diagnosis, treatment and follow-up</gtr:guidelineTitle><gtr:id>A103B5B1-8903-4DC8-95A3-9A5A5E23EFA4</gtr:id><gtr:impact>&amp;quot;Two large randomized trials and a meta-analysis support the use of neo-adjuvant chemotherapy before cystectomy for T2 and T3 disease&amp;quot;, based on our systematic review and meta-analysis of IPD (PMID: 15846746)</gtr:impact><gtr:outcomeId>JjmszCCaXV6</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type><gtr:url>http://europepmc.org/abstract/MED/15846746</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Lung SeqCon CTRT IPD (PMID:20351327) SEOM guideline 2010</gtr:description><gtr:geographicReach>Europe</gtr:geographicReach><gtr:guidelineTitle>SEOM Clinical Guidelines for the Treatment of Non-small-cell Lung Cancer: An Updated Edition</gtr:guidelineTitle><gtr:id>35565371-041C-48BF-A577-5AB26B9864C2</gtr:id><gtr:impact>&amp;quot;Concomitant chemoradiotherapy was shown to be superior to the induction chemotherapy approach&amp;quot;, based on our systematic review and meta-analysis of IPD (PMID: 20351327)</gtr:impact><gtr:outcomeId>LDP8bg1rVFA</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type><gtr:url>http://www.ingentaconnect.com/content/klu/12094/2010/00000012/00000011/00000588?crawler=true</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Bladder Adj CT IPD (PMID:15939530) AURO guideline 2010</gtr:description><gtr:geographicReach>Europe</gtr:geographicReach><gtr:guidelineTitle>New Italian guidelines on bladder cancer, based on the World Health Organization 2004 classification</gtr:guidelineTitle><gtr:id>DA5E9361-A99C-4CBE-A480-D287DB5147F7</gtr:id><gtr:impact>&amp;quot;Adjuvant chemotherapy is
feasible but a related survival benefit has not yet been ultimately confirmed by moderate and high-quality studies&amp;quot;, based on our systematic review and meta-analysis of IPD (PMID:15939530)</gtr:impact><gtr:outcomeId>kZQUGb7LVJ7</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type><gtr:url>http://europepmc.org/abstract/MED/15939530</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Oesophagus RT IPD (PMID:9635705) NCCN guideline 2012</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:guidelineTitle>NCCN Guidelines Version 2.2012 Esophageal and Esophagogastric Junction Cancers</gtr:guidelineTitle><gtr:id>0B426C72-B382-4A31-A490-A70BD84876EF</gtr:id><gtr:impact>&amp;quot;A meta-analysis from the Oesophageal Cancer Collaborative Group also showed no clear evidence of a survival advantage with preoperative radiation&amp;quot;, based on our systematic review and meta-analysis of IPD. (PMID: 9635705)</gtr:impact><gtr:outcomeId>dnJHKDDEQGA</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type><gtr:url>http://europepmc.org/abstract/MED/9635705</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Lung CT 95 IPD (PMID:7580546) ACR guideline NonSurgPoorPS 2008</gtr:description><gtr:geographicReach>North America</gtr:geographicReach><gtr:guidelineTitle>ACR Appropriateness Criteria NONSURGICAL TREATMENT FOR NON-SMALL-CELL LUNG CANCER: POOR PERFORMANCE STATUS/PALLIATIVE INTENT</gtr:guidelineTitle><gtr:id>049778DC-5497-4ADD-9333-5E5EF4547FB2</gtr:id><gtr:impact>Our systematic review and meta-analysis of IPD was cited as evidence in this guideline (PMID: 7580546)</gtr:impact><gtr:outcomeId>dCFf8krbCPQ</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type><gtr:url>http://europepmc.org/abstract/MED/7580546</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Sarcoma CT IPD (PMID:9400508) NCCN guideline SoftTisseSarcoma 2012</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:guidelineTitle>NCCN Clinical Practice Guidelines in Oncology v.2.2012 Soft Tissue Sarcoma</gtr:guidelineTitle><gtr:id>E2186789-65C1-42A2-8FD4-1279BE0B7E59</gtr:id><gtr:impact>&amp;quot;The result of the meta-analysis showed that doxorubicin-based chemotherapy prolongs local and distant recurrence and overall RFS in adults with localised, resectable STS of the extremity and was associated with decreased recurrence rates&amp;quot;, based on our systematic review and meta-analysis of IPD (PMID: 9400508)</gtr:impact><gtr:outcomeId>Jxo6FscQ9aQ</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type><gtr:url>http://europepmc.org/abstract/MED/9400508</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Lung SeqCon CTRT IPD (PMID:20351327) CCA guideline stage II inoperable 2012</gtr:description><gtr:geographicReach>Oceania</gtr:geographicReach><gtr:guidelineTitle>Clinical practice guidelines for the treatment of lung cancer. &amp;quot;What is the role of chemotherapy when added to radiotherapy in the treatment of inoperable stage II NSCLC?&amp;quot;</gtr:guidelineTitle><gtr:id>1C74D1BC-B8FC-49B1-A2AF-5138F51D4FAC</gtr:id><gtr:impact>Our systematic review and meta-analysis of IPD was cited as evidence in this guideline (PMID: 20351327)</gtr:impact><gtr:outcomeId>pt7YoZLpa9q</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Cervix CTRT IPD (PMID: 19001332, PMID: 20091664) GGPO guideline 2014</gtr:description><gtr:geographicReach>Europe</gtr:geographicReach><gtr:guidelineTitle>S3-Leitlinie Diagnostik, Therapie und Nachsorge der Patientin mit Zervixkarzinom v1.0 2014</gtr:guidelineTitle><gtr:id>30B2BF66-969B-4186-9DAF-431AA4C88B50</gtr:id><gtr:impact>Our systematic review and meta-analysis of IPD was cited as evidence in this guideline (PMID: 19001332, PMID: 20091664)</gtr:impact><gtr:outcomeId>56cdca63481104.44750742</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Cervix CTRT IPD (PMID:19001332) NCCN guideline 2014</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:guidelineTitle>NCCN Practice Guidelines in Oncology - v.1.2014 Cervical Cancer</gtr:guidelineTitle><gtr:id>AE3578A5-BEAB-41CE-A3F8-5B852610FD13</gtr:id><gtr:impact>Our systematic review and meta-analysis of IPD was cited as evidence in this guideline (PMID: 19001332)</gtr:impact><gtr:outcomeId>544f980db204d6.88958978</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Colorectal Anti-EGFR SR (PMID:22118887) NCCN guideline 2013</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:guidelineTitle>NCCN Practice Guidelines in Oncology v.2.2013. Colon Cancer</gtr:guidelineTitle><gtr:id>11192B05-2C21-458F-BD3D-961191FE2452</gtr:id><gtr:impact>&amp;quot;A recent meta-analysis concluded there was a clear benefit to the use of EGFR inhibitors in patients with KRAS-wild-type metastatic colorectal cancer&amp;quot;, based on our systematic review and meta-analysis of summary data (PMID: 22118887)</gtr:impact><gtr:outcomeId>tGeLrPhAWhf</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Lung SC IPD (PMID: 18678835) AIOT guideline Stage IIIb-IV 2012</gtr:description><gtr:geographicReach>Europe</gtr:geographicReach><gtr:guidelineTitle>Linee guida per la gestione integrata del paziente con tumore polmonare: NSCLC - Stadio IIIb-IV</gtr:guidelineTitle><gtr:id>153BE72B-4EEA-4281-85A5-4B6674176861</gtr:id><gtr:impact>&amp;quot;Nei pazienti affetti da NSCLC avanzato e PS 2 secondo la classificazione ECOG (sintomatici e costretti a letto ma per meno del 50% della giornata), la chemioterapia produce un beneficio rispetto alla sola terapia di supporto in termini di sopravvivenza globale e qualit&amp;agrave; di vita. Tali pazienti sono pertanto candidati a ricevere un trattamento chemioterapico di I linea.&amp;quot;, based on our systematic review and meta-analysis of IPD (PMID: 18678835)</gtr:impact><gtr:outcomeId>56cdac0a8a0aa8.49453514</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>VenousUlcers IPD (PMID:19376798) SIGN guideline 2010</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:guidelineTitle>SIGN120. Management of chronic venous leg ulcers</gtr:guidelineTitle><gtr:id>C2BC4B2E-BC10-4AE3-B13B-90E6D0E11E2B</gtr:id><gtr:impact>&amp;quot;A meta-analysis of RCTs with pooling of individual patient data from five trials comparing 4LB with short stretch bandage found that the 4LB was associated with a significantly shorter time to healing&amp;quot;, based on our systematic review and meta-analysis of IPD (PMID: 19376798)</gtr:impact><gtr:outcomeId>MbGWMqK2GEz</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type><gtr:url>http://www.sign.ac.uk/guidelines/fulltext/120/recommendations.html</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Lung SeqCon CTRT IPD (PMID:20351327) NCCN guideline 2012</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:guidelineTitle>NCCN Practice Guidelines in Oncology v.2.2012. Non-Small Cell Lung Cancer</gtr:guidelineTitle><gtr:id>0CEA5757-8C33-4D43-85CE-12E37D30C7EC</gtr:id><gtr:impact>&amp;quot;Concurrent chemoradiation appears superior to sequential therapy&amp;quot;; &amp;quot;When distant metastases are not present, the panel recommends that the patient be treated with definitive concurrent chemoradiation therapy&amp;quot;, based on our systematic review and meta-analysis of IPD (PMID: 20351327)</gtr:impact><gtr:outcomeId>UMxxXU8k8t7</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type><gtr:url>http://europepmc.org/abstract/MED/20351327</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Lung CT 95 IPD (PMID:7580546) AHS guideline 2011</gtr:description><gtr:geographicReach>North America</gtr:geographicReach><gtr:guidelineTitle>Non-Small Cell Lung Cancer Stage IV</gtr:guidelineTitle><gtr:id>C9BC6DAE-17D8-4FA3-A8B6-319CE5DC1D42</gtr:id><gtr:impact>Our systematic review and meta-analysis of IPD was cited as evidence in this guideline (PMID: 7580546)</gtr:impact><gtr:outcomeId>Biu69519Bvw</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type><gtr:url>http://europepmc.org/abstract/MED/7580546</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Lung CT 95 IPD (PMID:7580546) CCO guideline 7-10 2010</gtr:description><gtr:geographicReach>North America</gtr:geographicReach><gtr:guidelineTitle>First-line Systemic Chemotherapy in the Treatment of Advanced Non-Small Cell Lung Cancer . Evidence-Based Series #7-10 Version 2.2010</gtr:guidelineTitle><gtr:id>E0D4430D-DBDA-4981-9CC7-292C1C0A019A</gtr:id><gtr:impact>Our systematic review and meta-analysis of IPD was cited as evidence in this guideline (PMID: 7580546)</gtr:impact><gtr:outcomeId>m1gHCYQ7VYW</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type><gtr:url>http://europepmc.org/abstract/MED/7580546</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Lung Adj CT IPD (PMID:20338628) SIGN 137 guideline 2014</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:guidelineTitle>SIGN 137: Management of Lung cancer</gtr:guidelineTitle><gtr:id>3DBBD97F-1A8D-456C-A5B7-5B56415A21DF</gtr:id><gtr:impact>&amp;quot;Postoperative SACT in patients with completely resected stage II to IIIa NSCLC confers an overall survival
advantage of around 4% at five years (HR 0.86, 95% CI 0.8 to 0.92).&amp;quot; 

&amp;quot;Patients with good performance status (PS 0-1) who have completely resected NSCLC (stage II to
IIIa) should be offered platinum based postoperative systemic anticancer therapy&amp;quot;, based on our systematic review and meta-analysis of IPD (PMID: 20338628)</gtr:impact><gtr:outcomeId>544fb0b56d54f5.07164677</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Lung PORT IPD (PMID:9690404) ACR guideline N2 2013</gtr:description><gtr:geographicReach>North America</gtr:geographicReach><gtr:guidelineTitle>American College of Radiology ACR Appropriateness Criteria&amp;reg; INDUCTION AND ADJUVANT THERAPY FOR N2 NON-SMALL-CELL LUNG CANCER</gtr:guidelineTitle><gtr:id>C5F20A8F-9C39-404C-9629-C0185C2D4950</gtr:id><gtr:impact>Our systematic review and meta-analysis of IPD was cited as evidence in this guideline (PMID: 9690404)</gtr:impact><gtr:outcomeId>544fbf51189672.30003991</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Oesophagus RT IPD (PMID:10796823) ESMO guideline 2010</gtr:description><gtr:geographicReach>Europe</gtr:geographicReach><gtr:guidelineTitle>Esophageal cancer: Clinical Practice Guidelines for diagnosis, treatment and follow-up</gtr:guidelineTitle><gtr:id>C64B88D9-09A1-4E01-A0DF-0AC6AF37FB02</gtr:id><gtr:impact>&amp;quot;Preoperative (with and without postoperative) radiation does not add any survival benefit to surgery alone. This treatment is not recommended [I, A].&amp;quot;, based on our systematic review and meta-analysis of IPD (PMID: 10796823)</gtr:impact><gtr:outcomeId>MNnXbDXnX2a</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type><gtr:url>http://europepmc.org/abstract/MED/10796823</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Cervix Neo CT IPD (PMID:14602133) ACR guideline advanced 2010</gtr:description><gtr:geographicReach>North America</gtr:geographicReach><gtr:guidelineTitle>ACR Appropriateness Criteria ADVANCED CERVICAL CANCER</gtr:guidelineTitle><gtr:id>BDE23411-62D2-4910-8851-1A11F00787CC</gtr:id><gtr:impact>Our systematic review and meta-analysis of summary data was cited as evidence in this guideline (PMID: 14602133)</gtr:impact><gtr:outcomeId>DigwMtbLQba</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type><gtr:url>http://europepmc.org/abstract/MED/14602133</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Lung PORT IPD (PMID:9690404; 15603857) BTS/SCTS guideline 2010</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:guidelineTitle>Radical Management of Patients with Lung Cancer</gtr:guidelineTitle><gtr:id>716102AB-A0EC-4851-B792-7DF374CA045E</gtr:id><gtr:impact>Recommendation that postoperative radiotherapy (PORT) is not indicated after R0 complete resection and a research recommendation to conduct randomised trials looking at the effect of PORT in pN2 non-small cell lung cancer are both based on our systematic review and meta-analysis of IPD (PMID: 9690404; PMID: 15603857)</gtr:impact><gtr:outcomeId>EQ7YbK6FPKF</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type><gtr:url>http://europepmc.org/abstract/MED/9690404</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Lung PORT IPD (PMID:9690404; 15603857) ACCP guideline stage I&amp;amp;II 2013</gtr:description><gtr:geographicReach>North America</gtr:geographicReach><gtr:guidelineTitle>Treatment of Stage I &amp;amp; II Non-small Cell Lung Cancer. Diagnosis and Management of Lung Cancer, 3rd ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines</gtr:guidelineTitle><gtr:id>4AF1A0B2-2AB2-4399-8442-D2569B364C7B</gtr:id><gtr:impact>There are multiple randomized trials of PORT, all of which were collectively analyzed in a landmark study by the PORT Meta-analysis Trialists Group published almost 15 years ago. Because of confounders, it is impractical to use each individual randomized trial for guideline development, but rather, the aggregate data presented in the meta-analysis provide a more comprehensive view. For patients with completely resected pathologic stage I NSCLC, it is recommended that postoperative radiation therapy should not be used (Grade 1A)&amp;quot;, based on our systematic review and meta-analysis of IPD (PMID: 9690404; PMID: 15603857)</gtr:impact><gtr:outcomeId>AFGQVFZnbxQ</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Bladder Adj CT IPD (PMID:15939530; 16625650) ESMO guideline 2011</gtr:description><gtr:geographicReach>Europe</gtr:geographicReach><gtr:guidelineTitle>Bladder cancer: ESMO Practice Guidelines for diagnosis, treatment and follow-up</gtr:guidelineTitle><gtr:id>BEA92359-809B-4620-9078-5C7C724A37FA</gtr:id><gtr:impact>&amp;quot;Available trials provide insufficient evidence for the routine use of adjuvant chemotherapy in clinical practice [I, A].&amp;quot;, based on our systematic review and meta-analysis of IPD (PMID:15939530; PMID:16625650)</gtr:impact><gtr:outcomeId>L5UDj5yR4ug</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type><gtr:url>http://europepmc.org/abstract/MED/16625650</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Lung CT 95 IPD (PMID:7580546) GRS/GCS guideline 2010</gtr:description><gtr:geographicReach>Europe</gtr:geographicReach><gtr:guidelineTitle>Prevention, Diagnosis, Therapy and Follow-up of Lung Cancer</gtr:guidelineTitle><gtr:id>1DD65115-377B-4EDC-B7D7-3F0891F41EB1</gtr:id><gtr:impact>Our systematic review and meta-analysis of IPD was cited as Grade 1A evidence in this guideline (PMID: 7580546)</gtr:impact><gtr:outcomeId>JsB5qixejBy</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type><gtr:url>http://europepmc.org/abstract/MED/7580546</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Bladder Adj CT IPD (PMID:15939530) NCCN guideline 2014</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:guidelineTitle>NCCN Clinical Practice Guidelines in Oncology - v.1.2013 Bladder Cancer</gtr:guidelineTitle><gtr:id>3E055C75-3DE4-4ACC-8406-C96913B39084</gtr:id><gtr:impact>&amp;quot;Meta-analysis suggests a survival benefit to adjuvant therapy for pathologic T3, T4 or N+ disease at cystectomy&amp;quot;, based on our systematic review and meta-analysis of IPD (PMID: 15939530)</gtr:impact><gtr:outcomeId>544f8b67320084.46688514</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Lung Neo CT SR (PMID:17409927) CCA guideline stage II before 2012</gtr:description><gtr:geographicReach>Oceania</gtr:geographicReach><gtr:guidelineTitle>Clinical practice guidelines for the treatment of lung cancer. &amp;quot;What is the role of chemotherapy before surgery in the treatment of operable stage II NSCLC?&amp;quot;</gtr:guidelineTitle><gtr:id>17083BE3-50F6-4A90-9A8B-994CE2FDD416</gtr:id><gtr:impact>Our systematic review and meta-analysis of summary data was cited as evidence in this guideline (PMID: 17409927)

JTO 2006</gtr:impact><gtr:outcomeId>NAZWjGZ3X9u</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Bladder Neo CT IPD (PMID:15939524) NCCN guideline 2011</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:guidelineTitle>NCCN Clinical Practice Guidelines in Oncology - v.2.2011 Bladder Cancer</gtr:guidelineTitle><gtr:id>ACCF8646-757E-4374-8085-248D886527A9</gtr:id><gtr:impact>&amp;quot;In the most recent meta-analysis, a statistically significant decrease in the death rate was seen corresponding to an improvement in overall survival.46 The NCCN Bladder Cancer panel members recommend considering cisplatin-based neoadjuvant combination chemotherapy (Category 1 recommendation for T3 lesions and category 2A for T2 lesions).&amp;quot;, based on our systematic review and meta-analysis of IPD (PMID: 15939524)</gtr:impact><gtr:outcomeId>LWGU5r938Bn</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type><gtr:url>http://europepmc.org/abstract/MED/15939524</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Lung Neo CT SR (PMID: 17409927) ERS/ESTS guideline 2009</gtr:description><gtr:geographicReach>Europe</gtr:geographicReach><gtr:guidelineTitle>ERS/ESTS Clinical Guidelines on Fitness for Radical Therapy in Lung Cancer Patients (surgery and chemo-radiotherapy)</gtr:guidelineTitle><gtr:id>AB1F8518-D579-44BA-B606-99DFC5D99DF9</gtr:id><gtr:impact>Our systematic review and meta-analysis was cited as evidence in this guideline (PMID: 17409927)</gtr:impact><gtr:outcomeId>c7nsRisNQgz</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type><gtr:url>http://europepmc.org/abstract/MED/17409927</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Bladder Adj CT IPD (PMID:15939530) EAU guideline 2012</gtr:description><gtr:geographicReach>Europe</gtr:geographicReach><gtr:guidelineTitle>Guidelines on Bladder Cancer: Muscle-Invasive and Metastatic</gtr:guidelineTitle><gtr:id>5D6EC340-C63C-427E-9DD2-254726FB7341</gtr:id><gtr:impact>Our systematic review and meta-analysis of IPD was cited as key evidence in this guideline (PMID:15939530)</gtr:impact><gtr:outcomeId>K76nNYEM8wX</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type><gtr:url>http://europepmc.org/abstract/MED/15939530</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Lung SC IPD (PMID: 18678835) BHKC guideline 2013</gtr:description><gtr:geographicReach>Europe</gtr:geographicReach><gtr:guidelineTitle>SMALL CELL AND NON-SMALL CELL LUNG CANCER: DIAGNOSIS, TREATMENT AND FOLLOW-UP</gtr:guidelineTitle><gtr:id>E6736C8F-D169-4FBC-A687-AFAF7E616251</gtr:id><gtr:impact>The use of chemotherapy in patients with stage IV NSCLC with WHO/ECOG/Zubrod performance status (PS) of 0 or 1 and (based on clinical judgement) in some cases PS 2 is recommended. This is based on a recent metaanalysis that compared the efficacy of chemotherapy with BSC and showed a benefit to chemotherapy in reduction of risk of death and an increase in 1-year survival. The meta-analysis included 16 trials with a total of 2,714 patients; 12 trials used platinum-based regimens, and 13 reported the PS. The meta-analysis found that patients with a PS of 2 also received a benefit, although it was less than the benefit seen in patients with a PS of 0 to 1. Dutch guideline7 recommends to start chemotherapy as soon as possible based on a individual based meta-analysis of 2008 on 2714 patients showing a significant benefit of chemotherapy (HR, 0.77; 95% CI, 0.71 to 0.83; P =&amp;lt; 0.0001), equivalent to a relative increase in survival of 23% or an absolute improvement in survival of 9% at 12 months, increasing survival from 20% to 29%.&amp;quot;, based on our systematic review and meta-analysis of IPD (PMID: 18678835)</gtr:impact><gtr:outcomeId>544fa8f0694898.84584869</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Oesophagus RT IPD (PMID:10796823) SIGN guideline 2006</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:guidelineTitle>SIGN87 Management of oesophageal and gastric cancer. A national clinical guideline</gtr:guidelineTitle><gtr:id>D357C624-6D55-461C-9A27-A041F4C5E7AE</gtr:id><gtr:impact>&amp;quot;Pre-operative radiotherapy is not recommended for patients with oesophageal cancer&amp;quot;, based on our systematic review and meta-analysis of IPD (PMID: 10796823)</gtr:impact><gtr:outcomeId>6B2350BD351</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type><gtr:url>http://www.sign.ac.uk/pdf/sign87.pdf</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Endometrial CT SR (PMID:17150999; 22895938) CCO guideline 2014</gtr:description><gtr:geographicReach>North America</gtr:geographicReach><gtr:guidelineTitle>Systemic Therapy for Advanced or Recurrent Endometrial Cancer, and Advanced or Recurrent Uterine Papillary Serous Carcinoma</gtr:guidelineTitle><gtr:id>E9B3DDD9-1101-438B-A186-88D09D0E4C63</gtr:id><gtr:impact>Our systematic review and meta-analysis of summary data was cited as evidence in this guideline (PMID: 17150999; PMID: 22895938)</gtr:impact><gtr:outcomeId>544f9ad3d93ed1.85196787</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Lung CT 95 IPD (PMID:7580546) CCO guideline 7-1-2 2006</gtr:description><gtr:geographicReach>North America</gtr:geographicReach><gtr:guidelineTitle>Postoperative adjuvant chemotherapy with or without radiotherapy in completely resected non-small cell lung cancer. Practice guideline No 7-1-2</gtr:guidelineTitle><gtr:id>4BDE094E-563E-4840-8FF3-5DEFA20F4D7F</gtr:id><gtr:impact>Our systematic review and meta-analysis of IPD was cited as evidence in this guideline (PMID: 7580546)</gtr:impact><gtr:outcomeId>m8XAjP26NWr</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type><gtr:url>http://europepmc.org/abstract/MED/7580546</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Oesophagus RT IPD (PMID:9635705) NCCN guideline 2011</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:guidelineTitle>NCCN Practice Guidelines in Oncology - v.2.2011 Esophageal Cancer.</gtr:guidelineTitle><gtr:id>CAADE889-8269-49D5-9A81-EB3EEEC1EA06</gtr:id><gtr:impact>Our systematic review and meta-analysis of IPD was cited as key evidence in this guideline (PMID: 9635705)</gtr:impact><gtr:outcomeId>aCtHpjKEipd</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type><gtr:url>http://europepmc.org/abstract/MED/9635705</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Lung CT 95 IPD (PMID: 7580546) AOSCG guideline 2009</gtr:description><gtr:geographicReach>Asia</gtr:geographicReach><gtr:guidelineTitle>First-line systemic treatment of advanced stage non-small-cell lung cancer in Asia: consensus statement from the Asian Oncology Summit 2009</gtr:guidelineTitle><gtr:id>A1080AA2-4E42-41C5-88B0-028ACE27244A</gtr:id><gtr:impact>Multiple individual randomised studies and several meta-analyses have shown a survival benefit for systemic chemotherapy compared with best supportive care in patients with good performance status. Alkylating-agent based chemotherapy, however, was associated with a detrimental effect on survival. In a recent updated meta-analysis, based on our systematic review and meta-analysis of IPD (PMID: 7580546)</gtr:impact><gtr:outcomeId>ZLnreeET93k</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type><gtr:url>http://europepmc.org/abstract/MED/7580546</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Glioma CT IPD (PMID:11937180) ESMO guideline 2010</gtr:description><gtr:geographicReach>Europe</gtr:geographicReach><gtr:guidelineTitle>High-grade malignant glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up</gtr:guidelineTitle><gtr:id>22FC76DF-AAC2-405B-9B75-F810A19ED864</gtr:id><gtr:impact>&amp;quot;Based on a large meta-analysis [I, A] nitrosourea-based chemotherapy marginally improves survival&amp;quot;, based on our systematic review and meta-analysis of IPD (PMID:11937180)</gtr:impact><gtr:outcomeId>pgzkzSncKHu</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type><gtr:url>http://europepmc.org/abstract/MED/11937180</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Bladder Adj CT IPD (PMID:15939530) SEOM guideline 2011</gtr:description><gtr:geographicReach>Europe</gtr:geographicReach><gtr:guidelineTitle>SEOM clinical guidelines for the treatment of invasive bladder cancer</gtr:guidelineTitle><gtr:id>43D3FCCD-3E0A-443E-A129-E78DF0368C30</gtr:id><gtr:impact>Our systematic review and meta-analysis of IPD was cited as key evidence in this guideline (PMID:15939530)</gtr:impact><gtr:outcomeId>GiWQY9aFk4f</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type><gtr:url>http://europepmc.org/abstract/MED/21821489</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Lung CT 95 IPD (PMID:7580546) ESMO guideline 2008</gtr:description><gtr:geographicReach>Europe</gtr:geographicReach><gtr:guidelineTitle>Non-small cell lung cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up</gtr:guidelineTitle><gtr:id>E41F9AD8-3C24-401B-9978-C40677FB47D9</gtr:id><gtr:impact>Our systematic review and meta-analysis of IPD is used as evidence throughout this guideline for all stages of non-small cell lung cancer (PMID: 7580546)</gtr:impact><gtr:outcomeId>D93943D636E</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type><gtr:url>http://europepmc.org/abstract/MED/7580546</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Lung Adj CT IPD (PMID:20338628) CCA guideline stage II CT after operable 2014</gtr:description><gtr:geographicReach>Australia</gtr:geographicReach><gtr:guidelineTitle>Clinical practice guidelines for the treatment of lung cancer. What is the role of chemotherapy after surgery in the treatment of operable stage II NSCLC?</gtr:guidelineTitle><gtr:id>F5D0704B-46E9-4D6E-B145-5297BF999453</gtr:id><gtr:impact>Our systematic review and meta-analysis of IPD was cited as evidence in this guideline (PMID: 20338628)</gtr:impact><gtr:outcomeId>544fb12e311e96.74028414</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Lung PORT IPD (PMID:9690404) ACR guideline early 2013</gtr:description><gtr:geographicReach>North America</gtr:geographicReach><gtr:guidelineTitle>American College of Radiology ACR Appropriateness Criteria&amp;reg; EARLY-STAGE NON-SMALL-CELL LUNG CANCER</gtr:guidelineTitle><gtr:id>6633A367-B863-44F0-B431-5B3FF7B919B0</gtr:id><gtr:impact>&amp;quot;There is no established role for adjuvant radiotherapy (RT) after standard surgical resection of early-stage disease. In 1998, the Post Operative Radiation Therapy (PORT) trials group completed a large meta-analysis involving data from 9 randomized trials and reported on pooled outcomes from patients treated with or without adjuvant RT after resection for stage I to III NSCLC. This report revealed a 24% reduction in local recurrence but an absolute increase in mortality of 7% at 2 years when using adjuvant radiation, which on subset analysis was restricted to patients with stage I or II NSCLC.&amp;quot;, based on our systematic review and meta-analysis of IPD (PMID: 9690404)</gtr:impact><gtr:outcomeId>544fbfd082f395.61425645</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Lung Neo CT SR (PMID:17636828) ACCP guideline stage III 2013</gtr:description><gtr:geographicReach>North America</gtr:geographicReach><gtr:guidelineTitle>Treatment of Stage III Non-small Cell Lung Cancer. Diagnosis and Management of Lung Cancer, 3rd ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines</gtr:guidelineTitle><gtr:id>807EFE39-E401-4AAB-BCB3-2C35D77AF14B</gtr:id><gtr:impact>&amp;quot;A 2007 Cochrane meta-analysis (for stages I-III) revealed a benefit of platinum-based neoadjuvant chemotherapy over surgery alone (HR, 0.82; 95% CI, 0.69-0.97; P=.022), corresponding to an absolute benefit t of 6% to 7% in stages IB to IIIA and 3% to 5% in IIIb. When data from a European intergroup trial was added to this meta-analysis, the statistical significance was no longer present (HR, 0.88; 95% CI, 0.76-1.01; P=.07). When this meta-analysis was restricted to only patients with stage III disease, an HR of 0.73 (95% CI, 0.51-1.07; P 5 .1) was found. Taken together, these data demonstrate that surgery as the primary therapy for preoperatively identified (or suspected) N2 involvement is inferior to approaches involving neoadjuvant treatment&amp;quot;, based on our systematic review and meta-analysis of summary data (PMID: 17636828)</gtr:impact><gtr:outcomeId>qmNGhGGcsZY</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Lung Adj CT IPD (PMID:20338628) NCCN guideline 2013</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:guidelineTitle>NCCN Practice Guidelines in Oncology v.2.2013. Non-Small Cell Lung Cancer</gtr:guidelineTitle><gtr:id>C2576DA7-0C0E-4BB7-B92C-D28D85B84761</gtr:id><gtr:impact>&amp;quot;The panel recommends chemotherapy (category I ) for patients with negative surgical margins and stage II disease 1) Tlab-2a, N1; 2) T2b, N1; or 3) T3, NO disease&amp;quot;, based on our systematic review and meta-analysis of IPD (PMID: 20338628)</gtr:impact><gtr:outcomeId>fyHcMEKDAgn</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Lung CT 95 IPD (PMID: 7580546) ERS/ESTS guideline 2009</gtr:description><gtr:geographicReach>Europe</gtr:geographicReach><gtr:guidelineTitle>ERS/ESTS Clinical Guidelines on Fitness for Radical Therapy in Lung Cancer Patients (surgery and chemo-radiotherapy)</gtr:guidelineTitle><gtr:id>A6C065B6-77E2-409E-9569-8400CFD39125</gtr:id><gtr:impact>Our systematic review and meta-analysis of IPD was cited as evidence in this guideline (PMID: 7580546)</gtr:impact><gtr:outcomeId>CTw1D7SUESS</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type><gtr:url>http://europepmc.org/abstract/MED/7580546</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Lung Neo CT SR (PMID:17409927) CCA guideline stage I 2012</gtr:description><gtr:geographicReach>Oceania</gtr:geographicReach><gtr:guidelineTitle>Clinical practice guidelines for the treatment of lung cancer. &amp;quot;What is the role of chemotherapy before surgery in the treatment of operable stage I NSCLC?&amp;quot;</gtr:guidelineTitle><gtr:id>A9482A97-4397-406B-9210-D6A563C19711</gtr:id><gtr:impact>Our systematic review and meta-analysis of summary data was cited as evidence in this guideline (PMID: 17409927)</gtr:impact><gtr:outcomeId>C8XR9rpehrS</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Glioma CT IPD (PMID:11937180) SEOM guideline 2012</gtr:description><gtr:geographicReach>Europe</gtr:geographicReach><gtr:guidelineTitle>SEOM guideline for the treatment of malignant glioma</gtr:guidelineTitle><gtr:id>36FADD41-C9C5-4461-BE75-134DF6F803D5</gtr:id><gtr:impact>&amp;quot;Chemotherapy increases survival and reduces the risk of death in 15% according to a meta-analysis performed in 3000 patients&amp;quot;, based on our systematic review and meta-analysis of IPD (PMID:11937180)</gtr:impact><gtr:outcomeId>544f969c23bdd5.20716902</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Sarcoma CT IPD (PMID:9400508) ESMO guideline 2008</gtr:description><gtr:geographicReach>Europe</gtr:geographicReach><gtr:guidelineTitle>Soft tissue sarcomas: ESMO clinical recommendations for diagnosis, treatment and follow-up</gtr:guidelineTitle><gtr:id>715B5B9A-F349-4EE0-80B2-E2DFCC808758</gtr:id><gtr:impact>&amp;quot;Adjuvant chemotherapy is not standard treatment in adult-type soft tissue sarcomas and can be proposed as an option in the high risk individual patient&amp;quot;, based on our systematic review and meta-analysis of IPD (PMID: 9400508)</gtr:impact><gtr:outcomeId>E952C9F9CB2</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type><gtr:url>http://europepmc.org/abstract/MED/9400508</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Lung Neo CT SR (PMID:17409927) BTS/SCTS guideline 2010</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:guidelineTitle>Radical Management of Patients with Lung Cancer</gtr:guidelineTitle><gtr:id>39B64010-6E15-4855-8BE2-412E18884D24</gtr:id><gtr:impact>Our systematic review and meta-analysis of summary data was cited as evidence in this guideline (PMID: 17409927)</gtr:impact><gtr:outcomeId>at3pnaci8Kd</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type><gtr:url>http://europepmc.org/abstract/MED/17409927</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Bladder Adj CT IPD (PMID:16625650) AHS guideline 2011</gtr:description><gtr:geographicReach>North America</gtr:geographicReach><gtr:guidelineTitle>Clinical Practice Guideline: GU-002 Bladder Cancer</gtr:guidelineTitle><gtr:id>2E7F4ACE-30CD-40DA-A2A4-AAD38D29A9D2</gtr:id><gtr:impact>Our systematic review and meta-analysis of IPD was cited as key evidence in this guideline (PMID:16625650)</gtr:impact><gtr:outcomeId>sSvhdBzVH49</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type><gtr:url>http://europepmc.org/abstract/MED/16625650</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Glioma CT IPD (PMID: 11937180) ESMO guideline 2008</gtr:description><gtr:geographicReach>Europe</gtr:geographicReach><gtr:guidelineTitle>Malignant glioma: ESMO clinical recommendations for diagnosis, treatment and follow-up</gtr:guidelineTitle><gtr:id>37EAFCF3-5F71-4BA1-9488-0F151D83165F</gtr:id><gtr:impact>&amp;quot;Nitrosourea-based chemotherapy may marginally improve survival in selected patients&amp;quot; based on our systematic review and meta-analysis of IPD (PMID: 11937180)</gtr:impact><gtr:outcomeId>43C98C0EDEB</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type><gtr:url>http://europepmc.org/abstract/MED/11937180</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Lung PORT IPD (PMID:15846628) ESMO guideline 2013</gtr:description><gtr:geographicReach>Europe</gtr:geographicReach><gtr:guidelineTitle>Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up</gtr:guidelineTitle><gtr:id>DCFD2261-3912-42EB-A5E2-24742893C607</gtr:id><gtr:impact>&amp;quot;There is no indication that postoperative radiotherapy (PORT) improves outcome in patients with completely resected N0 or N1 disease, with a meta-analysis in fact demonstrating a detrimental effect on survival in these cases&amp;quot;. &amp;quot;PORT in completely resected early-stage NSCLC is therefore not recommended [I, A]&amp;quot;, based on our systematic review and meta-analysis of IPD (PMID: 15846628)</gtr:impact><gtr:outcomeId>BjyzGLj24cQ</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>VenousUlcers IPD (PMID:19376798) AAWC guideline 2014</gtr:description><gtr:geographicReach>North America</gtr:geographicReach><gtr:guidelineTitle>AAWC Venous Ulcer Guidelines</gtr:guidelineTitle><gtr:id>12F42D37-8557-4F45-96C1-057A8C2909C2</gtr:id><gtr:impact>Our systematic review and meta-analysis of IPD was cited as evidence in this guideline (PMID: 19376798)</gtr:impact><gtr:outcomeId>56cdd54f7da752.24529184</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Lung SeqCon CTRT IPD (PMID:20351327) ACR guideline NonSurgGoodPS 2014</gtr:description><gtr:geographicReach>North America</gtr:geographicReach><gtr:guidelineTitle>American College of Radiology ACR Appropriateness Criteria&amp;reg; NONSURGICAL TREATMENT FOR LOCALLY ADVANCED NON-SMALL-CELL LUNG CANCER: GOOD PERFORMANCE STATUS/DEFINITIVE INTENT</gtr:guidelineTitle><gtr:id>0181FB0B-6CED-4F8D-A1D0-08A00B664D1C</gtr:id><gtr:impact>&amp;quot;The NSCLC Collaborative Group discovered a significant survival advantage with concurrent chemoradiation compared with sequential treatment (hazard ratio: 0.84) with an absolute benefit of 5.7% at 3 years.The above data have provided strong support for the use of concurrent, platinum-based chemoradiation as the standard of care for unresectable stage IIIA/B NSCLC patients who have good performance status and minimal weight loss&amp;quot;, based on our systematic review and meta-analysis of IPD (PMID: 20351327)</gtr:impact><gtr:outcomeId>544fb6034e1666.61483247</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Cervix Neo CT SR (PMID:20091632) ACR guideline advanced 2012</gtr:description><gtr:geographicReach>North America</gtr:geographicReach><gtr:guidelineTitle>ACR Appropriateness Criteria ADVANCED CERVICAL CANCER</gtr:guidelineTitle><gtr:id>CE8592D2-5852-47F4-8BE7-3683CFDB7342</gtr:id><gtr:impact>Our systematic review and meta-analysis of summary data was cited as evidence in this guideline (PMID: 20091632)</gtr:impact><gtr:outcomeId>WgwzbJe6GmA</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Lung CT 95 IPD (PMID:7580546) BTS/SCTS joint guideline 2010</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:guidelineTitle>Radical Management of Patients with Lung Cancer</gtr:guidelineTitle><gtr:id>307A1A6B-552E-4BEF-8158-0627DEF57ABB</gtr:id><gtr:impact>Our systematic review and meta-analysis of IPD was cited as evidence in this guideline (PMID: 7580546)</gtr:impact><gtr:outcomeId>UHr1kksFaPU</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type><gtr:url>http://europepmc.org/abstract/MED/7580546</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Endometrial CT SR (PMID:17150999) AHS guideline 2012</gtr:description><gtr:geographicReach>North America</gtr:geographicReach><gtr:guidelineTitle>Clinical Practice GuidelineGYNE-002: Endometrial Cancer</gtr:guidelineTitle><gtr:id>4F03C67F-0B6D-4041-8060-390F330B5EE1</gtr:id><gtr:impact>&amp;quot;Humber, et al. 38 in 2007 concluded that combination chemotherapy was superior to single agent chemotherapy, with the addition of anthracyclines and taxanes to cisplatin giving the best response. Many studies since then have shown the superiority of carboplatin with paclitaxel, both in response and toxicity profile&amp;quot;, based on our systematic review and meta-analysis of summary data (PMID: 17150999)</gtr:impact><gtr:outcomeId>gR453w1dozh</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type><gtr:url>http://europepmc.org/abstract/MED/17150999</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Lung SeqCon CTRT IPD (PMID:20351327) AIOT guideline stage IIIb 2012</gtr:description><gtr:geographicReach>Europe</gtr:geographicReach><gtr:guidelineTitle>Linee guida per la gestione integrata del paziente con tumore polmonare: NSCLC - Stadio IIIb</gtr:guidelineTitle><gtr:id>01845B0E-F52A-4052-8664-841A279F7191</gtr:id><gtr:impact>&amp;quot;Nei pazienti affetti da nsclc allo stadio iiib il trattamento combinato chemio-radioterapico concomitante &amp;egrave; raccomandato quando tecnicamente fattibile e in pazienti selezionati con buone condizioni generali e assenza di comorbidit&amp;agrave;.&amp;quot;, based on our systematic review and meta-analysis of IPD (PMID: 20351327)</gtr:impact><gtr:outcomeId>56cdacd8417a79.35339403</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Lung SeqCon CTRT IPD (PMID:20351327) BHKC guideline 2013</gtr:description><gtr:geographicReach>Europe</gtr:geographicReach><gtr:guidelineTitle>SMALL CELL AND NON-SMALL CELL LUNG CANCER: DIAGNOSIS, TREATMENT AND FOLLOW-UP</gtr:guidelineTitle><gtr:id>54BC7276-563A-4EA6-B841-298CC9200B13</gtr:id><gtr:impact>&amp;quot;Patients receiving concurrent chemoradiotherapy have a better survival than patients receiving sequential chemoradiotherapy but have more oesophagitis.&amp;quot;

&amp;quot;When patients are considered for chemoradiation, it is recommended to offer concurrent chemoradiation in preference to sequential therapy if no contra-indications are present&amp;quot;, based on our systematic review and meta-analysis of IPD (PMID: 20351327)</gtr:impact><gtr:outcomeId>544fb41438f6a0.08482696</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Sarcoma CT IPD (PMID: 9400508) NICE guideline 2006</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:guidelineTitle>Improving outcomes for people with sarcoma</gtr:guidelineTitle><gtr:id>CB1A0149-1D7B-453E-A0BD-5A9D65CAB9A0</gtr:id><gtr:impact>Our systematic review and meta-analysis of IPD was cited as evidence in this guideline (PMID: 9400508)</gtr:impact><gtr:outcomeId>AFE4C841136</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type><gtr:url>http://europepmc.org/abstract/MED/9400508</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Cervix Neo CT SR (PMID:20091632) ACR guideline advanced 2010</gtr:description><gtr:geographicReach>North America</gtr:geographicReach><gtr:guidelineTitle>ACR Appropriateness Criteria ADVANCED CERVICAL CANCER</gtr:guidelineTitle><gtr:id>65380CC9-056D-4DF1-B410-D2A725435AEB</gtr:id><gtr:impact>Our systematic review and meta-analysis of summary data was cited as evidence in this guideline (PMID: 20091632)</gtr:impact><gtr:outcomeId>TMEBnWhwExu</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type><gtr:url>http://europepmc.org/abstract/MED/20091632</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Sarcoma CT IPD (PMID: 9400508) NCCN guideline SoftTissueSarcoma 2010</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:guidelineTitle>NCCN Clinical Practice Guidelines in Oncology v.2.2010 Soft Tissue Sarcoma</gtr:guidelineTitle><gtr:id>FC7308CD-3FF5-4BF7-85A4-39BD2E980809</gtr:id><gtr:impact>Our systematic review and meta-analysis of IPD was cited as evidence in this guideline (PMID: 9400508)</gtr:impact><gtr:outcomeId>kppHELo1LKB</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type><gtr:url>http://europepmc.org/abstract/MED/9400508</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Lung CT 95 IPD (PMID:7580546) ACR guideline NonSurgPoorPS 2012</gtr:description><gtr:geographicReach>North America</gtr:geographicReach><gtr:guidelineTitle>ACR Appropriateness Criteria NONSURGICAL TREATMENT FOR NON-SMALL-CELL LUNG CANCER: POOR PERFORMANCE STATUS/PALLIATIVE INTENT</gtr:guidelineTitle><gtr:id>42959C49-907E-4493-85C9-92682139D534</gtr:id><gtr:impact>The British Collaborative Group showed a 27% reduction in the risk of death and a 10% improvement in survival in 1 year based on our systematic review and meta-analysis of IPD(PMID:7580546)</gtr:impact><gtr:outcomeId>G7tC3CeyX2n</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type><gtr:url>http://europepmc.org/abstract/MED/7580546</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Lung PORT IPD (PMID: 9690404) NCCN guideline 2010</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:guidelineTitle>NCCN Practice Guidelines in Oncology v.2.2010. Non-Small Cell Lung Cancer</gtr:guidelineTitle><gtr:id>639B3B4D-7C89-421C-9978-4AE782B601CE</gtr:id><gtr:impact>Our systematic review and meta-analysis of IPD was cited as evidence in this guideline (PMID: 9690404)</gtr:impact><gtr:outcomeId>UXsMwU3dcB1</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type><gtr:url>http://europepmc.org/abstract/MED/9690404</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Lung PORT IPD (PMID:9690404; 15603857) CCO guideline 7-1-1 2006</gtr:description><gtr:geographicReach>North America</gtr:geographicReach><gtr:guidelineTitle>Postoperative Adjuvant Radiation Therapy in Stage II or IIIA Completely Resected Non-Small Cell Lung Cancer Practice Guideline Report #7-1-1</gtr:guidelineTitle><gtr:id>9EBDE23D-EE77-45BD-8ABE-45E8FAA232D1</gtr:id><gtr:impact>Our systematic review and meta-analysis of IPD was cited as evidence in this guideline (PMID: 9690404; PMID: 15603857)</gtr:impact><gtr:outcomeId>T6Xgv4McNJa</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type><gtr:url>http://europepmc.org/abstract/MED/9690404</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Bladder Neo CT IPD (PMID:12801735; 15939524) EAU guideline 2011</gtr:description><gtr:geographicReach>Europe</gtr:geographicReach><gtr:guidelineTitle>Guidelines on Bladder Cancer: Muscle-Invasive and Metastatic</gtr:guidelineTitle><gtr:id>665EFA1E-FBBF-470D-8D27-C2EFD26A8726</gtr:id><gtr:impact>&amp;quot;Neoadjuvant cisplatin-containing combination chemotherapy should be considered in muscleinvasive bladder cancer, irrespective of further treatment&amp;quot;, based on our systematic review and meta-analysis of IPD (PMID:12801735; PMID:15939524)</gtr:impact><gtr:outcomeId>gpnp7LUVMqL</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type><gtr:url>http://europepmc.org/abstract/MED/12801735</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Bladder Neo CT IPD (PMID:12801735) SEOM guideline 2011</gtr:description><gtr:geographicReach>Europe</gtr:geographicReach><gtr:guidelineTitle>SEOM clinical guidelines for the treatment of invasive bladder cancer</gtr:guidelineTitle><gtr:id>12ACC532-D11B-475A-BAE6-3227FF6606D4</gtr:id><gtr:impact>Our systematic review and meta-analysis of IPD was cited as key evidence in this guideline (PMID:12801735)</gtr:impact><gtr:outcomeId>EpzwRUT3XRK</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type><gtr:url>http://europepmc.org/abstract/MED/21821489</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Sarcoma CT IPD (PMID:10796873) NCCN guideline UterineNeoplasms 2009</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:guidelineTitle>NCCN Clinical Practice Guidelines in Oncology - v.1.2009 Uterine Neoplasms</gtr:guidelineTitle><gtr:id>6D1E08B4-9231-4E7B-B94B-03746E4A02BB</gtr:id><gtr:impact>Our systematic review and meta-analysis of IPD was cited as evidence in this guideline (PMID: 10796873)</gtr:impact><gtr:outcomeId>LToYkos3iYP</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Lung Neo CT SR (PMID:17409927) CCA guideline stage I CT after operable 2014</gtr:description><gtr:geographicReach>Australia</gtr:geographicReach><gtr:guidelineTitle>Clinical practice guidelines for the treatment of lung cancer. What is the role of chemotherapy after surgery in the treatment of operable stage I NSCLC?</gtr:guidelineTitle><gtr:id>F0C91B6E-BBA7-435E-B56E-2465C29F32E9</gtr:id><gtr:impact>Our systematic review and meta-analysis of summary data was cited as evidence in this guideline (PMID: 17409927)</gtr:impact><gtr:outcomeId>544fb36c06bcf2.12477010</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Lung Adj CT IPD (PMID:20338628) ACR guideline N2 2013</gtr:description><gtr:geographicReach>North America</gtr:geographicReach><gtr:guidelineTitle>American College of Radiology ACR Appropriateness Criteria&amp;reg; INDUCTION AND ADJUVANT THERAPY FOR N2 NON-SMALL-CELL LUNG CANCER</gtr:guidelineTitle><gtr:id>CCC490C3-7D53-498C-9F62-49753E8FD1D0</gtr:id><gtr:impact>&amp;quot;Adjuvant chemotherapy is the standard of care in patients with completely resected stage II and III NSCLC based on multiple randomized phase III trials and meta-analyses. Generally, the absolute OS benefit with chemotherapy at 5 years has been ~4%-15% with the most recent meta-analyses showing a 4%-5% benefit across all stages. This includes stage IIIA patients for whom the 5-year absolute survival benefit was also only 5% (95% confidence interval [CI], 3%-8%)&amp;quot;, based on our systematic review and meta-analysis of IPD (PMID: 20338628)</gtr:impact><gtr:outcomeId>544faf03da0985.96375466</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Lung CT 95 IPD (PMID:7580546) ACCP guideline stage IIIB 2007</gtr:description><gtr:geographicReach>North America</gtr:geographicReach><gtr:guidelineTitle>Treatment of non-small cell lung cancer, stage IIIB. ACCP evidence-based clinical practice guidelines (2nd edition)</gtr:guidelineTitle><gtr:id>8FE0BC77-8E64-4FD9-93E6-898D1947E528</gtr:id><gtr:impact>&amp;quot;For patients with stage IIIB disease without malignant pleural effusions, PS of 0 or 1, and minimal weight loss (&amp;lt;5%), platinum based combination chemoradiotherapy is recommended&amp;quot;, based on our systematic review and meta-analysis of IPD (PMID: 7580546)</gtr:impact><gtr:outcomeId>284B37EE760</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type><gtr:url>http://europepmc.org/abstract/MED/7580546</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Cervix CTRT SR (PMID:11564482) ESMO guideline 2010</gtr:description><gtr:geographicReach>Europe</gtr:geographicReach><gtr:guidelineTitle>Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up</gtr:guidelineTitle><gtr:id>652AB27B-3FCD-4EAB-9B7D-823ABB3540D0</gtr:id><gtr:impact>&amp;quot;Concomitant chemoradiation represents the standard. This modality is superior to radiotherapy alone for local control, metastases rate, disease-free and overall survival&amp;quot;, based on our systematic review and meta-analysis of summary data (PMID: 11564482)</gtr:impact><gtr:outcomeId>XGKxUxKgtDw</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type><gtr:url>http://europepmc.org/abstract/MED/11564482</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Cervix CTRT SR (PMID: 11564482) ESMO guideline 2009</gtr:description><gtr:geographicReach>Europe</gtr:geographicReach><gtr:guidelineTitle>Cervical Cancer: ESMO Clinical Recommendations for diagnosis, treatment and follow-up</gtr:guidelineTitle><gtr:id>B92DA5C5-9369-4CEF-B80A-DA7CE68BD560</gtr:id><gtr:impact>&amp;quot;Concomitant chemoradiation represents the standard. This modality is superior to radiotherapy alone for local control, metastases rate, disease-free and overall survival&amp;quot;, based on our systematic review and meta-analysis
of summary data (PMID: 11564482)</gtr:impact><gtr:outcomeId>DWCBkEAxojX</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type><gtr:url>http://europepmc.org/abstract/MED/11564482</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Lung PORT IPD (PMID:15846628) CCA guideline stage II after 2012</gtr:description><gtr:geographicReach>Oceania</gtr:geographicReach><gtr:guidelineTitle>Clinical practice guidelines for the treatment of lung cancer. &amp;quot;What is the role of radiotherapy after surgery in the treatment of operable stage II NSCLC?&amp;quot;</gtr:guidelineTitle><gtr:id>EB935A91-AAF3-49F7-92B8-DE2A867332DA</gtr:id><gtr:impact>&amp;quot;In patients who have had complete resection of stage II NSCLC, postoperative radiotherapy is not recommended&amp;quot;, based on our systematic review and meta-analysis of IPD (PMID: 15846628)</gtr:impact><gtr:outcomeId>Z9eWy4t8MDp</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Lung SC IPD (PMID:18678835) NCCN guideline 2011</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:guidelineTitle>NCCN Practice Guidelines in Oncology v.3.2011. Non-Small Cell Lung Cancer</gtr:guidelineTitle><gtr:id>272BEBF6-DB80-4045-86F5-CE203219A574</gtr:id><gtr:impact>Our systematic review and meta-analysis of IPD was cited as evidence in this guideline (PMID: 18678835)</gtr:impact><gtr:outcomeId>kBgYGLaxFAM</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type><gtr:url>http://europepmc.org/abstract/MED/18678835</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Oesophagus RT IPD (PMID:10796823) BHKC guideline 2012</gtr:description><gtr:geographicReach>Europe</gtr:geographicReach><gtr:guidelineTitle>Clinical Practice Guidelines Upper Gastrointestinal Cancer - update</gtr:guidelineTitle><gtr:id>637F9F3B-4C62-4032-9E8C-1FF91DA5ECC1</gtr:id><gtr:impact>&amp;quot;Preoperative radiotherapy is not associated with an improved survival
compared to surgery alone in patients with operable oesophageal
cancer&amp;quot;, based on our systematic review and meta-analysis of IPD (PMID: 10796823)</gtr:impact><gtr:outcomeId>ka3Ytoxp9kK</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type><gtr:url>http://europepmc.org/abstract/MED/10796823</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Bladder Neo CT IPD (PMID:15846746) ACCC guideline 2009</gtr:description><gtr:geographicReach>Europe</gtr:geographicReach><gtr:guidelineTitle>Bladdercarcinoma: Nation-wide guideline, Version: 1.0</gtr:guidelineTitle><gtr:id>FE19C933-6C5C-4A6E-A487-90ADC56EFB7E</gtr:id><gtr:impact>&amp;quot;There is no standard indication for administration of neoadjuvant chemotherapy in muscle-invasive urothelial carcinoma&amp;quot;, based on our systematic review and meta-analysis of IPD (PMID: 15846746)</gtr:impact><gtr:outcomeId>Sqpback4Xk3</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type><gtr:url>http://europepmc.org/abstract/MED/15846746</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Lung CT 95 IPD (PMID:7580546) AIOT guideline Stage I&amp;amp;II 2012</gtr:description><gtr:geographicReach>Europe</gtr:geographicReach><gtr:guidelineTitle>Associazione Italiana di Oncologia Toracica</gtr:guidelineTitle><gtr:id>A5862C8A-2D90-49A0-B193-D45A8802CBEB</gtr:id><gtr:impact>Our systematic review and meta-analysis of IPD was cited as evidence in this guideline (PMID: 7580546)</gtr:impact><gtr:outcomeId>56cda83205d906.88390256</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Lung SeqCon CTRT IPD (PMID:20351327) ESMO guideline 2013</gtr:description><gtr:geographicReach>Europe</gtr:geographicReach><gtr:guidelineTitle>Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up</gtr:guidelineTitle><gtr:id>1BE9E4A3-F395-4DF8-8848-8C5B786FCF53</gtr:id><gtr:impact>Induction chemotherapy followed by radiotherapy (mostly to a dose of 60-66 Gy in 30-33 fractions in 6-7 weeks), so-called sequential chemoradiotherapy, was compared with concurrent chemoradiotherapy to the same dose in many phase III trials and in a meta-analysis. Concurrent chemotherapy and radiotherapy lead to higher 5-year survival rates at the cost of a higher rate of reversible oesophagitis&amp;quot; The preferred treatment of unresectable LA-NSCLC is definitive concurrent chemotherapy and radiotherapy [I, A]&amp;quot;, based on our systematic review and meta-analysis of IPD (PMID: 20351327)</gtr:impact><gtr:outcomeId>m4SGy1KjDdQ</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Cervix CTRT SR (PMID: 11564482) ESMO guideline 2008</gtr:description><gtr:geographicReach>Europe</gtr:geographicReach><gtr:guidelineTitle>Cervical cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up</gtr:guidelineTitle><gtr:id>1C518CD8-4F8A-4105-AAD9-82A630E60EF6</gtr:id><gtr:impact>&amp;quot;Concomitant chemoradiation represents the standard. This modlity is suprior to radiotherapy alone for local control, metastases rate, diease-free and overall survival&amp;quot;, based on our systematic review and meta-analysis of summary data (PMID: 11564482)</gtr:impact><gtr:outcomeId>F5AB98B3F93</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type><gtr:url>http://europepmc.org/abstract/MED/11564482</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Cervix CTRT IPD (PMID:19001332) NCCN guideline 2013</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:guidelineTitle>NCCN Practice Guidelines in Oncology - v.1.2012 Cervical Cancer</gtr:guidelineTitle><gtr:id>04528F29-DF2A-40CB-9663-818B7E45B9AB</gtr:id><gtr:impact>Our systematic review and meta-analysis of IPD was cited as evidence in this guideline (PMID: 19001332)</gtr:impact><gtr:outcomeId>W6kQwq6usqP</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Paediatric HIV ART SR (PMID: 22786492) HHS/OARAC guideline Paediatric HIV 2014</gtr:description><gtr:geographicReach>North America</gtr:geographicReach><gtr:guidelineTitle>Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection</gtr:guidelineTitle><gtr:id>2BA2CE20-9A09-4481-9F91-B066B83EE60F</gtr:id><gtr:impact>&amp;quot;The Cochrane Collaboration recently published a review on the effectiveness of cART in HIV-infected children aged &amp;lt;2 years based on data from published randomized trials of early versus deferred cART. The authors concluded that immediate therapy reduces morbidity and mortality and may improve neurologic outcome, but that data supporting universal initiation of treatment between ages 1 and 2 years are less compelling&amp;quot;, based on our systematic review and meta-analysis of summary data (PMID: 22786492)</gtr:impact><gtr:outcomeId>544fc7876d3f93.40474993</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Lung PORT IPD (PMID:9690404) ACR guideline Induction/Adjuvant 2010</gtr:description><gtr:geographicReach>North America</gtr:geographicReach><gtr:guidelineTitle>ACR Appropriateness Criteria INDUCTION AND ADJUVANT THERAPY FOR N2 NON-SMALL-CELL LUNG CANCER</gtr:guidelineTitle><gtr:id>B8534982-3E70-42AD-9C97-09F5CEBD851F</gtr:id><gtr:impact>Our systematic review and meta-analysis of IPD was cited as evidence in this guideline (PMID: 9690404)</gtr:impact><gtr:outcomeId>Lv4EvetYUtM</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type><gtr:url>http://europepmc.org/abstract/MED/9690404</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Lung CT 95 IPD (PMID:7580546) ACCP guideline stage I&amp;amp;II 2013</gtr:description><gtr:geographicReach>North America</gtr:geographicReach><gtr:guidelineTitle>Treatment of Stage I &amp;amp; II Non-small Cell Lung Cancer. Diagnosis and Management of Lung Cancer, 3rd ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines</gtr:guidelineTitle><gtr:id>201B8E1A-D5F6-4B0B-8B7A-2B505E336155</gtr:id><gtr:impact>Our systematic review and meta-analysis of IPD was cited as evidence in this guideline (PMID: 7580546)</gtr:impact><gtr:outcomeId>L2jEV3raxoQ</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Lung SC IPD (PMID: 18678835) NCCN guideline 2010</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:guidelineTitle>NCCN Practice Guidelines in Oncology v.2.2010. Non-Small Cell Lung Cancer</gtr:guidelineTitle><gtr:id>763F3E6B-2A39-4EF3-A9D2-EB32451C99CE</gtr:id><gtr:impact>&amp;quot;Patients with stage IV disease who have a good PS, benefit from chemotherapy, usually with a platinum-based regimen&amp;quot;, based on our systematic review and meta-analysis of IPD (PMID: 18678835)</gtr:impact><gtr:outcomeId>W9DfHCp5jYS</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type><gtr:url>http://europepmc.org/abstract/MED/18678835</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Lung SC IPD (PMID: 18678835) ASCO guideline 2009</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:guidelineTitle>American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non-Small-Cell Lung Cancer</gtr:guidelineTitle><gtr:id>1CB291E0-33E6-4CF5-8558-4434A7DFFA5D</gtr:id><gtr:impact>&amp;quot;Evidence supports the use of chemotherapy_ in patients with stage IV? NSCLC with ECOG/Zubrod performance status of 0, 1, and possibly 2&amp;quot;, based on our systematic review and meta-analysis of IPD (PMID: 18678835)</gtr:impact><gtr:outcomeId>kc5mL747nQ8</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type><gtr:url>http://europepmc.org/abstract/MED/18678835</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Cervix CTRT IPD (PMID:19001332) ESMO guideline 2010</gtr:description><gtr:geographicReach>Europe</gtr:geographicReach><gtr:guidelineTitle>Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up</gtr:guidelineTitle><gtr:id>D1B2261F-7F2D-494E-B78B-12D0EB07836A</gtr:id><gtr:impact>&amp;quot;Concomitant chemoradiation represents the standard. This modality is superior to radiotherapy alone for local control, metastases rate, disease-free and overall survival&amp;quot;, based on our systematic review and meta-analysis of summary data (PMID: 19001332)</gtr:impact><gtr:outcomeId>RWuCeUB4XH8</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type><gtr:url>http://europepmc.org/abstract/MED/19001332</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Lung PORT IPD (PMID:15603857) ACCP guideline Stage I&amp;amp;II 2007</gtr:description><gtr:geographicReach>North America</gtr:geographicReach><gtr:guidelineTitle>Treatment of non-small cell lung cancer, stage I and stage II. ACCP evidence-based clinical practice guidelines (2nd edition)</gtr:guidelineTitle><gtr:id>7004A763-2E87-41B2-84BC-75ACB4D5AE4D</gtr:id><gtr:impact>&amp;quot;There continues to be evidence that postoperative radiotherapy is associated with a decrease in survival for patients with stage I (N0) and stage II (N1) NSCLC&amp;quot;, based on our systematic review and meta-analysis of IPD (PMID: 15603857)</gtr:impact><gtr:outcomeId>hW8NmEEyPxr</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type><gtr:url>http://europepmc.org/abstract/MED/15603857</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>VenousUlcers IPD (PMID:19376798) AAWC guideline 2011</gtr:description><gtr:geographicReach>North America</gtr:geographicReach><gtr:guidelineTitle>AAWC Venous Ulcer Guidelines</gtr:guidelineTitle><gtr:id>9064A380-F52C-4353-B5F0-B18D0ED9A33C</gtr:id><gtr:impact>Our systematic review and meta-analysis of IPD was cited as evidence in this guideline (PMID: 19376798)</gtr:impact><gtr:outcomeId>NtzTJHgA9iT</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type><gtr:url>http://europepmc.org/abstract/MED/19376798</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Lung SC IPD (PMID:18678835) IATO guideline 2011</gtr:description><gtr:geographicReach>Europe</gtr:geographicReach><gtr:guidelineTitle>Treatment of advanced non-small-cell lung cancer</gtr:guidelineTitle><gtr:id>4BEF96A9-4666-40D2-94CF-64ACBC1D4F55</gtr:id><gtr:impact>&amp;quot;There are no trials comparing chemotherapy versus BSC alone, but
important evidence supporting the role of chemotherapy in these
patients come from the individual patient data meta-analyses,
demonstrating a significant benefit with chemotherapy in patients
with advanced NSCLC&amp;quot;, based on our systematic review and meta-analysis of IPD (PMID: 18678835)</gtr:impact><gtr:outcomeId>U1GGFWSSQNk</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type><gtr:url>http://europepmc.org/abstract/MED/18678835</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Lung Neo CT SR (PMID:17409927) NICE guideline 2011</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:guidelineTitle>NICE guideline CG121:The diagnosis and treatment of lung cancer (update of NICE clinical guideline 24).</gtr:guidelineTitle><gtr:id>0BBB2E6F-8F35-4F9F-B897-EF1DC658DF1F</gtr:id><gtr:impact>&amp;quot;For patients with NSCLC who are suitable for surgery, do not offer neo-adjuvant chemotherapy outside a clinical trial&amp;quot;, based on our systematic review and meta-analysis of summary data (PMID: 17409927)</gtr:impact><gtr:outcomeId>ocEVgD48ciV</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type><gtr:url>http://www.nice.org.uk/CG121</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Bladder Neo CT IPD (PMID: 12801735; 15939524) AURO.it guideline 2009</gtr:description><gtr:geographicReach>Europe</gtr:geographicReach><gtr:guidelineTitle>Guidelines on Bladder and Upper Urinary Tract Cancer</gtr:guidelineTitle><gtr:id>1AFBC734-5365-468B-B33B-420A43C58DAC</gtr:id><gtr:impact>&amp;quot;Si suggerisce di considerare la chemioterapia neoadiuvante dopo discussione con il paziente a riguardo del rapporto costo/ beneficio&amp;quot;

&amp;quot;Nel 2005 l'Advanced Bladder Cancer (ABC) Meta-analysis Collaboration ha condotto una metanalisi dei dati individuali di 3005 pazienti di 11 studi randomizzati (alcuni dei quali gi&amp;agrave; considerati nella metanalisi di Winquist) di chemioterapia neoadiuvante + trattamento locale (radioterapia o cistectomia) versus trattamento locale [10] (H). Questa metanalisi, eccetto l'undicesimo studio successivamente inserito, era la rivalutazione di quella precedente pubblicata su Lancet nel 2003 [11] (H) relativa ai dati di 2688 pazienti di 10 studi clinici randomizzati che aveva evidenziato una riduzione del 13% del rischio di morte a favore della chemioterapia neoadiuvante (HR: 0.87; p=0.016). E' stato evidenziato un beneficio clinico associato alla chemioterapia neoadiuvante di combinazione &amp;quot;platinum-based&amp;quot; (HR= 0.86; p=0.003) con riduzione del 14% del rischio di morte, il che equivale ad un vantaggio assoluto di sopravvivenza del 5% e ad un vantaggio assoluto del 9% in termini di &amp;quot;disease-free survival&amp;quot; a 5 anni (HR: 0.78; p&amp;lt;0.0001), indipendentemente dal tipo di trattamento locale eseguito e dai sottogruppi di pazienti considerati.&amp;quot;

Translation:
&amp;quot;Use of noeadjuvant chemotherapy should be considered after discussions with the patient with respect to the cost/benefit of treatment&amp;quot;

&amp;quot;In 2005 the ABC Meta-analysis Collaboration conducted an IPD meta-analysis based on 3005 patients from 11 RCTs, looking at neoadjuvant chemotherapy + local treatment (radiotherapy or cystectomy) versus local treatment. This meta-analysis was an update of the one published in the Lancet in 2003, including an additional study. The Lancet 2003 study was based on 2688 patients from 10 RCTs and showed a 13% reduction in the risk of death with neoadjuvant chemotherapy (HR=0.87; p=0.016). There was a clinical benefit associated with platinum-based combination chemotherapy with a 14% reduction in the risk of death (HR=0.86; p=0.003) which is equivalent to a 5% absolute survival benefit and a 9% disease-free survival benefit at 5 years (HR=0.78; p&amp;lt;0.0001), independent of the type of local treatment received and across all patient subgroups.&amp;quot;, based on our systematic review and meta-analysis of IPD (PMID: 12801735; PMID: 15939524)</gtr:impact><gtr:outcomeId>544e2df0d2d2e4.70365053</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Lung SeqCon CTRT IPD (PMID:20351327) SEOM guideline 2013</gtr:description><gtr:geographicReach>Europe</gtr:geographicReach><gtr:guidelineTitle>SEOM clinical guidelines for the treatment of non-small cell lung cancer (NSCLC) 2013</gtr:guidelineTitle><gtr:id>E14A2146-60CC-4BD1-B826-5CE53644AE25</gtr:id><gtr:impact>&amp;quot;In patients with good performance status and without significant weight loss, concurrent chemoradiotherapy at systemic doses is superior to sequential radiochemotherapy, but at the cost of manageable increased acute esophageal toxicity&amp;quot;, based on our systematic review and meta-analysis of IPD (PMID: 20351327)</gtr:impact><gtr:outcomeId>544fb494606995.68085995</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Bladder Adj CT IPD (PMID:16625650) AHS guideline 2013</gtr:description><gtr:geographicReach>North America</gtr:geographicReach><gtr:guidelineTitle>Clinical Practice Guideline: GU-002 Bladder Cancer</gtr:guidelineTitle><gtr:id>549581A6-52F1-48B7-9817-6FC228423C76</gtr:id><gtr:impact>Our systematic review and meta-analysis of IPD was cited as key evidence in this guideline (PMID:16625650)</gtr:impact><gtr:outcomeId>VsgFkfp4rXc</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Lung SeqCon CTRT IPD (PMID:20351327) NCCN guideline 2013</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:guidelineTitle>NCCN Practice Guidelines in Oncology v.2.2013. Non-Small Cell Lung Cancer</gtr:guidelineTitle><gtr:id>99469AC2-8EBD-4BC4-B3C2-2C4DC9CB385C</gtr:id><gtr:impact>&amp;quot;When distant metastases are not present, the NCCN Panel recommends that the patient be treated with definitive concurrent chemoradiation therapy&amp;quot;, based on our systematic review and meta-analysis of IPD (PMID: 20351327)</gtr:impact><gtr:outcomeId>kUscV9WDKcn</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Colorectal Anti-EGFR SR (PMID:22118887) BHKC guideline 2014</gtr:description><gtr:geographicReach>Europe</gtr:geographicReach><gtr:guidelineTitle>COLON CANCER: DIAGNOSIS, TREATMENT AND FOLLOW-UP</gtr:guidelineTitle><gtr:id>3C4C4905-4E1F-4EE6-863D-798EBB82593E</gtr:id><gtr:impact>&amp;quot;KRAS mutation status is an effect modifier for anti-EGFR antibodies, with the efficacy of anti-EGFR antibodies limited to KRAS wild type patients. The systematic reviews by Vale et al. and Adelstein et al. confirmed this result&amp;quot;, based on our systematic review and meta-analysis of summary data (PMID: 22118887)</gtr:impact><gtr:outcomeId>544f995437dac4.49666653</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Cervix Neo CT SR (PMID:23235641) GGPO guideline 2014</gtr:description><gtr:geographicReach>Europe</gtr:geographicReach><gtr:guidelineTitle>S3-Leitlinie Diagnostik, Therapie und Nachsorge der Patientin mit Zervixkarzinom v1.0 2014</gtr:guidelineTitle><gtr:id>5FC0DD41-06D7-4008-964C-8399FF6E2B16</gtr:id><gtr:impact>&amp;quot;Eine medikament&amp;ouml;se neoadjuvante Therapie kann bei ausgew&amp;auml;hlten Risikopatientinnen durchgef&amp;uuml;hrt werden.&amp;quot;, based on our systematic review and meta-analysis of summary data (PMID: 23235641)</gtr:impact><gtr:outcomeId>56cdcba3425748.94730261</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Lung CT 95 IPD (PMID:7580546) ACR guideline PostOpAdj 2010</gtr:description><gtr:geographicReach>North America</gtr:geographicReach><gtr:guidelineTitle>ACR Appropriateness Criteria NONSURGICAL TREATMENT FOR NON-SMALL-CELL LUNG CANCER: POSTOPERATIVE ADJUVANT THERAPY IN NON-SMALL CELL LUNG CANCER</gtr:guidelineTitle><gtr:id>3EB2FCBB-72BA-4631-A773-AB3694618D34</gtr:id><gtr:impact>Our systematic review and meta-analysis of IPD was cited as evidence in this guideline (PMID: 7580546)</gtr:impact><gtr:outcomeId>Q3As7E4NDZR</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type><gtr:url>http://europepmc.org/abstract/MED/7580546</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Lung SeqCon CTRT IPD (PMID:20351327) NCCN guideline 2011</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:guidelineTitle>NCCN Practice Guidelines in Oncology v.3.2011. Non-Small Cell Lung Cancer</gtr:guidelineTitle><gtr:id>03A6AB93-BD25-4917-8F75-A693D9C4481D</gtr:id><gtr:impact>&amp;quot;Concurrent chemoradiation appears superior to sequential therapy&amp;quot;; &amp;quot;When distant metastases are not present, the panel recommends that the patient be treated with definitive concurrent chemoradiation therapy&amp;quot;, based on our systematic review and meta-analysis of IPD (PMID: 20351327)</gtr:impact><gtr:outcomeId>okZdfhvS65v</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type><gtr:url>http://europepmc.org/abstract/MED/20351327</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Lung CT 95 IPD (PMID: 7580546) BCCA guideline 6.1.04 2008</gtr:description><gtr:geographicReach>North America</gtr:geographicReach><gtr:guidelineTitle>Cancer Management Guidelines. Lung (including Mesothelioma &amp;amp; Thymoma) (6.1.04)</gtr:guidelineTitle><gtr:id>98B7C492-F4BD-415A-AE48-B915FA3E1F66</gtr:id><gtr:impact>Our systematic review and meta-analysis of IPD is used as evidence throughout this guideline for all stages of non-small cell lung cancer (PMID: 7580546)</gtr:impact><gtr:outcomeId>0716E04D45B</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type><gtr:url>http://europepmc.org/abstract/MED/7580546</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Endometrial CT SR (PMID:17150999) NCCN guideline UterineNeoplasms 2013</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:guidelineTitle>NCCN Practice Guidelines in Oncology v.1.2013. Uterine Neoplasms</gtr:guidelineTitle><gtr:id>E6144457-DC67-4820-B452-1FEBC7B81916</gtr:id><gtr:impact>&amp;quot;Chemotherapy for endometrial cancer has been extensively studied. Based on the current data, multiagent chemotherapy regimens are preferred for metastatic, recurrent, or high-risk disease, if tolerated. Single-agent therapy can also be used&amp;quot;, based on our systematic review and meta-analysis of summary data (PMID: 17150999)</gtr:impact><gtr:outcomeId>HjYMJEoEMJF</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Sarcoma CT IPD (PMID:9400508) CCO guideline 2011</gtr:description><gtr:geographicReach>North America</gtr:geographicReach><gtr:guidelineTitle>Adjuvant Chemotherapy Following Complete Resection of Soft Tissue Sarcoma in Adults: Practice Guideline Report 11-2</gtr:guidelineTitle><gtr:id>BDBB2A83-DED6-484C-B58E-DBE4F255EF6B</gtr:id><gtr:impact>Our systematic review and meta-analysis of IPD was cited as key evidence in this guideline (PMID: 9400508)</gtr:impact><gtr:outcomeId>LGEXVvG9LY2</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type><gtr:url>http://europepmc.org/abstract/MED/9400508</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Bladder Neo CT IPD (PMID:15846746) AHS guideline 2011</gtr:description><gtr:geographicReach>North America</gtr:geographicReach><gtr:guidelineTitle>Clinical Practice Guideline: GU-002 Bladder Cancer</gtr:guidelineTitle><gtr:id>7354AB03-187E-4488-A2DC-378DC529C3F2</gtr:id><gtr:impact>Our systematic review and meta-analysis of IPD was cited as key evidence in this guideline (PMID:15846746)</gtr:impact><gtr:outcomeId>aFeVknnQpM3</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type><gtr:url>http://europepmc.org/abstract/MED/15846746</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Bladder Adj CT IPD (PMID:15939530) JUA guideline 2010</gtr:description><gtr:geographicReach>Asia</gtr:geographicReach><gtr:guidelineTitle>Evidence-based clinical practice guidelines for bladder cancer</gtr:guidelineTitle><gtr:id>7B093717-55D9-4CDF-B0AB-3D42D9579E83</gtr:id><gtr:impact>&amp;quot;Perioperative chemotherapy might improve the therapeutic results for muscle-invasive bladder cancer. Preoperative and postoperative chemotherapy have their respective merits and demerits. At present, a definite improvement in survival rates has been shown only for preoperative cisplatin-based combination chemotherapy.(Grade of recommendation A.)&amp;quot;, based on our systematic review and meta-analysis of IPD (PMID:15939530)</gtr:impact><gtr:outcomeId>pYjTB88meJv</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type><gtr:url>http://europepmc.org/abstract/MED/15939530</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Sarcoma CT IPD (PMID:9400508) ESMO guideline 2009</gtr:description><gtr:geographicReach>Europe</gtr:geographicReach><gtr:guidelineTitle>Soft tissue sarcomas: ESMO Clinical Recommendations for diagnosis, treatment and follow-up</gtr:guidelineTitle><gtr:id>B8C9ABD9-0FA0-43F6-904B-29017D6396D2</gtr:id><gtr:impact>Our systematic review and meta-analysis of IPD was cited as evidence in this guideline (PMID: 9400508)</gtr:impact><gtr:outcomeId>qBfm1aiemLH</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type><gtr:url>http://europepmc.org/abstract/MED/9400508</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Bladder Neo CT IPD (PMID: 12801735; 15939524) EAU guideline 2014</gtr:description><gtr:geographicReach>Europe</gtr:geographicReach><gtr:guidelineTitle>Guidelines on Bladder Cancer: Muscle-Invasive and Metastatic</gtr:guidelineTitle><gtr:id>70207031-3DE5-42FE-A8CB-EB3880D55CD7</gtr:id><gtr:impact>&amp;quot;Neoadjuvant cisplatin-containing combination chemotherapy improves overall survival (5-8% at 5 years),&amp;quot; based on our systematic review and meta-analysis of IPD (PMID:12801735; PMID:15939524)</gtr:impact><gtr:outcomeId>544f7886aa2100.99082106</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Bladder Adj CT IPD (PMID: 15939530) EAU guideline 2008</gtr:description><gtr:geographicReach>Europe</gtr:geographicReach><gtr:guidelineTitle>Guidelines on bladder cancer. Muscle-invasive and metastatic</gtr:guidelineTitle><gtr:id>C29E886D-9B7C-4664-8832-16CF874F1762</gtr:id><gtr:impact>&amp;quot;Adjuvant chemotherapy is advised within clinical trials, but not for routine use, because it has not been studied sufficiently&amp;quot; based on our systematic review and meta-analysis of IPD (PMID: 15939530)</gtr:impact><gtr:outcomeId>5B4C1097AEC</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type><gtr:url>http://europepmc.org/abstract/MED/15939530</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Lung SC IPD (PMID: 18678835) SIGN 137 guideline 2014</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:guidelineTitle>SIGN 137: Management of Lung cancer</gtr:guidelineTitle><gtr:id>D98DC0F6-A5A0-4A57-ACFC-D1ACACA9CB8D</gtr:id><gtr:impact>&amp;quot;Results from a meta-analysis and systematic review demonstrate the benefit of SACT [systemic anticancer therapy] for patients with advanced non-small cell lung cancer (absolute improvement in survival of 9% at 12 months versus control)&amp;quot;, based on our systematic review and meta-analysis of IPD (PMID: 18678835)</gtr:impact><gtr:outcomeId>544fabf9cb3181.95118122</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Lung Neo CT SR (PMID:17409927) CCA guideline stage II CT before operable 2014</gtr:description><gtr:geographicReach>Australia</gtr:geographicReach><gtr:guidelineTitle>Clinical practice guidelines for the treatment of lung cancer. What is the role of chemotherapy before surgery in the treatment of operable stage II NSCLC?</gtr:guidelineTitle><gtr:id>F18962F7-568F-4854-AD66-B7233FC03E67</gtr:id><gtr:impact>Our systematic review and meta-analysis of summary data was cited as evidence in this guideline (PMID: 17409927)</gtr:impact><gtr:outcomeId>544fb30a672df3.72437796</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Cervix CTRT IPD (PMID:19001332) SCA guideline 2013</gtr:description><gtr:geographicReach>North America</gtr:geographicReach><gtr:guidelineTitle>Provincial Cervical Cancer Treatment Guidelines</gtr:guidelineTitle><gtr:id>88E1C355-8616-416C-B5E4-9A028313F57B</gtr:id><gtr:impact>Our systematic review and meta-analysis of IPD was cited as evidence in this guideline (PMID: 19001332)</gtr:impact><gtr:outcomeId>56cdae0ebe0547.38767758</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Sarcoma CT IPD (PMID:9400508) NCCN guideline SoftTissueSarcoma 2013</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:guidelineTitle>NCCN Clinical Practice Guidelines in Oncology v.1.2013 Soft Tissue Sarcoma</gtr:guidelineTitle><gtr:id>3CFDA70E-294A-4CDD-BA6C-700DCDBF2527</gtr:id><gtr:impact>Our systematic review and meta-analysis of IPD was cited as key evidence in this guideline (PMID: 9400508)</gtr:impact><gtr:outcomeId>ZvR7MVRPxqR</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Glioma CT IPD (PMID:11937180) NCCN guideline 2013</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:guidelineTitle>NCCN Clinical Practice Guidelines in Oncology - v.2.2012 Central Nervous System Cancers</gtr:guidelineTitle><gtr:id>05AE0847-82A9-4D64-A267-2EC7CFF1A941</gtr:id><gtr:impact>Our systematic review and meta-analysis of IPD was cited as evidence in this guideline (PMID:11937180)</gtr:impact><gtr:outcomeId>N88R2k199ir</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Oesophagus RT IPD (PMID:10796823) BSG guideline 2011</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:guidelineTitle>Guidelines for the management of oesophageal and gastric cancer</gtr:guidelineTitle><gtr:id>4E68AE86-32C7-4FD1-B991-FFC2B7D148D1</gtr:id><gtr:impact>&amp;quot;Preoperative radiotherapy is not recommended for potentially
resectable oesophageal squamous cell or adenocarcinoma&amp;quot;, based on our systematic review and meta-analysis of IPD (PMID: 10796823)</gtr:impact><gtr:outcomeId>NjXwMirMZCK</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type><gtr:url>http://europepmc.org/abstract/MED/10796823</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Lung Neo CT SR (PMID:17409927) ACR guideline Induction/Adjuvant 2010</gtr:description><gtr:geographicReach>North America</gtr:geographicReach><gtr:guidelineTitle>ACR Appropriateness Criteria INDUCTION AND ADJUVANT THERAPY FOR N2 NON-SMALL-CELL LUNG CANCER</gtr:guidelineTitle><gtr:id>BECE385A-776B-4D5F-A486-25B405F248E2</gtr:id><gtr:impact>Our systematic review and meta-analysis of summary data was cited as evidence in this guideline (PMID: 17409927)</gtr:impact><gtr:outcomeId>RZcD8BGGkwF</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type><gtr:url>http://europepmc.org/abstract/MED/17409927</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Lung PORT IPD (PMID:15603857; 15846628) ACCP guideline stage III 2013</gtr:description><gtr:geographicReach>North America</gtr:geographicReach><gtr:guidelineTitle>Treatment of Stage III Non-small Cell Lung Cancer. Diagnosis and Management of Lung Cancer, 3rd ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines</gtr:guidelineTitle><gtr:id>3289C1C5-F902-4881-BD11-3D2283FA2171</gtr:id><gtr:impact>&amp;quot;Meta-analyses of postoperative radiotherapy (PORT) in resected NSCLC indicated a survival detriment. Subsequent studies using meta-analyses or population-based databases showed varied results in patients found postoperatively to have N2 involvement. Although it appears that PORT might benefit some patients with N2 disease, presently, it cannot be recommended for unselected patients&amp;quot;, , based on our systematic review and meta-analysis of IPD (PMID: 15603857, (PMID: 15846628))</gtr:impact><gtr:outcomeId>dXgHnuvVRXg</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Cervix Neo CT IPD (PMID:14602133) ACR guideline advanced 2012</gtr:description><gtr:geographicReach>North America</gtr:geographicReach><gtr:guidelineTitle>ACR Appropriateness Criteria ADVANCED CERVICAL CANCER</gtr:guidelineTitle><gtr:id>1473DEE8-B2E4-4134-BE29-512BAFB4AF72</gtr:id><gtr:impact>Our systematic review and meta-analysis of summary data was cited as evidence in this guideline (PMID: 14602133)</gtr:impact><gtr:outcomeId>PdBNTruRqng</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>The hazard ratio is the best statistic to use in meta-analyses of time to event outcomes. However, when hazard ratios are not reported in trial publications the methods for estimating and including tem in meta-analylses can be difficult for non-statisticians to use. We have presented a simplified guide to these methods in workshops and in an an open-access paper that includes a downloadable spreadsheet to facilitate doing the calculations (PMID: 17555582).</gtr:description><gtr:id>08C0EF3A-413A-4704-9D79-97D62B94BA51</gtr:id><gtr:impact>Made it easier for systematic reviewers to do meta-analyses of time-to-event outcomes (such as time to death in cancer), which will ulitmately improve their quality and reliability.</gtr:impact><gtr:outcomeId>DBE7C16FC4C</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Practical methods for estimation of HRs from publications</gtr:title><gtr:type>Improvements to research infrastructure</gtr:type><gtr:url>http://europepmc.org/abstract/MED/17555582</gtr:url><gtr:yearFirstProvided>2006</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>The major statistical packages have been geared to the meta-analysis of aggregate data. None specifically support both the direct manipulation and analyses of and not individual patient data (IPD), but the sue of IPD is increasing. We re-developed our in-house software (SCHARP) to analyse and plot the results of IPD meta-analysis of all outcome types, and provided it to other research groups.</gtr:description><gtr:id>7D5FEF08-25C0-421E-8C45-BD3A13954D27</gtr:id><gtr:impact>Made it easier for systematic reviewers to analyse and plot the results of IPD meta-analyses. As per the licence agreement (by MRC Technology), research organisations using SCHARP for published analyses must acknolwedge the Clinical Trials Unit and MRC in their publications.</gtr:impact><gtr:outcomeId>E45C086B86F</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>SCHARP software for the plotting and analysis of IPD</gtr:title><gtr:type>Improvements to research infrastructure</gtr:type><gtr:yearFirstProvided>2008</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>196E4C5B-9E21-4C20-AEC4-14CA198355D3</gtr:id><gtr:title>Systematic review of therapeutic interventions in human prion disease.</gtr:title><gtr:parentPublicationTitle>Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7156ed1abac4e2954cb30a3009a9d087"><gtr:id>7156ed1abac4e2954cb30a3009a9d087</gtr:id><gtr:otherNames>Stewart LA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0028-3878</gtr:issn><gtr:outcomeId>E8BB2085E65</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>294F5EB6-41D4-4C7E-932C-A373DA090B40</gtr:id><gtr:title>Surrogate endpoints for overall survival in chemotherapy and radiotherapy trials in operable and locally advanced lung cancer: a re-analysis of meta-analyses of individual patients' data.</gtr:title><gtr:parentPublicationTitle>The Lancet. Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d1612bd2e3259fd34b87b10275c9a7bb"><gtr:id>d1612bd2e3259fd34b87b10275c9a7bb</gtr:id><gtr:otherNames>Mauguen A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1470-2045</gtr:issn><gtr:outcomeId>pm_13140_20_23680111</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>862FF184-E9DC-4081-83E3-BB8A290603BF</gtr:id><gtr:title>Chemotherapy and supportive care versus supportive care alone for advanced non-small cell lung cancer.</gtr:title><gtr:parentPublicationTitle>The Cochrane database of systematic reviews</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/94034e58cffffed21b57454e908c4767"><gtr:id>94034e58cffffed21b57454e908c4767</gtr:id><gtr:otherNames>Non-Small Cell Lung Cancer Collaborative Group</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1361-6137</gtr:issn><gtr:outcomeId>QBy3zR1CYrf</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4D117D45-8652-43EC-969F-8F1BE1C3521D</gtr:id><gtr:title>Concomitant chemoradiotherapy for cervical cancer: a systematic review and meta-analysis of individual patient data.</gtr:title><gtr:parentPublicationTitle>Gynecologic oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/83f08b2beb28ce764b737ec86c4b7a71"><gtr:id>83f08b2beb28ce764b737ec86c4b7a71</gtr:id><gtr:otherNames>Vale C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0090-8258</gtr:issn><gtr:outcomeId>pm_13140_10_16229878</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A8967FD6-1DE3-4851-B5BF-1470BDE8BA55</gtr:id><gtr:title>Adjuvant chemotherapy for invasive bladder cancer (individual patient data).</gtr:title><gtr:parentPublicationTitle>The Cochrane database of systematic reviews</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/87f4b6151140dac16043f711608f280d"><gtr:id>87f4b6151140dac16043f711608f280d</gtr:id><gtr:otherNames>Advanced Bladder Cancer (ABC) Meta-analysis Collaboration</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>1361-6137</gtr:issn><gtr:outcomeId>7BAB188095F</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DBEF8A06-E579-4D5D-A6CE-E299361CD493</gtr:id><gtr:title>Concomitant chemoradiation in cervical cancer: a meta-analysis using individual patient data from randomised clinical trials</gtr:title><gtr:parentPublicationTitle>European Society of  Gynaecological Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/83f08b2beb28ce764b737ec86c4b7a71"><gtr:id>83f08b2beb28ce764b737ec86c4b7a71</gtr:id><gtr:otherNames>Vale C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:outcomeId>EoDRDLdHx5J</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0ADE6A23-117E-4B9F-B6CB-739988EFF90A</gtr:id><gtr:title>Nonpharmacological Interventions for Caregivers of Stroke Survivors</gtr:title><gtr:parentPublicationTitle>Stroke</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/87d4c960eb59ba90af232a037faceb18"><gtr:id>87d4c960eb59ba90af232a037faceb18</gtr:id><gtr:otherNames>Legg L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:outcomeId>54510a4f6d6bc6.33445759</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EEF8E518-2652-4B89-BA96-08FD7D569C82</gtr:id><gtr:title>Neoadjuvant chemotherapy plus surgery versus surgery for cervical cancer.</gtr:title><gtr:parentPublicationTitle>The Cochrane database of systematic reviews</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8275873a4f2e2da2eebc90ae41a341c7"><gtr:id>8275873a4f2e2da2eebc90ae41a341c7</gtr:id><gtr:otherNames>Rydzewska L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1361-6137</gtr:issn><gtr:outcomeId>pm_13140_20_23235641</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B8FC09C8-2089-4090-A1AB-46543001EA17</gtr:id><gtr:title>Why i.p. therapy cannot yet be considered as a standard of care for the first-line treatment of ovarian cancer: a systematic review.</gtr:title><gtr:parentPublicationTitle>Annals of oncology : official journal of the European Society for Medical Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9cd713fc84e3fe3488cbd824f4f561b9"><gtr:id>9cd713fc84e3fe3488cbd824f4f561b9</gtr:id><gtr:otherNames>Swart AM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0923-7534</gtr:issn><gtr:outcomeId>FuneNr1Doe9</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1B681276-81FA-4794-BDC0-D5249AFC9E3E</gtr:id><gtr:title>A1-05: Concomitant radio-chemotherapy (RT-CT) versus sequential RT-CT in locally advanced non-small cell lung cancer (NSCLC): A meta-analysis using individual patient data (IPD) from randomised clinical trials (RCTs)</gtr:title><gtr:parentPublicationTitle>Journal of Thoracic Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5f105b3e78bf3e1ceca35944921d1be0"><gtr:id>5f105b3e78bf3e1ceca35944921d1be0</gtr:id><gtr:otherNames>Auperin A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:outcomeId>UNXn4AnjrNg</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2AFB8242-32B6-4A20-8875-73FC95D0C0FD</gtr:id><gtr:title>Time to publication for results of clinical trials.</gtr:title><gtr:parentPublicationTitle>The Cochrane database of systematic reviews</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8ea7ceb4716f40a842a96382b5c6aace"><gtr:id>8ea7ceb4716f40a842a96382b5c6aace</gtr:id><gtr:otherNames>Hopewell S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1361-6137</gtr:issn><gtr:outcomeId>4ECFBA2BC33</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B2A44111-F002-4CEC-8EA2-28EA04F92C19</gtr:id><gtr:title>Antiplatelet agents for prevention of pre-eclampsia.</gtr:title><gtr:parentPublicationTitle>Lancet (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bc69470e6849532e0d499f8884bdefdb"><gtr:id>bc69470e6849532e0d499f8884bdefdb</gtr:id><gtr:otherNames>Chandiramani M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0140-6736</gtr:issn><gtr:outcomeId>EycZt7VkFG2</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>43699C72-4164-4ECA-91E5-C7DE8066B1BC</gtr:id><gtr:title>Pre-operative chemotherapy improves survival and reduces recurrence in operable non-small cell lung cancer: Preliminary results of a systematic review and meta-analysis of individual patient data from 13 randomised trials</gtr:title><gtr:parentPublicationTitle>Journal of Thoracic Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/eea168bd96be1f2e60c3da6882a59f3d"><gtr:id>eea168bd96be1f2e60c3da6882a59f3d</gtr:id><gtr:otherNames>Burdett S, Rydzewska LH, Tierney JF, Pignon JP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:outcomeId>nssz6RXVLmu</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6FB2F840-4C32-4C8E-94F3-2763FAFEBF87</gtr:id><gtr:title>Substantial improvement in UK cervical cancer survival with chemoradiotherapy: results of a Royal College of Radiologists' audit.</gtr:title><gtr:parentPublicationTitle>Clinical oncology (Royal College of Radiologists (Great Britain))</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/21f668352004702303f2e8e0e2b26d93"><gtr:id>21f668352004702303f2e8e0e2b26d93</gtr:id><gtr:otherNames>Vale CL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0936-6555</gtr:issn><gtr:outcomeId>hjx95JqNvnA</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>57C94E25-C3DF-4DC5-BE63-5EEAD79CBCF9</gtr:id><gtr:title>Concomitant and neoadjuvant chemotherapy for cervical cancer.</gtr:title><gtr:parentPublicationTitle>Clinical oncology (Royal College of Radiologists (Great Britain))</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/663c60b99db378e47bc2ef1efd6bb108"><gtr:id>663c60b99db378e47bc2ef1efd6bb108</gtr:id><gtr:otherNames>Tierney JF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0936-6555</gtr:issn><gtr:outcomeId>pm_13140_10_18571391</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1D23A6F4-7DEC-4B7F-84F5-30A59585A9D6</gtr:id><gtr:title>Re: Andrew J. Stephenson, Michel Bolla, Alberto Briganti, et al. Postoperative radiation therapy for pathologically advanced prostate cancer after radical prostatectomy. Eur Urol 2012;61:443-51.</gtr:title><gtr:parentPublicationTitle>European urology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a3bc86594b102aaa9a8a5b2a19fee8e4"><gtr:id>a3bc86594b102aaa9a8a5b2a19fee8e4</gtr:id><gtr:otherNames>Sydes MR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0302-2838</gtr:issn><gtr:outcomeId>qnKKhV3h7jV</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AEDC2FAB-D622-404C-BCCA-DC5CFF3012D3</gtr:id><gtr:title>The effects of acupuncture on rates of clinical pregnancy among women undergoing in vitro fertilization: a systematic review and meta-analysis.</gtr:title><gtr:parentPublicationTitle>Human reproduction update</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/060b45b68c69c2ef6b71ab6957943318"><gtr:id>060b45b68c69c2ef6b71ab6957943318</gtr:id><gtr:otherNames>Manheimer E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1355-4786</gtr:issn><gtr:outcomeId>545a1ca45b4c46.65901278</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>184E638F-DF88-4E4A-A247-AA9A3859858B</gtr:id><gtr:title>Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two meta-analyses of individual patient data.</gtr:title><gtr:parentPublicationTitle>Lancet (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/69c6d369ee015d6c3bed5ce617ba52bc"><gtr:id>69c6d369ee015d6c3bed5ce617ba52bc</gtr:id><gtr:otherNames>NSCLC Meta-analyses Collaborative Group</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0140-6736</gtr:issn><gtr:outcomeId>qPj7pnyY8SY</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3DF641EB-33A5-4D0E-AB1E-96C43B06D193</gtr:id><gtr:title>Neoadjuvant chemotherapy plus surgery versus surgery for cervical cancer.</gtr:title><gtr:parentPublicationTitle>The Cochrane database of systematic reviews</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8275873a4f2e2da2eebc90ae41a341c7"><gtr:id>8275873a4f2e2da2eebc90ae41a341c7</gtr:id><gtr:otherNames>Rydzewska L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1361-6137</gtr:issn><gtr:outcomeId>oikqtf63843</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CB3E5422-C467-42FB-9E6D-61922D55B338</gtr:id><gtr:title>Non-pharmacological interventions for caregivers of stroke survivors.</gtr:title><gtr:parentPublicationTitle>The Cochrane database of systematic reviews</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b7a8610a1b8611357056ded0a4f00f4c"><gtr:id>b7a8610a1b8611357056ded0a4f00f4c</gtr:id><gtr:otherNames>Legg LA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1361-6137</gtr:issn><gtr:outcomeId>XDSWVGwS4mk</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B5C9FD71-EDC9-4B1E-9746-C783B9CA511F</gtr:id><gtr:title>The theoretical argument for intensifying systemic chemotherapy upfront followed by concurrent chemoradiotherapy in the management of locally advanced non-small cell lung cancer (NSCLC)</gtr:title><gtr:parentPublicationTitle>LUNG CANCER</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ea472cbf69d489521f55fbefe49eb882"><gtr:id>ea472cbf69d489521f55fbefe49eb882</gtr:id><gtr:otherNames>Mitra S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2004-01-01</gtr:date><gtr:issn>0169-5002</gtr:issn><gtr:outcomeId>DTh78bDuEFP</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>14FBD9C8-6AC1-4F0A-822D-44A519E3E96A</gtr:id><gtr:title>Does anti-EGFR therapy improve outcome in advanced colorectal cancer? A systematic review and meta-analysis.</gtr:title><gtr:parentPublicationTitle>Cancer treatment reviews</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/21f668352004702303f2e8e0e2b26d93"><gtr:id>21f668352004702303f2e8e0e2b26d93</gtr:id><gtr:otherNames>Vale CL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0305-7372</gtr:issn><gtr:outcomeId>pm_13140_20_22118887</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E687DBA3-B41F-45BF-81D9-9834FD075B6E</gtr:id><gtr:title>Practical methods for incorporating summary time-to-event data into meta-analysis.</gtr:title><gtr:parentPublicationTitle>Trials</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/663c60b99db378e47bc2ef1efd6bb108"><gtr:id>663c60b99db378e47bc2ef1efd6bb108</gtr:id><gtr:otherNames>Tierney JF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1745-6215</gtr:issn><gtr:outcomeId>1AC37624F64</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D5744B7E-C1C0-4418-8AC2-EF9EB97D85B2</gtr:id><gtr:title>Individual patient data-based meta-analysis assessing pre-operative chemotherapy in resectable oesophagael carcinoma</gtr:title><gtr:parentPublicationTitle>Journal of Clinical Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1950e7a09d261589052f8618fd07014f"><gtr:id>1950e7a09d261589052f8618fd07014f</gtr:id><gtr:otherNames>Thirion PG, Michiels S, Le Maitre A, Tierney J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:outcomeId>XCgbtJgyahf</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B583C5BD-E324-46C4-BDF8-527C78F17E34</gtr:id><gtr:title>Four layer bandage compared with short stretch bandage for venous leg ulcers: systematic review and meta-analysis of randomised controlled trials with data from individual patients.</gtr:title><gtr:parentPublicationTitle>BMJ (Clinical research ed.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/889e61258177965005c3e2cb2de6b761"><gtr:id>889e61258177965005c3e2cb2de6b761</gtr:id><gtr:otherNames>O'Meara S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0959-535X</gtr:issn><gtr:outcomeId>A673AC58510</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0ACF06F4-376A-400E-A2D1-F1C70497D16A</gtr:id><gtr:title>Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: individual patient data meta-analysis.</gtr:title><gtr:parentPublicationTitle>The Cochrane database of systematic reviews</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2f10c9387b4debcee272f08552868d36"><gtr:id>2f10c9387b4debcee272f08552868d36</gtr:id><gtr:otherNames>Chemoradiotherapy for Cervical Cancer Meta-analysis Collaboration (CCCMAC)</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1361-6137</gtr:issn><gtr:outcomeId>gKPPNy38nA3</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>25ECAD95-E9B4-4447-A522-48B38B817A85</gtr:id><gtr:title>Chemotherapy for advanced, recurrent or metastatic endometrial carcinoma.</gtr:title><gtr:parentPublicationTitle>The Cochrane database of systematic reviews</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/21f668352004702303f2e8e0e2b26d93"><gtr:id>21f668352004702303f2e8e0e2b26d93</gtr:id><gtr:otherNames>Vale CL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1361-6137</gtr:issn><gtr:outcomeId>pm_13140_20_22895938</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8DD02133-D8C3-41AC-820C-631C338CCDF6</gtr:id><gtr:title>Obtaining funding for IPD meta-analyses: 'top tips' for a successful funding application</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4aa3dcb246ed9046e42f7a840e19b77c"><gtr:id>4aa3dcb246ed9046e42f7a840e19b77c</gtr:id><gtr:otherNames>Rydzewska Larysa</gtr:otherNames></gtr:author></gtr:authors><gtr:outcomeId>CMZLz78gJmx</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6E4F716E-4FA1-411A-9BEA-EE8ED7CB180E</gtr:id><gtr:title>Evaluation of patient involvement in a systematic review and meta-analysis of individual patient data in cervical cancer treatment.</gtr:title><gtr:parentPublicationTitle>Systematic reviews</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/21f668352004702303f2e8e0e2b26d93"><gtr:id>21f668352004702303f2e8e0e2b26d93</gtr:id><gtr:otherNames>Vale CL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>2046-4053</gtr:issn><gtr:outcomeId>pm_13140_20_22587912</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3EB5AC37-235C-43CF-9724-5D15EB464F10</gtr:id><gtr:title>Individual patient data (IPD) meta-analysis in resectable non-small cell lung cancer (NSCLC)</gtr:title><gtr:parentPublicationTitle>Journal of Thoracic Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e0eeea8facbaee5b6ec4c234e41ea51b"><gtr:id>e0eeea8facbaee5b6ec4c234e41ea51b</gtr:id><gtr:otherNames>Pignon JP, Burdett S, Auperin A, Tierney JF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:outcomeId>Gwr1QKWHHED</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B53E268F-076D-4555-937D-2572E0FD6811</gtr:id><gtr:title>Preoperative chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual participant data.</gtr:title><gtr:parentPublicationTitle>Lancet (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/23fa91483503a67bd1d74f4b5d05c549"><gtr:id>23fa91483503a67bd1d74f4b5d05c549</gtr:id><gtr:otherNames>NSCLC Meta-analysis Collaborative Group</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0140-6736</gtr:issn><gtr:outcomeId>545a1cfb869a30.86948911</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3D84210F-DB38-4E2C-9285-11FA6EFF496A</gtr:id><gtr:title>Effectiveness of antiretroviral therapy in HIV-infected children under 2 years of age.</gtr:title><gtr:parentPublicationTitle>The Cochrane database of systematic reviews</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8c6149905b45decff9078bd06677f39c"><gtr:id>8c6149905b45decff9078bd06677f39c</gtr:id><gtr:otherNames>Penazzato M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1361-6137</gtr:issn><gtr:outcomeId>pm_13140_20_22786492</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A24F266B-88A4-498E-BE57-A711CFABCFEA</gtr:id><gtr:title>Preoperative chemotherapy for non-small-cell lung cancer - Authors' reply</gtr:title><gtr:parentPublicationTitle>The Lancet</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7c4225def80303de4a226d3422d01ee2"><gtr:id>7c4225def80303de4a226d3422d01ee2</gtr:id><gtr:otherNames>Burdett S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:outcomeId>545a1d438b72b9.57560499</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>793455B5-B56C-45EF-B80C-C426EFC6455A</gtr:id><gtr:title>Surgery and radiotherapy plus adjuvant chemotherapy versus surgery and radiotherapy in non-small cell lung cancer (NSCLC): A meta-analysis using individual patient data (IPD) from randomised clinical trials</gtr:title><gtr:parentPublicationTitle>Journal of Clinical Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8c59c123dfb6b3db7711d3045c9d3293"><gtr:id>8c59c123dfb6b3db7711d3045c9d3293</gtr:id><gtr:otherNames>Le Pechoux C, Tribodet H, Pignon JP, Burdett S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:outcomeId>MMHimkYYug9</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2AEBA8E7-BD03-401F-8C05-D73F51A9FD89</gtr:id><gtr:title>Concomitant chemoradiation for cervical cancer: a meta-analysis using individual patient data from randomised controlled trials</gtr:title><gtr:parentPublicationTitle>International Journal of Gynecological Cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7636000b68fd2837c3e086671beaa8f0"><gtr:id>7636000b68fd2837c3e086671beaa8f0</gtr:id><gtr:otherNames>Vale CL, Tierney JF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:outcomeId>cKMsBm3X5VA</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C16C2799-F7C4-48DA-A814-1E840183F306</gtr:id><gtr:title>Concomitant radiochemotherapy (RT-CT) versus sequential RT-CT in locally advanced non-small cell lung cancer (NSCLC): A meta-analysis using individual patient data (IPD) from randomised clinical trials (RCTs)</gtr:title><gtr:parentPublicationTitle>International Journal of Radiation Oncology Biology Physics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bd7bf18b2c7b9dd0ad19f9a9e037ce39"><gtr:id>bd7bf18b2c7b9dd0ad19f9a9e037ce39</gtr:id><gtr:otherNames>Rolland E, Le Pechoux C, Curran WJ, Furuse K, Fournel P, Uitterhoeve L, Clamon G, Ulutin HG, Stewart LA, Auperin A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:outcomeId>mCt8QRNzUfV</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>84EDE014-5F99-4BE6-A464-C3B86F331598</gtr:id><gtr:title>NeOProM: Neonatal Oxygenation Prospective Meta-analysis Collaboration study protocol.</gtr:title><gtr:parentPublicationTitle>BMC pediatrics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/51745a911dc9ecd1f48fca348ed3b6f7"><gtr:id>51745a911dc9ecd1f48fca348ed3b6f7</gtr:id><gtr:otherNames>Askie LM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1471-2431</gtr:issn><gtr:outcomeId>VaU6JQuxykp</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CF1945E8-DE84-423F-B22E-C5ACEA3902D1</gtr:id><gtr:title>B2-03: Supportive care and chemotherapy (CT) versus supportive care alone in advanced non-small cell lung cancer (NSCLC): A meta-analysis using individual patient data (IPD) from randomised controlled trials (RCTs)</gtr:title><gtr:parentPublicationTitle>Journal of Thoracic Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7c4225def80303de4a226d3422d01ee2"><gtr:id>7c4225def80303de4a226d3422d01ee2</gtr:id><gtr:otherNames>Burdett S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:outcomeId>UjbLmRzTGeo</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DD33B37C-4FCA-433F-87F1-40EDC1A67AB9</gtr:id><gtr:title>Caseload and outcome after brachytherapy.</gtr:title><gtr:parentPublicationTitle>Clinical oncology (Royal College of Radiologists (Great Britain))</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2f08c12518382bae79091c7ca2c1c971"><gtr:id>2f08c12518382bae79091c7ca2c1c971</gtr:id><gtr:otherNames>Symonds P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0936-6555</gtr:issn><gtr:outcomeId>pm_13140_20_23830972</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AAA7306D-18EE-40AE-AFFC-69FC4DF43455</gtr:id><gtr:title>A closer look at the effects of postoperative radiotherapy by stage and nodal status: updated results of an individual participant data meta-analysis in non-small-cell lung cancer.</gtr:title><gtr:parentPublicationTitle>Lung cancer (Amsterdam, Netherlands)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7c4225def80303de4a226d3422d01ee2"><gtr:id>7c4225def80303de4a226d3422d01ee2</gtr:id><gtr:otherNames>Burdett S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0169-5002</gtr:issn><gtr:outcomeId>pm_13140_20_23453644</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>61DFCFFA-B149-47A7-9D92-36692ED71921</gtr:id><gtr:title>Supportive care and chemotherapy versus supportive care alone in advanced non-small cell lung cancer (NSCLC): a meta-analysis using individual patient data (IPD) from randomised clinical trials</gtr:title><gtr:parentPublicationTitle>Journal of Clinical Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ea8026149a918be73d2edbaf9825927b"><gtr:id>ea8026149a918be73d2edbaf9825927b</gtr:id><gtr:otherNames>Burdett S, Stewart LA, Tierney JF, Le Pechoux C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:outcomeId>f2pk4yYaf1Q</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>39C5A643-C9E8-423D-AB9C-386F61DE19A1</gtr:id><gtr:title>Surgery and adjuvant chemotherapy compared to surgery alone in non-small cell lung cancer (NSCLC): A meta-analysis using individual patient data (IPD) from randomized clinical trials</gtr:title><gtr:parentPublicationTitle>Journal of Clinical Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/980bab1b0bc281be97574e9ff8fb49da"><gtr:id>980bab1b0bc281be97574e9ff8fb49da</gtr:id><gtr:otherNames>Stewart LA, Burdett S, Tierney JF, Pignon JP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:outcomeId>EfAENz6tyhX</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B48BF6C5-AE3D-4238-B8AF-5E74F3FAD6C8</gtr:id><gtr:title>Cochrane Handbook for Systematic Reviews of Interventions</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c3a7f2945b6d9308e43a8e17e791500d"><gtr:id>c3a7f2945b6d9308e43a8e17e791500d</gtr:id><gtr:otherNames>Stewart L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:isbn>9780470712184</gtr:isbn><gtr:outcomeId>BxooubEJsbc</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6BC42FF4-B617-43A7-B580-F0E91E3377B2</gtr:id><gtr:title>Aspirin and cancer: has aspirin been overlooked as an adjuvant therapy?</gtr:title><gtr:parentPublicationTitle>British journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2a71af17ab23169ccaa01135ba3297c2"><gtr:id>2a71af17ab23169ccaa01135ba3297c2</gtr:id><gtr:otherNames>Langley RE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0007-0920</gtr:issn><gtr:outcomeId>tejuenc2ovB</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A755F9AB-B11B-4EEC-B920-869CB578BD9A</gtr:id><gtr:title>Protocol for a systematic review and individual patient data meta-analysis of prognostic factors of foot ulceration in people with diabetes: the international research collaboration for the prediction of diabetic foot ulcerations (PODUS).</gtr:title><gtr:parentPublicationTitle>BMC medical research methodology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7caf08ea521ae8777e689866dc68cf39"><gtr:id>7caf08ea521ae8777e689866dc68cf39</gtr:id><gtr:otherNames>Crawford F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1471-2288</gtr:issn><gtr:outcomeId>pm_13140_20_23414550</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4A9A3CE8-ED75-43B8-A0D5-ECF240586550</gtr:id><gtr:title>Chemotherapy for advanced, recurrent or metastatic endometrial cancer: a systematic review of Cochrane collaboration.</gtr:title><gtr:parentPublicationTitle>Annals of oncology : official journal of the European Society for Medical Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d555ed2b3902c7a6d1840b76786e74b5"><gtr:id>d555ed2b3902c7a6d1840b76786e74b5</gtr:id><gtr:otherNames>Humber CE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0923-7534</gtr:issn><gtr:outcomeId>A32093D1657</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7BEC11C5-A9C9-4DAC-985D-8F1478698407</gtr:id><gtr:title>Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer.</gtr:title><gtr:parentPublicationTitle>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3c98ef439e1f67be562aa4151108e4b8"><gtr:id>3c98ef439e1f67be562aa4151108e4b8</gtr:id><gtr:otherNames>Aup?rin A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0732-183X</gtr:issn><gtr:outcomeId>NgBEEVYcQLz</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8A52DD05-C3F2-4306-9D2F-D1DD6962A14B</gtr:id><gtr:title>Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data from 16 randomized controlled trials.</gtr:title><gtr:parentPublicationTitle>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6e3049a1d8200e9586f44d31e7397f5b"><gtr:id>6e3049a1d8200e9586f44d31e7397f5b</gtr:id><gtr:otherNames>NSCLC Meta-Analyses Collaborative Group</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0732-183X</gtr:issn><gtr:outcomeId>A757C62FDAC</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BCE981DE-C01E-4372-865D-FBB1C900FC18</gtr:id><gtr:title>Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: a systematic review and meta-analysis of individual patient data from 18 randomized trials.</gtr:title><gtr:parentPublicationTitle>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ed10cb1cedc60fad18823744f6001afc"><gtr:id>ed10cb1cedc60fad18823744f6001afc</gtr:id><gtr:otherNames>Chemoradiotherapy for Cervical Cancer Meta-Analysis Collaboration</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0732-183X</gtr:issn><gtr:outcomeId>0A2A4530CF1</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>72FA0FA5-CFBD-4528-88DF-45F26D84A4BD</gtr:id><gtr:title>Impact of K-ras status on the effects of EGFR-targeted monoclonal antibody (MAb) therapy in advanced colorectal cancer (ACRC): A systematic review and meta-analysis of randomized controlled trials (RCTs)</gtr:title><gtr:parentPublicationTitle>JOURNAL OF CLINICAL ONCOLOGY</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/aa35c657b62618285902116da82b8907"><gtr:id>aa35c657b62618285902116da82b8907</gtr:id><gtr:otherNames>Vale C.</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0732-183X</gtr:issn><gtr:outcomeId>Gaz2zgJtpYk</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C7CD2259-4FA0-426E-959A-A9B32FE78E17</gtr:id><gtr:title>Re: Emilio Bria, Enzo Maria Ruggeri, Edmondo Terzoli, Francesco Cognetti, Camillo Francesco Pollera and Diana Giannarelli. Adjuvant chemotherapy for bladder cancer: the chance for meta-analyses comparison. Eur Urol 2007;51:576-7.</gtr:title><gtr:parentPublicationTitle>European urology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/83f08b2beb28ce764b737ec86c4b7a71"><gtr:id>83f08b2beb28ce764b737ec86c4b7a71</gtr:id><gtr:otherNames>Vale C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0302-2838</gtr:issn><gtr:outcomeId>pm_13140_10_16854518</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C8596B12-0B80-4C98-A61A-2E094471B5AA</gtr:id><gtr:title>C3-05: Chemotherapy (CT) in addition to surgery or surgery plus radiotherapy (RT) in non-small cell lung cancer (NSCLC): Two meta-analyses using individual patient data (IPD) from randomised controlled trials (RCTs)</gtr:title><gtr:parentPublicationTitle>Journal of Thoracic Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7c4225def80303de4a226d3422d01ee2"><gtr:id>7c4225def80303de4a226d3422d01ee2</gtr:id><gtr:otherNames>Burdett S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:outcomeId>ocdKdQAw7cd</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0080441A-0B14-4793-B993-8F39C376F82E</gtr:id><gtr:title>Tips and tricks for understanding and using SR results. No. 7: time-to-event data</gtr:title><gtr:parentPublicationTitle>Evidence-Based Child Health: A Cochrane Review Journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b773248f61c5b1aa1085f0acf173c938"><gtr:id>b773248f61c5b1aa1085f0acf173c938</gtr:id><gtr:otherNames>van Dalen E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:outcomeId>NKi263AnreA</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>97FE907C-BD98-4F57-AFF2-B72E3B9DD56D</gtr:id><gtr:title>A1-04: Sequential radio-chemotherapy (RT-CT) versus radiotherapy alone (RT) and concomitant RT-CT versus RT alone in locally advanced non-small cell lung cancer (NSCLC): Two meta-analyses using individual patient data (IPD) from randomised clinical trials (RCTs)</gtr:title><gtr:parentPublicationTitle>Journal of Thoracic Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9b98da009b74f38cba1357ff57fb3acd"><gtr:id>9b98da009b74f38cba1357ff57fb3acd</gtr:id><gtr:otherNames>Rolland E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:outcomeId>srVjWPe7aPy</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4997BAFC-CE07-41E6-99C1-F95404BBD490</gtr:id><gtr:title>Chemotherapy and surgery versus surgery alone in non-small cell lung cancer.</gtr:title><gtr:parentPublicationTitle>The Cochrane database of systematic reviews</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3cf9e5c57a0e9e55cb8747cd201299fb"><gtr:id>3cf9e5c57a0e9e55cb8747cd201299fb</gtr:id><gtr:otherNames>Burdett SS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1361-6137</gtr:issn><gtr:outcomeId>F05E60E04CE</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B5EDDE67-653D-446E-AFC8-01EE3B9F1AAC</gtr:id><gtr:title>Antiplatelet agents for prevention of pre-eclampsia: a meta-analysis of individual patient data.</gtr:title><gtr:parentPublicationTitle>Lancet (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/51745a911dc9ecd1f48fca348ed3b6f7"><gtr:id>51745a911dc9ecd1f48fca348ed3b6f7</gtr:id><gtr:otherNames>Askie LM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0140-6736</gtr:issn><gtr:outcomeId>9D57ACFD6B3</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9BEB8333-B4E3-403F-AA6C-A109EAFFD40C</gtr:id><gtr:title>A systematic review and meta-analysis of the literature: chemotherapy and surgery versus surgery alone in non-small cell lung cancer.</gtr:title><gtr:parentPublicationTitle>Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7c4225def80303de4a226d3422d01ee2"><gtr:id>7c4225def80303de4a226d3422d01ee2</gtr:id><gtr:otherNames>Burdett S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>1556-0864</gtr:issn><gtr:outcomeId>FD3FA47176D</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MC_U122861323</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>7C58A707-1BF6-4573-A44F-30B271C80813</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Cancer</gtr:text></gtr:healthCategory><gtr:healthCategory><gtr:id>F3822669-BB5A-4BB4-BAE0-DCB9DE36E092</gtr:id><gtr:percentage>25</gtr:percentage><gtr:text>Generic Health Relevance</gtr:text></gtr:healthCategory><gtr:healthCategory><gtr:id>A77DAE3A-499B-4F46-971D-6C82F51F9C2E</gtr:id><gtr:percentage>25</gtr:percentage><gtr:text>Stroke</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>90487A08-C473-4CEB-B6D9-011A74AD06CF</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>8.4  Research design and methodologies</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>